assay_id,assay_organism,bao_format,tissue_id,variant_id,confidence_score,assay_tissue,chembl_id,assay_category,curated_by,assay_test_type,doc_id,src_assay_id,relationship_type,tid,src_id,description,assay_type,assay_tax_id
1,,BAO_0000019,,,8,,CHEMBL615117,,Autocuration,,11087,,H,12052,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,
2,,BAO_0000219,,,0,,CHEMBL615118,,Autocuration,,684,,U,22226,1,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,
3,,BAO_0000019,,,0,,CHEMBL615119,,Autocuration,,15453,,U,22226,1,,B,
4,Bos taurus,BAO_0000249,,,4,,CHEMBL615120,,Autocuration,,17841,,H,104729,1,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,9913.0
5,Homo sapiens,BAO_0000219,,,1,,CHEMBL615121,,Intermediate,,17430,,N,80001,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0
6,Homo sapiens,BAO_0000219,,,1,,CHEMBL615122,,Intermediate,,17430,,N,80001,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0
7,Mus musculus,BAO_0000219,,,1,,CHEMBL615123,,Intermediate,,13799,,N,80001,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,10090.0
8,Homo sapiens,BAO_0000219,,,1,,CHEMBL615124,,Expert,,17774,,N,80001,1,In vitro cell cytotoxicity was determined against 143B cell line,F,9606.0
9,Homo sapiens,BAO_0000219,,,1,,CHEMBL615125,,Intermediate,,3801,,N,80001,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,9606.0
10,Homo sapiens,BAO_0000219,,,1,,CHEMBL615126,,Intermediate,,17430,,N,80001,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0
11,Homo sapiens,BAO_0000219,,,1,,CHEMBL615127,,Intermediate,,17430,,N,80001,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0
12,Homo sapiens,BAO_0000219,,,1,,CHEMBL615128,,Expert,,17774,,N,80001,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,9606.0
13,Staphylococcus aureus,BAO_0000218,,,1,,CHEMBL857900,,Intermediate,,11324,,N,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0
14,Staphylococcus aureus,BAO_0000218,,,1,,CHEMBL615129,,Intermediate,,11324,,N,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0
15,Staphylococcus aureus,BAO_0000218,,,1,,CHEMBL615130,,Intermediate,,11324,,N,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0
16,Staphylococcus aureus,BAO_0000218,,,1,,CHEMBL615131,,Intermediate,,11324,,N,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0
17,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL884521,,Expert,,11347,,D,100122,1,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,10116.0
18,,BAO_0000357,,,8,,CHEMBL615132,,Autocuration,,16474,,H,12054,1,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,
19,,BAO_0000019,,,8,,CHEMBL615133,,Autocuration,,10091,,H,12054,1,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,
20,,BAO_0000357,,,8,,CHEMBL615134,,Autocuration,,16474,,H,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,
21,,BAO_0000357,,,8,,CHEMBL615135,,Autocuration,,16474,,H,12054,1,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,
22,,BAO_0000357,,,8,,CHEMBL615136,,Autocuration,,16474,,H,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,
23,,BAO_0000357,,,8,,CHEMBL615137,,Autocuration,,16474,,H,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,
24,,BAO_0000357,,,8,,CHEMBL615138,,Autocuration,,16474,,H,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,
25,,BAO_0000219,,,0,,CHEMBL836324,,Autocuration,,14352,,U,22226,1,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,
26,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL615139,,Autocuration,,5646,,H,12054,1,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,9986.0
27,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL615140,,Autocuration,,5646,,H,12054,1,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,9986.0
28,,BAO_0000219,,,8,,CHEMBL615141,,Autocuration,,10997,,H,12426,1,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,
29,soya bean,BAO_0000357,,,8,,CHEMBL615142,,Autocuration,,6309,,H,12054,1,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,3847.0
30,Glycine max,BAO_0000357,,,8,,CHEMBL615143,,Autocuration,,167,,H,12054,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,3847.0
31,Glycine max,BAO_0000357,,,8,,CHEMBL615144,,Autocuration,,167,,H,12054,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,3847.0
32,Glycine max,BAO_0000357,,,8,,CHEMBL872867,,Autocuration,,11087,,H,12054,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,3847.0
33,Glycine max,BAO_0000357,,,8,,CHEMBL615145,,Autocuration,,11087,,H,12054,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,3847.0
34,Glycine max,BAO_0000357,,,8,,CHEMBL615146,,Autocuration,,13622,,H,12054,1,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0
35,Glycine max,BAO_0000357,,,8,,CHEMBL615147,,Autocuration,,13622,,H,12054,1,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0
36,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615148,,Autocuration,,11347,,U,22226,1,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,10116.0
37,Escherichia coli,BAO_0000019,,,0,,CHEMBL615149,,Autocuration,,5926,,U,22226,1,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,562.0
38,,BAO_0000019,,,0,,CHEMBL615150,,Autocuration,,4567,,U,22226,1,Dissociation constant with dimeric 16S rRNA RNA construct B,B,
39,,BAO_0000225,,,3,,CHEMBL615151,,Intermediate,,3782,,M,22222,1,Dissociation constant towards 16S rRNA construct A,B,
40,,BAO_0000225,,,3,,CHEMBL615152,,Intermediate,,3782,,M,22222,1,Dissociation constant towards 16S rRNA construct B,B,
41,Escherichia coli,BAO_0000225,,,3,,CHEMBL615153,,Expert,,4466,,M,100263,1,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,562.0
42,Escherichia coli,BAO_0000225,,,3,,CHEMBL615154,,Expert,,6592,,M,100263,1,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,562.0
43,,BAO_0000019,,,8,,CHEMBL615155,,Autocuration,,898,,H,13053,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
44,,BAO_0000019,,,8,,CHEMBL615156,,Autocuration,,898,,H,13053,1,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
45,Homo sapiens,BAO_0000019,,,8,,CHEMBL615157,,Autocuration,,13163,,H,20001,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0
46,Homo sapiens,BAO_0000019,,,8,,CHEMBL615158,,Autocuration,,13163,,H,20001,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0
47,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615159,,Expert,,10691,,D,12971,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0
48,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615172,,Expert,,10691,,D,12971,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0
49,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615173,,Expert,,10691,,D,12971,1,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0
50,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615174,,Expert,,10691,,D,12971,1,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0
51,,BAO_0000019,,,8,,CHEMBL884518,,Autocuration,,898,,H,13053,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
52,,BAO_0000357,,,8,,CHEMBL615175,,Autocuration,,912,,H,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,
53,,BAO_0000357,,,8,,CHEMBL615176,,Autocuration,,912,,H,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,
54,,BAO_0000357,,,8,,CHEMBL615177,,Autocuration,,912,,H,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,
55,Rattus norvegicus,BAO_0000249,,,5,,CHEMBL615178,,Autocuration,,15103,,D,104740,1,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,10116.0
56,Homo sapiens,BAO_0000219,,,1,,CHEMBL615179,,Intermediate,,5116,,N,80002,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,9606.0
57,Rattus norvegicus,BAO_0000219,,,7,,CHEMBL615180,,Autocuration,,14578,,D,104835,1,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,10116.0
58,Rattus norvegicus,BAO_0000219,,,7,,CHEMBL615181,,Autocuration,,14578,,D,104821,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,10116.0
59,Rattus norvegicus,BAO_0000219,,,7,,CHEMBL615182,,Autocuration,,14578,,D,104848,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,10116.0
60,Homo sapiens,BAO_0000219,,,1,,CHEMBL615183,,Expert,,4787,,N,80002,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,9606.0
61,Homo sapiens,BAO_0000219,,,1,,CHEMBL615184,,Intermediate,,4787,,N,80002,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,9606.0
62,Homo sapiens,BAO_0000219,,,1,,CHEMBL615185,,Intermediate,,3547,,N,80002,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,9606.0
63,Homo sapiens,BAO_0000219,,,1,,CHEMBL615186,,Intermediate,,3547,,N,80002,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,9606.0
64,Homo sapiens,BAO_0000219,,,1,,CHEMBL615187,,Intermediate,,6726,,N,80002,1,Effective dose of compound against replication of 1A9 cell line was evaluated,F,9606.0
65,Homo sapiens,BAO_0000219,,,1,,CHEMBL885343,,Expert,,3455,,N,80002,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,9606.0
66,Homo sapiens,BAO_0000219,,,1,,CHEMBL615188,,Intermediate,,5726,,N,80002,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,9606.0
67,Homo sapiens,BAO_0000219,,,1,,CHEMBL615189,,Intermediate,,5726,,N,80002,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,9606.0
68,Homo sapiens,BAO_0000219,,,1,,CHEMBL615190,,Intermediate,,5726,,N,80002,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,9606.0
69,Homo sapiens,BAO_0000219,,,1,,CHEMBL615191,,Intermediate,,3395,,N,80002,1,Inhibitory activity against Taxol resistant 1A9 cell lines,F,9606.0
70,Homo sapiens,BAO_0000219,,,1,,CHEMBL615192,,Expert,,3415,,N,80002,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,9606.0
71,Homo sapiens,BAO_0000219,,,1,,CHEMBL827083,,Expert,,3415,,N,80002,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,9606.0
72,Homo sapiens,BAO_0000219,,,1,,CHEMBL615193,,Expert,,17099,,N,80002,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,9606.0
73,Homo sapiens,BAO_0000219,,,1,,CHEMBL615194,,Intermediate,,17099,,N,80002,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,9606.0
74,Homo sapiens,BAO_0000219,,,1,,CHEMBL615195,,Intermediate,,17099,,N,80002,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,9606.0
75,Homo sapiens,BAO_0000219,,,1,,CHEMBL615196,,Intermediate,,17099,,N,80002,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,9606.0
76,Homo sapiens,BAO_0000219,,,1,,CHEMBL615197,,Intermediate,,17721,,N,81072,1,Inhibitory concentration against Jurkat cells,F,9606.0
77,,BAO_0000019,,,0,,CHEMBL615198,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,
78,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615199,,Expert,,11347,,D,100121,1,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,10116.0
79,,BAO_0000357,,,8,,CHEMBL615200,,Expert,,17117,,H,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,
80,,BAO_0000357,,,8,,CHEMBL615201,,Expert,,17117,,H,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,
81,,BAO_0000357,,,8,,CHEMBL615202,,Expert,,17117,,H,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,
82,Candida albicans,BAO_0000251,,,8,,CHEMBL615203,,Autocuration,,11375,,H,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,5476.0
83,Candida albicans,BAO_0000251,,,8,,CHEMBL615204,,Autocuration,,11375,,H,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,5476.0
84,Saccharomyces cerevisiae,BAO_0000251,,,8,,CHEMBL615205,,Autocuration,,11375,,H,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,4932.0
85,Saccharomyces cerevisiae,BAO_0000251,,,8,,CHEMBL615206,,Autocuration,,11375,,H,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,4932.0
86,Sus scrofa,BAO_0000251,2107.0,,8,Liver,CHEMBL615207,,Autocuration,,11375,,H,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,9823.0
87,Rattus norvegicus,BAO_0000019,,,8,,CHEMBL827084,,Autocuration,,791,,H,11231,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,10116.0
88,Rattus norvegicus,BAO_0000019,,,8,,CHEMBL615208,,Autocuration,,791,,H,11231,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,10116.0
89,Rattus norvegicus,BAO_0000019,,,8,,CHEMBL615209,,Autocuration,,791,,H,11231,1,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,10116.0
90,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615210,,Autocuration,,11375,,D,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,10116.0
91,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615211,,Autocuration,,11375,,D,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0
92,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615212,,Autocuration,,153,,D,12083,1,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0
93,,BAO_0000357,,,8,,CHEMBL615213,,Expert,,8269,,H,11377,1,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,
94,,BAO_0000357,,,8,,CHEMBL615273,,Expert,,8269,,H,11377,1,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,
95,Homo sapiens,BAO_0000219,,,1,,CHEMBL615274,,Expert,,17653,,N,81020,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,9606.0
96,Homo sapiens,BAO_0000219,,,1,,CHEMBL615275,,Intermediate,,14277,,N,81020,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,9606.0
97,Homo sapiens,BAO_0000219,,,1,,CHEMBL615276,,Intermediate,,1717,,N,81020,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,9606.0
98,Homo sapiens,BAO_0000219,,,1,,CHEMBL615277,,Intermediate,,14091,,N,81020,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,9606.0
99,Homo sapiens,BAO_0000219,,,1,,CHEMBL615326,,Intermediate,,14091,,N,81020,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,9606.0
100,Hepatitis B virus,BAO_0000218,,,1,,CHEMBL883130,,Expert,,17653,,N,50606,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,10407.0
101,Homo sapiens,BAO_0000219,,,1,,CHEMBL884519,,Intermediate,,13105,,N,81020,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,9606.0
102,Homo sapiens,BAO_0000219,,,1,,CHEMBL615327,,Intermediate,,1717,,N,81020,1,Concentration required to inhibit 50% of 2.2.15 cell line,F,9606.0
103,Homo sapiens,BAO_0000219,,,1,,CHEMBL615328,,Intermediate,,13105,,N,81020,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,9606.0
104,Homo sapiens,BAO_0000218,,,1,,CHEMBL615329,,Intermediate,,13600,,N,50587,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,9606.0
105,Homo sapiens,BAO_0000218,,,1,,CHEMBL615330,,Intermediate,,13467,,N,50587,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,9606.0
106,Hepatitis B virus,BAO_0000218,,,1,,CHEMBL615331,,Expert,,17477,,N,50606,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,10407.0
107,Homo sapiens,BAO_0000218,,,1,,CHEMBL615332,,Intermediate,,1593,,N,50587,1,In vitro anti-HBV activity in 2.2.15 cells,F,9606.0
108,Homo sapiens,BAO_0000218,,,1,,CHEMBL615333,,Intermediate,,1593,,N,50587,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,9606.0
109,Homo sapiens,BAO_0000218,,,1,,CHEMBL615334,,Intermediate,,15089,,N,50587,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,9606.0
110,Homo sapiens,BAO_0000218,,,1,,CHEMBL615335,,Intermediate,,15089,,N,50587,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,9606.0
111,Homo sapiens,BAO_0000218,,,1,,CHEMBL615336,,Intermediate,,1593,,N,50587,1,Cytotoxicity in 2.2.15 cells,F,9606.0
112,Homo sapiens,BAO_0000218,,,1,,CHEMBL615337,,Intermediate,,1593,,N,50587,1,Cytotoxicity in 2.2.15 cells; Not determined,F,9606.0
113,Homo sapiens,BAO_0000218,,,1,,CHEMBL615338,,Intermediate,,13600,,N,50587,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,9606.0
114,Homo sapiens,BAO_0000218,,,1,,CHEMBL615339,,Intermediate,,13467,,N,50587,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,9606.0
115,Homo sapiens,BAO_0000218,,,1,,CHEMBL615340,,Intermediate,,13467,,N,50587,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,9606.0
116,Homo sapiens,BAO_0000219,,,1,,CHEMBL615341,,Intermediate,,14764,,N,81020,1,Antiviral activity against HBV was determined in 2.215 cell line,F,9606.0
117,Homo sapiens,BAO_0000251,,,0,,CHEMBL615342,,Autocuration,,6531,,U,22226,1,Inhibition of 20-HETE synthesis in human renal microsomes,B,9606.0
118,,BAO_0000019,,,0,,CHEMBL615343,,Autocuration,,17322,,U,22226,1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,
119,Homo sapiens,BAO_0000219,,,1,,CHEMBL615344,,Intermediate,,17072,,N,80612,1,Inhibitory concentration against 2008 (ovarian) cells,F,9606.0
120,Homo sapiens,BAO_0000219,,,1,,CHEMBL615345,,Intermediate,,16936,,N,80612,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,9606.0
121,Homo sapiens,BAO_0000219,,,1,,CHEMBL615346,,Intermediate,,16936,,N,80612,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,9606.0
122,Homo sapiens,BAO_0000219,,,1,,CHEMBL615347,,Intermediate,,17146,,N,80612,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,9606.0
123,Homo sapiens,BAO_0000219,,,1,,CHEMBL615348,,Intermediate,,17146,,N,80612,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,9606.0
124,Homo sapiens,BAO_0000219,,,1,,CHEMBL827085,,Intermediate,,10797,,N,80613,1,In vitro inhibition of 2008/R ovarian cancer cell line,F,9606.0
125,Homo sapiens,BAO_0000219,,,1,,CHEMBL615349,,Intermediate,,10797,,N,80613,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,9606.0
126,Homo sapiens,BAO_0000219,,,1,,CHEMBL615350,,Intermediate,,10797,,N,80614,1,In vitro inhibition of 2008/S ovarian cancer cell line,F,9606.0
127,Homo sapiens,BAO_0000219,,,1,,CHEMBL615351,,Intermediate,,10797,,N,80614,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,9606.0
128,Homo sapiens,BAO_0000220,,,2,,CHEMBL615352,,Expert,,4823,,S,100256,1,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,9606.0
129,Homo sapiens,BAO_0000220,,,2,,CHEMBL615353,,Intermediate,,12912,,S,100256,1,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,9606.0
130,,BAO_0000220,,,2,,CHEMBL615354,,Expert,,2957,,S,100256,1,Inhibition of chymotrypsin-like activity of 20S proteasome,B,
131,,BAO_0000220,,,2,,CHEMBL615355,,Expert,,2957,,S,100256,1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,
132,,BAO_0000220,,,2,,CHEMBL615356,,Intermediate,,3260,,S,100256,1,Inhibitory activity against 20S proteosome,B,
133,Homo sapiens,BAO_0000019,,,0,,CHEMBL615357,,Autocuration,,3451,,U,22226,1,Compound was tested for inhibitory activity against tryptase,B,9606.0
134,Homo sapiens,BAO_0000219,,,1,,CHEMBL615358,,Intermediate,,13885,,N,81020,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,9606.0
135,Homo sapiens,BAO_0000219,,,1,,CHEMBL827086,,Intermediate,,13885,,N,81020,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,9606.0
136,,BAO_0000019,,,0,,CHEMBL615359,,Autocuration,,3676,,U,22226,1,Compound was tested for the inhibition of Alpha-glucosidase,B,
137,,BAO_0000357,,,8,,CHEMBL615360,,Autocuration,,6043,,H,235,1,Inhibitory concentration against human neutrophil elastase (HNE),B,
138,Rattus norvegicus,BAO_0000218,948.0,,0,Heart,CHEMBL615361,,Autocuration,,11140,,U,22226,1,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,10116.0
139,,BAO_0000019,,,8,,CHEMBL615362,,Autocuration,,10543,,H,19640,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,
140,,BAO_0000019,,,8,,CHEMBL615363,,Expert,,10543,,H,19640,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,
141,,BAO_0000357,,,8,,CHEMBL615364,,Autocuration,,10543,,H,19640,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,
142,,BAO_0000019,,,8,,CHEMBL615365,,Expert,,10543,,H,19640,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,
143,Mus musculus,BAO_0000219,,,1,,CHEMBL615366,,Intermediate,,11365,,N,80360,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,10090.0
144,Mus musculus,BAO_0000219,,,1,,CHEMBL615367,,Intermediate,,11365,,N,80360,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,10090.0
145,Homo sapiens,BAO_0000219,,,1,,CHEMBL615368,,Intermediate,,11803,,N,80384,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,9606.0
146,Ovis aries,BAO_0000019,,,0,,CHEMBL615369,,Autocuration,,11803,,U,22226,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,9940.0
147,Ovis aries,BAO_0000019,,,0,,CHEMBL615370,,Autocuration,,11803,,U,22226,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,9940.0
148,,BAO_0000357,,,8,,CHEMBL615673,,Autocuration,,12278,,H,191,1,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,
149,Homo sapiens,BAO_0000019,,,0,,CHEMBL615674,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,9606.0
150,Homo sapiens,BAO_0000019,,,0,,CHEMBL615675,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,9606.0
151,Homo sapiens,BAO_0000219,,,0,,CHEMBL615676,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,9606.0
152,Homo sapiens,BAO_0000219,,,0,,CHEMBL615677,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,9606.0
153,Homo sapiens,BAO_0000219,,,0,,CHEMBL615678,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,9606.0
154,Homo sapiens,BAO_0000219,,,0,,CHEMBL615679,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,9606.0
155,Homo sapiens,BAO_0000019,,,0,,CHEMBL615680,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,9606.0
156,Homo sapiens,BAO_0000019,,,0,,CHEMBL615681,,Autocuration,,8249,,U,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,9606.0
157,,BAO_0000249,,,6,,CHEMBL857972,,Autocuration,,16992,,H,104290,1,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,
158,Streptococcus pyogenes,BAO_0000218,,,1,,CHEMBL857899,,Intermediate,,10543,,N,50264,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,1314.0
159,Human herpesvirus 3,BAO_0000218,,,1,,CHEMBL615371,,Intermediate,,17833,,N,50527,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,10335.0
160,vericilla zoster virus,BAO_0000218,,,1,,CHEMBL615372,,Expert,,17290,,N,50527,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,10335.0
161,vericilla zoster virus,BAO_0000218,,,1,,CHEMBL615373,,Intermediate,,17290,,N,50527,1,Antiviral activity against 07/1 strain of VZV; ND: No data,F,10335.0
162,vericilla zoster virus,BAO_0000218,,,1,,CHEMBL615374,,Intermediate,,17290,,N,50527,1,Antiviral activity against 07/1 strain of VZV; ND=No data,F,10335.0
163,escherichia cloac,BAO_0000218,,,1,,CHEMBL615375,,Intermediate,,10932,,N,50145,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,561.0
164,,BAO_0000019,,,0,,CHEMBL615376,,Autocuration,,9707,,U,22226,1,Ratio of Ki at A2 to Ki at A1 receptors,B,
165,Candida albicans,BAO_0000249,,,8,,CHEMBL615377,,Expert,,2346,,H,11143,1,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,5476.0
166,Candida glabrata CBS 138,BAO_0000357,,,8,,CHEMBL615378,,Expert,,2205,,H,18077,1,"Inhibition of 1,3-beta-glucan synthase",B,284593.0
167,Homo sapiens,BAO_0000219,,,1,,CHEMBL615379,,Intermediate,,11900,,N,80609,1,Inhibition of growth of 1-87 human tumor cell line,F,9606.0
168,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL615380,,Expert,,14864,,D,12166,1,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,10116.0
169,Glycine max,BAO_0000357,,,9,,CHEMBL615381,,Autocuration,,16474,,D,100171,1,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,3847.0
170,Glycine max,BAO_0000357,,,9,,CHEMBL615382,,Autocuration,,16474,,D,100171,1,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,3847.0
171,Glycine max,BAO_0000357,,,9,,CHEMBL615383,,Autocuration,,16474,,D,100171,1,% inhibition against soybean 1-lipoxygenase (SLO),B,3847.0
172,Glycine max,BAO_0000357,,,9,,CHEMBL615384,,Autocuration,,16474,,D,100171,1,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,3847.0
173,Glycine max,BAO_0000357,,,9,,CHEMBL615385,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,3847.0
174,Glycine max,BAO_0000357,,,9,,CHEMBL615386,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,3847.0
175,Glycine max,BAO_0000357,,,9,,CHEMBL615387,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,3847.0
176,Glycine max,BAO_0000357,,,9,,CHEMBL615388,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,3847.0
177,Glycine max,BAO_0000357,,,9,,CHEMBL615214,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,3847.0
178,Glycine max,BAO_0000357,,,9,,CHEMBL827087,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,3847.0
179,Glycine max,BAO_0000357,,,9,,CHEMBL615215,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,3847.0
180,Glycine max,BAO_0000357,,,9,,CHEMBL615216,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,3847.0
181,Glycine max,BAO_0000357,,,9,,CHEMBL615217,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,3847.0
182,Glycine max,BAO_0000357,,,9,,CHEMBL615218,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,3847.0
183,Glycine max,BAO_0000357,,,9,,CHEMBL615219,,Autocuration,,3094,,D,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,3847.0
184,Mus musculus,BAO_0000019,,,0,,CHEMBL615220,,Autocuration,,10413,,U,22226,1,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,10090.0
185,Mus musculus,BAO_0000219,,,1,,CHEMBL615221,,Intermediate,,16929,,N,80049,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,10090.0
186,,BAO_0000019,,,0,,CHEMBL615222,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,
187,,BAO_0000357,,,8,,CHEMBL615223,,Autocuration,,16587,,H,11489,1,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,
188,,BAO_0000357,,,8,,CHEMBL615224,,Autocuration,,16587,,H,11862,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,
189,,BAO_0000357,,,8,,CHEMBL615225,,Autocuration,,16587,,H,11862,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,
190,,BAO_0000357,,,8,,CHEMBL615226,,Autocuration,,16587,,H,11489,1,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,
191,,BAO_0000357,,,8,,CHEMBL615227,,Autocuration,,16587,,H,11862,1,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,
192,Bos taurus,BAO_0000019,,,9,,CHEMBL615228,,Expert,,8058,,D,12347,1,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,9913.0
193,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615229,,Expert,,9065,,D,100120,1,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,10116.0
194,Rattus norvegicus,BAO_0000357,2369.0,,9,Adrenal gland,CHEMBL615230,,Expert,,8865,,D,100120,1,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,10116.0
195,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615231,,Expert,,9066,,D,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0
196,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL884520,,Expert,,8394,,D,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0
197,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615232,,Expert,,8394,,D,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,10116.0
198,,BAO_0000019,,,8,,CHEMBL615233,,Autocuration,,6431,,H,10328,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,
199,,BAO_0000357,,,8,,CHEMBL827088,,Autocuration,,6431,,H,11490,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,
200,,BAO_0000357,,,8,,CHEMBL615234,,Autocuration,,6431,,H,11490,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,
201,,BAO_0000019,,,8,,CHEMBL615235,,Autocuration,,9295,,H,11134,1,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,
202,,BAO_0000019,,,8,,CHEMBL615236,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
203,,BAO_0000019,,,8,,CHEMBL615237,,Autocuration,,13622,,H,11134,1,Compound was tested in vitro for inhibition of 12-LO human platelet,B,
204,,BAO_0000019,,,8,,CHEMBL615238,,Autocuration,,12079,,H,11134,1,Inhibitory concentration against human platelet 12-lipoxygenase,F,
205,,BAO_0000019,,,8,,CHEMBL615239,,Autocuration,,13622,,H,11134,1,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,
206,Homo sapiens,BAO_0000019,,,9,,CHEMBL615240,,Autocuration,,12079,,D,11134,1,Inhibitory concentration against human platelet 12-lipoxygenase,F,9606.0
207,,BAO_0000019,,,8,,CHEMBL615241,,Expert,,13500,,H,11835,1,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,
208,,BAO_0000357,,,8,,CHEMBL615242,,Expert,,13723,,H,11601,1,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,
209,,BAO_0000019,,,8,,CHEMBL615243,,Autocuration,,16474,,H,11134,1,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,
210,,BAO_0000019,,,8,,CHEMBL615244,,Autocuration,,1630,,H,11134,1,Inhibitory activity against human platelet 12-lipoxygenase,B,
211,,BAO_0000019,,,8,,CHEMBL615245,,Autocuration,,167,,H,11134,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,
212,,BAO_0000019,,,8,,CHEMBL615246,,Autocuration,,16474,,H,11134,1,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,
213,,BAO_0000019,,,8,,CHEMBL615247,,Autocuration,,167,,H,11134,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,
214,,BAO_0000019,,,8,,CHEMBL615248,,Autocuration,,16474,,H,11134,1,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,
215,,BAO_0000357,,,8,,CHEMBL615249,,Autocuration,,10091,,H,11601,1,Inhibitory activity towards porcine 12-lipoxygenase,B,
216,,BAO_0000357,,,8,,CHEMBL615250,,Autocuration,,11966,,H,11601,1,Tested for inhibition against porcine 12-LO,B,
217,,BAO_0000019,,,8,,CHEMBL615251,,Autocuration,,951,,H,12052,1,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,
218,,BAO_0000019,,,8,,CHEMBL615252,,Autocuration,,10997,,H,12052,1,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,
219,,BAO_0000019,,,8,,CHEMBL828340,,Expert,,10193,,H,12052,1,In vitro inhibition of rat platelet 12-lipoxygenase,B,
220,,BAO_0000019,,,8,,CHEMBL615253,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
221,,BAO_0000019,,,8,,CHEMBL615254,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,
222,,BAO_0000019,,,8,,CHEMBL615255,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,
223,,BAO_0000019,,,8,,CHEMBL615256,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
224,,BAO_0000019,,,8,,CHEMBL615257,,Autocuration,,10193,,H,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,
225,,BAO_0000019,,,8,,CHEMBL615258,,Autocuration,,11087,,H,12052,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,
226,Homo sapiens,BAO_0000219,,,1,,CHEMBL615259,,Intermediate,,15569,,N,80007,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,9606.0
227,Homo sapiens,BAO_0000219,,,1,,CHEMBL615260,,Expert,,12989,,N,80007,1,In vitro antitumor activity against 41M cell line.,F,9606.0
228,Homo sapiens,BAO_0000219,,,1,,CHEMBL615261,,Intermediate,,16745,,N,80007,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,9606.0
229,Homo sapiens,BAO_0000219,,,1,,CHEMBL615262,,Intermediate,,15569,,N,80007,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,9606.0
230,Homo sapiens,BAO_0000219,,,1,,CHEMBL615263,,Expert,,12989,,N,80007,1,In vitro antitumor activity against 41McisR cell line.,F,9606.0
231,Homo sapiens,BAO_0000219,,,1,,CHEMBL838393,,Expert,,12989,,N,80007,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,9606.0
232,Homo sapiens,BAO_0000219,,,1,,CHEMBL615264,,Intermediate,,16745,,N,80007,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,9606.0
233,Homo sapiens,BAO_0000357,,,9,,CHEMBL615265,,Expert,,6210,,D,84,1,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,9606.0
234,Homo sapiens,BAO_0000357,,,9,,CHEMBL615266,,Expert,,6210,,D,68,1,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,9606.0
235,,BAO_0000357,,,8,,CHEMBL615267,,Expert,,6226,,H,68,1,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,
236,,BAO_0000357,,,8,,CHEMBL615268,,Expert,,17855,,H,10201,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,
237,,BAO_0000357,,,8,,CHEMBL615269,,Expert,,17855,,H,10201,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,
238,,BAO_0000357,,,8,,CHEMBL615270,,Expert,,17855,,H,10201,1,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,
239,,BAO_0000357,,,8,,CHEMBL615271,,Autocuration,,10413,,H,12220,1,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,
240,Escherichia coli,BAO_0000357,,,8,,CHEMBL615272,,Autocuration,,10413,,H,11303,1,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0
241,Escherichia coli,BAO_0000357,,,8,,CHEMBL615103,,Autocuration,,10413,,H,11303,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0
242,Escherichia coli,BAO_0000357,,,8,,CHEMBL615104,,Autocuration,,10413,,H,11303,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,562.0
243,,BAO_0000357,,,8,,CHEMBL615105,,Autocuration,,10413,,H,12220,1,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,
244,,BAO_0000357,,,8,,CHEMBL872866,,Autocuration,,10413,,H,12220,1,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,
245,Sus scrofa,BAO_0000357,,,8,,CHEMBL615106,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0
246,Sus scrofa,BAO_0000019,,,8,,CHEMBL615107,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,9823.0
247,Sus scrofa,BAO_0000357,,,8,,CHEMBL615108,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,9823.0
248,Sus scrofa,BAO_0000357,,,8,,CHEMBL615109,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,9823.0
249,Sus scrofa,BAO_0000357,,,8,,CHEMBL615110,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0
250,Sus scrofa,BAO_0000019,,,8,,CHEMBL840105,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0
251,Sus scrofa,BAO_0000019,,,8,,CHEMBL615111,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,9823.0
252,Sus scrofa,BAO_0000019,,,8,,CHEMBL615112,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,9823.0
253,Sus scrofa,BAO_0000019,,,8,,CHEMBL615113,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,9823.0
254,Sus scrofa,BAO_0000019,,,8,,CHEMBL615114,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,9823.0
255,Sus scrofa,BAO_0000357,,,8,,CHEMBL615115,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0
256,Sus scrofa,BAO_0000019,,,8,,CHEMBL615116,,Autocuration,,7587,,H,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0
257,,BAO_0000357,,,8,,CHEMBL615698,,Autocuration,,7323,,H,11303,1,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,
258,Sus scrofa,BAO_0000019,,,0,,CHEMBL615699,,Autocuration,,7587,,U,22226,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,9823.0
259,Sus scrofa,BAO_0000019,,,0,,CHEMBL615700,,Autocuration,,7587,,U,22226,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,9823.0
260,Saccharomyces cerevisiae,BAO_0000357,,,8,,CHEMBL615701,,Expert,,13750,,H,100249,1,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,4932.0
261,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615702,,Autocuration,,7662,,U,22226,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0
262,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615703,,Autocuration,,7662,,U,22226,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0
263,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615704,,Autocuration,,7662,,U,22226,1,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,10116.0
264,,BAO_0000019,,,6,,CHEMBL615705,,Autocuration,,12211,,H,104698,1,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,
265,,BAO_0000019,,,6,,CHEMBL615706,,Autocuration,,12211,,H,104698,1,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,
266,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL615707,,Intermediate,,12211,,D,20033,1,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,10141.0
267,,BAO_0000019,,,8,,CHEMBL615708,,Expert,,12211,,H,10623,1,Stimulatory activity of intragastric pressure was tested in the rat,F,
268,,BAO_0000357,,,8,,CHEMBL615709,,Autocuration,,15453,,H,121,1,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,
269,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615710,,Autocuration,,11884,,U,22226,1,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,10116.0
270,,BAO_0000019,,,8,,CHEMBL615711,,Autocuration,,7185,,H,12688,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,
271,Homo sapiens,BAO_0000357,,,9,,CHEMBL615712,,Expert,,6876,,D,121,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,9606.0
272,Homo sapiens,BAO_0000357,,,9,,CHEMBL836325,,Expert,,6876,,D,121,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,9606.0
273,,BAO_0000019,,,8,,CHEMBL615713,,Autocuration,,11863,,H,12198,1,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,
274,,BAO_0000357,,,8,,CHEMBL615714,,Autocuration,,11863,,H,12198,1,Inhibition constant of high-affinity 5-HT uptake,B,
275,,BAO_0000019,,,8,,CHEMBL615715,,Autocuration,,11863,,H,12198,1,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,
276,,BAO_0000019,,,8,,CHEMBL615716,,Autocuration,,11863,,H,12198,1,Maximum rate was determined for high affinity transport of 5-HT,F,
277,,BAO_0000019,,,4,,CHEMBL615717,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-HT uptake,F,
278,,BAO_0000019,,,8,,CHEMBL881818,,Expert,,15796,,H,10577,1,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,
279,Bos taurus,BAO_0000357,,,8,,CHEMBL884540,,Expert,,15796,,H,105,1,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,9913.0
280,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL615718,,Autocuration,,12801,,D,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,10116.0
281,,BAO_0000224,,,4,,CHEMBL615719,,Autocuration,,12801,,H,104744,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,
282,,BAO_0000249,,,4,,CHEMBL615720,,Autocuration,,12120,,H,104744,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,
283,,BAO_0000249,,,4,,CHEMBL615721,,Autocuration,,12120,,H,104744,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,
284,,BAO_0000019,,,4,,CHEMBL615722,,Autocuration,,11963,,H,104744,1,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
285,,BAO_0000019,,,8,,CHEMBL615723,,Autocuration,,11701,,H,51,1,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,
286,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615724,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
287,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615725,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
288,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615726,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
289,,BAO_0000218,,,8,,CHEMBL615727,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,
290,Cavia porcellus,BAO_0000019,,,9,,CHEMBL615728,,Intermediate,,11574,,D,105570,1,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,10141.0
291,,BAO_0000219,,,8,,CHEMBL857971,,Autocuration,,15779,,H,279,1,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
292,,BAO_0000357,,,8,,CHEMBL615729,,Autocuration,,15363,,H,107,1,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,
293,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615730,,Expert,,15363,,D,12687,1,Efficacy against 5-hydroxytryptamine 2A receptor,F,10116.0
294,,BAO_0000019,,,8,,CHEMBL615731,,Expert,,15329,,H,12687,1,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,
295,,BAO_0000019,,,8,,CHEMBL615732,,Expert,,15329,,H,12687,1,Relative potency towards 5-HT2A receptor of rat tail artery,F,
296,,BAO_0000019,,,8,,CHEMBL615733,,Expert,,15329,,H,12687,1,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,
297,,BAO_0000019,,,8,,CHEMBL615734,,Expert,,15329,,H,12687,1,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,
298,,BAO_0000019,,,8,,CHEMBL615735,,Autocuration,,15329,,H,12687,1,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,
299,,BAO_0000019,,,8,,CHEMBL615736,,Expert,,15329,,H,12687,1,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,
300,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL615737,,Intermediate,,273,,D,20033,1,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0
301,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL615738,,Intermediate,,273,,D,20033,1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,10141.0
302,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL615739,,Intermediate,,273,,D,20033,1,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0
303,,BAO_0000357,,,8,,CHEMBL615278,,Autocuration,,12092,,H,10623,1,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,
304,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615279,,Expert,,1317,,D,10623,1,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,10116.0
305,,BAO_0000357,,,8,,CHEMBL615280,,Expert,,12409,,H,168,1,Binding affinity against 5-hydroxytryptamine 4 receptor,B,
306,Gallus gallus,BAO_0000019,,,0,,CHEMBL615281,,Autocuration,,11126,,U,22226,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,9031.0
307,Homo sapiens,BAO_0000019,,,0,,CHEMBL615282,,Autocuration,,11126,,U,22226,1,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,9606.0
308,Homo sapiens,BAO_0000019,,,0,,CHEMBL615283,,Autocuration,,11126,,U,22226,1,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,9606.0
309,Homo sapiens,BAO_0000219,,,1,,CHEMBL615284,,Autocuration,,11126,,N,80156,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,9606.0
310,Homo sapiens,BAO_0000019,,,0,,CHEMBL615285,,Autocuration,,11126,,U,22226,1,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,9606.0
311,Homo sapiens,BAO_0000019,,,0,,CHEMBL615286,,Autocuration,,11126,,U,22226,1,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,9606.0
312,Homo sapiens,BAO_0000219,,,7,,CHEMBL615287,,Autocuration,,17807,,D,104703,1,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,9606.0
313,,BAO_0000220,,,2,,CHEMBL615288,,Intermediate,,16575,,S,100256,1,Chymotryptic inhibitory activity against 26S proteasome,F,
314,,BAO_0000220,,,2,,CHEMBL615289,,Intermediate,,15407,,S,100256,1,Inhibitory activity against 26S proteasome degradation of IkB,B,
315,Homo sapiens,BAO_0000219,,,1,,CHEMBL615290,,Intermediate,,10797,,N,81034,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,9606.0
316,Homo sapiens,BAO_0000219,,,1,,CHEMBL884522,,Intermediate,,10797,,N,81034,1,In vitro inhibition of 2780/S ovarian cancer cell line,F,9606.0
317,Homo sapiens,BAO_0000019,,,0,,CHEMBL615291,,Autocuration,,3469,,U,22226,1,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,9606.0
318,,BAO_0000225,,,3,,CHEMBL615292,,Intermediate,,16037,,M,22222,1,Association constant for binding to AATT 28-mer AATT hairpin,B,
319,,BAO_0000225,,,3,,CHEMBL615293,,Intermediate,,16037,,M,22222,1,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,
320,,BAO_0000225,,,3,,CHEMBL615294,,Intermediate,,16037,,M,22222,1,Reaction Rate Parameter for 28-mer AATT hairpin,B,
321,,BAO_0000225,,,3,,CHEMBL615295,,Intermediate,,16037,,M,22222,1,Reaction Rate Parameter for 28-mer AATT hairpin,B,
322,Homo sapiens,BAO_0000019,,,0,,CHEMBL825021,,Autocuration,,16524,,U,22226,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,9606.0
323,Homo sapiens,BAO_0000019,,,0,,CHEMBL615296,,Autocuration,,16524,,U,22226,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,9606.0
324,Homo sapiens,BAO_0000019,,,0,,CHEMBL615297,,Autocuration,,16524,,U,22226,1,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,9606.0
325,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL615298,,Autocuration,,16758,,U,22226,1,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,10029.0
326,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL615299,,Autocuration,,16758,,U,22226,1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,10029.0
327,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL615300,,Autocuration,,16758,,U,22226,1,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,10029.0
328,,BAO_0000357,,,8,,CHEMBL615301,,Autocuration,,14360,,H,241,1,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,
329,Homo sapiens,BAO_0000357,,,9,,CHEMBL615302,,Expert,,14360,,D,241,1,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,9606.0
330,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615303,,Autocuration,,9964,,U,22226,1,Selectivity ratio of ID50 in liver and heart,B,10116.0
331,,BAO_0000019,,,8,,CHEMBL615304,,Autocuration,,9964,,H,12132,1,"Selectivity, ratio of relative ID50 in liver and heart",B,
332,,BAO_0000019,,,8,,CHEMBL615305,,Autocuration,,9964,,H,12132,1,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,
333,,BAO_0000218,,,8,,CHEMBL615306,,Autocuration,,9964,,H,12132,1,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
334,,BAO_0000218,,,8,,CHEMBL615307,,Autocuration,,9964,,H,12132,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
335,,BAO_0000218,,,8,,CHEMBL615308,,Autocuration,In vivo,9964,,H,12132,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
336,,BAO_0000218,,,8,,CHEMBL615309,,Autocuration,In vivo,9964,,H,12132,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,
337,,BAO_0000019,,,0,,CHEMBL615310,,Autocuration,,9964,,U,22226,1,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,
338,,BAO_0000019,,,8,,CHEMBL615311,,Autocuration,,9964,,H,12132,1,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,
339,Homo sapiens,BAO_0000019,,,0,,CHEMBL615312,,Autocuration,,9964,,U,22226,1,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,9606.0
340,,BAO_0000019,,,8,,CHEMBL615313,,Autocuration,,9964,,H,12132,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,
341,,BAO_0000019,,,8,,CHEMBL615314,,Autocuration,,9964,,H,12132,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,
342,,BAO_0000019,,,8,,CHEMBL615315,,Autocuration,,9964,,H,12132,1,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,
343,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615316,,Autocuration,,9964,,U,22226,1,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,10116.0
344,,BAO_0000218,,,8,,CHEMBL615317,,Autocuration,In vivo,9964,,H,12132,1,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,
345,,BAO_0000218,,,8,,CHEMBL615318,,Autocuration,,9964,,H,12132,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
346,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615319,,Autocuration,,9964,,U,22226,1,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,10116.0
347,,BAO_0000019,,,8,,CHEMBL615320,,Autocuration,,9964,,H,12132,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,
348,,BAO_0000019,,,8,,CHEMBL615321,,Autocuration,,9964,,H,12132,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,
349,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615322,,Autocuration,,3796,,U,22226,1,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,10116.0
350,Escherichia coli,BAO_0000357,,,8,,CHEMBL615323,,Autocuration,,4251,,H,19690,1,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0
351,Escherichia coli,BAO_0000357,,,8,,CHEMBL615407,,Autocuration,,4251,,H,19690,1,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0
352,Escherichia coli,BAO_0000357,,,8,,CHEMBL857267,,Autocuration,,4251,,H,19690,1,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0
353,Escherichia coli,BAO_0000357,,,8,,CHEMBL615408,,Autocuration,,4251,,H,19690,1,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0
354,,BAO_0000357,,,8,,CHEMBL615409,,Autocuration,,166,,H,19690,1,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,
355,,BAO_0000357,,,8,,CHEMBL615410,,Autocuration,,17861,,H,19690,1,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,
356,,BAO_0000357,,,8,,CHEMBL615411,,Autocuration,,166,,H,19690,1,Inhibition constant against 3-dehydroquinate synthase,B,
357,,BAO_0000357,,,8,,CHEMBL615412,,Autocuration,,166,,H,19690,1,Association rate constant against 3-dehydroquinate synthase,B,
358,,BAO_0000357,,,8,,CHEMBL615413,,Autocuration,,166,,H,19690,1,Rate constant against 3-dehydroquinate synthase,B,
359,,BAO_0000019,,,0,,CHEMBL615414,,Autocuration,,3548,,U,22226,1,Inhibitory activity against fuc-TVII,B,
360,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615415,,Autocuration,,9877,,D,12236,1,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0
361,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615416,,Autocuration,,9877,,D,12236,1,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0
362,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615417,,Autocuration,,9877,,D,12236,1,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0
363,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615418,,Autocuration,,9877,,D,12236,1,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0
364,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615419,,Autocuration,,9877,,D,12236,1,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0
365,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615420,,Autocuration,,9877,,D,12236,1,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,10116.0
366,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615421,,Autocuration,,9877,,D,12236,1,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,10116.0
367,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615422,,Autocuration,,9877,,D,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,10116.0
368,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615423,,Autocuration,,9877,,D,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,10116.0
369,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL872868,,Autocuration,,9877,,D,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,10116.0
370,Rattus norvegicus,BAO_0000251,2107.0,,9,Liver,CHEMBL615424,,Autocuration,,9877,,D,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,10116.0
371,,BAO_0000224,,,4,,CHEMBL825022,,Autocuration,,3003,,H,104832,1,Inhibitory activity against 3-phosphoglycerate kinase.,B,
372,,BAO_0000224,,,4,,CHEMBL615425,,Autocuration,,3003,,H,104832,1,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,
373,,BAO_0000224,,,4,,CHEMBL615426,,Autocuration,,3003,,H,104832,1,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,
374,Homo sapiens,BAO_0000357,,,9,,CHEMBL615427,,Expert,,17185,,D,10612,1,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,9606.0
375,Homo sapiens,BAO_0000219,,,1,,CHEMBL615428,,Intermediate,,6072,,N,80616,1,Cytotoxicity on 3677 melanoma cells,F,9606.0
376,Homo sapiens,BAO_0000219,,,1,,CHEMBL615429,,Intermediate,,6072,,N,80616,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,9606.0
377,Mus musculus,BAO_0000219,,,1,,CHEMBL615430,,Intermediate,,5018,,N,80617,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,10090.0
378,Homo sapiens,BAO_0000019,,,0,,CHEMBL615431,,Intermediate,,2852,,U,22226,1,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,9606.0
379,,BAO_0000218,,,0,,CHEMBL615432,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,
380,,BAO_0000218,,,0,,CHEMBL615433,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,
381,Human rhinovirus 14,BAO_0000019,,,9,,CHEMBL615434,,Expert,,3245,,D,12464,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,12131.0
382,Human rhinovirus sp.,BAO_0000218,,,1,,CHEMBL615435,,Intermediate,,3245,,N,50085,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,169066.0
383,human rhinovirus type 14,BAO_0000218,,,1,,CHEMBL615436,,Intermediate,,3877,,N,50679,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,169066.0
384,human rhinovirus type 14,BAO_0000218,,,1,,CHEMBL615437,,Intermediate,,3877,,N,50679,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,169066.0
385,Human rhinovirus 14,BAO_0000019,,,9,,CHEMBL615438,,Expert,,5861,,D,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0
386,Human rhinovirus 14,BAO_0000019,,,9,,CHEMBL615439,,Expert,,5861,,D,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0
387,Human rhinovirus 14,BAO_0000019,,,9,,CHEMBL615440,,Expert,,5861,,D,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0
388,Human rhinovirus 14,BAO_0000019,,,9,,CHEMBL615441,,Expert,,5861,,D,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,12131.0
389,Enterovirus,BAO_0000218,,,1,,CHEMBL615641,,Intermediate,,13748,,N,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,12059.0
390,Enterovirus,BAO_0000218,,,1,,CHEMBL872065,,Intermediate,,13748,,N,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,12059.0
391,Enterovirus,BAO_0000218,,,1,,CHEMBL825023,,Intermediate,,13748,,N,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,12059.0
392,Enterovirus,BAO_0000218,,,1,,CHEMBL615642,,Intermediate,,13748,,N,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,12059.0
393,Human rhinovirus B,BAO_0000357,,,8,,CHEMBL615643,,Expert,,13748,,H,12464,1,Inhibition of human rhinovirus 3C protease,B,147712.0
394,Homo sapiens,BAO_0000019,,,0,,CHEMBL615644,,Autocuration,,17699,,U,22226,1,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,9606.0
395,Mus musculus,BAO_0000218,,,1,,CHEMBL615645,,Intermediate,,7145,,N,80619,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,10090.0
396,Mus musculus,BAO_0000218,,,1,,CHEMBL615646,,Intermediate,,7145,,N,80619,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,10090.0
397,Mus musculus,BAO_0000218,,,1,,CHEMBL615647,,Intermediate,,7145,,N,80619,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,10090.0
398,Mus musculus,BAO_0000218,,,1,,CHEMBL615648,,Intermediate,,7145,,N,80619,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,10090.0
399,Mus musculus,BAO_0000218,,,1,,CHEMBL615649,,Intermediate,,7145,,N,80619,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,10090.0
400,Mus musculus,BAO_0000218,,,1,,CHEMBL615650,,Intermediate,,7145,,N,80619,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,10090.0
401,Mus musculus,BAO_0000218,,,1,,CHEMBL615651,,Intermediate,,5325,,N,80620,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0
402,Mus musculus,BAO_0000218,,,1,,CHEMBL615652,,Intermediate,,5325,,N,80620,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0
403,Mus musculus,BAO_0000218,,,1,,CHEMBL615653,,Expert,,5325,,N,80620,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,10090.0
404,Mus musculus,BAO_0000219,,,1,,CHEMBL615654,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,10090.0
405,Mus musculus,BAO_0000219,,,1,,CHEMBL615655,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,10090.0
406,Mus musculus,BAO_0000219,,,1,,CHEMBL825024,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,10090.0
407,Mus musculus,BAO_0000219,,,1,,CHEMBL615656,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,10090.0
408,Mus musculus,BAO_0000219,,,1,,CHEMBL615657,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,10090.0
409,Mus musculus,BAO_0000219,,,1,,CHEMBL615658,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,10090.0
410,Mus musculus,BAO_0000219,,,1,,CHEMBL615659,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,10090.0
411,Mus musculus,BAO_0000219,,,1,,CHEMBL615660,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,10090.0
412,Mus musculus,BAO_0000219,,,1,,CHEMBL615661,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0
413,Mus musculus,BAO_0000219,,,1,,CHEMBL615662,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,10090.0
414,Mus musculus,BAO_0000219,,,1,,CHEMBL615663,,Intermediate,,16169,,N,80620,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,10090.0
415,Mus musculus,BAO_0000219,,,1,,CHEMBL615664,,Intermediate,,16169,,N,80620,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,10090.0
416,Mus musculus,BAO_0000219,,,1,,CHEMBL615665,,Intermediate,,16169,,N,80620,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,10090.0
417,Mus musculus,BAO_0000219,,,1,,CHEMBL615666,,Intermediate,,16169,,N,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0
418,Mus musculus,BAO_0000219,,,1,,CHEMBL615667,,Intermediate,,16169,,N,80620,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0
419,Mus musculus,BAO_0000219,,,1,,CHEMBL615668,,Intermediate,,16169,,N,80620,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0
420,Mus musculus,BAO_0000219,,,1,,CHEMBL615669,,Intermediate,,16169,,N,80620,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0
421,Mus musculus,BAO_0000219,,,1,,CHEMBL615670,,Intermediate,,16169,,N,80620,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0
422,Mus musculus,BAO_0000219,,,1,,CHEMBL836739,,Intermediate,,16169,,N,80620,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0
423,Mus musculus,BAO_0000219,,,1,,CHEMBL615671,,Intermediate,,16169,,N,80620,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0
424,Mus musculus,BAO_0000219,,,1,,CHEMBL615672,,Intermediate,,16169,,N,80620,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0
425,Mus musculus,BAO_0000219,,,1,,CHEMBL615791,,Intermediate,,16169,,N,80620,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0
426,Mus musculus,BAO_0000219,,,1,,CHEMBL615792,,Intermediate,,16169,,N,80620,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0
427,Mus musculus,BAO_0000219,,,1,,CHEMBL615793,,Intermediate,,16169,,N,80620,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0
428,Mus musculus,BAO_0000219,,,1,,CHEMBL615794,,Intermediate,,16169,,N,80620,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0
429,Mus musculus,BAO_0000219,,,1,,CHEMBL615795,,Intermediate,,16169,,N,80620,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0
430,Homo sapiens,BAO_0000219,,,1,,CHEMBL615590,,Intermediate,,15547,,N,80621,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,9606.0
431,,BAO_0000218,,,0,,CHEMBL615591,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,
432,,BAO_0000218,,,0,,CHEMBL615592,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,
433,,BAO_0000218,,,0,,CHEMBL615593,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,
434,,BAO_0000218,,,0,,CHEMBL615594,,Autocuration,,8663,,U,22226,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,
435,Mus musculus,BAO_0000219,,,1,,CHEMBL615595,,Intermediate,,4504,,N,80951,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0
436,Mus musculus,BAO_0000219,,,1,,CHEMBL615596,,Intermediate,,4504,,N,80951,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0
437,,BAO_0000219,,,8,,CHEMBL615597,,Expert,,12695,,H,11169,1,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,
438,Mus musculus,BAO_0000219,,,1,,CHEMBL615598,,Intermediate,,12695,,N,80951,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,10090.0
439,Mus musculus,BAO_0000219,,,1,,CHEMBL615599,,Intermediate,,12695,,N,80951,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,10090.0
440,Mus musculus,BAO_0000219,,,1,,CHEMBL615600,,Expert,,17642,,N,80951,1,Effective dose against murine 3T3 fibroblasts cells,F,10090.0
441,Mus musculus,BAO_0000219,,,1,,CHEMBL615601,,Expert,,17642,,N,80951,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,10090.0
442,Mus musculus,BAO_0000219,,,1,,CHEMBL615602,,Expert,,12340,,N,80951,1,Cytotoxic effect on 3T3 cells,F,10090.0
443,Mus musculus,BAO_0000219,,,1,,CHEMBL615603,,Expert,,12340,,N,80951,1,Cytotoxic effect on 3T3 cells,F,10090.0
444,Mus musculus,BAO_0000219,,,1,,CHEMBL615604,,Intermediate,,12716,,N,80951,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,10090.0
445,Mus musculus,BAO_0000219,,,1,,CHEMBL615605,,Intermediate,,6277,,N,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0
446,Mus musculus,BAO_0000219,,,1,,CHEMBL615606,,Intermediate,,6277,,N,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,10090.0
447,Mus musculus,BAO_0000219,,,1,,CHEMBL884526,,Expert,,6277,,N,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,10090.0
448,Mus musculus,BAO_0000219,,,1,,CHEMBL615607,,Expert,,6277,,N,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,10090.0
449,Mus musculus,BAO_0000219,,,1,,CHEMBL615608,,Intermediate,,6277,,N,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,10090.0
450,Mus musculus,BAO_0000219,,,1,,CHEMBL615609,,Expert,,6277,,N,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,10090.0
451,Mus musculus,BAO_0000219,,,1,,CHEMBL615682,,Expert,,6277,,N,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,10090.0
452,Mus musculus,BAO_0000219,,,1,,CHEMBL615683,,Intermediate,,6277,,N,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,10090.0
453,Mus musculus,BAO_0000218,,,1,,CHEMBL615684,,Expert,,17780,,N,80951,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,10090.0
454,Mus musculus,BAO_0000219,,,7,,CHEMBL615685,,Autocuration,,12751,,D,104860,1,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,10090.0
455,Mus musculus,BAO_0000219,,,1,,CHEMBL615686,,Expert,,12380,,N,80951,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,10090.0
456,Mus musculus,BAO_0000219,,,1,,CHEMBL615687,,Intermediate,,14892,,N,80951,1,Inhibitory activity against 3T3 cell line,F,10090.0
457,Mus musculus,BAO_0000219,,,1,,CHEMBL884523,,Intermediate,,12695,,N,80951,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,10090.0
458,,BAO_0000019,,,8,,CHEMBL615688,,Expert,,12695,,H,11169,1,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,
459,Mus musculus,BAO_0000219,,,1,,CHEMBL615689,,Intermediate,,12695,,N,80951,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,10090.0
460,Mus musculus,BAO_0000219,,,1,,CHEMBL615690,,Intermediate,,12695,,N,80951,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,10090.0
461,,BAO_0000019,,,8,,CHEMBL615691,,Expert,,12695,,H,11169,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,
462,,BAO_0000019,,,8,,CHEMBL615692,,Expert,,12695,,H,11169,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,
463,Mus musculus,BAO_0000219,,,1,,CHEMBL615693,,Intermediate,,6277,,N,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0
464,Mus musculus,BAO_0000219,,,1,,CHEMBL615324,,Expert,,6277,,N,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,10090.0
465,Homo sapiens,BAO_0000219,,,9,,CHEMBL615325,,Expert,,4959,,D,9,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,9606.0
466,Homo sapiens,BAO_0000219,,,9,,CHEMBL615490,,Expert,,4959,,D,9,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,9606.0
467,Homo sapiens,BAO_0000219,,,9,,CHEMBL615491,,Expert,,4959,,D,188,1,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,9606.0
468,Homo sapiens,BAO_0000219,,,9,,CHEMBL615492,,Expert,,4959,,D,188,1,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,9606.0
469,Mus musculus,BAO_0000219,,,1,,CHEMBL615493,,Intermediate,,12082,,N,80951,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,10090.0
470,Mus musculus,BAO_0000219,,,1,,CHEMBL615494,,Intermediate,,12082,,N,80951,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,10090.0
471,Mus musculus,BAO_0000219,,,1,,CHEMBL615495,,Intermediate,,12082,,N,80951,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,10090.0
472,Mus musculus,BAO_0000219,,,1,,CHEMBL615496,,Intermediate,,12082,,N,80951,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,10090.0
473,Mus musculus,BAO_0000219,,,1,,CHEMBL615497,,Intermediate,,2643,,N,80951,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,10090.0
474,Mus musculus,BAO_0000219,,,1,,CHEMBL615498,,Expert,,11926,,N,80951,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,10090.0
475,Mus musculus,BAO_0000219,,,1,,CHEMBL615499,,Intermediate,,15204,,N,80951,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,10090.0
476,Mus musculus,BAO_0000219,,,1,,CHEMBL835522,,Expert,,15992,,N,80951,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,10090.0
477,Mus musculus,BAO_0000219,,,1,,CHEMBL615500,,Intermediate,,16279,,N,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,10090.0
478,Mus musculus,BAO_0000219,,,1,,CHEMBL615501,,Intermediate,,16279,,N,80951,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0
479,Mus musculus,BAO_0000219,,,1,,CHEMBL615502,,Intermediate,,16279,,N,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0
480,Mus musculus,BAO_0000219,,,1,,CHEMBL615503,,Intermediate,,16279,,N,80951,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0
481,Mus musculus,BAO_0000219,,,1,,CHEMBL615504,,Intermediate,,16279,,N,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0
482,Mus musculus,BAO_0000219,,,1,,CHEMBL615505,,Intermediate,,16279,,N,80951,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0
483,Mus musculus,BAO_0000219,,,1,,CHEMBL615506,,Expert,,12831,,N,80951,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,10090.0
484,Mus musculus,BAO_0000219,,,1,,CHEMBL615507,,Intermediate,,13497,,N,80951,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,10090.0
485,,BAO_0000218,,,1,,CHEMBL615508,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
486,Mus musculus,BAO_0000219,,,1,,CHEMBL615509,,Intermediate,,13618,,N,80006,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,10090.0
487,Mus musculus,BAO_0000219,,,1,,CHEMBL615510,,Intermediate,,11902,,N,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,10090.0
488,Mus musculus,BAO_0000219,,,1,,CHEMBL615511,,Intermediate,,11902,,N,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,10090.0
489,Mus musculus,BAO_0000219,,,1,,CHEMBL615512,,Intermediate,,11902,,N,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,10090.0
490,Mus musculus,BAO_0000218,,,1,,CHEMBL615513,,Intermediate,,14840,,N,80006,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,10090.0
491,Mus musculus,BAO_0000218,,,1,,CHEMBL615514,,Intermediate,,14840,,N,80006,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,10090.0
492,,BAO_0000219,,,1,,CHEMBL615515,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,
493,,BAO_0000219,,,1,,CHEMBL615516,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,
494,,BAO_0000219,,,1,,CHEMBL615517,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
495,,BAO_0000219,,,1,,CHEMBL615518,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,
496,,BAO_0000219,,,1,,CHEMBL615519,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
497,,BAO_0000218,,,1,,CHEMBL615520,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,
498,,BAO_0000218,,,1,,CHEMBL615521,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,
499,,BAO_0000218,,,1,,CHEMBL615522,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,
500,,BAO_0000218,,,1,,CHEMBL615523,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
501,,BAO_0000218,,,1,,CHEMBL615524,,Expert,,13715,,N,80006,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,
502,,BAO_0000218,,,1,,CHEMBL615525,,Expert,,13715,,N,80006,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
503,,BAO_0000218,,,1,,CHEMBL615526,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,
504,,BAO_0000218,,,1,,CHEMBL615527,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
505,,BAO_0000218,,,1,,CHEMBL615528,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,
506,,BAO_0000218,,,1,,CHEMBL615529,,Expert,,13715,,N,80006,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
507,,BAO_0000218,,,1,,CHEMBL615530,,Expert,,13715,,N,80006,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
508,,BAO_0000218,,,1,,CHEMBL615531,,Expert,,13715,,N,80006,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,
509,,BAO_0000219,,,1,,CHEMBL615532,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,
510,,BAO_0000219,,,1,,CHEMBL615533,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
511,,BAO_0000219,,,1,,CHEMBL615534,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,
512,,BAO_0000218,,,1,,CHEMBL615535,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,
513,,BAO_0000218,,,1,,CHEMBL615536,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
514,,BAO_0000218,,,1,,CHEMBL615537,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
515,,BAO_0000218,,,1,,CHEMBL615538,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
516,,BAO_0000218,,,1,,CHEMBL836166,,Intermediate,,13715,,N,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,
517,,BAO_0000219,,,8,,CHEMBL615539,,Expert,,6411,,H,11214,1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,
518,Mus musculus,BAO_0000219,,,1,,CHEMBL615540,,Intermediate,,6411,,N,80006,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,10090.0
519,,BAO_0000219,,,8,,CHEMBL615541,,Expert,,6411,,H,11214,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,
520,Mus musculus,BAO_0000219,,,1,,CHEMBL615542,,Expert,,3966,,N,80006,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,10090.0
521,Mus musculus,BAO_0000219,,,1,,CHEMBL615543,,Intermediate,,3966,,N,80006,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,10090.0
522,Mus musculus,BAO_0000219,,,1,,CHEMBL615544,,Expert,,15556,,N,80006,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,10090.0
523,Mus musculus,BAO_0000219,,,1,,CHEMBL615545,,Expert,,5845,,N,80006,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0
524,Mus musculus,BAO_0000219,,,1,,CHEMBL615546,,Expert,,14422,,N,80006,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0
525,Mus musculus,BAO_0000219,,,1,,CHEMBL615547,,Expert,,5845,,N,80006,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,10090.0
526,Mus musculus,BAO_0000219,,,1,,CHEMBL615548,,Expert,,14508,,N,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,10090.0
527,Mus musculus,BAO_0000219,,,1,,CHEMBL615549,,Expert,,14508,,N,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,10090.0
528,Mus musculus,BAO_0000219,,,1,,CHEMBL615550,,Expert,,14508,,N,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,10090.0
529,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615551,,Intermediate,,6349,,N,80622,1,Inhibitory activity against rat fibroblast (3Y1) cell line,F,10116.0
530,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615552,,Expert,,15899,,N,80622,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,10116.0
531,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615553,,Expert,,15899,,N,80622,1,Cytotoxicity in 3Y1 cells.,F,10116.0
532,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615554,,Expert,,15899,,N,80622,1,Cytostatic effect in 3Y1 cells.,F,10116.0
533,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615555,,Intermediate,,15899,,N,80622,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,10116.0
534,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL615556,,Expert,,17038,,N,80622,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,10116.0
535,,BAO_0000019,,,0,,CHEMBL615557,,Autocuration,,12421,,U,22226,1,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,
536,,BAO_0000019,,,0,,CHEMBL615558,,Autocuration,,12947,,U,22226,1,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,
537,,BAO_0000019,,,0,,CHEMBL872066,,Autocuration,,12947,,U,22226,1,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,
538,Sus scrofa,BAO_0000019,,,9,,CHEMBL615559,,Expert,,4896,,D,11607,1,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,9823.0
539,,BAO_0000019,,,8,,CHEMBL615560,,Autocuration,,6148,,H,11607,1,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,
540,,BAO_0000019,,,8,,CHEMBL615561,,Autocuration,,16432,,H,11607,1,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,
541,,BAO_0000019,,,8,,CHEMBL857062,,Expert,,4978,,H,11607,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,
542,,BAO_0000019,,,8,,CHEMBL615562,,Expert,,4978,,H,11607,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,
543,,BAO_0000019,,,8,,CHEMBL615563,,Autocuration,,3723,,H,11607,1,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,
544,,BAO_0000357,,,8,,CHEMBL615564,,Autocuration,,3518,,H,11607,1,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,
545,,BAO_0000019,,,8,,CHEMBL615565,,Autocuration,,4164,,H,11607,1,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,
546,,BAO_0000019,,,8,,CHEMBL615566,,Autocuration,,3518,,H,11607,1,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,
547,Sus scrofa,BAO_0000019,,,9,,CHEMBL615567,,Expert,,4164,,D,11607,1,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,9823.0
548,,BAO_0000019,,,8,,CHEMBL615568,,Autocuration,,3518,,H,11607,1,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,
549,,BAO_0000357,,,8,,CHEMBL615569,,Autocuration,,3518,,H,11607,1,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,
550,,BAO_0000019,,,8,,CHEMBL615570,,Autocuration,,4978,,H,11607,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,
551,,BAO_0000019,,,8,,CHEMBL615571,,Autocuration,,4978,,H,11607,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,
552,,BAO_0000224,,,4,,CHEMBL615572,,Autocuration,,6455,,H,104733,1,Binding affinity against melatonin (MT1) receptor (pC1),B,
553,,BAO_0000019,,,0,,CHEMBL615573,,Autocuration,,2222,,U,22226,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,
554,,BAO_0000019,,,0,,CHEMBL615574,,Autocuration,,13020,,U,22226,1,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,
555,,BAO_0000019,,,0,,CHEMBL615575,,Autocuration,,13021,,U,22226,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,
556,,BAO_0000357,,,8,,CHEMBL615576,,Autocuration,,14532,,H,10619,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,
557,,BAO_0000357,,,8,,CHEMBL615577,,Autocuration,,14118,,H,10619,1,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,
558,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615578,,Autocuration,,11884,,H,51,1,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,
559,,BAO_0000357,,,8,,CHEMBL615579,,Expert,,13969,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,
560,,BAO_0000357,,,8,,CHEMBL615580,,Expert,,13392,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor,B,
561,,BAO_0000019,,,8,,CHEMBL615581,,Expert,,14430,,H,51,1,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,
562,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615582,,Autocuration,,12248,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,
563,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615583,,Autocuration,,12249,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,
564,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615584,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
565,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL833691,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
566,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615585,,Autocuration,,9995,,H,51,1,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
567,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615586,,Autocuration,,9995,,H,51,1,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
568,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL884524,,Autocuration,,9995,,H,51,1,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
569,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615587,,Autocuration,,12249,,H,51,1,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,
570,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615588,,Autocuration,,11799,,H,51,1,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,
571,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL615589,,Expert,,14331,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,10116.0
572,Bos taurus,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615442,,Expert,,11884,,H,51,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,9913.0
573,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615443,,Autocuration,,14331,,H,51,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,
574,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615444,,Autocuration,,11701,,H,51,1,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,
575,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615445,,Expert,,11701,,H,51,1,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,
576,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615446,,Autocuration,,12248,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,
577,,BAO_0000219,,,8,,CHEMBL615447,,Autocuration,,12248,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,
578,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615448,,Expert,,12248,,H,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,
579,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615449,,Expert,,12249,,H,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,
580,,BAO_0000219,,,8,,CHEMBL615450,,Autocuration,,12248,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
581,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615451,,Expert,,11799,,H,51,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,
582,,BAO_0000357,,,8,,CHEMBL615452,,Autocuration,,634,,H,51,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,
583,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615453,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
584,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615454,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
585,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615455,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
586,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615456,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
587,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615457,,Autocuration,,9995,,H,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,
588,,BAO_0000218,10000000.0,,8,Hippocampus,CHEMBL615458,,Expert,,12210,,H,51,1,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,
589,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615459,,Expert,,13311,,H,51,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
590,Homo sapiens,BAO_0000219,,,9,,CHEMBL615460,,Expert,,2331,,D,51,1,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,9606.0
591,Cavia porcellus,BAO_0000019,,,8,,CHEMBL615461,,Autocuration,,1375,,H,51,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,10141.0
592,Cavia porcellus,BAO_0000019,,,8,,CHEMBL615462,,Autocuration,,1375,,H,51,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,10141.0
593,Cavia porcellus,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615463,,Autocuration,,11574,,H,51,1,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,10141.0
594,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615464,,Autocuration,,12867,,H,51,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0
595,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615465,,Autocuration,,12867,,H,51,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0
596,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615466,,Autocuration,,12867,,H,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0
597,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615467,,Autocuration,,12867,,H,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0
598,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615468,,Autocuration,,12867,,H,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0
599,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL615469,,Autocuration,,12867,,H,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,10141.0
600,Cavia porcellus,BAO_0000357,,,8,,CHEMBL615470,,Autocuration,,11574,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0
601,Cavia porcellus,BAO_0000357,,,8,,CHEMBL615471,,Autocuration,,13114,,H,51,1,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0
602,Cavia porcellus,BAO_0000357,,,8,,CHEMBL615472,,Autocuration,,13181,,H,51,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,10141.0
603,Cavia porcellus,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL883242,,Autocuration,,10639,,H,106,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,10141.0
604,Cavia porcellus,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615473,,Autocuration,,10639,,H,106,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,10141.0
605,Cricetulus griseus,BAO_0000218,,,8,,CHEMBL615474,,Autocuration,,11883,,H,11863,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,10029.0
606,,BAO_0000357,,,8,,CHEMBL615475,,Autocuration,,17785,,H,51,1,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,
607,,BAO_0000219,,,8,,CHEMBL615476,,Autocuration,,1558,,H,51,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,
608,,BAO_0000219,,,8,,CHEMBL615477,,Autocuration,,1558,,H,51,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,
609,,BAO_0000019,,,8,,CHEMBL615478,,Autocuration,,15740,,H,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,
610,,BAO_0000219,,,8,,CHEMBL615160,,Autocuration,,17624,,H,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,
611,,BAO_0000219,,,8,,CHEMBL615161,,Expert,,17624,,H,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,
612,,BAO_0000219,,,8,,CHEMBL615162,,Autocuration,,17624,,H,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,
613,,BAO_0000219,,,8,,CHEMBL615163,,Autocuration,,17624,,H,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,
614,,BAO_0000219,,,8,,CHEMBL615164,,Expert,,17624,,H,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
615,,BAO_0000219,,,8,,CHEMBL615165,,Expert,,17624,,H,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
616,,BAO_0000219,,,8,,CHEMBL615166,,Autocuration,,17624,,H,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,
617,,BAO_0000219,,,8,,CHEMBL615167,,Autocuration,,14256,,H,51,1,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,
618,Homo sapiens,BAO_0000219,,,9,,CHEMBL615168,,Expert,,3445,,D,51,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0
619,Homo sapiens,BAO_0000219,,,9,,CHEMBL615169,,Expert,,3445,,D,51,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,9606.0
620,Homo sapiens,BAO_0000219,,,9,,CHEMBL615170,,Expert,,17200,,D,51,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,9606.0
621,Homo sapiens,BAO_0000219,,,9,,CHEMBL615171,,Expert,,17200,,D,51,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,9606.0
622,,BAO_0000019,,,8,,CHEMBL615694,,Autocuration,,15180,,H,51,1,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,
623,,BAO_0000019,,,8,,CHEMBL615695,,Autocuration,,15180,,H,51,1,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,
624,,BAO_0000019,,,8,,CHEMBL615696,,Autocuration,,16026,,H,51,1,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
625,,BAO_0000219,,,8,,CHEMBL615697,,Autocuration,,2759,,H,51,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
626,Homo sapiens,BAO_0000219,,,9,,CHEMBL859410,,Expert,,2759,,D,51,1,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0
627,,BAO_0000219,,,8,,CHEMBL615841,,Autocuration,,2759,,H,51,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,
628,Homo sapiens,BAO_0000219,,,9,,CHEMBL615842,,Expert,,2759,,D,51,1,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0
629,,BAO_0000219,,,8,,CHEMBL835003,,Autocuration,,2759,,H,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
630,,BAO_0000219,,,8,,CHEMBL615843,,Autocuration,,2759,,H,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,
631,Homo sapiens,BAO_0000219,,,9,,CHEMBL615979,,Expert,,2759,,D,51,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0
632,,BAO_0000219,,,8,,CHEMBL615980,,Autocuration,,2759,,H,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,
633,Homo sapiens,BAO_0000219,,,9,,CHEMBL615981,,Expert,,2759,,D,51,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0
634,Homo sapiens,BAO_0000019,,,9,,CHEMBL615982,,Expert,,3445,,D,51,1,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,9606.0
635,Homo sapiens,BAO_0000019,,,9,,CHEMBL615983,,Expert,,5272,,D,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0
636,Homo sapiens,BAO_0000019,,,9,,CHEMBL615984,,Expert,,5272,,D,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,9606.0
637,Homo sapiens,BAO_0000019,,,9,,CHEMBL615985,,Expert,,5272,,D,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,9606.0
638,,BAO_0000219,,,8,,CHEMBL615986,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
639,,BAO_0000219,,,8,,CHEMBL615987,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
640,,BAO_0000219,,,8,,CHEMBL615988,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,
641,,BAO_0000219,,,8,,CHEMBL615989,,Expert,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
642,,BAO_0000219,,,8,,CHEMBL615990,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,
643,,BAO_0000219,,,8,,CHEMBL615991,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,
644,,BAO_0000219,,,8,,CHEMBL615992,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
645,,BAO_0000219,,,8,,CHEMBL615993,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,
646,,BAO_0000219,,,8,,CHEMBL615994,,Expert,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
647,,BAO_0000219,,,8,,CHEMBL615995,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,
648,,BAO_0000219,,,8,,CHEMBL615996,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
649,,BAO_0000219,,,8,,CHEMBL615997,,Autocuration,,17624,,H,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,
650,,BAO_0000019,,,8,,CHEMBL615998,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
651,,BAO_0000019,,,8,,CHEMBL615999,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
652,,BAO_0000019,,,8,,CHEMBL616000,,Autocuration,,6563,,H,51,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,
653,,BAO_0000219,,,8,,CHEMBL616001,,Autocuration,,17296,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
654,Homo sapiens,BAO_0000019,,,9,,CHEMBL616002,,Expert,,6876,,D,51,1,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,9606.0
655,,BAO_0000019,,,8,,CHEMBL616003,,Expert,,6876,,H,51,1,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,
656,Homo sapiens,BAO_0000019,,,9,,CHEMBL616004,,Expert,,5272,,D,51,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,9606.0
657,Homo sapiens,BAO_0000019,,,9,,CHEMBL616005,,Expert,,5272,,D,51,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,9606.0
658,,BAO_0000019,,,8,,CHEMBL616006,,Autocuration,,5548,,H,51,1,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
659,,BAO_0000019,,,8,,CHEMBL616007,,Expert,,5548,,H,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,
660,,BAO_0000019,,,8,,CHEMBL616008,,Autocuration,,5548,,H,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
661,,BAO_0000019,,,8,,CHEMBL616009,,Autocuration,,5548,,H,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
662,,BAO_0000019,,,8,,CHEMBL616010,,Expert,,5929,,H,51,1,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,
663,Homo sapiens,BAO_0000019,,,9,,CHEMBL616011,,Expert,,5929,,D,51,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,9606.0
664,Homo sapiens,BAO_0000019,,,9,,CHEMBL615740,,Expert,,5929,,D,51,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,9606.0
665,,BAO_0000019,,,8,,CHEMBL615741,,Autocuration,,16245,,H,51,1,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,
666,,BAO_0000019,,,8,,CHEMBL615742,,Expert,,5640,,H,51,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,
667,,BAO_0000019,,,8,,CHEMBL615743,,Autocuration,,5640,,H,51,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,
668,,BAO_0000219,,,8,,CHEMBL615744,,Autocuration,,14509,,H,51,1,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,
669,,BAO_0000219,,,8,,CHEMBL615745,,Expert,,14509,,H,51,1,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,
670,,BAO_0000357,,,8,,CHEMBL615746,,Autocuration,,15331,,H,51,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
671,,BAO_0000357,,,8,,CHEMBL615747,,Autocuration,,15331,,H,51,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
672,,BAO_0000019,,,8,,CHEMBL615748,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
673,,BAO_0000019,,,8,,CHEMBL615749,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,
674,,BAO_0000019,,,8,,CHEMBL615750,,Autocuration,,6563,,H,51,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,
675,Homo sapiens,BAO_0000019,,,9,,CHEMBL616259,,Expert,,6563,,D,51,1,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,9606.0
676,,BAO_0000019,,,8,,CHEMBL616260,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
677,Homo sapiens,BAO_0000019,,,9,,CHEMBL616261,,Expert,,5272,,D,51,1,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,9606.0
678,Homo sapiens,BAO_0000019,,,9,,CHEMBL616262,,Expert,,5272,,D,51,1,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0
679,Homo sapiens,BAO_0000019,,,9,,CHEMBL616263,,Expert,,5272,,D,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0
680,Homo sapiens,BAO_0000019,,,9,,CHEMBL616264,,Expert,,5272,,D,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,9606.0
681,Homo sapiens,BAO_0000019,,,9,,CHEMBL616265,,Expert,,5272,,D,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,9606.0
682,Homo sapiens,BAO_0000019,,,9,,CHEMBL616266,,Expert,,5272,,D,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0
683,Homo sapiens,BAO_0000019,,,9,,CHEMBL616267,,Expert,,5272,,D,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0
684,Homo sapiens,BAO_0000019,,,9,,CHEMBL616268,,Expert,,5272,,D,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,9606.0
685,Homo sapiens,BAO_0000357,,,9,,CHEMBL616269,,Expert,,16146,,D,51,1,Inhibition of human 5-hydroxytryptamine 1A receptor,B,9606.0
686,,BAO_0000219,,,8,,CHEMBL884528,,Autocuration,,17624,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
687,,BAO_0000219,,,9,,CHEMBL616270,,Expert,,13706,,D,105,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,
688,,BAO_0000219,,,8,,CHEMBL616271,,Autocuration,,15250,,H,51,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,
689,,BAO_0000219,,,8,,CHEMBL616272,,Autocuration,,17624,,H,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
690,,BAO_0000357,,,8,,CHEMBL616273,,Expert,,6861,,H,51,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,
691,Homo sapiens,BAO_0000357,,,9,,CHEMBL616274,,Expert,,17200,,D,51,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,9606.0
692,,BAO_0000219,,,8,,CHEMBL616275,,Autocuration,,17624,,H,51,1,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,
693,,BAO_0000219,,,8,,CHEMBL616276,,Autocuration,,17624,,H,51,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
694,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616277,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0
695,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616278,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,10116.0
696,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616279,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,10116.0
697,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616280,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0
698,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616281,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,10116.0
699,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616282,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0
700,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616283,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,10116.0
701,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616284,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,10116.0
702,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616285,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,10116.0
703,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616286,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,10116.0
704,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616287,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,10116.0
705,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616288,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,10116.0
706,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL616289,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,10116.0
707,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615610,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,10116.0
708,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615611,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,10116.0
709,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615612,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,10116.0
710,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615613,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,10116.0
711,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615614,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,10116.0
712,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL615615,,Autocuration,In vivo,12058,,U,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0
713,,BAO_0000019,,,4,,CHEMBL615616,,Autocuration,,11440,,H,105093,1,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,
714,,BAO_0000249,1898.0,,8,Hypothalamus,CHEMBL615617,,Autocuration,,6238,,H,11923,1,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,
715,,BAO_0000019,,,8,,CHEMBL615618,,Autocuration,,10046,,H,10577,1,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,
716,,BAO_0000019,,,8,,CHEMBL615619,,Autocuration,,10046,,H,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,
717,,BAO_0000019,,,8,,CHEMBL615620,,Expert,,10046,,H,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,
718,,BAO_0000357,,,8,,CHEMBL615621,,Autocuration,,167,,H,55,1,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,
719,,BAO_0000357,,,8,,CHEMBL615622,,Autocuration,,167,,H,55,1,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,
720,,BAO_0000019,,,8,,CHEMBL615623,,Autocuration,,11520,,H,12166,1,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,
721,,BAO_0000019,,,8,,CHEMBL615624,,Autocuration,,11520,,H,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
722,,BAO_0000019,,,8,,CHEMBL615625,,Autocuration,,11520,,H,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
723,,BAO_0000019,,,8,,CHEMBL767045,,Autocuration,,11520,,H,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
724,Cavia porcellus,BAO_0000019,,,8,,CHEMBL615626,,Autocuration,,135,,H,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,10141.0
725,Cavia porcellus,BAO_0000019,,,8,,CHEMBL615627,,Autocuration,,135,,H,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,10141.0
726,Cavia porcellus,BAO_0000019,,,8,,CHEMBL615628,,Autocuration,,11311,,H,55,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,10141.0
727,Cavia porcellus,BAO_0000357,,,8,,CHEMBL615629,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,10141.0
728,Homo sapiens,BAO_0000357,,,9,,CHEMBL615630,,Expert,,12281,,D,55,1,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,9606.0
729,,BAO_0000219,,,8,,CHEMBL615631,,Autocuration,,11311,,H,55,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,
730,,BAO_0000218,,,8,,CHEMBL615632,,Autocuration,,12576,,H,17087,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,
731,,BAO_0000357,,,8,,CHEMBL615633,,Autocuration,,12281,,H,17087,1,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,
732,,BAO_0000218,,,8,,CHEMBL615634,,Autocuration,,12576,,H,17087,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,
733,Sus scrofa,BAO_0000019,,,8,,CHEMBL615635,,Expert,,11089,,H,55,1,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,9823.0
734,,BAO_0000357,,,8,,CHEMBL615636,,Expert,,11006,,H,12166,1,In vitro inhibition of rat 5-Lipoxygenase,B,
735,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615637,,Expert,,11481,,D,12166,1,Inhibitory activity against 5-Lipoxygenase,B,10116.0
736,,BAO_0000219,,,8,,CHEMBL615638,,Expert,,10864,,H,12166,1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,
737,,BAO_0000219,,,8,,CHEMBL615639,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
738,,BAO_0000219,,,8,,CHEMBL615640,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,
739,,BAO_0000019,,,8,,CHEMBL615796,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,
740,,BAO_0000219,,,8,,CHEMBL615845,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,
741,,BAO_0000357,,,8,,CHEMBL615846,,Autocuration,,11006,,H,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,
742,,BAO_0000219,,,8,,CHEMBL615847,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,
743,,BAO_0000357,,,8,,CHEMBL615848,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,
744,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615849,,Autocuration,,11481,,U,22226,1,Ratio of IC50 against 5-LO and COX,B,10116.0
745,,BAO_0000357,,,8,,CHEMBL615850,,Autocuration,,11006,,H,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,
746,,BAO_0000357,,,8,,CHEMBL615851,,Autocuration,,11006,,H,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,
747,,BAO_0000219,,,8,,CHEMBL615852,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,
748,,BAO_0000019,,,8,,CHEMBL615853,,Autocuration,,11006,,H,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,
749,,BAO_0000357,2367.0,,8,Prostate gland,CHEMBL884527,,Autocuration,,4288,,H,120,1,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,
750,Columba livia,BAO_0000019,,,0,,CHEMBL872871,,Autocuration,,7587,,U,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,8932.0
751,Columba livia,BAO_0000019,,,0,,CHEMBL615854,,Autocuration,,7587,,U,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,8932.0
752,Columba livia,BAO_0000019,,,0,,CHEMBL767046,,Autocuration,,7587,,U,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,8932.0
753,,BAO_0000357,,,8,,CHEMBL615855,,Autocuration,,11249,,H,10732,1,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,
754,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615856,,Expert,,8003,,D,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,10116.0
755,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615857,,Expert,,8003,,D,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0
756,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615858,,Expert,,8003,,D,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0
757,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615859,,Expert,,12416,,H,10576,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,
758,,BAO_0000357,,,8,,CHEMBL615860,,Autocuration,,16293,,H,51,1,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,
759,Oryctolagus cuniculus,BAO_0000019,,,0,,CHEMBL615861,,Autocuration,,13047,,U,22226,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0
760,Oryctolagus cuniculus,BAO_0000019,,,0,,CHEMBL615862,,Autocuration,,13047,,U,22226,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0
761,Oryctolagus cuniculus,BAO_0000019,,,0,,CHEMBL615863,,Autocuration,,13047,,U,22226,1,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,9986.0
762,Oryctolagus cuniculus,BAO_0000019,,,0,,CHEMBL615864,,Autocuration,,13047,,U,22226,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0
763,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL615865,,Autocuration,,10085,,H,104744,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,
764,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL615866,,Autocuration,,10085,,H,104744,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,
765,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL615867,,Autocuration,,10085,,H,104744,1,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,
766,,BAO_0000249,,,4,,CHEMBL615868,,Autocuration,,9841,,H,104744,1,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,
767,Rattus norvegicus,BAO_0000249,,,5,,CHEMBL615869,,Autocuration,,8822,,D,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,10116.0
768,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL615870,,Autocuration,,9806,,D,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,10116.0
769,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL615871,,Autocuration,,9806,,D,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,10116.0
770,,BAO_0000224,,,4,,CHEMBL615872,,Autocuration,,8868,,H,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,
771,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL833492,,Autocuration,,9036,,H,104744,1,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,
772,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL615873,,Autocuration,,11374,,H,104744,1,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,
773,,BAO_0000224,,,4,,CHEMBL615479,,Autocuration,,10881,,H,104744,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,
774,,BAO_0000019,,,4,,CHEMBL615480,,Autocuration,,8822,,H,104744,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,
775,Rattus norvegicus,BAO_0000249,,,5,,CHEMBL615481,,Autocuration,,9806,,D,104744,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,10116.0
776,,BAO_0000019,,,4,,CHEMBL872869,,Autocuration,,15463,,H,104744,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
777,,BAO_0000019,,,4,,CHEMBL615482,,Autocuration,,15463,,H,104744,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
778,,BAO_0000221,955.0,,4,Brain,CHEMBL615483,,Autocuration,,14542,,H,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,
779,,BAO_0000221,955.0,,4,Brain,CHEMBL615484,,Autocuration,,14542,,H,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,
780,,BAO_0000019,,,4,,CHEMBL615485,,Autocuration,,8569,,H,104744,1,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,
781,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL615486,,Autocuration,,10062,,D,104744,1,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,10116.0
782,,BAO_0000224,,,4,,CHEMBL615487,,Autocuration,,4771,,H,104744,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,
783,,BAO_0000224,,,4,,CHEMBL615488,,Autocuration,,10062,,H,104744,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
784,,BAO_0000224,,,4,,CHEMBL615489,,Autocuration,,10062,,H,104744,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
785,,BAO_0000224,,,4,,CHEMBL615389,,Autocuration,,10062,,H,104744,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
786,,BAO_0000019,,,4,,CHEMBL615390,,Autocuration,,15463,,H,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,
787,,BAO_0000019,,,4,,CHEMBL615391,,Autocuration,,15463,,H,104744,1,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,
788,,BAO_0000224,,,4,,CHEMBL615392,,Autocuration,,9098,,H,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,
789,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615393,,Autocuration,,3070,,U,22226,1,Affinity for 5-hydroxytryptamine 1 receptor,B,10116.0
790,,BAO_0000221,955.0,,4,Brain,CHEMBL615394,,Autocuration,,14542,,H,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,
791,,BAO_0000221,955.0,,4,Brain,CHEMBL615395,,Autocuration,,14542,,H,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,
792,,BAO_0000224,,,4,,CHEMBL615396,,Autocuration,,6398,,H,104744,1,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,
793,,BAO_0000221,955.0,,4,Brain,CHEMBL615397,,Autocuration,,1344,,H,104744,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,
794,,BAO_0000019,,,4,,CHEMBL615398,,Autocuration,,11963,,H,104744,1,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
795,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615399,,Autocuration,,8908,,U,22226,1,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,10116.0
796,,BAO_0000019,,,4,,CHEMBL615400,,Autocuration,,9098,,H,104744,1,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,
797,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL615401,,Autocuration,,8841,,D,104744,1,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,10116.0
798,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL615402,,Autocuration,,8814,,U,22226,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,10116.0
799,,BAO_0000019,,,4,,CHEMBL615403,,Autocuration,,11752,,H,104744,1,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,
800,,BAO_0000221,955.0,,4,Brain,CHEMBL615404,,Autocuration,,11642,,H,104744,1,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,
801,,BAO_0000019,,,4,,CHEMBL615781,,Autocuration,,11642,,H,104744,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,
802,,BAO_0000220,955.0,,4,Brain,CHEMBL615782,,Autocuration,,9231,,H,104744,1,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,
803,,BAO_0000221,955.0,,4,Brain,CHEMBL615783,,Autocuration,,11351,,H,104744,1,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,
804,,BAO_0000019,,,0,,CHEMBL873481,,Autocuration,,4639,,U,22226,1,Compound was tested for binding affinity against 5-HT1 receptor,B,
805,,BAO_0000019,,,0,,CHEMBL615784,,Autocuration,,1205,,U,22226,1,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,
806,,BAO_0000357,,,8,,CHEMBL615785,,Expert,,10025,,H,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,
807,,BAO_0000249,,,8,,CHEMBL615786,,Autocuration,,13241,,H,10576,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,
808,,BAO_0000218,,,8,,CHEMBL615787,,Autocuration,In vivo,16245,,H,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,
809,,BAO_0000218,,,8,,CHEMBL615788,,Autocuration,In vivo,16245,,H,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,
810,,BAO_0000019,,,8,,CHEMBL767044,,Autocuration,,12438,,H,10576,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,
811,,BAO_0000218,,,8,,CHEMBL615789,,Autocuration,In vivo,16245,,H,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,
812,,BAO_0000218,,,8,,CHEMBL615790,,Autocuration,In vivo,16245,,H,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,
813,,BAO_0000019,,,8,,CHEMBL615813,,Autocuration,,15740,,H,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,
814,,BAO_0000219,,,8,,CHEMBL615814,,Autocuration,,15535,,H,10576,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,
815,,BAO_0000219,,,8,,CHEMBL615815,,Expert,,15535,,H,51,1,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,
816,,BAO_0000219,,,8,,CHEMBL615816,,Autocuration,,15535,,H,10576,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,
817,,BAO_0000249,,,8,,CHEMBL615817,,Expert,,9888,,H,10576,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,
818,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615818,,Autocuration,,10085,,H,10576,1,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,
819,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615819,,Autocuration,,10085,,H,10576,1,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,
820,,BAO_0000249,,,8,,CHEMBL615820,,Expert,,17331,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,
821,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615821,,Expert,,10845,,D,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,10116.0
822,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615822,,Expert,,10845,,D,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0
823,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615823,,Expert,,10845,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,
824,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615824,,Expert,,10845,,D,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,10116.0
825,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615825,,Expert,,10845,,D,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0
826,,BAO_0000357,,,8,,CHEMBL615826,,Expert,,13730,,H,10576,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,
827,,BAO_0000249,,,8,,CHEMBL615827,,Expert,,13508,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,
828,,BAO_0000249,10000000.0,,8,Hippocampus,CHEMBL615828,,Expert,,13508,,H,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,
829,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615829,,Expert,,12073,,H,10576,1,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
830,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615830,,Autocuration,,4671,,H,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,
831,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615831,,Expert,,13631,,H,10576,1,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,
832,,BAO_0000357,,,8,,CHEMBL615832,,Autocuration,,12438,,H,10576,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,
833,,BAO_0000019,,,8,,CHEMBL615833,,Autocuration,,10483,,H,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,
834,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615834,,Autocuration,,10483,,H,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,
835,,BAO_0000249,,,8,,CHEMBL615835,,Intermediate,,12352,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,
836,,BAO_0000249,10000000.0,,8,Hippocampus,CHEMBL615836,,Autocuration,,14732,,H,10576,1,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,
837,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615837,,Expert,,11049,,D,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,10116.0
838,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615838,,Expert,,11049,,D,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,10116.0
839,,BAO_0000249,,,8,,CHEMBL615839,,Expert,,13657,,H,10576,1,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,
840,,BAO_0000019,,,8,,CHEMBL884525,,Autocuration,,11473,,H,10576,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,
841,,BAO_0000249,,,8,,CHEMBL615840,,Autocuration,,2014,,H,10576,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,
842,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615405,,Expert,,3086,,H,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
843,,BAO_0000019,,,8,,CHEMBL615406,,Expert,,15854,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
844,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615900,,Expert,,10922,,H,10576,1,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,
845,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615901,,Expert,,13346,,H,10576,1,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,
846,,BAO_0000357,,,8,,CHEMBL615902,,Expert,,15311,,H,10576,1,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,
847,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615903,,Autocuration,,10922,,H,10576,1,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,
848,,BAO_0000357,,,8,,CHEMBL615904,,Autocuration,,10025,,H,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,
849,,BAO_0000357,,,8,,CHEMBL615905,,Expert,,10025,,H,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,
850,,BAO_0000019,,,8,,CHEMBL615906,,Autocuration,,9742,,H,10576,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,
851,,BAO_0000019,,,8,,CHEMBL615907,,Autocuration,,9742,,H,10576,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,
852,,BAO_0000019,,,8,,CHEMBL615908,,Expert,,12304,,H,10576,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
853,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615909,,Autocuration,,15789,,H,10576,1,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,
854,,BAO_0000019,,,8,,CHEMBL615910,,Autocuration,,9912,,H,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,
855,,BAO_0000019,,,8,,CHEMBL615911,,Autocuration,,9912,,H,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,
856,,BAO_0000019,,,8,,CHEMBL615912,,Autocuration,,9912,,H,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,
857,,BAO_0000019,,,8,,CHEMBL615913,,Expert,,16693,,H,10576,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,
858,,BAO_0000357,,,8,,CHEMBL615914,,Expert,,13276,,H,10576,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
859,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615915,,Autocuration,,12678,,H,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,
860,,BAO_0000357,,,8,,CHEMBL615916,,Autocuration,,11825,,H,10576,1,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,
861,,BAO_0000357,,,8,,CHEMBL615917,,Expert,,12443,,H,10576,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,
862,,BAO_0000357,,,8,,CHEMBL615918,,Expert,,13830,,H,10576,1,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,
863,,BAO_0000249,10000000.0,,8,Hippocampus,CHEMBL615919,,Expert,,14286,,H,10576,1,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,
864,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615920,,Expert,,14356,,D,10576,1,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,10116.0
865,,BAO_0000357,,,8,,CHEMBL615921,,Autocuration,,15306,,H,10576,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,
866,,BAO_0000357,,,8,,CHEMBL615922,,Expert,,15306,,H,10576,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,
867,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL881290,,Expert,,16616,,D,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0
868,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615923,,Autocuration,,3651,,H,10576,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,
869,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615924,,Autocuration,,14331,,H,10576,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,
870,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615925,,Autocuration,,14331,,H,10576,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,
871,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615926,,Expert,,14178,,D,10576,1,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,10116.0
872,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615927,,Expert,,10639,,D,10576,1,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,10116.0
873,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615928,,Autocuration,,12306,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,
874,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615929,,Expert,,1348,,D,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,10116.0
875,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615930,,Autocuration,,13605,,H,10576,1,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,
876,,BAO_0000219,,,8,,CHEMBL615931,,Autocuration,,17624,,H,51,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
877,,BAO_0000219,,,8,,CHEMBL615932,,Autocuration,,17624,,H,51,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
878,,BAO_0000219,,,8,,CHEMBL615933,,Autocuration,,17624,,H,51,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
879,,BAO_0000357,,,8,,CHEMBL615934,,Autocuration,,15267,,H,51,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,
880,,BAO_0000357,,,8,,CHEMBL615935,,Autocuration,,16532,,H,51,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,
881,,BAO_0000019,,,8,,CHEMBL615936,,Autocuration,,6563,,H,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
882,,BAO_0000219,,,8,,CHEMBL615937,,Autocuration,,4751,,H,51,1,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,
883,,BAO_0000357,,,8,,CHEMBL615938,,Autocuration,,15463,,H,51,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,
884,,BAO_0000357,,,8,,CHEMBL615797,,Autocuration,,3805,,H,51,1,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,
885,,BAO_0000357,,,8,,CHEMBL615798,,Autocuration,,5640,,H,51,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
886,,BAO_0000357,,,8,,CHEMBL872870,,Autocuration,,6563,,H,51,1,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,
887,,BAO_0000357,,,8,,CHEMBL615799,,Autocuration,,5548,,H,51,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,
888,,BAO_0000357,,,8,,CHEMBL615800,,Autocuration,,6347,,H,51,1,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,
889,,BAO_0000219,,,8,,CHEMBL615801,,Autocuration,,17296,,H,51,1,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
890,,BAO_0000019,,,8,,CHEMBL615802,,Autocuration,,13047,,H,51,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,
891,,BAO_0000357,,,8,,CHEMBL615803,,Autocuration,,15740,,H,51,1,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,
892,,BAO_0000019,,,8,,CHEMBL835002,,Expert,,5640,,H,51,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,
893,,BAO_0000019,,,8,,CHEMBL615804,,Autocuration,,5640,,H,51,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,
894,,BAO_0000219,,,8,,CHEMBL615805,,Expert,,17211,,H,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,
895,,BAO_0000219,,,8,,CHEMBL615806,,Autocuration,,4751,,H,51,1,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,
896,Homo sapiens,BAO_0000357,,,9,,CHEMBL615807,,Expert,,6491,,D,51,1,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,9606.0
897,,BAO_0000357,,,8,,CHEMBL615808,,Autocuration,,4707,,H,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,
898,Homo sapiens,BAO_0000357,,,9,,CHEMBL615809,,Expert,,13910,,D,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,9606.0
899,,BAO_0000219,,,8,,CHEMBL615810,,Autocuration,,16190,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,
900,,BAO_0000357,,,8,,CHEMBL615811,,Autocuration,,16633,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
901,,BAO_0000219,,,8,,CHEMBL615812,,Autocuration,,11898,,H,51,1,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,
902,,BAO_0000219,,,8,,CHEMBL615751,,Autocuration,,11898,,H,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
903,,BAO_0000357,,,8,,CHEMBL615752,,Autocuration,,14331,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,
904,,BAO_0000219,,,8,,CHEMBL615753,,Expert,,17624,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,
905,,BAO_0000219,,,8,,CHEMBL615754,,Autocuration,,17624,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,
906,,BAO_0000357,,,8,,CHEMBL615755,,Autocuration,,3307,,H,51,1,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,
907,Homo sapiens,BAO_0000219,,,9,,CHEMBL615756,,Expert,,6563,,D,51,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0
908,,BAO_0000019,,,8,,CHEMBL615757,,Autocuration,,14165,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,
909,,BAO_0000357,,,8,,CHEMBL615758,,Autocuration,,5732,,H,51,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,
910,,BAO_0000357,,,8,,CHEMBL615759,,Expert,,13366,,H,51,1,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,
911,,BAO_0000357,,,8,,CHEMBL615760,,Autocuration,,17626,,H,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,
912,,BAO_0000219,,,8,,CHEMBL615761,,Expert,,6588,,H,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,
913,,BAO_0000357,,,8,,CHEMBL872104,,Autocuration,,16209,,H,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,
914,,BAO_0000357,,,8,,CHEMBL615762,,Autocuration,,15463,,H,51,1,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
915,,BAO_0000357,,,8,,CHEMBL615763,,Autocuration,,15463,,H,51,1,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
916,,BAO_0000357,,,8,,CHEMBL615764,,Autocuration,,14770,,H,51,1,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,
917,,BAO_0000219,,,8,,CHEMBL615765,,Autocuration,,16245,,H,51,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,
918,,BAO_0000019,,,8,,CHEMBL615766,,Autocuration,,16245,,H,51,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,
919,,BAO_0000357,,,8,,CHEMBL615767,,Autocuration,,5548,,H,51,1,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,
920,,BAO_0000357,,,8,,CHEMBL615768,,Expert,,5548,,H,51,1,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
921,,BAO_0000357,,,8,,CHEMBL615769,,Autocuration,,5548,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
922,,BAO_0000357,,,8,,CHEMBL615770,,Expert,,6876,,H,51,1,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,
923,,BAO_0000357,,,8,,CHEMBL615771,,Autocuration,,2598,,H,51,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
924,,BAO_0000357,,,8,,CHEMBL615772,,Expert,,17785,,H,51,1,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,
925,,BAO_0000357,,,8,,CHEMBL615773,,Autocuration,,6013,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
926,,BAO_0000357,,,8,,CHEMBL615774,,Expert,,5929,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,
927,,BAO_0000357,,,8,,CHEMBL615775,,Autocuration,,16633,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
928,,BAO_0000357,,,8,,CHEMBL615776,,Autocuration,,1558,,H,51,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,
929,,BAO_0000357,,,8,,CHEMBL615777,,Expert,,16026,,H,51,1,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
930,,BAO_0000219,,,8,,CHEMBL615778,,Autocuration,,12469,,H,51,1,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,
931,Homo sapiens,BAO_0000357,,,9,,CHEMBL615779,,Expert,,15874,,D,51,1,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,9606.0
932,,BAO_0000357,,,8,,CHEMBL615780,,Autocuration,,15874,,H,51,1,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,
933,,BAO_0000357,,,8,,CHEMBL616298,,Autocuration,,3935,,H,51,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,
934,,BAO_0000357,,,8,,CHEMBL616299,,Autocuration,,15818,,H,51,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,
935,,BAO_0000219,,,8,,CHEMBL616300,,Autocuration,,13706,,H,51,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,
936,,BAO_0000219,,,8,,CHEMBL616301,,Expert,,13729,,H,51,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,
937,,BAO_0000019,,,8,,CHEMBL616302,,Autocuration,,15413,,H,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,
938,,BAO_0000019,,,8,,CHEMBL616117,,Autocuration,,15413,,H,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,
939,,BAO_0000019,,,8,,CHEMBL616118,,Autocuration,,15413,,H,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,
940,,BAO_0000019,,,8,,CHEMBL616119,,Autocuration,,15413,,H,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,
941,Homo sapiens,BAO_0000219,,,9,,CHEMBL616120,,Expert,,3445,,D,51,1,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0
942,,BAO_0000357,,,8,,CHEMBL616121,,Autocuration,,15740,,H,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,
943,,BAO_0000357,,,8,,CHEMBL616122,,Autocuration,,15740,,H,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,
944,,BAO_0000357,,,8,,CHEMBL616123,,Autocuration,,17626,,H,51,1,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,
945,Homo sapiens,BAO_0000357,,,9,,CHEMBL616124,,Expert,,4234,,D,51,1,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,9606.0
946,,BAO_0000357,,,8,,CHEMBL616125,,Expert,,5640,,H,51,1,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,
947,Rattus norvegicus,BAO_0000357,,,8,,CHEMBL616126,,Expert,,5272,,H,51,1,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,10116.0
948,,BAO_0000219,,,8,,CHEMBL616127,,Autocuration,,4622,,H,51,1,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,
949,,BAO_0000019,,,8,,CHEMBL616128,,Expert,,17085,,H,51,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,
950,,BAO_0000357,,,8,,CHEMBL616129,,Autocuration,,3025,,H,51,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,
951,,BAO_0000357,,,8,,CHEMBL616130,,Expert,,15315,,H,51,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,
952,,BAO_0000357,,,8,,CHEMBL616131,,Autocuration,,15267,,H,51,1,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,
953,,BAO_0000219,,,8,,CHEMBL616132,,Autocuration,,17158,,H,51,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,
954,Homo sapiens,BAO_0000219,,,9,,CHEMBL616133,,Expert,,14214,,D,51,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,9606.0
955,,BAO_0000357,,,8,,CHEMBL616134,,Autocuration,,17133,,H,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
956,,BAO_0000357,,,8,,CHEMBL616135,,Autocuration,,16532,,H,51,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,
957,Homo sapiens,BAO_0000357,,,9,,CHEMBL616136,,Expert,,2391,,D,51,1,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,9606.0
958,,BAO_0000019,,,8,,CHEMBL616137,,Autocuration,,14447,,H,51,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,
959,,BAO_0000019,,,8,,CHEMBL872105,,Autocuration,,14447,,H,51,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,
960,,BAO_0000357,,,8,,CHEMBL616138,,Autocuration,,15086,,H,51,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,
961,Homo sapiens,BAO_0000357,,,9,,CHEMBL616139,,Expert,,13051,,D,51,1,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,9606.0
962,,BAO_0000019,,,8,,CHEMBL616140,,Autocuration,,16026,,H,51,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,
963,,BAO_0000019,,,8,,CHEMBL616141,,Expert,,17085,,H,51,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,
964,,BAO_0000357,,,8,,CHEMBL616142,,Autocuration,,17133,,H,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
965,,BAO_0000357,,,8,,CHEMBL616143,,Autocuration,,17133,,H,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,
966,,BAO_0000219,,,8,,CHEMBL616144,,Autocuration,,17211,,H,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
967,,BAO_0000219,,,8,,CHEMBL616145,,Autocuration,,17211,,H,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,
968,,BAO_0000219,,,8,,CHEMBL616012,,Autocuration,,17211,,H,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
969,,BAO_0000219,,,8,,CHEMBL616013,,Autocuration,,17211,,H,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
970,,BAO_0000019,,,8,,CHEMBL616014,,Autocuration,,16394,,H,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
971,,BAO_0000019,,,8,,CHEMBL616015,,Autocuration,,16394,,H,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
972,,BAO_0000019,,,8,,CHEMBL616016,,Autocuration,,16394,,H,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
973,,BAO_0000218,,,8,,CHEMBL616017,,Autocuration,In vivo,16394,,H,51,1,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,
974,,BAO_0000019,,,8,,CHEMBL616018,,Autocuration,,16394,,H,51,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,
975,,BAO_0000019,,,8,,CHEMBL616019,,Autocuration,,15740,,H,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,
976,,BAO_0000019,,,8,,CHEMBL616020,,Autocuration,,15740,,H,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,
977,,BAO_0000357,,,8,,CHEMBL858018,,Autocuration,,15740,,H,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,
978,,BAO_0000219,,,8,,CHEMBL616021,,Autocuration,,17296,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
979,,BAO_0000019,,,8,,CHEMBL616022,,Expert,,5640,,H,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,
980,,BAO_0000019,,,8,,CHEMBL616023,,Autocuration,,5640,,H,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,
981,,BAO_0000019,,,8,,CHEMBL616024,,Autocuration,,5640,,H,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,
982,,BAO_0000019,,,8,,CHEMBL616025,,Autocuration,,5640,,H,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,
983,,BAO_0000219,,,8,,CHEMBL616026,,Autocuration,,2759,,H,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
984,,BAO_0000019,,,8,,CHEMBL616027,,Autocuration,,16394,,H,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,
985,Homo sapiens,BAO_0000019,,,9,,CHEMBL616028,,Expert,,16394,,D,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,9606.0
986,Homo sapiens,BAO_0000019,,,9,,CHEMBL616029,,Expert,,3445,,D,51,1,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,9606.0
987,,BAO_0000219,,,8,,CHEMBL616030,,Expert,,4316,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,
988,,BAO_0000019,,,8,,CHEMBL616031,,Expert,,4316,,H,51,1,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,
989,Homo sapiens,BAO_0000019,,,9,,CHEMBL616032,,Expert,,15180,,D,51,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0
990,Homo sapiens,BAO_0000019,,,9,,CHEMBL616033,,Expert,,15180,,D,51,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0
991,,BAO_0000019,,,8,,CHEMBL616034,,Autocuration,,15042,,H,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
992,,BAO_0000019,,,8,,CHEMBL616035,,Autocuration,,15042,,H,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
993,,BAO_0000019,,,8,,CHEMBL616036,,Autocuration,,15042,,H,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,
994,,BAO_0000019,,,8,,CHEMBL616037,,Autocuration,,15042,,H,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
995,,BAO_0000019,,,8,,CHEMBL616038,,Autocuration,,15042,,H,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
996,,BAO_0000019,,,8,,CHEMBL616039,,Autocuration,,15042,,H,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
997,,BAO_0000019,,,8,,CHEMBL616040,,Autocuration,,15042,,H,51,1,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,
998,Homo sapiens,BAO_0000219,,,9,,CHEMBL616041,,Expert,,15180,,D,51,1,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0
999,Homo sapiens,BAO_0000219,,,9,,CHEMBL616042,,Expert,,15180,,D,51,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0
1000,Homo sapiens,BAO_0000219,,,9,,CHEMBL616043,,Expert,,15180,,D,51,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0
1001,,BAO_0000019,,,8,,CHEMBL616044,,Autocuration,,16245,,H,51,1,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,
1002,,BAO_0000019,,,8,,CHEMBL616045,,Autocuration,,16026,,H,51,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
1003,,BAO_0000219,,,8,,CHEMBL616046,,Autocuration,,17296,,H,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
1004,,BAO_0000219,,,8,,CHEMBL616047,,Autocuration,,2759,,H,51,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,
1005,,BAO_0000219,,,8,,CHEMBL616048,,Autocuration,,2759,,H,51,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,
1006,Homo sapiens,BAO_0000219,,,9,,CHEMBL616049,,Expert,,2759,,D,51,1,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,9606.0
1007,,BAO_0000219,,,8,,CHEMBL616050,,Autocuration,,2759,,H,51,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,
1008,,BAO_0000219,,,8,,CHEMBL616051,,Expert,,15419,,H,51,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,
1009,,BAO_0000219,,,8,,CHEMBL616212,,Autocuration,,15419,,H,51,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,
1010,,BAO_0000019,,,8,,CHEMBL616213,,Autocuration,,16026,,H,51,1,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
1011,,BAO_0000219,,,8,,CHEMBL616214,,Expert,In vitro,1414,,H,51,1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,
1012,,BAO_0000219,,,8,,CHEMBL616215,,Expert,In vitro,1414,,H,51,1,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,
1013,,BAO_0000357,,,8,,CHEMBL616216,,Autocuration,,12861,,H,51,1,Binding activity radioligand.,B,
1014,,BAO_0000019,,,8,,CHEMBL616217,,Autocuration,,12861,,H,51,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1015,,BAO_0000357,,,8,,CHEMBL616218,,Autocuration,,5104,,H,51,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,
1016,,BAO_0000357,,,8,,CHEMBL616219,,Autocuration,,5105,,H,51,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,
1017,,BAO_0000357,,,8,,CHEMBL616220,,Autocuration,,16312,,H,51,1,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,
1018,Homo sapiens,BAO_0000357,,,9,,CHEMBL833493,,Expert,,15180,,D,51,1,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,9606.0
1019,,BAO_0000357,,,8,,CHEMBL616221,,Autocuration,,5033,,H,51,1,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,
1020,Homo sapiens,BAO_0000219,,,9,,CHEMBL616222,,Expert,,16909,,D,51,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0
1021,,BAO_0000019,,,8,,CHEMBL616223,,Autocuration,,2590,,H,51,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,
1022,,BAO_0000019,,,8,,CHEMBL616224,,Autocuration,,2590,,H,51,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,
1023,,BAO_0000019,,,8,,CHEMBL616225,,Expert,,16394,,H,51,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,
1024,Homo sapiens,BAO_0000219,,,9,,CHEMBL616226,,Expert,,4540,,D,51,1,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,9606.0
1025,,BAO_0000219,,,8,,CHEMBL616227,,Autocuration,,17296,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,
1026,,BAO_0000219,,,8,,CHEMBL616228,,Autocuration,,17296,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,
1027,,BAO_0000219,,,8,,CHEMBL616229,,Autocuration,,15779,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,
1028,,BAO_0000219,,,8,,CHEMBL616230,,Autocuration,,15779,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,
1029,,BAO_0000219,,,8,,CHEMBL616231,,Autocuration,,15779,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,
1030,,BAO_0000357,,,8,,CHEMBL616232,,Autocuration,,6166,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,
1031,,BAO_0000219,,,8,,CHEMBL616233,,Autocuration,,15779,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,
1032,,BAO_0000219,,,8,,CHEMBL857973,,Autocuration,,4199,,H,51,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,
1033,,BAO_0000219,,,8,,CHEMBL616234,,Autocuration,,15316,,H,51,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,
1034,,BAO_0000357,,,8,,CHEMBL616235,,Autocuration,,14875,,H,51,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,
1035,,BAO_0000219,,,8,,CHEMBL616236,,Expert,,14727,,H,51,1,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,
1036,,BAO_0000019,,,8,,CHEMBL616237,,Expert,,14727,,H,51,1,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,
1037,,BAO_0000219,,,8,,CHEMBL616238,,Autocuration,,15146,,H,51,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,
1038,,BAO_0000219,,,8,,CHEMBL616239,,Autocuration,,5213,,H,51,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,
1039,,BAO_0000219,,,8,,CHEMBL616240,,Autocuration,,16429,,H,51,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,
1040,Homo sapiens,BAO_0000219,,,9,,CHEMBL616241,,Expert,,15042,,D,51,1,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,9606.0
1041,,BAO_0000219,,,8,,CHEMBL616242,,Autocuration,,14818,,H,51,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,
1042,,BAO_0000219,,,8,,CHEMBL616243,,Autocuration,,4829,,H,51,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,
1043,,BAO_0000357,,,9,,CHEMBL616244,,Expert,,17200,,D,51,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,
1044,Homo sapiens,BAO_0000357,,,9,,CHEMBL616245,,Autocuration,,13051,,D,51,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,9606.0
1045,,BAO_0000357,,,8,,CHEMBL616246,,Autocuration,,5486,,H,106,1,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,
1046,,BAO_0000357,,,8,,CHEMBL616247,,Autocuration,,5254,,H,105,1,Binding affinity against 5-HT1D receptor,B,
1047,,BAO_0000357,,,8,,CHEMBL616248,,Autocuration,,5254,,H,105,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1048,,BAO_0000357,,,8,,CHEMBL616249,,Autocuration,,15331,,H,107,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
1049,Homo sapiens,BAO_0000357,,,8,,CHEMBL616250,,Autocuration,,13506,,H,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,9606.0
1050,,BAO_0000357,,,8,,CHEMBL616251,,Autocuration,,15267,,H,51,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,
1051,,BAO_0000218,,,8,,CHEMBL616252,,Autocuration,In vivo,16616,,H,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,
1052,,BAO_0000218,,,8,,CHEMBL616253,,Autocuration,In vivo,16616,,H,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,
1053,,BAO_0000218,,,8,,CHEMBL616254,,Autocuration,In vivo,16616,,H,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,
1054,Mus musculus,BAO_0000218,,,9,,CHEMBL616255,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,10090.0
1055,Mus musculus,BAO_0000218,,,9,,CHEMBL832872,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,10090.0
1056,Mus musculus,BAO_0000218,,,9,,CHEMBL616256,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,10090.0
1057,Mus musculus,BAO_0000218,,,9,,CHEMBL616257,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,10090.0
1058,Mus musculus,BAO_0000218,,,9,,CHEMBL616258,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,10090.0
1059,Mus musculus,BAO_0000218,,,9,,CHEMBL616384,,Expert,,16616,,D,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,10090.0
1060,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616385,,Autocuration,,10297,,H,11863,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,
1061,,BAO_0000357,,,8,,CHEMBL616386,,Expert,,13704,,H,11863,1,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,
1062,Mus musculus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616387,,Expert,,10297,,D,11863,1,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0
1063,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616388,,Autocuration,,10297,,H,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,
1064,Mus musculus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616389,,Expert,,10297,,D,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0
1065,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616390,,Autocuration,,10297,,H,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,
1066,,BAO_0000357,,,8,,CHEMBL616391,,Autocuration,,217,,H,11863,1,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,
1067,Mus musculus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616392,,Expert,,10297,,D,11863,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,10090.0
1068,Sus scrofa,BAO_0000357,,,8,,CHEMBL616393,,Autocuration,,4921,,H,51,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,9823.0
1069,Sus scrofa,BAO_0000357,,,8,,CHEMBL616394,,Autocuration,,4921,,H,51,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,9823.0
1070,Sus scrofa,BAO_0000019,,,8,,CHEMBL616395,,Autocuration,,4996,,H,51,1,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,9823.0
1071,Sus scrofa,BAO_0000357,,,8,,CHEMBL616396,,Autocuration,,12918,,H,51,1,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,9823.0
1072,Sus scrofa,BAO_0000019,,,8,,CHEMBL872907,,Autocuration,,5333,,H,51,1,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0
1073,Sus scrofa,BAO_0000019,,,8,,CHEMBL616397,,Autocuration,,4437,,H,51,1,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0
1074,Sus scrofa,BAO_0000019,,,8,,CHEMBL616398,,Autocuration,,1742,,H,51,1,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,9823.0
1075,Sus scrofa,BAO_0000357,,,8,,CHEMBL616399,,Expert,,16688,,H,51,1,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,9823.0
1076,Sus scrofa,BAO_0000357,,,8,,CHEMBL857065,,Autocuration,,12861,,H,51,1,Binding activity radioligand.,B,9823.0
1077,Sus scrofa,BAO_0000019,,,8,,CHEMBL616400,,Expert,,12861,,H,51,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0
1078,Sus scrofa,BAO_0000019,,,8,,CHEMBL616401,,Autocuration,,12861,,H,51,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0
1079,,BAO_0000019,,,8,,CHEMBL616402,,Expert,,12490,,H,10624,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,
1080,Sus scrofa,BAO_0000019,,,8,,CHEMBL616403,,Expert,,11828,,H,51,1,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,9823.0
1081,Sus scrofa,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616404,,Autocuration,,11866,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,9823.0
1082,Sus scrofa,BAO_0000249,,,8,,CHEMBL616405,,Autocuration,,12827,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,9823.0
1083,Sus scrofa,BAO_0000019,,,8,,CHEMBL616406,,Autocuration,,12918,,H,51,1,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,9823.0
1084,Sus scrofa,BAO_0000019,,,8,,CHEMBL616407,,Expert,,12919,,H,51,1,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,9823.0
1085,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616408,,Autocuration,,13047,,H,51,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,9986.0
1086,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616409,,Expert,,15796,,D,10576,1,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,10116.0
1087,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616410,,Expert,,3651,,D,10576,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,10116.0
1088,,BAO_0000357,,,8,,CHEMBL616411,,Autocuration,,188,,H,10576,1,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,
1089,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616412,,Expert,,16616,,D,10576,1,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0
1090,Rattus norvegicus,BAO_0000249,10000000.0,,9,Hippocampus,CHEMBL616413,,Expert,,16616,,D,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0
1091,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616414,,Autocuration,,12306,,H,10576,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,
1092,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616415,,Expert,,17167,,D,10576,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,10116.0
1093,,BAO_0000019,,,8,,CHEMBL616416,,Autocuration,,14776,,H,10576,1,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,
1094,,BAO_0000357,,,8,,CHEMBL616417,,Expert,,12158,,H,10576,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,
1095,,BAO_0000357,,,8,,CHEMBL616418,,Autocuration,,13481,,H,10576,1,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,
1096,,BAO_0000219,,,8,,CHEMBL616419,,Autocuration,In vitro,13427,,H,10576,1,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
1097,,BAO_0000357,,,8,,CHEMBL616420,,Autocuration,,10210,,H,10576,1,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,
1098,,BAO_0000249,,,8,,CHEMBL616421,,Autocuration,,10205,,H,10576,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,
1099,,BAO_0000249,,,8,,CHEMBL616422,,Autocuration,,10205,,H,10576,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,
1100,,BAO_0000249,,,8,,CHEMBL616423,,Expert,,10205,,H,10576,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,
1101,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616424,,Expert,,12280,,D,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,10116.0
1102,,BAO_0000357,,,8,,CHEMBL616425,,Expert,,17386,,H,10576,1,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,
1103,,BAO_0000357,,,8,,CHEMBL616426,,Expert,,13654,,H,10576,1,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,
1104,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616427,,Autocuration,,14423,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,
1105,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616428,,Autocuration,,15412,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,
1106,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616290,,Autocuration,,12073,,H,10576,1,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1107,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616052,,Expert,,4101,,D,10576,1,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,10116.0
1108,,BAO_0000357,,,8,,CHEMBL616053,,Autocuration,,10062,,H,10576,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,
1109,,BAO_0000249,,,8,,CHEMBL616054,,Autocuration,,6238,,H,10576,1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,
1110,,BAO_0000357,,,8,,CHEMBL616055,,Autocuration,,16273,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1111,,BAO_0000357,,,8,,CHEMBL616056,,Autocuration,,11139,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,
1112,,BAO_0000019,,,8,,CHEMBL616057,,Expert,,16796,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,
1113,Rattus norvegicus,BAO_0000221,955.0,,9,Brain,CHEMBL616058,,Expert,,9548,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,10116.0
1114,,BAO_0000221,955.0,,8,Brain,CHEMBL616059,,Autocuration,,10381,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,
1115,,BAO_0000249,,,8,,CHEMBL616060,,Autocuration,,13408,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,
1116,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616061,,Expert,,13825,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,10116.0
1117,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616062,,Expert,,11147,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,
1118,,BAO_0000249,,,8,,CHEMBL616063,,Autocuration,,10552,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,
1119,,BAO_0000249,2435.0,,8,Striatum,CHEMBL616064,,Autocuration,,10552,,H,10576,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,
1120,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616065,,Expert,,17136,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,10116.0
1121,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616066,,Expert,,5778,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,10116.0
1122,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616067,,Autocuration,,13481,,H,10576,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
1123,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616068,,Autocuration,,13481,,H,10576,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,
1124,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616069,,Intermediate,,13630,,H,10576,1,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,
1125,,BAO_0000249,,,8,,CHEMBL616070,,Expert,,16245,,H,10576,1,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1126,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616071,,Autocuration,,14509,,H,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,
1127,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616072,,Expert,,14509,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,
1128,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616073,,Autocuration,,14509,,H,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,
1129,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616074,,Autocuration,,14509,,H,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,
1130,,BAO_0000019,,,8,,CHEMBL616075,,Expert,,14256,,H,10576,1,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,
1131,,BAO_0000357,,,8,,CHEMBL616076,,Autocuration,,11139,,H,10576,1,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,
1132,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616077,,Expert,,11047,,D,10576,1,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,10116.0
1133,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616078,,Expert,,11047,,D,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,10116.0
1134,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616079,,Expert,,11047,,D,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,10116.0
1135,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL616080,,Expert,,2395,,D,10576,1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0
1136,,BAO_0000357,,,8,,CHEMBL616081,,Autocuration,,9699,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1137,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616082,,Expert,,12028,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,10116.0
1138,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616083,,Autocuration,,12028,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,
1139,,BAO_0000019,,,8,,CHEMBL616084,,Autocuration,,5815,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
1140,,BAO_0000019,,,8,,CHEMBL616085,,Expert,,16616,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,
1141,,BAO_0000019,,,8,,CHEMBL616086,,Autocuration,,5815,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,
1142,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616087,,Autocuration,,2761,,H,10576,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,
1143,,BAO_0000357,,,8,,CHEMBL616088,,Expert,,13133,,H,10576,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,
1144,,BAO_0000019,,,8,,CHEMBL616089,,Autocuration,,10444,,H,10576,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,
1145,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616090,,Expert,,13278,,D,10576,1,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,10116.0
1146,,BAO_0000357,,,8,,CHEMBL616091,,Autocuration,,15874,,H,10576,1,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,
1147,,BAO_0000249,2435.0,,8,Striatum,CHEMBL616092,,Autocuration,,10552,,H,10576,1,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,
1148,,BAO_0000357,,,8,,CHEMBL616093,,Autocuration,,11130,,H,10576,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,
1149,,BAO_0000218,,,8,,CHEMBL616094,,Autocuration,In vivo,11130,,H,10576,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,
1150,,BAO_0000221,955.0,,8,Brain,CHEMBL616095,,Autocuration,,14542,,H,10576,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,
1151,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616096,,Expert,,13670,,D,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,10116.0
1152,,BAO_0000249,,,8,,CHEMBL616097,,Expert,,9888,,H,10576,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,
1153,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616098,,Expert,,3678,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,10116.0
1154,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616099,,Autocuration,,11332,,H,10576,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,
1155,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616100,,Autocuration,,11332,,H,10576,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,
1156,,BAO_0000357,,,8,,CHEMBL616101,,Expert,,1185,,H,10576,1,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,
1157,,BAO_0000249,,,8,,CHEMBL616102,,Expert,,2014,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,
1158,,BAO_0000357,,,8,,CHEMBL616103,,Autocuration,,1185,,H,10576,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,
1159,,BAO_0000019,,,8,,CHEMBL616104,,Expert,,14429,,H,10576,1,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,
1160,,BAO_0000019,,,8,,CHEMBL616105,,Expert,,16288,,H,10576,1,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,
1161,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616106,,Expert,,5432,,D,10576,1,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,10116.0
1162,,BAO_0000019,,,8,,CHEMBL616107,,Autocuration,,14429,,H,10576,1,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,
1163,,BAO_0000357,,,8,,CHEMBL616108,,Expert,,13672,,H,10576,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,
1164,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616109,,Expert,,11296,,H,10576,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,
1165,,BAO_0000357,,,8,,CHEMBL616110,,Autocuration,,11296,,H,10576,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,
1166,,BAO_0000219,,,8,,CHEMBL616111,,Expert,,14749,,H,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,
1167,,BAO_0000019,,,8,,CHEMBL616112,,Expert,,15086,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,
1168,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616113,,Autocuration,,13462,,H,10576,1,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,
1169,,BAO_0000019,,,8,,CHEMBL616114,,Autocuration,,15363,,H,10576,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,
1170,,BAO_0000019,,,8,,CHEMBL616115,,Autocuration,,15363,,H,10576,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,
1171,,BAO_0000357,,,8,,CHEMBL616116,,Autocuration,,10796,,H,10576,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,
1172,,BAO_0000221,955.0,,8,Brain,CHEMBL615844,,Expert,,12816,,H,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,
1173,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615939,,Expert,,13542,,H,10576,1,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,
1174,,BAO_0000019,,,8,,CHEMBL615940,,Expert,,13308,,H,10576,1,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,
1175,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615941,,Expert,,13541,,H,10576,1,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,
1176,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615942,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,
1177,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615943,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,
1178,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615944,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,
1179,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615945,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,
1180,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615946,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,
1181,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615947,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,
1182,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615948,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,
1183,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615949,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,
1184,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615950,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,
1185,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615951,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,
1186,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615952,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,
1187,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615953,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,
1188,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615954,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,
1189,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL615955,,Expert,,10058,,D,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0
1190,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615956,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,
1191,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL615957,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,
1192,,BAO_0000019,,,8,,CHEMBL615958,,Expert,,12879,,H,10576,1,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,
1193,,BAO_0000019,,,8,,CHEMBL615959,,Expert,,11964,,H,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,
1194,,BAO_0000019,,,8,,CHEMBL615960,,Autocuration,,11964,,H,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,
1195,,BAO_0000019,,,8,,CHEMBL615961,,Autocuration,,11964,,H,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,
1196,,BAO_0000221,955.0,,8,Brain,CHEMBL615962,,Expert,,9548,,H,10576,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,
1197,,BAO_0000019,,,8,,CHEMBL615963,,Expert,,9098,,H,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,
1198,,BAO_0000019,,,8,,CHEMBL615964,,Autocuration,,9098,,H,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,
1199,,BAO_0000019,,,8,,CHEMBL615965,,Autocuration,,9098,,H,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,
1200,,BAO_0000219,,,8,,CHEMBL615966,,Expert,,13248,,H,10576,1,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,
1201,,BAO_0000249,,,8,,CHEMBL615967,,Expert,,3147,,H,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,
1202,,BAO_0000019,,,8,,CHEMBL615968,,Expert,,13949,,H,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,
1203,,BAO_0000218,,,8,,CHEMBL615969,,Autocuration,,11883,,H,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,
1204,,BAO_0000218,,,8,,CHEMBL615970,,Autocuration,,11883,,H,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,
1205,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL615971,,Expert,,11883,,D,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,10116.0
1206,,BAO_0000249,,,8,,CHEMBL615972,,Expert,,15535,,H,10576,1,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1207,,BAO_0000249,,,8,,CHEMBL615973,,Autocuration,,15535,,H,10576,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,
1208,,BAO_0000249,,,8,,CHEMBL615974,,Autocuration,,15535,,H,10576,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,
1209,Homo sapiens,BAO_0000219,,,9,,CHEMBL615975,,Expert,,16372,,D,51,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0
1210,,BAO_0000249,,,8,,CHEMBL615976,,Expert,,14608,,H,10576,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,
1211,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL872106,,Expert,,4795,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0
1212,,BAO_0000357,,,8,,CHEMBL615977,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
1213,,BAO_0000357,,,8,,CHEMBL615978,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,
1214,,BAO_0000357,,,8,,CHEMBL616166,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,
1215,,BAO_0000357,,,8,,CHEMBL616167,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,
1216,,BAO_0000357,,,8,,CHEMBL616168,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,
1217,,BAO_0000357,,,8,,CHEMBL616169,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,
1218,,BAO_0000357,,,8,,CHEMBL616170,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,
1219,,BAO_0000357,,,8,,CHEMBL616171,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,
1220,,BAO_0000357,,,8,,CHEMBL616172,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,
1221,,BAO_0000357,,,8,,CHEMBL616173,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,
1222,,BAO_0000357,,,8,,CHEMBL616174,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,
1223,,BAO_0000357,,,8,,CHEMBL616175,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,
1224,,BAO_0000357,,,8,,CHEMBL616176,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,
1225,,BAO_0000357,,,8,,CHEMBL616177,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,
1226,,BAO_0000357,,,8,,CHEMBL616178,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,
1227,,BAO_0000019,,,8,,CHEMBL616179,,Autocuration,,9742,,H,10576,1,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,
1228,,BAO_0000357,,,8,,CHEMBL616180,,Autocuration,,12073,,H,10576,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,
1229,,BAO_0000357,,,8,,CHEMBL616181,,Autocuration,,4101,,H,10576,1,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,
1230,,BAO_0000019,,,8,,CHEMBL616182,,Autocuration,,15360,,H,10576,1,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,
1231,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616183,,Autocuration,,11576,,H,10576,1,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,
1232,,BAO_0000019,,,8,,CHEMBL615874,,Expert,,5834,,H,10576,1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,
1233,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL615875,,Expert,,2395,,D,10576,1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0
1234,,BAO_0000019,,,8,,CHEMBL615876,,Autocuration,,1375,,H,10576,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,
1235,,BAO_0000019,,,8,,CHEMBL615877,,Autocuration,,1375,,H,10576,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,
1236,,BAO_0000357,,,8,,CHEMBL615878,,Autocuration,,3967,,H,10576,1,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,
1237,,BAO_0000357,,,8,,CHEMBL615879,,Expert,,12884,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,
1238,,BAO_0000357,,,8,,CHEMBL615880,,Expert,,2343,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,
1239,,BAO_0000019,,,8,,CHEMBL615881,,Autocuration,,11511,,H,10576,1,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,
1240,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL615882,,Expert,,11511,,D,10576,1,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,10116.0
1241,,BAO_0000218,,,8,,CHEMBL615883,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,
1242,,BAO_0000218,,,8,,CHEMBL615884,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,
1243,,BAO_0000218,,,8,,CHEMBL615885,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,
1244,,BAO_0000218,,,8,,CHEMBL615886,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,
1245,,BAO_0000218,,,8,,CHEMBL615887,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,
1246,,BAO_0000218,,,8,,CHEMBL615888,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,
1247,,BAO_0000218,,,8,,CHEMBL615889,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,
1248,,BAO_0000218,,,8,,CHEMBL615890,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,
1249,,BAO_0000218,,,8,,CHEMBL615891,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,
1250,,BAO_0000218,,,8,,CHEMBL615892,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,
1251,,BAO_0000218,,,8,,CHEMBL615893,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,
1252,,BAO_0000218,,,8,,CHEMBL615894,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,
1253,,BAO_0000218,,,8,,CHEMBL615895,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,
1254,,BAO_0000218,,,8,,CHEMBL615896,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,
1255,,BAO_0000218,,,8,,CHEMBL615897,,Autocuration,In vivo,16394,,H,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,
1256,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL615898,,Expert,,16616,,D,10576,1,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0
1257,,BAO_0000019,,,8,,CHEMBL615899,,Autocuration,,16796,,H,10576,1,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,
1258,,BAO_0000019,,,8,,CHEMBL616291,,Autocuration,,16796,,H,10576,1,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,
1259,,BAO_0000357,,,8,,CHEMBL616292,,Autocuration,,15629,,H,10576,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,
1260,,BAO_0000249,,,8,,CHEMBL616293,,Autocuration,,13241,,H,10576,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,
1261,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616294,,Expert,,12073,,H,10576,1,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1262,,BAO_0000249,10000000.0,,8,Hippocampus,CHEMBL616295,,Autocuration,,14286,,H,10576,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,
1263,,BAO_0000221,955.0,,8,Brain,CHEMBL616296,,Autocuration,,14542,,H,10576,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,
1264,,BAO_0000019,,,8,,CHEMBL616297,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,
1265,,BAO_0000019,,,8,,CHEMBL616605,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,
1266,,BAO_0000019,,,8,,CHEMBL616606,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,
1267,,BAO_0000019,,,8,,CHEMBL616607,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,
1268,,BAO_0000019,,,8,,CHEMBL616608,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,
1269,,BAO_0000019,,,8,,CHEMBL616609,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,
1270,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616610,,Expert,,13630,,D,10576,1,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,10116.0
1271,,BAO_0000019,,,8,,CHEMBL616611,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,
1272,,BAO_0000019,,,8,,CHEMBL616612,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,
1273,,BAO_0000019,,,8,,CHEMBL616613,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,
1274,,BAO_0000019,,,8,,CHEMBL616614,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,
1275,,BAO_0000019,,,8,,CHEMBL616615,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,
1276,,BAO_0000019,,,8,,CHEMBL616616,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,
1277,,BAO_0000019,,,8,,CHEMBL616617,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,
1278,,BAO_0000019,,,8,,CHEMBL616618,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,
1279,,BAO_0000019,,,8,,CHEMBL616619,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,
1280,,BAO_0000019,,,8,,CHEMBL616620,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,
1281,,BAO_0000019,,,8,,CHEMBL616621,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,
1282,,BAO_0000019,,,8,,CHEMBL616622,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,
1283,,BAO_0000019,,,8,,CHEMBL616146,,Expert,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,
1284,,BAO_0000019,,,8,,CHEMBL832873,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,
1285,,BAO_0000019,,,8,,CHEMBL616147,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,
1286,,BAO_0000019,,,8,,CHEMBL872872,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,
1287,,BAO_0000019,,,8,,CHEMBL616148,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,
1288,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616149,,Autocuration,,9783,,H,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,
1289,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616150,,Expert,,9783,,H,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,
1290,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616151,,Expert,,14331,,D,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,10116.0
1291,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL872873,,Expert,,15260,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,
1292,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616670,,Autocuration,,15260,,H,10576,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,
1293,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616671,,Autocuration,,15260,,H,10576,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,
1294,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL884861,,Expert,,16616,,D,10576,1,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0
1295,,BAO_0000357,,,8,,CHEMBL616672,,Autocuration,,15629,,H,10576,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,
1296,,BAO_0000019,,,8,,CHEMBL616673,,Autocuration,,15086,,H,10576,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,
1297,,BAO_0000019,,,8,,CHEMBL616674,,Expert,,5717,,H,10576,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,
1298,,BAO_0000357,,,8,,CHEMBL616675,,Autocuration,,12652,,H,10576,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,
1299,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616676,,Autocuration,,14608,,H,10576,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,
1300,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616677,,Autocuration,,12306,,H,10576,1,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,
1301,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616678,,Autocuration,,12306,,H,10576,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,
1302,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616679,,Expert,,15247,,D,10576,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,10116.0
1303,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616680,,Expert,,17529,,H,10576,1,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,
1304,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616681,,Autocuration,,14826,,H,10576,1,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1305,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616682,,Autocuration,,14826,,H,10576,1,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1306,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616683,,Autocuration,,13241,,H,10576,1,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,
1307,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616684,,Autocuration,,14093,,H,10576,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,
1308,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616685,,Autocuration,,14093,,H,10576,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,
1309,,BAO_0000221,955.0,,8,Brain,CHEMBL616686,,Autocuration,,14442,,H,10576,1,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,
1310,,BAO_0000357,,,8,,CHEMBL616687,,Autocuration,,9919,,H,10576,1,Affinity for 5-hydroxytryptamine 1A receptor site,B,
1311,,BAO_0000357,,,8,,CHEMBL616688,,Autocuration,,9919,,H,10576,1,Affinity for 5-hydroxytryptamine 1A receptor site,B,
1312,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616689,,Autocuration,,11440,,H,10576,1,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,
1313,,BAO_0000357,,,8,,CHEMBL616690,,Autocuration,,11257,,H,10576,1,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,
1314,,BAO_0000357,,,8,,CHEMBL616691,,Expert,,10330,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,
1315,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616692,,Expert,,17331,,D,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,10116.0
1316,,BAO_0000249,,,8,,CHEMBL616693,,Expert,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,
1317,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616694,,Expert,,12058,,D,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,10116.0
1318,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616695,,Autocuration,,9699,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,
1319,,BAO_0000357,,,8,,CHEMBL616696,,Autocuration,,9547,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,
1320,,BAO_0000357,,,8,,CHEMBL616697,,Autocuration,,10330,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,
1321,,BAO_0000357,,,8,,CHEMBL616698,,Autocuration,,14331,,H,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,
1322,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616949,,Expert,,14060,,D,10576,1,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,10116.0
1323,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616950,,Autocuration,,14744,,H,10576,1,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,
1324,,BAO_0000357,,,8,,CHEMBL832875,,Autocuration,,13506,,H,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,
1325,,BAO_0000221,955.0,,8,Brain,CHEMBL616951,,Expert,,10862,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,
1326,,BAO_0000221,955.0,,8,Brain,CHEMBL616952,,Expert,,10862,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,
1327,,BAO_0000357,,,8,,CHEMBL616953,,Expert,,10062,,H,10576,1,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,
1328,,BAO_0000357,,,8,,CHEMBL616954,,Autocuration,,12073,,H,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,
1329,,BAO_0000357,,,8,,CHEMBL616955,,Autocuration,,14875,,H,106,1,GTPgammaS radioligand binding assay,B,
1330,,BAO_0000357,,,8,,CHEMBL616956,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,
1331,,BAO_0000019,,,8,,CHEMBL616957,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,
1332,,BAO_0000019,,,8,,CHEMBL616958,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,
1333,,BAO_0000357,,,8,,CHEMBL616959,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,
1334,,BAO_0000357,,,8,,CHEMBL616960,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,
1335,,BAO_0000019,,,8,,CHEMBL616961,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,
1336,,BAO_0000219,,,8,,CHEMBL616962,,Expert,,17211,,H,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,
1337,,BAO_0000219,,,8,,CHEMBL616963,,Autocuration,,17211,,H,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,
1338,Homo sapiens,BAO_0000357,,,9,,CHEMBL616524,,Expert,,6491,,D,106,1,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,9606.0
1339,,BAO_0000219,,,8,,CHEMBL616525,,Autocuration,,16190,,H,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,
1340,,BAO_0000019,,,8,,CHEMBL872908,,Autocuration,,14165,,H,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,
1341,,BAO_0000019,,,8,,CHEMBL616526,,Autocuration,,14165,,H,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,
1342,Homo sapiens,BAO_0000357,,,9,,CHEMBL616527,,Expert,,4234,,D,106,1,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,9606.0
1343,,BAO_0000219,,,8,,CHEMBL616528,,Expert,,6328,,H,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,
1344,,BAO_0000357,,,8,,CHEMBL616529,,Autocuration,,14770,,H,106,1,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1345,,BAO_0000357,,,8,,CHEMBL616530,,Autocuration,,2598,,H,106,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,
1346,,BAO_0000357,,,8,,CHEMBL616531,,Expert,,6897,,H,106,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,
1347,,BAO_0000357,,,8,,CHEMBL616532,,Autocuration,,6897,,H,106,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,
1348,,BAO_0000357,,,8,,CHEMBL616533,,Autocuration,,6013,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,
1349,,BAO_0000357,,,8,,CHEMBL616534,,Expert,,5843,,H,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,
1350,,BAO_0000357,,,8,,CHEMBL616535,,Expert,,14454,,H,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,
1351,,BAO_0000357,,,8,,CHEMBL616536,,Autocuration,,16209,,H,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,
1352,,BAO_0000357,,,8,,CHEMBL616537,,Autocuration,,3935,,H,106,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,
1353,,BAO_0000219,,,8,,CHEMBL616538,,Expert,,13729,,H,106,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,
1354,,BAO_0000019,,,8,,CHEMBL616539,,Expert,,14251,,H,106,1,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,
1355,,BAO_0000019,,,8,,CHEMBL616540,,Expert,,17085,,H,106,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,
1356,,BAO_0000357,,,8,,CHEMBL616429,,Autocuration,,3025,,H,106,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,
1357,,BAO_0000357,,,8,,CHEMBL616430,,Expert,,15315,,H,106,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,
1358,Homo sapiens,BAO_0000219,,,9,,CHEMBL616431,,Expert,,14214,,D,106,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,9606.0
1359,Homo sapiens,BAO_0000357,,,9,,CHEMBL616432,,Expert,,3804,,D,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,9606.0
1360,Homo sapiens,BAO_0000357,,,9,,CHEMBL616433,,Expert,,2391,,D,106,1,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,9606.0
1361,Homo sapiens,BAO_0000357,,,9,,CHEMBL616434,,Expert,,4175,,D,106,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0
1362,,BAO_0000219,,,8,,CHEMBL616435,,Autocuration,,17296,,H,106,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,
1363,,BAO_0000019,,,8,,CHEMBL616436,,Expert,,17085,,H,106,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,
1364,,BAO_0000219,,,8,,CHEMBL616437,,Autocuration,,17211,,H,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,
1365,,BAO_0000219,,,8,,CHEMBL616438,,Autocuration,,17211,,H,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,
1366,,BAO_0000219,,,8,,CHEMBL616439,,Autocuration,,17211,,H,106,1,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,
1367,Homo sapiens,BAO_0000357,,,9,,CHEMBL616440,,Expert,,15926,,D,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,9606.0
1368,,BAO_0000219,,,8,,CHEMBL616441,,Autocuration,,16312,,H,106,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,
1369,,BAO_0000357,,,8,,CHEMBL616442,,Expert,,5843,,H,106,1,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,
1370,,BAO_0000357,,,8,,CHEMBL616443,,Autocuration,,5843,,H,106,1,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,
1371,,BAO_0000219,,,8,,CHEMBL616444,,Expert,,16312,,H,106,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,
1372,Homo sapiens,BAO_0000357,,,9,,CHEMBL616445,,Expert,,15926,,D,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0
1373,Homo sapiens,BAO_0000357,,,9,,CHEMBL616446,,Expert,,15926,,D,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0
1374,Homo sapiens,BAO_0000219,,,9,,CHEMBL616447,,Expert,,4540,,D,106,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0
1375,,BAO_0000357,,,8,,CHEMBL616448,,Autocuration,,6166,,H,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,
1376,,BAO_0000219,,,8,,CHEMBL616449,,Autocuration,,17296,,H,106,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,
1377,,BAO_0000219,,,8,,CHEMBL616450,,Autocuration,,17296,,H,106,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,
1378,,BAO_0000219,,,8,,CHEMBL857974,,Autocuration,,17296,,H,106,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,
1379,,BAO_0000219,,,8,,CHEMBL616451,,Autocuration,,15779,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
1380,,BAO_0000219,,,8,,CHEMBL616452,,Autocuration,,15779,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
1381,,BAO_0000219,,,8,,CHEMBL616453,,Autocuration,,15779,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,
1382,,BAO_0000219,,,8,,CHEMBL616454,,Autocuration,,4199,,H,106,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,
1383,Homo sapiens,BAO_0000357,,,9,,CHEMBL616455,,Expert,,14875,,D,106,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0
1384,,BAO_0000219,,,8,,CHEMBL616456,,Autocuration,,15146,,H,106,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,
1385,,BAO_0000357,,,8,,CHEMBL616457,,Autocuration,,5213,,H,106,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,
1386,,BAO_0000219,,,8,,CHEMBL616458,,Autocuration,,14818,,H,106,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,
1387,,BAO_0000219,,,8,,CHEMBL616459,,Autocuration,,4829,,H,106,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,
1388,,BAO_0000019,,,8,,CHEMBL616460,,Expert,,14454,,H,106,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,
1389,,BAO_0000019,,,8,,CHEMBL616461,,Expert,,14454,,H,106,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,
1390,,BAO_0000219,,,8,,CHEMBL616462,,Autocuration,,14875,,H,106,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,
1391,,BAO_0000219,,,8,,CHEMBL616463,,Autocuration,,14875,,H,106,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,
1392,,BAO_0000019,,,8,,CHEMBL616464,,Autocuration,,15250,,H,105,1,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,
1393,,BAO_0000219,,,8,,CHEMBL616465,,Autocuration,,15250,,H,105,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,
1394,,BAO_0000357,,,8,,CHEMBL832874,,Autocuration,,15086,,H,17105,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,
1395,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616184,,Autocuration,,3025,,H,106,1,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,9986.0
1396,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616185,,Autocuration,,14998,,H,106,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,9986.0
1397,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616186,,Intermediate,,14998,,H,106,1,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,9986.0
1398,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616187,,Autocuration,,14998,,H,106,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,9986.0
1399,,BAO_0000357,,,8,,CHEMBL616188,,Expert,,13969,,H,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,
1400,,BAO_0000357,,,9,,CHEMBL873475,,Intermediate,,13392,,D,10577,1,Binding affinity for 5-hydroxytryptamine 1B receptor,B,
1401,Rattus norvegicus,BAO_0000019,2435.0,,9,Striatum,CHEMBL616189,,Expert,,3651,,D,10577,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,10116.0
1402,,BAO_0000357,,,8,,CHEMBL616190,,Expert,,10025,,H,10577,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,
1403,,BAO_0000357,,,8,,CHEMBL616191,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,
1404,,BAO_0000357,,,8,,CHEMBL616192,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,
1405,,BAO_0000357,,,8,,CHEMBL616193,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,
1406,,BAO_0000357,,,8,,CHEMBL616194,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,
1407,,BAO_0000357,,,8,,CHEMBL616195,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,
1408,,BAO_0000357,,,8,,CHEMBL616196,,Autocuration,,13863,,H,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,
1409,,BAO_0000249,10000000.0,,8,Hippocampus,CHEMBL616197,,Autocuration,,4622,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,
1410,,BAO_0000019,,,8,,CHEMBL616198,,Intermediate,,14911,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,
1411,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616199,,Autocuration,,12678,,H,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,
1412,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616200,,Expert,,12678,,H,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,
1413,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616201,,Expert,,14235,,H,10576,1,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
1414,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616202,,Expert,,14949,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,
1415,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616203,,Expert,,14949,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,
1416,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616204,,Expert,,14949,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,
1417,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616205,,Expert,,14949,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,
1418,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616206,,Expert,,14949,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,
1419,,BAO_0000249,,,8,,CHEMBL616207,,Expert,,16118,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,
1420,,BAO_0000249,,,8,,CHEMBL616208,,Autocuration,,3268,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,
1421,,BAO_0000249,,,8,,CHEMBL616209,,Autocuration,,3268,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,
1422,,BAO_0000357,,,8,,CHEMBL616210,,Expert,,16117,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,
1423,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616211,,Expert,,9783,,H,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,
1424,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616504,,Autocuration,,9783,,H,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,
1425,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616505,,Expert,,14356,,D,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0
1426,,BAO_0000019,,,8,,CHEMBL616506,,Autocuration,,15740,,H,10576,1,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,
1427,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL872107,,Autocuration,,12306,,H,10576,1,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,
1428,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616507,,Expert,,13348,,D,10576,1,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,10116.0
1429,,BAO_0000249,,,8,,CHEMBL616303,,Autocuration,,10394,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,
1430,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616304,,Autocuration,,15260,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,
1431,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616305,,Expert,,10046,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,
1432,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616306,,Intermediate,,15260,,H,10576,1,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,
1433,,BAO_0000357,,,8,,CHEMBL616307,,Autocuration,,12851,,H,10576,1,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,
1434,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL881829,,Expert,,2148,,D,10576,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,10116.0
1435,,BAO_0000357,,,8,,CHEMBL616308,,Expert,,13134,,H,10576,1,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,
1436,,BAO_0000019,,,8,,CHEMBL616309,,Autocuration,,12462,,H,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,
1437,,BAO_0000019,,,8,,CHEMBL616310,,Expert,,12462,,H,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,
1438,,BAO_0000219,,,8,,CHEMBL616311,,Autocuration,,12462,,H,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,
1439,,BAO_0000357,,,8,,CHEMBL616312,,Expert,,11933,,H,10576,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,
1440,,BAO_0000357,,,8,,CHEMBL616313,,Autocuration,,11933,,H,10576,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,
1441,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616314,,Expert,,403,,D,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0
1442,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616315,,Autocuration,,15538,,H,10576,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1443,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616567,,Autocuration,,15538,,H,10576,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,
1444,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616568,,Autocuration,,15538,,H,10576,1,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,
1445,,BAO_0000019,,,8,,CHEMBL616569,,Intermediate,,12464,,H,10576,1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,
1446,,BAO_0000357,,,8,,CHEMBL616570,,Expert,,1455,,H,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,
1447,,BAO_0000357,,,8,,CHEMBL616571,,Autocuration,,12652,,H,10576,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,
1448,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616572,,Autocuration,,12639,,H,10576,1,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,
1449,,BAO_0000249,,,8,,CHEMBL616573,,Expert,,13949,,H,10576,1,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,
1450,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616574,,Expert,,12463,,D,10576,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,10116.0
1451,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616575,,Expert,,14829,,H,10576,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,
1452,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL872108,,Autocuration,,14829,,H,10576,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,
1453,,BAO_0000357,,,8,,CHEMBL616576,,Autocuration,,12092,,H,10576,1,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,
1454,,BAO_0000249,,,8,,CHEMBL616577,,Autocuration,,403,,H,10576,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,
1455,,BAO_0000249,,,8,,CHEMBL616578,,Autocuration,,403,,H,10576,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,
1456,,BAO_0000357,,,8,,CHEMBL616579,,Expert,,3967,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,
1457,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616580,,Expert,,12771,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,10116.0
1458,,BAO_0000019,,,8,,CHEMBL616581,,Autocuration,,15086,,H,10576,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,
1459,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616582,,Autocuration,,14909,,H,10576,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1460,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616583,,Expert,,14949,,H,10576,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,
1461,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616584,,Expert,,2309,,D,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,10116.0
1462,,BAO_0000357,,,8,,CHEMBL616585,,Expert,,4170,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1463,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616586,,Expert,,11642,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,10116.0
1464,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616587,,Autocuration,,11642,,H,10576,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,
1465,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616588,,Autocuration,,12953,,H,10576,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,
1466,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616589,,Autocuration,,12953,,H,10576,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,
1467,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616590,,Expert,,12953,,H,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,
1468,,BAO_0000219,,,8,,CHEMBL616591,,Expert,,12903,,H,10576,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,
1469,,BAO_0000357,,,8,,CHEMBL616592,,Expert,,12536,,H,10576,1,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,
1470,,BAO_0000357,,,8,,CHEMBL616593,,Autocuration,,10058,,H,10576,1,The inhibition activity of 5-HT1A at 1 uM,B,
1471,,BAO_0000219,,,8,,CHEMBL616594,,Expert,,12902,,H,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,
1472,,BAO_0000249,,,8,,CHEMBL616595,,Expert,,14057,,H,10576,1,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,
1473,,BAO_0000357,,,8,,CHEMBL616596,,Autocuration,,11296,,H,10576,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,
1474,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616597,,Autocuration,,11296,,H,10576,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,
1475,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616598,,Expert,,11296,,H,10576,1,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,
1476,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616599,,Expert,,16616,,D,10576,1,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,10116.0
1477,Rattus norvegicus,BAO_0000249,10000000.0,,9,Hippocampus,CHEMBL616600,,Expert,,16616,,D,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0
1478,,BAO_0000019,,,8,,CHEMBL616601,,Autocuration,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,
1479,,BAO_0000019,,,8,,CHEMBL616602,,Autocuration,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,
1480,,BAO_0000019,,,8,,CHEMBL616603,,Autocuration,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,
1481,,BAO_0000019,,,8,,CHEMBL616604,,Autocuration,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,
1482,,BAO_0000249,,,8,,CHEMBL616316,,Autocuration,,17136,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,
1483,,BAO_0000249,,,8,,CHEMBL616317,,Autocuration,,17136,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,
1484,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616318,,Expert,,16616,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,10116.0
1485,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616319,,Autocuration,,17331,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,
1486,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616320,,Autocuration,,17331,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,
1487,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616321,,Expert,,17167,,D,10576,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,10116.0
1488,,BAO_0000019,,,8,,CHEMBL616322,,Autocuration,,15740,,H,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,
1489,,BAO_0000019,,,8,,CHEMBL616323,,Autocuration,,15740,,H,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,
1490,,BAO_0000357,,,8,,CHEMBL616324,,Autocuration,,4671,,H,10576,1,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,
1491,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616325,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,
1492,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616326,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,
1493,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616327,,Autocuration,,10058,,H,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,
1494,,BAO_0000357,,,8,,CHEMBL616328,,Autocuration,,12073,,H,10576,1,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,
1495,,BAO_0000249,,,8,,CHEMBL858110,,Autocuration,,2759,,H,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,
1496,,BAO_0000249,,,8,,CHEMBL616329,,Autocuration,,2759,,H,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,
1497,,BAO_0000249,,,8,,CHEMBL616330,,Autocuration,,2759,,H,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,
1498,,BAO_0000249,,,8,,CHEMBL616331,,Autocuration,,2759,,H,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,
1499,,BAO_0000249,,,8,,CHEMBL616332,,Autocuration,,2759,,H,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,
1500,,BAO_0000249,955.0,,8,Brain,CHEMBL857063,,Autocuration,,9737,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,
1501,,BAO_0000019,,,8,,CHEMBL616333,,Autocuration,,9737,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,
1502,,BAO_0000019,,,8,,CHEMBL616334,,Expert,,5717,,H,10576,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,
1503,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616335,,Autocuration,,12253,,H,10576,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,
1504,,BAO_0000019,,,8,,CHEMBL616336,,Autocuration,,14025,,H,10576,1,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,
1505,,BAO_0000249,,,8,,CHEMBL616337,,Expert,,10425,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,
1506,,BAO_0000019,,,8,,CHEMBL616338,,Autocuration,,14998,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,
1507,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616339,,Autocuration,,13694,,H,10576,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,
1508,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616340,,Autocuration,,13694,,H,10576,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,
1509,,BAO_0000357,,,8,,CHEMBL616341,,Autocuration,,4342,,H,10576,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,
1510,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616342,,Expert,,12936,,D,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,10116.0
1511,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616343,,Expert,,13144,,D,10576,1,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,10116.0
1512,,BAO_0000019,,,8,,CHEMBL616344,,Expert,,13343,,H,10576,1,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,
1513,,BAO_0000357,,,8,,CHEMBL616345,,Expert,,12132,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
1514,,BAO_0000019,,,8,,CHEMBL616346,,Expert,,15419,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,
1515,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616347,,Autocuration,,1479,,H,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,
1516,,BAO_0000019,,,8,,CHEMBL616348,,Expert,,14287,,H,10576,1,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,
1517,,BAO_0000357,,,8,,CHEMBL616349,,Expert,,13116,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor,B,
1518,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616152,,Expert,,2759,,D,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,10116.0
1519,,BAO_0000249,,,8,,CHEMBL616153,,Autocuration,,2759,,H,10576,1,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,
1520,,BAO_0000019,,,8,,CHEMBL616154,,Expert,,14748,,H,10576,1,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,
1521,,BAO_0000019,,,8,,CHEMBL616155,,Autocuration,,12304,,H,10576,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
1522,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616156,,Expert,,12409,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,10116.0
1523,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL616157,,Expert,,12409,,D,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,10116.0
1524,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616158,,Autocuration,,13267,,H,10576,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,
1525,,BAO_0000357,,,8,,CHEMBL616159,,Autocuration,,15194,,H,10576,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
1526,,BAO_0000357,,,8,,CHEMBL616160,,Expert,,14256,,H,10576,1,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,
1527,,BAO_0000019,,,8,,CHEMBL616161,,Autocuration,,16567,,H,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,
1528,,BAO_0000019,,,8,,CHEMBL616162,,Autocuration,,15740,,H,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,
1529,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616163,,Expert,,13278,,D,12687,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0
1530,,BAO_0000249,,,8,,CHEMBL616164,,Expert,,1970,,H,10626,1,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1531,,BAO_0000221,955.0,,8,Brain,CHEMBL616165,,Autocuration,,10034,,H,10576,1,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,
1532,Rattus norvegicus,BAO_0000019,,,8,,CHEMBL616355,,Autocuration,,13348,,H,51,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,10116.0
1533,,BAO_0000019,,,8,,CHEMBL616356,,Autocuration,,13630,,H,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,
1534,,BAO_0000221,955.0,,8,Brain,CHEMBL616357,,Autocuration,,10862,,H,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,
1535,,BAO_0000019,,,8,,CHEMBL616358,,Autocuration,,12058,,H,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,
1536,,BAO_0000357,,,8,,CHEMBL616359,,Autocuration,,4639,,H,51,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,
1537,,BAO_0000357,,,8,,CHEMBL616360,,Expert,,15453,,H,51,1,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,
1538,,BAO_0000357,,,8,,CHEMBL616361,,Expert,,4820,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1539,,BAO_0000357,,,8,,CHEMBL616362,,Autocuration,,1089,,H,51,1,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,
1540,,BAO_0000249,,,8,,CHEMBL616363,,Autocuration,,386,,H,51,1,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,
1541,,BAO_0000357,,,8,,CHEMBL616364,,Autocuration,,6011,,H,51,1,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,
1542,,BAO_0000357,,,8,,CHEMBL616365,,Autocuration,,5014,,H,51,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,
1543,,BAO_0000357,,,8,,CHEMBL616366,,Expert,,4402,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,
1544,,BAO_0000357,,,8,,CHEMBL872906,,Expert,,17066,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1545,,BAO_0000357,,,8,,CHEMBL616367,,Autocuration,,17515,,H,51,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,
1546,,BAO_0000357,,,8,,CHEMBL616368,,Autocuration,,2474,,H,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1547,,BAO_0000357,,,8,,CHEMBL616369,,Autocuration,,4775,,H,51,1,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,
1548,Homo sapiens,BAO_0000357,,,9,,CHEMBL616370,,Expert,,14294,,D,51,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,9606.0
1549,Homo sapiens,BAO_0000357,,,9,,CHEMBL616371,,Expert,,14294,,D,51,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,9606.0
1550,,BAO_0000219,,,8,,CHEMBL616372,,Autocuration,,12249,,H,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1551,,BAO_0000219,,,8,,CHEMBL616373,,Expert,,11376,,H,51,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,
1552,,BAO_0000218,,,8,,CHEMBL616374,,Autocuration,In vivo,2474,,H,51,1,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
1553,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL616375,,Autocuration,,13311,,H,51,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,
1554,,BAO_0000357,,,8,,CHEMBL616376,,Autocuration,,4373,,H,51,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,
1555,,BAO_0000357,,,8,,CHEMBL857064,,Expert,,1633,,H,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,
1556,,BAO_0000357,,,8,,CHEMBL616377,,Autocuration,,11866,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,
1557,,BAO_0000357,,,8,,CHEMBL616378,,Autocuration,,4373,,H,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,
1558,,BAO_0000357,,,8,,CHEMBL616379,,Autocuration,,4687,,H,51,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,
1559,,BAO_0000357,,,8,,CHEMBL616380,,Autocuration,,16946,,H,11863,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,
1560,,BAO_0000357,,,8,,CHEMBL616381,,Autocuration,,13291,,H,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,
1561,,BAO_0000357,,,8,,CHEMBL616382,,Autocuration,,14159,,H,11863,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,
1562,,BAO_0000357,,,8,,CHEMBL616383,,Autocuration,,10812,,H,11863,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,
1563,Mus musculus,BAO_0000219,,,9,,CHEMBL616350,,Expert,,3032,,D,11863,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,10090.0
1564,,BAO_0000357,,,8,,CHEMBL616351,,Autocuration,,16655,,H,11863,1,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,
1565,,BAO_0000357,,,8,,CHEMBL616352,,Autocuration,,14532,,H,11863,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,
1566,,BAO_0000357,,,8,,CHEMBL616353,,Autocuration,,13944,,H,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1567,,BAO_0000357,,,8,,CHEMBL616354,,Autocuration,,13033,,H,11863,1,Binding affinity against serotonergic 5-HT1a receptor,B,
1568,,BAO_0000357,,,8,,CHEMBL616508,,Autocuration,,10321,,H,11863,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,
1569,Mus musculus,BAO_0000357,,,9,,CHEMBL616559,,Expert,,2968,,D,11863,1,Binding affinity for 5-hydroxytryptamine 1A receptor,B,10090.0
1570,,BAO_0000357,,,8,,CHEMBL616560,,Autocuration,,13964,,H,11863,1,Binding affinity at 5-hydroxytryptamine 1A receptor,B,
1571,,BAO_0000357,,,8,,CHEMBL616561,,Autocuration,,15527,,H,11863,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,
1572,,BAO_0000219,,,8,,CHEMBL616562,,Autocuration,,12248,,H,11863,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1573,,BAO_0000219,,,8,,CHEMBL616563,,Autocuration,,12249,,H,11863,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1574,,BAO_0000357,,,8,,CHEMBL616564,,Autocuration,,15120,,H,11863,1,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,
1575,,BAO_0000357,,,8,,CHEMBL616565,,Autocuration,,13313,,H,11863,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,
1576,,BAO_0000218,,,8,,CHEMBL616566,,Autocuration,,2613,,H,11863,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,
1577,,BAO_0000357,,,8,,CHEMBL616989,,Autocuration,,16700,,H,11863,1,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,
1578,,BAO_0000357,,,8,,CHEMBL857975,,Autocuration,,2201,,H,11863,1,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,
1579,Mus musculus,BAO_0000357,,,9,,CHEMBL616990,,Expert,,1274,,D,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10090.0
1580,,BAO_0000357,,,8,,CHEMBL616991,,Autocuration,,1317,,H,11863,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,
1581,,BAO_0000357,,,8,,CHEMBL616992,,Autocuration,,12146,,H,11863,1,Tested against 5-hydroxytryptamine 1A receptor,B,
1582,,BAO_0000357,,,8,,CHEMBL616993,,Autocuration,,14059,,H,11863,1,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,
1583,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616994,,Expert,,14025,,H,106,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,9986.0
1584,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616995,,Autocuration,,14025,,H,106,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,9986.0
1585,Gorilla gorilla,BAO_0000219,,,9,,CHEMBL616996,,Intermediate,,14447,,D,105571,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0
1586,Cavia porcellus,BAO_0000218,,,8,,CHEMBL616997,,Autocuration,In vivo,3025,,H,106,1,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0
1587,Cavia porcellus,BAO_0000218,,,8,,CHEMBL616998,,Autocuration,In vivo,3025,,H,106,1,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0
1588,Cavia porcellus,BAO_0000019,,,8,,CHEMBL616999,,Autocuration,,15329,,H,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,10141.0
1589,Cavia porcellus,BAO_0000019,,,8,,CHEMBL617000,,Autocuration,,15329,,H,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,10141.0
1590,Cavia porcellus,BAO_0000019,,,8,,CHEMBL617001,,Autocuration,,15847,,H,106,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,10141.0
1591,Cavia porcellus,BAO_0000019,,,8,,CHEMBL858111,,Autocuration,,15847,,H,106,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,10141.0
1592,,BAO_0000019,,,8,,CHEMBL617002,,Autocuration,,14165,,H,106,1,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,
1593,,BAO_0000019,,,8,,CHEMBL617003,,Autocuration,,14214,,H,106,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,
1594,,BAO_0000019,,,8,,CHEMBL617004,,Autocuration,,14214,,H,106,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,
1595,Homo sapiens,BAO_0000019,,,9,,CHEMBL617005,,Expert,,14214,,D,106,1,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,9606.0
1596,Homo sapiens,BAO_0000219,,,9,,CHEMBL616623,,Expert,,13729,,D,106,1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,9606.0
1597,,BAO_0000219,,,8,,CHEMBL616624,,Autocuration,,3025,,H,106,1,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,
1598,,BAO_0000357,,,8,,CHEMBL883243,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,
1599,,BAO_0000019,,,8,,CHEMBL616625,,Autocuration,,2391,,H,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,
1600,,BAO_0000219,,,8,,CHEMBL616626,,Expert,,14956,,H,106,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,
1601,,BAO_0000219,,,8,,CHEMBL616627,,Autocuration,,2598,,H,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,
1602,,BAO_0000219,,,8,,CHEMBL616628,,Autocuration,,2598,,H,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,
1603,,BAO_0000219,,,8,,CHEMBL616629,,Autocuration,,2598,,H,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,
1604,,BAO_0000219,,,8,,CHEMBL616630,,Autocuration,,2598,,H,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,
1605,,BAO_0000019,,,8,,CHEMBL616631,,Expert,,14956,,H,106,1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,
1606,,BAO_0000019,,,8,,CHEMBL616632,,Autocuration,,14956,,H,106,1,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,
1607,Homo sapiens,BAO_0000357,,,9,,CHEMBL616633,,Expert,,14214,,D,106,1,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,9606.0
1608,,BAO_0000219,,,8,,CHEMBL616634,,Expert,,3463,,H,106,1,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,
1609,,BAO_0000357,,,8,,CHEMBL616635,,Autocuration,,15331,,H,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,
1610,Homo sapiens,BAO_0000357,,,9,,CHEMBL885358,,Expert,,16146,,D,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor,B,9606.0
1611,Homo sapiens,BAO_0000219,,,9,,CHEMBL616636,,Expert,,14159,,D,106,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,9606.0
1612,,BAO_0000219,,,8,,CHEMBL616637,,Expert,,14158,,H,106,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,
1613,,BAO_0000357,,,8,,CHEMBL616638,,Autocuration,,14159,,H,106,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,
1614,,BAO_0000219,,,8,,CHEMBL616639,,Expert,,15250,,H,106,1,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,
1615,,BAO_0000219,,,8,,CHEMBL616640,,Expert,,15250,,H,106,1,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,
1616,,BAO_0000219,,,8,,CHEMBL616641,,Expert,,15331,,H,106,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,
1617,,BAO_0000219,,,8,,CHEMBL616642,,Expert,,15332,,H,106,1,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,
1618,,BAO_0000219,,,8,,CHEMBL616643,,Expert,,14956,,H,106,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,
1619,,BAO_0000357,,,8,,CHEMBL616644,,Autocuration,,3805,,H,106,1,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,
1620,,BAO_0000357,,,8,,CHEMBL616645,,Autocuration,,14875,,H,106,1,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,
1621,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616646,,Autocuration,,14454,,H,105,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0
1622,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616647,,Expert,,14454,,H,105,1,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0
1623,,BAO_0000357,,,8,,CHEMBL616509,,Autocuration,,16288,,H,105,1,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,
1624,,BAO_0000357,,,8,,CHEMBL616510,,Autocuration,,16288,,H,105,1,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,
1625,,BAO_0000357,,,8,,CHEMBL616511,,Autocuration,,16312,,H,105,1,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,
1626,Bos taurus,BAO_0000357,,,8,,CHEMBL616512,,Expert,,1348,,H,105,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,9913.0
1627,Bos taurus,BAO_0000357,,,8,,CHEMBL616513,,Autocuration,,5834,,H,105,1,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,9913.0
1628,Bos taurus,BAO_0000019,2435.0,,8,Striatum,CHEMBL616514,,Autocuration,,13366,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0
1629,Bos taurus,BAO_0000357,,,8,,CHEMBL616515,,Expert,,1414,,H,105,1,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,9913.0
1630,Bos taurus,BAO_0000019,,,8,,CHEMBL616516,,Autocuration,,14998,,H,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,9913.0
1631,Bos taurus,BAO_0000357,,,8,,CHEMBL616517,,Autocuration,,11473,,H,105,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0
1632,Bos taurus,BAO_0000357,,,8,,CHEMBL616518,,Autocuration,,11473,,H,105,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0
1633,Bos taurus,BAO_0000357,,,8,,CHEMBL616519,,Autocuration,,10639,,H,105,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0
1634,Bos taurus,BAO_0000357,,,8,,CHEMBL616520,,Autocuration,,10639,,H,105,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0
1635,Bos taurus,BAO_0000357,,,8,,CHEMBL616521,,Autocuration,,1375,,H,105,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,9913.0
1636,Bos taurus,BAO_0000357,,,8,,CHEMBL616522,,Autocuration,,1375,,H,105,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,9913.0
1637,Bos taurus,BAO_0000357,,,8,,CHEMBL884531,,Autocuration,,16532,,H,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0
1638,Bos taurus,BAO_0000357,,,8,,CHEMBL616523,,Autocuration,,11147,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,9913.0
1639,Bos taurus,BAO_0000019,2435.0,,8,Striatum,CHEMBL616731,,Autocuration,,13366,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0
1640,Bos taurus,BAO_0000019,,,8,,CHEMBL616732,,Autocuration,,10444,,H,105,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,9913.0
1641,Bos taurus,BAO_0000357,,,8,,CHEMBL616733,,Autocuration,,16532,,H,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,9913.0
1642,Bos taurus,BAO_0000357,,,8,,CHEMBL616734,,Autocuration,,16532,,H,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0
1643,Bos taurus,BAO_0000249,,,8,,CHEMBL616735,,Autocuration,,12827,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,9913.0
1644,Bos taurus,BAO_0000249,,,8,,CHEMBL616736,,Autocuration,,12827,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,9913.0
1645,Bos taurus,BAO_0000019,,,8,,CHEMBL616737,,Expert,,12919,,H,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0
1646,Bos taurus,BAO_0000019,,,8,,CHEMBL616738,,Autocuration,,14025,,H,105,1,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,9913.0
1647,Bos taurus,BAO_0000019,,,8,,CHEMBL616739,,Expert,,12919,,H,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0
1648,Bos taurus,BAO_0000019,,,8,,CHEMBL616740,,Expert,,12919,,H,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0
1649,Bos taurus,BAO_0000019,,,8,,CHEMBL616741,,Expert,,12919,,H,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0
1650,Gorilla gorilla,BAO_0000219,,,8,,CHEMBL616742,,Autocuration,,14447,,H,105,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0
1651,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616743,,Intermediate,,1375,,D,105570,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,10141.0
1652,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616744,,Intermediate,,1375,,D,105570,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,10141.0
1653,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616745,,Intermediate,,12409,,D,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,10141.0
1654,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616746,,Intermediate,,12409,,D,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0
1655,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616747,,Intermediate,,12409,,D,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,10141.0
1656,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616748,,Intermediate,,12409,,D,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,10141.0
1657,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616648,,Intermediate,,12409,,D,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,10141.0
1658,Cavia porcellus,BAO_0000357,,,9,,CHEMBL616649,,Intermediate,,11574,,D,105570,1,Binding affinity against 5-hydroxytryptamine 1D receptor,B,10141.0
1659,Cavia porcellus,BAO_0000357,,,9,,CHEMBL616650,,Intermediate,,1558,,D,105570,1,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,10141.0
1660,Cavia porcellus,BAO_0000218,,,9,,CHEMBL616651,,Intermediate,,12409,,D,105570,1,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0
1661,Cavia porcellus,BAO_0000218,,,9,,CHEMBL616652,,Intermediate,,12409,,D,105570,1,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0
1662,Cavia porcellus,BAO_0000218,,,9,,CHEMBL616653,,Intermediate,,12409,,D,105570,1,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0
1663,Cavia porcellus,BAO_0000218,,,9,,CHEMBL616654,,Intermediate,,12409,,D,105570,1,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,10141.0
1664,Cavia porcellus,BAO_0000019,,,9,,CHEMBL616655,,Intermediate,,12253,,D,105570,1,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,10141.0
1665,Cavia porcellus,BAO_0000357,,,9,,CHEMBL616656,,Intermediate,,12936,,D,105570,1,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,10141.0
1666,Cavia porcellus,BAO_0000019,,,8,,CHEMBL616657,,Autocuration,,13181,,H,105,1,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,10141.0
1667,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL616658,,Intermediate,,12409,,D,105570,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,10141.0
1668,Cavia porcellus,BAO_0000357,,,9,,CHEMBL616659,,Intermediate,,10639,,D,105570,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,10141.0
1669,,BAO_0000357,,,8,,CHEMBL616660,,Autocuration,,5254,,H,51,1,Binding affinity against 5-hydroxytryptamine 1D receptor,B,
1670,,BAO_0000357,,,8,,CHEMBL616661,,Autocuration,,13051,,H,106,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,
1671,,BAO_0000019,,,8,,CHEMBL616662,,Expert,,3463,,H,105,1,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,
1672,,BAO_0000019,,,8,,CHEMBL616663,,Autocuration,,15315,,H,105,1,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,
1673,,BAO_0000019,,,8,,CHEMBL616664,,Autocuration,,6011,,H,105,1,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,
1674,Homo sapiens,BAO_0000219,,,9,,CHEMBL881820,,Expert,,14159,,D,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,9606.0
1675,,BAO_0000219,,,8,,CHEMBL616665,,Autocuration,,14159,,H,105,1,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,
1676,,BAO_0000219,,,8,,CHEMBL616666,,Expert,,15250,,H,105,1,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,
1677,,BAO_0000219,,,8,,CHEMBL616667,,Autocuration,,15250,,H,105,1,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,
1678,,BAO_0000219,,,8,,CHEMBL616668,,Expert,,15331,,H,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,
1679,Homo sapiens,BAO_0000219,,,9,,CHEMBL616669,,Expert,,15332,,D,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,9606.0
1680,,BAO_0000219,,,8,,CHEMBL617040,,Expert,,15332,,H,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,
1681,,BAO_0000219,,,8,,CHEMBL617041,,Autocuration,,3294,,H,105,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,
1682,,BAO_0000219,,,8,,CHEMBL617042,,Expert,,14158,,H,105,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,
1683,,BAO_0000219,,,8,,CHEMBL617043,,Expert,,14956,,H,105,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,
1684,,BAO_0000019,,,8,,CHEMBL617044,,Autocuration,,12469,,H,105,1,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,
1685,,BAO_0000219,,,8,,CHEMBL617045,,Expert,,3463,,H,105,1,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,
1686,Homo sapiens,BAO_0000219,,,9,,CHEMBL617046,,Expert,,15250,,D,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0
1687,Homo sapiens,BAO_0000219,,,9,,CHEMBL617047,,Expert,,15250,,D,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0
1688,,BAO_0000019,,,8,,CHEMBL617048,,Expert,,14956,,H,105,1,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,
1689,,BAO_0000019,,,8,,CHEMBL616897,,Autocuration,,14159,,H,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,
1690,Homo sapiens,BAO_0000019,,,9,,CHEMBL616898,,Expert,,14159,,D,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,9606.0
1691,Homo sapiens,BAO_0000219,,,9,,CHEMBL858201,,Expert,,14499,,D,105,1,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,9606.0
1692,,BAO_0000019,,,8,,CHEMBL616899,,Autocuration,,15315,,H,105,1,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,
1693,,BAO_0000219,,,8,,CHEMBL616900,,Autocuration,In vitro,3294,,H,105,1,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,
1694,,BAO_0000219,,,8,,CHEMBL616901,,Expert,,3463,,H,105,1,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,
1695,,BAO_0000357,,,8,,CHEMBL616902,,Autocuration,,15331,,H,105,1,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,
1696,Homo sapiens,BAO_0000219,,,9,,CHEMBL616903,,Expert,,14159,,D,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0
1697,,BAO_0000219,,,8,,CHEMBL616904,,Expert,,14158,,H,105,1,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,
1698,,BAO_0000357,,,8,,CHEMBL616905,,Autocuration,,14159,,H,105,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,
1699,,BAO_0000219,,,8,,CHEMBL616906,,Expert,,15250,,H,105,1,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,
1700,,BAO_0000219,,,8,,CHEMBL616907,,Expert,,15250,,H,105,1,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1701,,BAO_0000219,,,8,,CHEMBL616908,,Expert,,15331,,H,105,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1702,Homo sapiens,BAO_0000219,,,9,,CHEMBL616909,,Expert,,15332,,D,105,1,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0
1703,Homo sapiens,BAO_0000219,,,9,,CHEMBL616910,,Expert,,14499,,D,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0
1704,,BAO_0000219,,,8,,CHEMBL616911,,Expert,,15332,,H,105,1,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1705,,BAO_0000219,,,8,,CHEMBL616912,,Expert,,14956,,H,105,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,
1706,,BAO_0000357,,,8,,CHEMBL616913,,Autocuration,,3805,,H,105,1,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,
1707,Homo sapiens,BAO_0000219,,,9,,CHEMBL616914,,Expert,,6011,,D,105,1,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,9606.0
1708,,BAO_0000219,,,8,,CHEMBL616915,,Autocuration,,16190,,H,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,
1709,,BAO_0000019,,,8,,CHEMBL616916,,Autocuration,,14165,,H,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,
1710,Homo sapiens,BAO_0000357,,,9,,CHEMBL616917,,Expert,,4234,,D,105,1,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,9606.0
1711,,BAO_0000357,,,8,,CHEMBL616918,,Autocuration,,15527,,H,105,1,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,
1712,,BAO_0000219,,,8,,CHEMBL616919,,Expert,,6328,,H,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,
1713,,BAO_0000357,,,8,,CHEMBL616920,,Autocuration,,16209,,H,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,
1714,,BAO_0000357,,,8,,CHEMBL872914,,Autocuration,,14770,,H,105,1,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,
1715,,BAO_0000357,,,8,,CHEMBL616921,,Autocuration,,2598,,H,105,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,
1716,,BAO_0000357,,,8,,CHEMBL616922,,Expert,,6897,,H,105,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,
1717,,BAO_0000357,,,8,,CHEMBL616923,,Autocuration,,6013,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,
1718,,BAO_0000357,,,8,,CHEMBL616924,,Expert,,5843,,H,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,
1719,,BAO_0000357,,,8,,CHEMBL875909,,Expert,,14454,,H,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,
1720,,BAO_0000357,,,8,,CHEMBL616925,,Autocuration,,14454,,H,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,
1721,,BAO_0000357,,,8,,CHEMBL616926,,Autocuration,,14454,,H,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,
1722,,BAO_0000357,,,8,,CHEMBL616927,,Autocuration,,15818,,H,105,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,
1723,,BAO_0000219,,,8,,CHEMBL616928,,Expert,,13729,,H,105,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,
1724,Homo sapiens,BAO_0000219,,,9,,CHEMBL616929,,Expert,In vitro,6011,,D,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,9606.0
1725,Homo sapiens,BAO_0000357,,,9,,CHEMBL616930,,Expert,,4234,,D,105,1,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,9606.0
1726,,BAO_0000019,,,8,,CHEMBL616931,,Expert,,17085,,H,105,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,
1727,,BAO_0000357,,,8,,CHEMBL616932,,Autocuration,,3025,,H,105,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,
1728,,BAO_0000357,,,8,,CHEMBL616933,,Expert,,15315,,H,105,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,
1729,Homo sapiens,BAO_0000219,,,9,,CHEMBL616934,,Expert,,14214,,D,105,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,9606.0
1730,Homo sapiens,BAO_0000357,,,9,,CHEMBL616935,,Expert,,3804,,D,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0
1731,,BAO_0000357,,,8,,CHEMBL616936,,Autocuration,,16700,,H,105,1,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,
1732,Homo sapiens,BAO_0000357,,,9,,CHEMBL616937,,Expert,,2391,,D,105,1,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,9606.0
1733,Homo sapiens,BAO_0000357,,,9,,CHEMBL616938,,Expert,,4175,,D,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0
1734,,BAO_0000019,,,8,,CHEMBL616939,,Autocuration,,17085,,H,105,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,
1735,,BAO_0000019,,,8,,CHEMBL616940,,Expert,,17085,,H,105,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,
1736,Homo sapiens,BAO_0000357,,,9,,CHEMBL616941,,Expert,,15926,,D,105,1,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,9606.0
1737,,BAO_0000219,,,8,,CHEMBL616942,,Autocuration,,16312,,H,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,
1738,,BAO_0000219,,,8,,CHEMBL616943,,Autocuration,,16312,,H,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,
1739,,BAO_0000219,,,4,,CHEMBL616944,,Autocuration,,14956,,H,104802,1,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,
1740,,BAO_0000019,,,8,,CHEMBL616945,,Autocuration,,3294,,H,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,
1741,,BAO_0000357,,,8,,CHEMBL616946,,Autocuration,,12861,,H,105,1,Binding activity radioligand.,B,
1742,,BAO_0000019,,,8,,CHEMBL616947,,Autocuration,,12861,,H,105,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1743,,BAO_0000219,,,8,,CHEMBL616948,,Expert,,16312,,H,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,
1744,,BAO_0000357,,,8,,CHEMBL616851,,Autocuration,,5104,,H,105,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,
1745,,BAO_0000357,,,8,,CHEMBL616852,,Autocuration,,5105,,H,105,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,
1746,,BAO_0000357,,,8,,CHEMBL616853,,Autocuration,,14499,,H,105,1,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,
1747,Homo sapiens,BAO_0000357,,,9,,CHEMBL616854,,Expert,,15926,,D,105,1,Binding activity against human 5-hydroxytryptamine 1D receptor,B,9606.0
1748,Homo sapiens,BAO_0000219,,,9,,CHEMBL616855,,Expert,,4540,,D,105,1,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0
1749,,BAO_0000219,,,8,,CHEMBL616856,,Autocuration,,15779,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,
1750,,BAO_0000219,,,8,,CHEMBL616857,,Autocuration,,15779,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
1751,,BAO_0000357,,,8,,CHEMBL616858,,Autocuration,,6166,,H,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,
1752,,BAO_0000219,,,8,,CHEMBL616859,,Autocuration,,15779,,H,105,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,
1753,,BAO_0000219,,,8,,CHEMBL616860,,Autocuration,,15779,,H,105,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,
1754,,BAO_0000219,,,8,,CHEMBL616861,,Autocuration,,17451,,H,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,
1755,,BAO_0000219,,,8,,CHEMBL616541,,Autocuration,,17451,,H,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,
1756,,BAO_0000219,,,8,,CHEMBL616542,,Autocuration,,17451,,H,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,
1757,,BAO_0000219,,,8,,CHEMBL616543,,Autocuration,,4199,,H,105,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,
1758,Homo sapiens,BAO_0000357,,,9,,CHEMBL616544,,Expert,,14875,,D,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0
1759,,BAO_0000219,,,8,,CHEMBL616545,,Autocuration,,15146,,H,105,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,
1760,,BAO_0000357,,,8,,CHEMBL616546,,Autocuration,,5213,,H,105,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,
1761,,BAO_0000219,,,8,,CHEMBL616547,,Autocuration,,14818,,H,105,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,
1762,,BAO_0000219,,,8,,CHEMBL616548,,Autocuration,,4829,,H,105,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,
1763,,BAO_0000019,,,8,,CHEMBL616549,,Expert,,14454,,H,105,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,
1764,,BAO_0000019,,,8,,CHEMBL616550,,Expert,,14454,,H,105,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,
1765,,BAO_0000357,,,8,,CHEMBL857066,,Autocuration,,5254,,H,108,1,Binding affinity against 5-HT2C receptor,B,
1766,,BAO_0000357,,,8,,CHEMBL616551,,Autocuration,,5254,,H,108,1,Binding affinity against 5-hydroxytryptamine 1D receptor,B,
1767,,BAO_0000357,,,8,,CHEMBL616552,,Autocuration,,10639,,H,10577,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,
1768,,BAO_0000019,,,8,,CHEMBL832876,,Autocuration,,10639,,H,10577,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,
1769,,BAO_0000019,,,8,,CHEMBL616553,,Expert,,12352,,H,10577,1,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,
1770,,BAO_0000357,,,8,,CHEMBL616554,,Autocuration,,9098,,H,10577,1,Binding affinity towards 5-HT1B was determined,B,
1771,,BAO_0000019,,,8,,CHEMBL616555,,Expert,,14430,,H,10577,1,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,
1772,,BAO_0000019,,,8,,CHEMBL616556,,Expert,,13657,,H,10577,1,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,
1773,,BAO_0000019,,,8,,CHEMBL616557,,Autocuration,,13657,,H,10577,1,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,
1774,,BAO_0000019,,,8,,CHEMBL616558,,Expert,,15854,,H,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
1775,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616749,,Expert,,10639,,D,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,10116.0
1776,,BAO_0000357,,,8,,CHEMBL616750,,Autocuration,,10025,,H,10577,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,
1777,,BAO_0000357,,,8,,CHEMBL616751,,Autocuration,,10025,,H,10577,1,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,
1778,,BAO_0000249,,,8,,CHEMBL616752,,Autocuration,,14286,,H,10577,1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,
1779,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616753,,Autocuration,,3651,,H,10577,1,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,
1780,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616754,,Expert,,14178,,D,10577,1,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,10116.0
1781,,BAO_0000019,,,8,,CHEMBL616755,,Autocuration,,10639,,H,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,
1782,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616756,,Autocuration,,13605,,H,10577,1,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,
1783,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616757,,Autocuration,,5834,,H,10577,1,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,
1784,,BAO_0000357,2435.0,,8,Striatum,CHEMBL616758,,Autocuration,,10922,,H,10577,1,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,
1785,,BAO_0000249,,,8,,CHEMBL616759,,Autocuration,,14286,,H,10577,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,
1786,,BAO_0000357,,,8,,CHEMBL616760,,Autocuration,,11825,,H,10577,1,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,
1787,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616761,,Autocuration,,14826,,H,10577,1,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,
1788,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616762,,Autocuration,,9699,,H,10577,1,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,
1789,,BAO_0000019,,,8,,CHEMBL616763,,Autocuration,,14423,,H,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,
1790,,BAO_0000357,,,8,,CHEMBL872909,,Expert,,10062,,H,10577,1,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,
1791,,BAO_0000357,,,8,,CHEMBL616764,,Autocuration,,10062,,H,10577,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,
1792,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616765,,Expert,,12280,,D,10577,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,10116.0
1793,,BAO_0000357,2435.0,,8,Striatum,CHEMBL616766,,Autocuration,,15412,,H,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,
1794,,BAO_0000357,2435.0,,8,Striatum,CHEMBL616767,,Autocuration,,15412,,H,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,
1795,,BAO_0000357,,,8,,CHEMBL616768,,Autocuration,,10062,,H,10577,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,
1796,,BAO_0000357,,,8,,CHEMBL616769,,Autocuration,,11147,,H,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,
1797,,BAO_0000019,,,8,,CHEMBL616770,,Autocuration,,9547,,H,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,
1798,,BAO_0000019,,,8,,CHEMBL616771,,Autocuration,,10444,,H,10577,1,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,
1799,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616772,,Autocuration,,12469,,H,10577,1,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,
1800,,BAO_0000019,,,8,,CHEMBL616773,,Expert,,9098,,H,10577,1,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,
1801,,BAO_0000019,,,8,,CHEMBL616774,,Autocuration,,9098,,H,10577,1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,
1802,,BAO_0000357,,,8,,CHEMBL616775,,Autocuration,,9699,,H,10577,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,
1803,,BAO_0000249,,,8,,CHEMBL616776,,Autocuration,,10394,,H,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,
1804,,BAO_0000357,,,8,,CHEMBL616777,,Autocuration,,12092,,H,10577,1,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,
1805,,BAO_0000357,,,8,,CHEMBL616778,,Autocuration,,16700,,H,10577,1,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,
1806,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616779,,Expert,,403,,D,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,10116.0
1807,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616780,,Expert,,12771,,D,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,10116.0
1808,,BAO_0000019,,,8,,CHEMBL616781,,Autocuration,,11642,,H,10577,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,
1809,,BAO_0000357,,,8,,CHEMBL616782,,Autocuration,,12953,,H,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,
1810,,BAO_0000357,,,8,,CHEMBL616783,,Autocuration,,12953,,H,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,
1811,,BAO_0000019,2435.0,,8,Striatum,CHEMBL616784,,Expert,,12953,,H,10577,1,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,
1812,,BAO_0000357,,,8,,CHEMBL616785,,Autocuration,,12953,,H,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,
1813,,BAO_0000249,955.0,,8,Brain,CHEMBL857067,,Autocuration,,9737,,H,10577,1,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,
1814,,BAO_0000019,,,8,,CHEMBL616786,,Autocuration,,9737,,H,10577,1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,
1815,,BAO_0000249,955.0,,8,Brain,CHEMBL616787,,Autocuration,,9737,,H,10577,1,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,
1816,,BAO_0000357,,,8,,CHEMBL616788,,Autocuration,,12827,,H,10577,1,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,
1817,,BAO_0000357,,,8,,CHEMBL616789,,Autocuration,,5033,,H,10577,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,
1818,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616790,,Expert,,9786,,D,10577,1,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,10116.0
1819,,BAO_0000357,,,8,,CHEMBL616791,,Expert,,13116,,H,10577,1,Binding affinity at 5-hydroxytryptamine 1B receptor,B,
1820,,BAO_0000019,,,8,,CHEMBL616792,,Autocuration,,16429,,H,10577,1,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,
1821,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL616793,,Expert,,12409,,D,10577,1,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,10116.0
1822,,BAO_0000357,,,8,,CHEMBL616794,,Autocuration,,15194,,H,10577,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,
1823,,BAO_0000357,,,8,,CHEMBL616795,,Autocuration,,15194,,H,10577,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1824,,BAO_0000019,,,4,,CHEMBL616796,,Autocuration,,5486,,H,104686,1,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,
1825,,BAO_0000357,,,8,,CHEMBL616797,,Autocuration,,4639,,H,106,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,
1826,,BAO_0000249,,,8,,CHEMBL616798,,Autocuration,,386,,H,106,1,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,
1827,,BAO_0000357,,,8,,CHEMBL616799,,Autocuration,,2474,,H,106,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,
1828,,BAO_0000357,,,8,,CHEMBL616800,,Autocuration,,6011,,H,106,1,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,
1829,,BAO_0000357,,,8,,CHEMBL616801,,Autocuration,,5014,,H,106,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,
1830,,BAO_0000357,,,8,,CHEMBL616802,,Autocuration,,17515,,H,106,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,
1831,,BAO_0000357,,,8,,CHEMBL616803,,Autocuration,,4373,,H,106,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,
1832,,BAO_0000357,,,8,,CHEMBL857068,,Expert,,1633,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,
1833,,BAO_0000357,,,8,,CHEMBL616804,,Autocuration,,1633,,H,106,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,
1834,,BAO_0000357,,,8,,CHEMBL616805,,Autocuration,,4373,,H,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,
1835,,BAO_0000357,,,8,,CHEMBL616806,,Autocuration,,4687,,H,106,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,
1836,,BAO_0000357,,,8,,CHEMBL616807,,Autocuration,,11574,,H,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor,B,
1837,,BAO_0000357,,,8,,CHEMBL616808,,Autocuration,,10321,,H,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,
1838,,BAO_0000357,,,8,,CHEMBL616809,,Autocuration,,15527,,H,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1839,,BAO_0000357,,,8,,CHEMBL616810,,Autocuration,,17200,,H,106,1,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,
1840,,BAO_0000224,,,4,,CHEMBL616811,,Autocuration,,14423,,H,104802,1,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,
1841,Bos taurus,BAO_0000357,,,8,,CHEMBL616812,,Autocuration,,5834,,H,108,1,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,9913.0
1842,Sus scrofa,BAO_0000357,,,8,,CHEMBL616813,,Autocuration,,11473,,H,108,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,9823.0
1843,Sus scrofa,BAO_0000357,,,8,,CHEMBL616814,,Autocuration,,11473,,H,108,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,9823.0
1844,Sus scrofa,BAO_0000357,,,8,,CHEMBL616815,,Autocuration,,10639,,H,108,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0
1845,Sus scrofa,BAO_0000357,,,8,,CHEMBL616816,,Autocuration,,10639,,H,108,1,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0
1846,Sus scrofa,BAO_0000357,,,8,,CHEMBL616817,,Autocuration,,14331,,H,108,1,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,9823.0
1847,Sus scrofa,BAO_0000357,,,8,,CHEMBL616818,,Autocuration,,10796,,H,108,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,9823.0
1848,Sus scrofa,BAO_0000357,,,8,,CHEMBL616819,,Expert,,9098,,H,108,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,9823.0
1849,Sus scrofa,BAO_0000357,,,8,,CHEMBL616820,,Expert,,14331,,H,108,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,9823.0
1850,Sus scrofa,BAO_0000019,,,8,,CHEMBL616821,,Expert,,11828,,H,108,1,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,9823.0
1851,Sus scrofa,BAO_0000357,,,8,,CHEMBL616822,,Autocuration,,11866,,H,108,1,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,9823.0
1852,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616823,,Autocuration,,13047,,H,108,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0
1853,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616824,,Autocuration,,188,,D,12689,1,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,10116.0
1854,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616825,,Autocuration,,11825,,D,12689,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0
1855,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616826,,Autocuration,,11825,,D,12689,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0
1856,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616827,,Expert,,11624,,D,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,10116.0
1857,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616828,,Autocuration,,11139,,D,12689,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,10116.0
1858,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616829,,Autocuration,,11147,,D,12689,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,10116.0
1859,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616830,,Autocuration,,10444,,D,12689,1,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,10116.0
1860,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616831,,Expert,,11624,,D,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,B,10116.0
1861,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616832,,Autocuration,,11662,,D,12689,1,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0
1862,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616833,,Autocuration,,11662,,D,12689,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0
1863,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616834,,Expert,,11662,,D,12689,1,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0
1864,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL829595,,Autocuration,,11662,,D,12689,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0
1865,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616835,,Autocuration,,9098,,D,12689,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,10116.0
1866,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL872910,,Autocuration,,10394,,D,12689,1,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,10116.0
1867,,BAO_0000357,,,8,,CHEMBL616836,,Expert,,11933,,H,12689,1,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,
1868,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL616837,,Autocuration,,12092,,D,12689,1,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,10116.0
1869,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL616466,,Autocuration,,12253,,D,12689,1,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,10116.0
1870,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL616467,,Autocuration,,12253,,D,12689,1,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,10116.0
1871,,BAO_0000357,,,8,,CHEMBL616468,,Autocuration,,1558,,H,108,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,
1872,,BAO_0000357,,,8,,CHEMBL616469,,Autocuration,,2474,,H,108,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,
1873,,BAO_0000357,,,8,,CHEMBL616470,,Autocuration,,2474,,H,108,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,
1874,,BAO_0000357,,,8,,CHEMBL616471,,Autocuration,,11574,,H,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,B,
1875,,BAO_0000357,,,8,,CHEMBL616472,,Autocuration,,1558,,H,12689,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,
1876,,BAO_0000357,,,8,,CHEMBL616473,,Autocuration,,13944,,H,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,B,
1877,,BAO_0000357,,,8,,CHEMBL616474,,Autocuration,,13033,,H,12689,1,Binding affinity against serotonergic 5-HT1c receptor,B,
1878,,BAO_0000357,,,8,,CHEMBL616475,,Autocuration,,10321,,H,12689,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,
1879,,BAO_0000357,,,8,,CHEMBL616476,,Autocuration,,11866,,H,12689,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,
1880,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616477,,Autocuration,,14454,,H,105,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,9986.0
1881,,BAO_0000224,,,4,,CHEMBL616478,,Autocuration,,11574,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,
1882,,BAO_0000224,,,4,,CHEMBL616479,,Autocuration,,11574,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,
1883,,BAO_0000019,,,4,,CHEMBL616480,,Autocuration,,13631,,H,104686,1,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,
1884,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL616481,,Autocuration,,9630,,D,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,10116.0
1885,Rattus norvegicus,BAO_0000249,,,5,,CHEMBL616482,,Autocuration,,8822,,D,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,10116.0
1886,Rattus norvegicus,BAO_0000221,955.0,,5,Brain,CHEMBL884713,,Autocuration,,9064,,D,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,10116.0
1887,,BAO_0000224,,,4,,CHEMBL616483,,Autocuration,,8868,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,
1888,,BAO_0000224,,,4,,CHEMBL616484,,Autocuration,,9064,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,
1889,,BAO_0000019,,,4,,CHEMBL616485,,Autocuration,,9806,,H,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,
1890,,BAO_0000224,,,4,,CHEMBL616486,,Autocuration,,9098,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
1891,,BAO_0000224,,,4,,CHEMBL616487,,Autocuration,,8868,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,
1892,,BAO_0000224,,,4,,CHEMBL616488,,Autocuration,,12765,,H,104686,1,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,
1893,,BAO_0000019,,,4,,CHEMBL616489,,Autocuration,,11049,,H,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1894,,BAO_0000019,,,4,,CHEMBL616490,,Autocuration,,11049,,H,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1895,,BAO_0000019,,,4,,CHEMBL616491,,Autocuration,,11049,,H,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,
1896,,BAO_0000019,,,4,,CHEMBL616492,,Autocuration,,11049,,H,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,
1897,,BAO_0000019,,,4,,CHEMBL616493,,Autocuration,,11049,,H,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1898,,BAO_0000019,,,4,,CHEMBL616494,,Autocuration,,11473,,H,104686,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,
1899,,BAO_0000019,,,4,,CHEMBL616495,,Autocuration,,11473,,H,104686,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,
1900,,BAO_0000019,,,4,,CHEMBL616496,,Autocuration,,3086,,H,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,
1901,,BAO_0000019,,,4,,CHEMBL616497,,Autocuration,,11049,,H,104686,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1902,,BAO_0000019,,,4,,CHEMBL616498,,Autocuration,,11049,,H,104686,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1903,,BAO_0000019,,,4,,CHEMBL616499,,Autocuration,,10639,,H,104686,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,
1904,,BAO_0000019,,,4,,CHEMBL616500,,Autocuration,,10922,,H,104686,1,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,
1905,Rattus norvegicus,BAO_0000221,955.0,,5,Brain,CHEMBL616501,,Autocuration,,9064,,D,104686,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0
1906,,BAO_0000221,955.0,,4,Brain,CHEMBL616502,,Autocuration,,10748,,H,104686,1,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,
1907,,BAO_0000249,,,4,,CHEMBL884529,,Autocuration,,11614,,H,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,
1908,,BAO_0000249,,,4,,CHEMBL616503,,Autocuration,,11615,,H,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,
1909,,BAO_0000224,,,4,,CHEMBL616964,,Autocuration,,11615,,H,104686,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,
1910,,BAO_0000249,,,4,,CHEMBL616965,,Autocuration,,11614,,H,104686,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,
1911,,BAO_0000224,,,4,,CHEMBL616966,,Autocuration,,11702,,H,104686,1,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,
1912,,BAO_0000224,,,4,,CHEMBL616967,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
1913,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL616968,,Autocuration,,11702,,D,104686,1,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,10116.0
1914,,BAO_0000224,,,4,,CHEMBL616969,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
1915,,BAO_0000019,,,4,,CHEMBL884530,,Autocuration,,13346,,H,104686,1,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,
1916,,BAO_0000224,,,4,,CHEMBL616970,,Autocuration,,10025,,H,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,
1917,,BAO_0000224,,,4,,CHEMBL616971,,Autocuration,,10025,,H,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,
1918,,BAO_0000224,,,4,,CHEMBL616972,,Autocuration,,10025,,H,104686,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,
1919,,BAO_0000224,,,4,,CHEMBL616973,,Autocuration,,9036,,H,104686,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,
1920,,BAO_0000224,,,4,,CHEMBL616974,,Autocuration,,9036,,H,104686,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,
1921,,BAO_0000019,,,4,,CHEMBL616975,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,
1922,,BAO_0000019,,,4,,CHEMBL616976,,Autocuration,,12304,,H,104686,1,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,
1923,,BAO_0000224,,,4,,CHEMBL616977,,Autocuration,,13276,,H,104686,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,
1924,,BAO_0000224,,,4,,CHEMBL616978,,Autocuration,,11825,,H,104686,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,
1925,,BAO_0000224,,,4,,CHEMBL616979,,Autocuration,,12443,,H,104686,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,
1926,,BAO_0000224,,,4,,CHEMBL616980,,Autocuration,,13830,,H,104686,1,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,
1927,,BAO_0000249,,,4,,CHEMBL616981,,Autocuration,,9592,,H,104686,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,
1928,,BAO_0000249,,,4,,CHEMBL616982,,Autocuration,,9592,,H,104686,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,
1929,,BAO_0000224,,,4,,CHEMBL616983,,Autocuration,,10881,,H,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,
1930,,BAO_0000019,,,4,,CHEMBL616984,,Autocuration,,13605,,H,104686,1,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,
1931,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL616985,,Autocuration,,11624,,D,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,10116.0
1932,,BAO_0000224,,,4,,CHEMBL616986,,Autocuration,,4101,,H,104686,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,
1933,,BAO_0000224,,,4,,CHEMBL616987,,Autocuration,,4101,,H,104686,1,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,
1934,,BAO_0000019,,,4,,CHEMBL616988,,Autocuration,,15360,,H,104686,1,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,
1935,,BAO_0000019,,,4,,CHEMBL617243,,Autocuration,,11576,,H,104686,1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,
1936,,BAO_0000019,,,4,,CHEMBL617244,,Autocuration,,5834,,H,104686,1,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,
1937,Rattus norvegicus,BAO_0000219,,,5,,CHEMBL617245,,Autocuration,,2395,,D,104686,1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0
1938,,BAO_0000249,,,4,,CHEMBL617246,,Autocuration,,11965,,H,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,
1939,,BAO_0000224,,,4,,CHEMBL617546,,Autocuration,,3967,,H,104686,1,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,
1940,,BAO_0000249,,,4,,CHEMBL617547,,Autocuration,,11130,,H,104686,1,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,
1941,,BAO_0000219,,,4,,CHEMBL617548,,Autocuration,In vitro,13427,,H,104686,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
1942,,BAO_0000224,,,4,,CHEMBL617549,,Autocuration,,9443,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
1943,,BAO_0000224,,,4,,CHEMBL617550,,Autocuration,,9443,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,
1944,,BAO_0000224,,,4,,CHEMBL617551,,Autocuration,,11825,,H,104686,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,
1945,,BAO_0000249,,,4,,CHEMBL617552,,Autocuration,,12120,,H,104686,1,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,
1946,,BAO_0000249,,,4,,CHEMBL617553,,Autocuration,,12120,,H,104686,1,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,
1947,,BAO_0000019,1515.0,,4,Thoracic aorta,CHEMBL617554,,Autocuration,,11963,,H,104686,1,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,
1948,,BAO_0000019,,,4,,CHEMBL617555,,Autocuration,,9069,,H,104686,1,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,
1949,,BAO_0000224,,,4,,CHEMBL617556,,Autocuration,,8868,,H,104686,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,
1950,,BAO_0000357,,,8,,CHEMBL617557,,Autocuration,,17200,,H,10624,1,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,
1951,,BAO_0000357,,,8,,CHEMBL617558,,Autocuration,,17200,,H,10624,1,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,
1952,,BAO_0000357,,,8,,CHEMBL617559,,Expert,,13969,,H,17106,1,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,
1953,,BAO_0000357,,,9,,CHEMBL617560,,Expert,,13392,,D,17106,1,Binding affinity for 5-hydroxytryptamine 1D receptor,B,
1954,,BAO_0000249,,,8,,CHEMBL617561,,Autocuration,,1742,,H,17106,1,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1955,,BAO_0000249,,,8,,CHEMBL617562,,Autocuration,,1742,,H,17106,1,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1956,,BAO_0000357,2435.0,,8,Striatum,CHEMBL617563,,Autocuration,,14331,,H,17106,1,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,
1957,,BAO_0000019,,,8,,CHEMBL617564,,Autocuration,,12861,,H,17106,1,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,
1958,,BAO_0000019,,,8,,CHEMBL617565,,Expert,,12861,,H,17106,1,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,
1959,,BAO_0000357,,,8,,CHEMBL856076,,Autocuration,,12861,,H,17106,1,Binding activity radioligand.,B,
1960,,BAO_0000019,,,8,,CHEMBL617566,,Autocuration,,12861,,H,17106,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
1961,,BAO_0000019,,,8,,CHEMBL875911,,Expert,,12861,,H,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1962,,BAO_0000019,,,8,,CHEMBL617567,,Autocuration,,12861,,H,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,
1963,,BAO_0000249,,,8,,CHEMBL617568,,Autocuration,,675,,H,17106,1,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1964,,BAO_0000019,,,8,,CHEMBL617569,,Expert,,12490,,H,17106,1,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,
1965,,BAO_0000249,,,8,,CHEMBL617570,,Expert,,11828,,H,17106,1,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,
1966,,BAO_0000357,,,8,,CHEMBL617571,,Autocuration,,11866,,H,17106,1,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,
1967,Sus scrofa,BAO_0000357,,,8,,CHEMBL617572,,Autocuration,,773,,H,105,1,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,9823.0
1968,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL617573,,Expert,,13047,,H,105,1,The compound was tested for intrinsic activity against 5-HT1D receptor,B,9986.0
1969,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL617574,,Autocuration,,13047,,H,105,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0
1970,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL617575,,Expert,,13047,,H,105,1,The compound was tested for binding affinity against 5-HT1D receptor,B,9986.0
1971,,BAO_0000357,,,8,,CHEMBL617576,,Autocuration,,188,,H,10578,1,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,
1972,,BAO_0000019,,,8,,CHEMBL617577,,Autocuration,,10639,,H,10578,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,
1973,,BAO_0000019,,,8,,CHEMBL617578,,Autocuration,,12438,,H,10578,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,
1974,,BAO_0000357,,,8,,CHEMBL617579,,Autocuration,,12438,,H,10578,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,
1975,,BAO_0000019,,,8,,CHEMBL617580,,Expert,,15854,,H,10578,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
1976,,BAO_0000249,,,8,,CHEMBL617581,,Autocuration,,10394,,H,10578,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,
1977,,BAO_0000357,,,8,,CHEMBL617582,,Autocuration,,12092,,H,10578,1,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,
1978,,BAO_0000019,,,8,,CHEMBL617583,,Expert,,3389,,H,10578,1,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,
1979,,BAO_0000357,,,8,,CHEMBL617584,,Autocuration,,6011,,H,105,1,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,
1980,,BAO_0000357,,,8,,CHEMBL617585,,Autocuration,,4639,,H,105,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,
1981,,BAO_0000357,,,8,,CHEMBL875912,,Autocuration,,2474,,H,105,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,
1982,,BAO_0000357,,,8,,CHEMBL617586,,Autocuration,,5014,,H,105,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,
1983,,BAO_0000357,,,8,,CHEMBL617587,,Autocuration,,17515,,H,105,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,
1984,,BAO_0000357,,,8,,CHEMBL617588,,Autocuration,,11866,,H,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,
1985,,BAO_0000357,,,8,,CHEMBL857980,,Autocuration,,4687,,H,105,1,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,
1986,,BAO_0000357,,,8,,CHEMBL617589,,Autocuration,,12146,,H,105,1,Tested against 5-hydroxytryptamine 1D receptor,B,
1987,,BAO_0000357,,,8,,CHEMBL617590,,Autocuration,,10321,,H,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,
1988,,BAO_0000219,,,8,,CHEMBL617591,,Autocuration,,13267,,H,105,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,
1989,Homo sapiens,BAO_0000357,,,9,,CHEMBL617592,,Expert,,1274,,D,105,1,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,9606.0
1990,,BAO_0000357,,,8,,CHEMBL617593,,Autocuration,,15250,,H,105,1,,B,
1991,,BAO_0000219,,,8,,CHEMBL617594,,Autocuration,,13706,,H,106,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
1992,,BAO_0000219,,,8,,CHEMBL617595,,Autocuration,,13706,,H,105,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
1993,,BAO_0000219,,,8,,CHEMBL617596,,Autocuration,,13706,,H,105,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,
1994,,BAO_0000219,,,8,,CHEMBL617597,,Autocuration,,13706,,H,105,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,
1995,,BAO_0000019,,,8,,CHEMBL617598,,Autocuration,,13047,,H,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,
1996,,BAO_0000357,,,8,,CHEMBL872916,,Autocuration,,13366,,H,105,1,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,
1997,,BAO_0000357,,,8,,CHEMBL617599,,Expert,,13366,,H,105,1,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,
1998,,BAO_0000357,,,8,,CHEMBL617091,,Autocuration,,1558,,H,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,
1999,,BAO_0000219,,,8,,CHEMBL617092,,Expert,,12902,,H,105,1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,
2000,,BAO_0000219,,,8,,CHEMBL617093,,Autocuration,,13706,,H,105,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
2001,,BAO_0000019,,,8,,CHEMBL617094,,Autocuration,,13706,,H,105,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,
2002,,BAO_0000019,,,8,,CHEMBL617095,,Autocuration,,13706,,H,105,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2003,,BAO_0000019,,,8,,CHEMBL617096,,Autocuration,,14251,,H,105,1,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2004,,BAO_0000019,,,8,,CHEMBL617097,,Autocuration,,14251,,H,105,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2005,,BAO_0000019,,,8,,CHEMBL617098,,Autocuration,,14251,,H,105,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2006,,BAO_0000357,,,8,,CHEMBL617301,,Autocuration,,13313,,H,105,1,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,
2007,,BAO_0000357,,,8,,CHEMBL617302,,Autocuration,,13313,,H,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,
2008,,BAO_0000357,,,8,,CHEMBL617303,,Autocuration,,13366,,H,105,1,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,
2009,,BAO_0000357,,,8,,CHEMBL617304,,Expert,,13051,,H,105,1,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,
2010,,BAO_0000219,,,8,,CHEMBL617305,,Expert,,12903,,H,105,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2011,Homo sapiens,BAO_0000219,,,9,,CHEMBL617306,,Autocuration,,12469,,D,105,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,9606.0
2012,,BAO_0000357,,,8,,CHEMBL617307,,Autocuration,,5619,,H,17106,1,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,
2013,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL617308,,Autocuration,,13047,,H,105,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0
2014,,BAO_0000357,,,8,,CHEMBL617309,,Autocuration,,16633,,H,105,1,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,
2015,,BAO_0000357,,,8,,CHEMBL617310,,Autocuration,,16633,,H,105,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,
2016,,BAO_0000357,,,8,,CHEMBL617311,,Autocuration,,16633,,H,105,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,
2017,,BAO_0000357,,,8,,CHEMBL617312,,Autocuration,,16633,,H,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,
2018,,BAO_0000357,,,8,,CHEMBL617313,,Autocuration,,3269,,H,105,1,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,
2019,,BAO_0000357,,,8,,CHEMBL617314,,Expert,,12409,,H,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,
2020,,BAO_0000019,,,8,,CHEMBL617315,,Autocuration,,13706,,H,106,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2021,,BAO_0000219,,,8,,CHEMBL617316,,Autocuration,,13706,,H,106,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,
2022,,BAO_0000219,,,8,,CHEMBL617317,,Autocuration,,13706,,H,106,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,
2023,,BAO_0000219,,,8,,CHEMBL617318,,Autocuration,,12903,,H,106,1,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2024,,BAO_0000019,,,8,,CHEMBL617319,,Autocuration,,13047,,H,106,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,
2025,,BAO_0000357,,,9,,CHEMBL617320,,Expert,,13366,,D,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2026,,BAO_0000357,,,9,,CHEMBL617321,,Expert,,13366,,D,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2027,,BAO_0000357,,,9,,CHEMBL617322,,Expert,,13366,,D,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2028,,BAO_0000357,,,8,,CHEMBL616862,,Autocuration,,13366,,H,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,
2029,,BAO_0000357,,,8,,CHEMBL616863,,Autocuration,,13366,,H,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,
2030,,BAO_0000219,,,8,,CHEMBL616864,,Autocuration,,12469,,H,106,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,
2031,,BAO_0000219,,,8,,CHEMBL616865,,Autocuration,,13706,,H,106,1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,
2032,,BAO_0000219,,,8,,CHEMBL616866,,Autocuration,,13706,,H,106,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,
2033,,BAO_0000019,,,8,,CHEMBL616867,,Autocuration,,13706,,H,106,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2034,,BAO_0000219,,,8,,CHEMBL616868,,Expert,,12902,,H,106,1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,
2035,,BAO_0000357,,,8,,CHEMBL616869,,Expert,,13051,,H,105,1,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,
2036,,BAO_0000219,,,8,,CHEMBL616870,,Expert,,12903,,H,106,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2037,,BAO_0000219,,,8,,CHEMBL616871,,Autocuration,,1558,,H,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,
2038,,BAO_0000219,,,8,,CHEMBL616872,,Autocuration,,1558,,H,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,
2039,,BAO_0000219,,,8,,CHEMBL616873,,Autocuration,,1558,,H,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,
2040,,BAO_0000219,,,8,,CHEMBL616838,,Autocuration,,1558,,H,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,
2041,,BAO_0000357,,,8,,CHEMBL616839,,Autocuration,,1558,,H,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,
2042,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL616840,,Autocuration,,13047,,H,106,1,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,9986.0
2043,,BAO_0000357,,,8,,CHEMBL616841,,Autocuration,,13313,,H,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,
2044,,BAO_0000357,,,8,,CHEMBL616842,,Autocuration,,13313,,H,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,
2045,,BAO_0000357,,,8,,CHEMBL857976,,Expert,,12409,,H,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,
2046,,BAO_0000219,,,8,,CHEMBL616843,,Autocuration,,15250,,H,10618,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,
2047,Homo sapiens,BAO_0000357,,,9,,CHEMBL616844,,Expert,,1348,,D,10618,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,9606.0
2048,,BAO_0000357,,,8,,CHEMBL616845,,Autocuration,,1348,,H,10618,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,
2049,Homo sapiens,BAO_0000357,,,9,,CHEMBL616846,,Expert,,4234,,D,10618,1,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,9606.0
2050,,BAO_0000357,,,8,,CHEMBL616847,,Autocuration,,16209,,H,10618,1,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,
2051,,BAO_0000019,,,8,,CHEMBL616848,,Autocuration,,10444,,H,10618,1,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,
2052,,BAO_0000357,,,8,,CHEMBL616849,,Autocuration,,3935,,H,10618,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,
2053,,BAO_0000357,,,8,,CHEMBL872911,,Autocuration,,15818,,H,10618,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,
2054,,BAO_0000019,,,8,,CHEMBL616850,,Autocuration,,17085,,H,10618,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,
2055,Homo sapiens,BAO_0000219,,,9,,CHEMBL616699,,Expert,,12936,,D,10618,1,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,9606.0
2056,,BAO_0000357,,,8,,CHEMBL616700,,Autocuration,,6166,,H,10618,1,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,
2057,,BAO_0000219,,,8,,CHEMBL616701,,Autocuration,,15779,,H,10618,1,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
2058,,BAO_0000219,,,8,,CHEMBL616702,,Autocuration,,15779,,H,10618,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,
2059,,BAO_0000219,,,8,,CHEMBL616703,,Autocuration,,15779,,H,10618,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,
2060,,BAO_0000357,,,8,,CHEMBL616704,,Autocuration,,13181,,H,10618,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,
2061,,BAO_0000219,,,8,,CHEMBL616705,,Autocuration,,4199,,H,10618,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,
2062,,BAO_0000357,,,8,,CHEMBL616706,,Autocuration,,14875,,H,10618,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,
2063,,BAO_0000219,,,8,,CHEMBL616707,,Autocuration,,15146,,H,10618,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,
2064,,BAO_0000357,,,8,,CHEMBL616708,,Autocuration,,5213,,H,10618,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,
2065,,BAO_0000357,,,8,,CHEMBL616709,,Autocuration,,12146,,H,10618,1,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,
2066,,BAO_0000219,,,8,,CHEMBL616710,,Autocuration,,13267,,H,10618,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,
2067,,BAO_0000219,,,8,,CHEMBL616711,,Autocuration,,14818,,H,10618,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,
2068,,BAO_0000219,,,8,,CHEMBL616712,,Autocuration,,4829,,H,10618,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,
2069,,BAO_0000357,,,8,,CHEMBL616713,,Autocuration,,4373,,H,10618,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,
2070,,BAO_0000357,,,8,,CHEMBL616714,,Autocuration,,4373,,H,10618,1,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,
2071,,BAO_0000357,,,8,,CHEMBL616715,,Autocuration,,14159,,H,10618,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,
2072,,BAO_0000357,,,8,,CHEMBL616716,,Autocuration,,16633,,H,10618,1,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,
2073,,BAO_0000019,,,8,,CHEMBL616717,,Autocuration,,17085,,H,279,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,
2074,,BAO_0000019,,,8,,CHEMBL616718,,Expert,,17085,,H,279,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,
2075,,BAO_0000019,,,8,,CHEMBL875905,,Autocuration,,16209,,H,279,1,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,
2076,,BAO_0000019,,,8,,CHEMBL616719,,Autocuration,,16209,,H,279,1,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,
2077,,BAO_0000019,,,8,,CHEMBL616720,,Expert,,17085,,H,279,1,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,
2078,,BAO_0000357,,,8,,CHEMBL616721,,Autocuration,,14159,,H,279,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,
2079,,BAO_0000219,,,8,,CHEMBL616722,,Autocuration,,15250,,H,279,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,
2080,,BAO_0000357,,,8,,CHEMBL616723,,Autocuration,,3805,,H,279,1,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,
2081,,BAO_0000219,,,8,,CHEMBL616724,,Autocuration,,16190,,H,279,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,
2082,,BAO_0000357,,,8,,CHEMBL616725,,Autocuration,,16190,,H,279,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,
2083,,BAO_0000357,,,8,,CHEMBL616726,,Autocuration,,16209,,H,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,
2084,,BAO_0000357,,,8,,CHEMBL616727,,Autocuration,,16209,,H,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,
2085,,BAO_0000357,,,8,,CHEMBL616728,,Autocuration,,16209,,H,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,
2086,,BAO_0000357,,,8,,CHEMBL616729,,Autocuration,,6866,,H,279,1,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,
2087,,BAO_0000019,,,8,,CHEMBL616730,,Expert,,17085,,H,279,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,
2088,,BAO_0000357,,,8,,CHEMBL617125,,Autocuration,,16312,,H,279,1,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,
2089,,BAO_0000357,,,8,,CHEMBL857977,,Autocuration,,6166,,H,279,1,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,
2090,,BAO_0000219,,,8,,CHEMBL617126,,Autocuration,,15779,,H,279,1,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
2091,,BAO_0000219,,,8,,CHEMBL617127,,Autocuration,,4199,,H,279,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,
2092,,BAO_0000357,,,8,,CHEMBL617128,,Autocuration,,14875,,H,279,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,
2093,,BAO_0000219,,,8,,CHEMBL617129,,Autocuration,,15146,,H,279,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,
2094,,BAO_0000357,,,8,,CHEMBL617130,,Autocuration,,5213,,H,279,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,
2095,,BAO_0000219,,,8,,CHEMBL617131,,Autocuration,,14818,,H,279,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,
2096,,BAO_0000219,,,8,,CHEMBL617132,,Autocuration,,4829,,H,279,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,
2097,,BAO_0000219,,,8,,CHEMBL617133,,Autocuration,,4829,,H,279,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,
2098,,BAO_0000357,,,8,,CHEMBL617134,,Autocuration,,4373,,H,279,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,
2099,,BAO_0000357,,,8,,CHEMBL617135,,Autocuration,,4373,,H,279,1,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,
2100,,BAO_0000357,,,8,,CHEMBL617136,,Autocuration,,5014,,H,279,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,
2101,,BAO_0000019,,,4,,CHEMBL617137,,Autocuration,,11662,,H,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,
2102,,BAO_0000019,,,4,,CHEMBL617138,,Autocuration,,11662,,H,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,
2103,,BAO_0000019,,,4,,CHEMBL617139,,Autocuration,,11662,,H,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2104,,BAO_0000019,,,8,,CHEMBL617140,,Autocuration,,14093,,H,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,
2105,,BAO_0000218,,,4,,CHEMBL617141,,Autocuration,In vivo,11200,,H,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,
2106,,BAO_0000019,,,4,,CHEMBL858112,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2107,,BAO_0000019,,,8,,CHEMBL617142,,Intermediate,,12352,,H,17005,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,
2108,Bos taurus,BAO_0000019,,,0,,CHEMBL617143,,Autocuration,,13657,,U,22226,1,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,9913.0
2109,Bos taurus,BAO_0000019,,,0,,CHEMBL617144,,Autocuration,,14331,,U,22226,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,9913.0
2110,Bos taurus,BAO_0000019,,,0,,CHEMBL617145,,Autocuration,,14331,,U,22226,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,9913.0
2111,,BAO_0000019,,,0,,CHEMBL617146,,Autocuration,,14331,,U,22226,1,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,
2112,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617147,,Autocuration,,12685,,H,104784,1,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,10141.0
2113,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617148,,Autocuration,,14389,,H,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,10141.0
2114,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617149,,Autocuration,,14386,,H,104784,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,10141.0
2115,,BAO_0000224,,,4,,CHEMBL617150,,Autocuration,,5732,,H,104784,1,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,
2116,,BAO_0000224,,,4,,CHEMBL617151,,Autocuration,,16293,,H,104784,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
2117,,BAO_0000224,,,4,,CHEMBL617201,,Autocuration,,2078,,H,104784,1,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,
2118,,BAO_0000357,,,8,,CHEMBL617202,,Autocuration,,5486,,H,10209,1,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,
2119,,BAO_0000218,,,4,,CHEMBL617203,,Autocuration,In vivo,11820,,H,104826,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,
2120,,BAO_0000019,,,4,,CHEMBL617204,,Autocuration,,10297,,H,104826,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,
2121,,BAO_0000224,,,4,,CHEMBL617205,,Autocuration,,13704,,H,104826,1,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,
2122,Mus musculus,BAO_0000019,,,5,,CHEMBL617206,,Autocuration,,10297,,D,104826,1,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,10090.0
2123,,BAO_0000218,,,4,,CHEMBL617207,,Autocuration,In vivo,11820,,H,104826,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,
2124,Mus musculus,BAO_0000019,,,5,,CHEMBL617208,,Autocuration,,10297,,D,104826,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,10090.0
2125,,BAO_0000224,,,4,,CHEMBL617209,,Autocuration,,11555,,H,104826,1,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2126,,BAO_0000224,,,4,,CHEMBL617210,,Autocuration,,11555,,H,104826,1,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,
2127,,BAO_0000224,,,4,,CHEMBL617211,,Autocuration,,11555,,H,104826,1,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,
2128,Mus musculus,BAO_0000019,,,5,,CHEMBL617212,,Autocuration,,10297,,D,104826,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,10090.0
2129,Sus scrofa,BAO_0000224,,,4,,CHEMBL617213,,Autocuration,,16688,,H,104784,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,9823.0
2130,Sus scrofa,BAO_0000224,,,4,,CHEMBL617214,,Autocuration,,16688,,H,104784,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,9823.0
2131,,BAO_0000221,,,0,,CHEMBL617215,,Autocuration,,5333,,U,22226,1,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,
2132,,BAO_0000221,,,0,,CHEMBL617216,,Autocuration,,4437,,U,22226,1,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,
2133,Sus scrofa,BAO_0000357,,,8,,CHEMBL617217,,Autocuration,,5033,,H,17005,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,9823.0
2134,,BAO_0000019,,,4,,CHEMBL617218,,Autocuration,,15267,,H,104686,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,
2135,,BAO_0000019,,,4,,CHEMBL872913,,Autocuration,,15267,,H,104686,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,
2136,,BAO_0000019,,,4,,CHEMBL617219,,Autocuration,,11820,,H,104826,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,
2137,,BAO_0000224,,,4,,CHEMBL873482,,Autocuration,,9069,,H,104686,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,
2138,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617220,,Autocuration,,9162,,D,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,10116.0
2139,,BAO_0000019,,,4,,CHEMBL617221,,Autocuration,,9162,,H,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,
2140,,BAO_0000019,,,4,,CHEMBL617222,,Autocuration,,9162,,H,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,
2141,,BAO_0000019,,,4,,CHEMBL875906,,Autocuration,,10428,,H,104686,1,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,
2142,,BAO_0000019,,,4,,CHEMBL617223,,Autocuration,,9628,,H,104686,1,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,
2143,,BAO_0000224,,,4,,CHEMBL617224,,Autocuration,,12704,,H,104686,1,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,
2144,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617225,,Autocuration,,15453,,D,104686,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,10116.0
2145,,BAO_0000224,,,4,,CHEMBL617226,,Autocuration,,188,,H,104686,1,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,
2146,,BAO_0000224,,,4,,CHEMBL617227,,Autocuration,,10349,,H,104686,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,
2147,,BAO_0000224,,,4,,CHEMBL617228,,Autocuration,,10349,,H,104686,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,
2148,,BAO_0000224,,,4,,CHEMBL617229,,Autocuration,,8868,,H,104686,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,
2149,,BAO_0000224,,,4,,CHEMBL617230,,Autocuration,,10025,,H,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,
2150,,BAO_0000224,,,4,,CHEMBL617231,,Autocuration,,10025,,H,104686,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,
2151,,BAO_0000224,,,4,,CHEMBL617232,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,
2152,,BAO_0000224,,,4,,CHEMBL617233,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,
2153,,BAO_0000224,,,4,,CHEMBL617234,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
2154,,BAO_0000019,,,4,,CHEMBL617235,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,
2155,,BAO_0000019,,,4,,CHEMBL617236,,Autocuration,,11702,,H,104686,1,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,
2156,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL617237,,Autocuration,,10085,,H,104686,1,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,
2157,,BAO_0000221,10000000.0,,4,Hippocampus,CHEMBL617238,,Autocuration,,10085,,H,104686,1,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,
2158,Rattus norvegicus,BAO_0000221,955.0,,5,Brain,CHEMBL617239,,Autocuration,,9630,,D,104686,1,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,10116.0
2159,,BAO_0000019,,,4,,CHEMBL617240,,Autocuration,,11070,,H,104686,1,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,
2160,,BAO_0000249,,,4,,CHEMBL617241,,Autocuration,,9841,,H,104686,1,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,
2161,,BAO_0000249,,,4,,CHEMBL875907,,Autocuration,,9841,,H,104686,1,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,
2162,,BAO_0000019,,,4,,CHEMBL617242,,Autocuration,,13291,,H,104686,1,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,
2163,,BAO_0000019,,,4,,CHEMBL617152,,Autocuration,,10590,,H,104686,1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,
2164,Rattus norvegicus,BAO_0000221,955.0,,5,Brain,CHEMBL617153,,Autocuration,,9064,,D,104686,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0
2165,Rattus norvegicus,BAO_0000249,,,5,,CHEMBL617154,,Autocuration,,12268,,D,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,10116.0
2166,,BAO_0000221,955.0,,4,Brain,CHEMBL617155,,Autocuration,,13508,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,
2167,,BAO_0000019,,,4,,CHEMBL617156,,Autocuration,,11279,,H,104686,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,
2168,,BAO_0000019,,,4,,CHEMBL617157,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,
2169,,BAO_0000019,,,4,,CHEMBL617158,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2170,,BAO_0000019,,,4,,CHEMBL617159,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,
2171,,BAO_0000019,,,4,,CHEMBL617160,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,
2172,,BAO_0000019,,,4,,CHEMBL858113,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2173,,BAO_0000220,955.0,,4,Brain,CHEMBL617247,,Autocuration,,9231,,H,104686,1,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,
2174,,BAO_0000019,,,4,,CHEMBL617248,,Autocuration,,9737,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,
2175,,BAO_0000249,955.0,,4,Brain,CHEMBL617249,,Autocuration,,9737,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,
2176,,BAO_0000019,,,4,,CHEMBL617250,,Autocuration,,9737,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,
2177,,BAO_0000019,,,4,,CHEMBL617251,,Autocuration,,9737,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,
2178,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617252,,Autocuration,,11828,,D,104686,1,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,10116.0
2179,,BAO_0000019,,,4,,CHEMBL617006,,Autocuration,,12253,,H,104686,1,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,
2180,,BAO_0000019,,,4,,CHEMBL617007,,Autocuration,,12253,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,
2181,,BAO_0000019,,,4,,CHEMBL617008,,Autocuration,,11279,,H,104686,1,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,
2182,,BAO_0000019,,,4,,CHEMBL617009,,Autocuration,,11866,,H,104686,1,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,
2183,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617010,,Autocuration,,14424,,D,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,10116.0
2184,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL857978,,Autocuration,,15180,,D,104686,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0
2185,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617011,,Autocuration,,15180,,D,104686,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0
2186,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617012,,Autocuration,,9786,,D,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,10116.0
2187,,BAO_0000224,,,4,,CHEMBL617013,,Autocuration,,12132,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,
2188,,BAO_0000249,,,4,,CHEMBL617014,,Autocuration,,5486,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,
2189,,BAO_0000019,,,4,,CHEMBL617015,,Autocuration,,15316,,H,104686,1,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,
2190,,BAO_0000019,,,4,,CHEMBL617016,,Autocuration,,16429,,H,104686,1,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,
2191,,BAO_0000224,,,4,,CHEMBL617017,,Autocuration,,14617,,H,104686,1,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,
2192,,BAO_0000221,955.0,,4,Brain,CHEMBL617018,,Autocuration,,11351,,H,104686,1,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,
2193,,BAO_0000019,,,4,,CHEMBL617019,,Autocuration,,11279,,H,104686,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,
2194,,BAO_0000019,,,4,,CHEMBL617020,,Autocuration,,9523,,H,105075,1,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2195,,BAO_0000019,,,4,,CHEMBL617021,,Autocuration,,9523,,H,105075,1,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2196,,BAO_0000019,,,4,,CHEMBL617022,,Autocuration,,9523,,H,105075,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2197,,BAO_0000019,,,4,,CHEMBL617023,,Autocuration,,9523,,H,105075,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2198,,BAO_0000019,,,4,,CHEMBL617024,,Autocuration,,9523,,H,105075,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2199,,BAO_0000019,,,4,,CHEMBL617025,,Autocuration,,9523,,H,105075,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2200,,BAO_0000224,,,4,,CHEMBL617026,,Autocuration,,9523,,H,105075,1,Hill coefficient of compound was determined,B,
2201,,BAO_0000019,,,0,,CHEMBL617027,,Autocuration,,4771,,U,22226,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,
2202,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617028,,Autocuration,,5033,,D,104686,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,10116.0
2203,,BAO_0000019,,,8,,CHEMBL617029,,Expert,,10845,,H,12687,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,
2204,,BAO_0000019,,,8,,CHEMBL875908,,Expert,,10845,,H,12687,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,
2205,,BAO_0000357,,,8,,CHEMBL617030,,Autocuration,,16288,,H,12687,1,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,
2206,,BAO_0000019,,,8,,CHEMBL617031,,Autocuration,,16288,,H,12687,1,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,
2207,,BAO_0000019,,,8,,CHEMBL617032,,Autocuration,,16190,,H,12687,1,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,
2208,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617033,,Autocuration,,12463,,D,104686,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,10116.0
2209,,BAO_0000224,,,4,,CHEMBL617034,,Autocuration,,9699,,H,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,
2210,,BAO_0000224,,,4,,CHEMBL617035,,Autocuration,,9699,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,
2211,,BAO_0000019,,,4,,CHEMBL617036,,Autocuration,,11662,,H,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2212,,BAO_0000224,,,4,,CHEMBL617037,,Autocuration,,1205,,H,104784,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,
2213,,BAO_0000219,,,0,,CHEMBL617038,,Autocuration,,11376,,U,22226,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,
2214,,BAO_0000219,,,4,,CHEMBL617039,,Autocuration,,11376,,H,104784,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,
2215,,BAO_0000224,,,4,,CHEMBL617161,,Autocuration,,4639,,H,104784,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,
2216,,BAO_0000224,,,4,,CHEMBL617162,,Autocuration,,2222,,H,104784,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,
2217,,BAO_0000224,,,4,,CHEMBL617163,,Autocuration,,1558,,H,104784,1,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,
2218,,BAO_0000224,,,4,,CHEMBL617164,,Autocuration,,1089,,H,104784,1,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,
2219,,BAO_0000249,,,4,,CHEMBL617165,,Autocuration,,386,,H,104784,1,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,
2220,,BAO_0000224,,,4,,CHEMBL617166,,Autocuration,,2474,,H,104784,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,
2221,,BAO_0000224,,,4,,CHEMBL617167,,Autocuration,,17066,,H,104784,1,Binding affinity towards 5-HT2 receptor,B,
2222,,BAO_0000224,,,4,,CHEMBL872912,,Autocuration,,959,,H,104784,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,
2223,,BAO_0000224,,,4,,CHEMBL617168,,Autocuration,,6398,,H,104784,1,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,
2224,,BAO_0000224,,,4,,CHEMBL617169,,Autocuration,,11889,,H,104686,1,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,
2225,,BAO_0000224,,,4,,CHEMBL617170,,Autocuration,,4221,,H,104784,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2226,,BAO_0000224,,,4,,CHEMBL617171,,Autocuration,,11026,,H,104784,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,
2227,,BAO_0000224,,,4,,CHEMBL617172,,Autocuration,,11866,,H,104784,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,
2228,,BAO_0000224,,,4,,CHEMBL617173,,Autocuration,,4221,,H,104784,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2229,,BAO_0000019,,,0,,CHEMBL617174,,Autocuration,,13950,,U,22226,1,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2230,,BAO_0000224,,,4,,CHEMBL617175,,Autocuration,,1263,,H,104784,1,5-hydroxytryptamine 2 receptor binding affinity,B,
2231,,BAO_0000357,,,8,,CHEMBL617176,,Autocuration,,13291,,H,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,
2232,,BAO_0000357,,,8,,CHEMBL617177,,Autocuration,,10812,,H,17005,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,
2233,,BAO_0000224,,,4,,CHEMBL617178,,Autocuration,,13020,,H,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,
2234,,BAO_0000224,,,4,,CHEMBL617179,,Autocuration,,13021,,H,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,
2235,,BAO_0000224,,,4,,CHEMBL617180,,Autocuration,,13020,,H,104784,1,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,
2236,,BAO_0000357,,,8,,CHEMBL617181,,Autocuration,,14532,,H,17005,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,
2237,,BAO_0000357,,,8,,CHEMBL617182,,Autocuration,,13944,,H,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor,B,
2238,,BAO_0000357,,,8,,CHEMBL617183,,Autocuration,,14331,,H,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor,B,
2239,,BAO_0000357,,,8,,CHEMBL617184,,Autocuration,,14118,,H,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,
2240,,BAO_0000357,,,8,,CHEMBL617185,,Autocuration,,13033,,H,17005,1,Binding affinity against serotonergic 5-HT2 receptor,B,
2241,,BAO_0000357,,,8,,CHEMBL617186,,Autocuration,,10321,,H,17005,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,
2242,,BAO_0000357,,,8,,CHEMBL617187,,Autocuration,,12918,,H,17005,1,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,
2243,,BAO_0000357,,,8,,CHEMBL617188,,Autocuration,,15120,,H,17005,1,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,
2244,,BAO_0000218,,,8,,CHEMBL617189,,Autocuration,,2613,,H,17005,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,
2245,Homo sapiens,BAO_0000224,,,5,,CHEMBL617190,,Autocuration,,13378,,D,104784,1,Inhibitory activity against cloned human 5-HT2 receptor,B,9606.0
2246,Homo sapiens,BAO_0000219,,,5,,CHEMBL617191,,Autocuration,,2331,,D,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,9606.0
2247,Homo sapiens,BAO_0000219,,,5,,CHEMBL617192,,Autocuration,,2331,,D,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,9606.0
2248,Homo sapiens,BAO_0000219,,,5,,CHEMBL617193,,Autocuration,,2331,,D,104784,1,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,9606.0
2249,Homo sapiens,BAO_0000219,,,5,,CHEMBL617194,,Autocuration,,2331,,D,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,9606.0
2250,,BAO_0000224,,,4,,CHEMBL617195,,Autocuration,,4170,,H,104784,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2251,,BAO_0000224,,,4,,CHEMBL881830,,Autocuration,,15453,,H,104784,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,
2252,,BAO_0000357,,,8,,CHEMBL617196,,Autocuration,,1479,,H,17005,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2253,,BAO_0000224,,,4,,CHEMBL617197,,Autocuration,,11139,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,
2254,,BAO_0000357,,,8,,CHEMBL617198,,Expert,,13969,,H,17005,1,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,
2255,,BAO_0000357,,,8,,CHEMBL873476,,Expert,,13392,,H,17005,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2256,,BAO_0000019,,,8,,CHEMBL617199,,Expert,,14430,,H,17005,1,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,
2257,Cavia porcellus,BAO_0000357,,,8,,CHEMBL617200,,Autocuration,,13181,,H,107,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0
2258,,BAO_0000357,,,8,,CHEMBL617484,,Autocuration,,17200,,H,51,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2259,,BAO_0000357,,,8,,CHEMBL617485,,Autocuration,,17200,,H,107,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2260,,BAO_0000357,,,8,,CHEMBL617486,,Autocuration,,17200,,H,51,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2261,,BAO_0000357,,,8,,CHEMBL858022,,Autocuration,,13463,,H,107,1,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,
2262,,BAO_0000219,,,8,,CHEMBL617049,,Autocuration,,6347,,H,107,1,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,
2263,Homo sapiens,BAO_0000219,,,9,,CHEMBL617050,,Expert,,6857,,D,107,1,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0
2264,,BAO_0000219,,,8,,CHEMBL617051,,Autocuration,,4176,,H,107,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,
2265,,BAO_0000219,,,8,,CHEMBL617052,,Autocuration,,4176,,H,107,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,
2266,,BAO_0000219,,,8,,CHEMBL617053,,Autocuration,,4176,,H,107,1,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,
2267,,BAO_0000219,,,8,,CHEMBL617054,,Autocuration,,6347,,H,107,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,
2268,,BAO_0000219,,,8,,CHEMBL617055,,Autocuration,,6347,,H,107,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,
2269,,BAO_0000357,,,8,,CHEMBL882924,,Autocuration,,15331,,H,107,1,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,
2270,Homo sapiens,BAO_0000357,,,9,,CHEMBL617056,,Expert,,16146,,D,107,1,Inhibition of human 5-hydroxytryptamine 2A receptor,B,9606.0
2271,,BAO_0000219,,,8,,CHEMBL617057,,Autocuration,,15250,,H,107,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2272,,BAO_0000219,,,8,,CHEMBL617058,,Expert,,13631,,H,107,1,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,
2273,,BAO_0000357,,,8,,CHEMBL617059,,Autocuration,,3805,,H,107,1,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,
2274,,BAO_0000219,,,8,,CHEMBL617060,,Autocuration,,4011,,H,107,1,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,
2275,,BAO_0000219,,,8,,CHEMBL617061,,Expert,,4012,,H,107,1,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,
2276,,BAO_0000219,,,8,,CHEMBL617062,,Expert,,6366,,H,107,1,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,
2277,,BAO_0000219,,,8,,CHEMBL617063,,Expert,,15949,,H,107,1,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2278,,BAO_0000019,,,8,,CHEMBL617064,,Autocuration,,14093,,H,107,1,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,
2279,,BAO_0000019,,,8,,CHEMBL617065,,Autocuration,,13481,,H,107,1,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,
2280,,BAO_0000219,,,8,,CHEMBL617066,,Autocuration,,6347,,H,107,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,
2281,,BAO_0000219,,,8,,CHEMBL617067,,Autocuration,,6347,,H,107,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,
2282,,BAO_0000019,,,8,,CHEMBL617068,,Autocuration,,14093,,H,107,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,
2283,,BAO_0000019,,,8,,CHEMBL617069,,Autocuration,,14093,,H,107,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,
2284,,BAO_0000019,,,8,,CHEMBL617070,,Autocuration,,13481,,H,107,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,
2285,,BAO_0000357,,,8,,CHEMBL617071,,Autocuration,,14442,,H,107,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,
2286,,BAO_0000357,,,8,,CHEMBL872915,,Autocuration,,14442,,H,107,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2287,,BAO_0000357,,,8,,CHEMBL617072,,Autocuration,,14755,,H,107,1,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,
2288,,BAO_0000357,,,8,,CHEMBL617073,,Autocuration,,16441,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,
2289,,BAO_0000357,,,8,,CHEMBL617074,,Autocuration,,14744,,H,107,1,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,
2290,,BAO_0000219,,,8,,CHEMBL617075,,Expert,,16659,,H,107,1,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2291,,BAO_0000357,,,8,,CHEMBL617076,,Autocuration,,3307,,H,107,1,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,
2292,Homo sapiens,BAO_0000019,,,9,,CHEMBL617077,,Expert,,6857,,D,107,1,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,9606.0
2293,,BAO_0000357,,,8,,CHEMBL617078,,Expert,,5635,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,
2294,Homo sapiens,BAO_0000357,,,9,,CHEMBL617079,,Expert,,4234,,D,107,1,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,9606.0
2295,,BAO_0000357,,,8,,CHEMBL617080,,Autocuration,,15527,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,
2296,,BAO_0000219,,,8,,CHEMBL617081,,Expert,,6588,,H,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,
2297,,BAO_0000219,,,8,,CHEMBL617082,,Expert,,13631,,H,107,1,Binding affinity towards human 5-HT2A receptor in BEK cells,B,
2298,,BAO_0000357,,,8,,CHEMBL617083,,Autocuration,,17723,,H,107,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,
2299,,BAO_0000357,,,8,,CHEMBL617084,,Autocuration,,14770,,H,107,1,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,
2300,Homo sapiens,BAO_0000357,,,9,,CHEMBL617085,,Expert,,16293,,D,107,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0
2301,,BAO_0000357,,,8,,CHEMBL617086,,Autocuration,,16209,,H,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2302,,BAO_0000219,,,8,,CHEMBL617087,,Autocuration,,12469,,H,107,1,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,
2303,,BAO_0000357,,,8,,CHEMBL617088,,Autocuration,,15363,,H,107,1,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,
2304,,BAO_0000357,,,8,,CHEMBL617089,,Autocuration,,15363,,H,107,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,
2305,,BAO_0000019,,,8,,CHEMBL617090,,Expert,,16441,,H,107,1,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,
2306,,BAO_0000357,,,8,,CHEMBL617513,,Autocuration,,8,,H,107,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,
2307,,BAO_0000219,,,8,,CHEMBL617514,,Autocuration,,4176,,H,107,1,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,
2308,,BAO_0000019,,,8,,CHEMBL617515,,Autocuration,,17085,,H,107,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,
2309,,BAO_0000357,,,8,,CHEMBL617516,,Autocuration,,17200,,H,107,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2310,Homo sapiens,BAO_0000357,,,9,,CHEMBL617517,,Expert,,17200,,D,107,1,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,9606.0
2311,Homo sapiens,BAO_0000219,,,9,,CHEMBL617518,,Expert,,4013,,D,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,9606.0
2312,,BAO_0000357,,,8,,CHEMBL617519,,Autocuration,,5088,,H,107,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2313,Homo sapiens,BAO_0000357,,,9,,CHEMBL617520,,Expert,,5088,,D,107,1,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,9606.0
2314,,BAO_0000357,,,8,,CHEMBL617521,,Autocuration,,5088,,H,107,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,
2315,Homo sapiens,BAO_0000357,,,9,,CHEMBL617522,,Expert,,5088,,D,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,9606.0
2316,,BAO_0000357,,,8,,CHEMBL617523,,Autocuration,,5088,,H,107,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,
2317,,BAO_0000357,,,8,,CHEMBL617524,,Autocuration,,5088,,H,107,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2318,,BAO_0000019,,,4,,CHEMBL617525,,Autocuration,,9786,,H,104686,1,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,
2319,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617526,,Autocuration,,9205,,D,104686,1,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,10116.0
2320,,BAO_0000224,,,4,,CHEMBL617527,,Autocuration,,11257,,H,104686,1,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,
2321,,BAO_0000019,,,4,,CHEMBL617528,,Autocuration,,9362,,H,104686,1,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,
2322,,BAO_0000019,,,4,,CHEMBL617529,,Autocuration,,9362,,H,104686,1,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,
2323,,BAO_0000224,,,4,,CHEMBL617530,,Autocuration,,10590,,H,104686,1,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,
2324,,BAO_0000019,,,4,,CHEMBL617531,,Autocuration,,10468,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,
2325,,BAO_0000019,,,4,,CHEMBL617532,,Autocuration,,13050,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,
2326,,BAO_0000019,,,4,,CHEMBL617533,,Autocuration,,11624,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,
2327,,BAO_0000019,,,4,,CHEMBL617534,,Autocuration,,10468,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,
2328,,BAO_0000224,,,4,,CHEMBL617535,,Autocuration,,10330,,H,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,
2329,,BAO_0000224,,,4,,CHEMBL617536,,Autocuration,,10062,,H,104686,1,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,
2330,,BAO_0000224,,,4,,CHEMBL617537,,Autocuration,,11642,,H,104686,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,
2331,,BAO_0000224,,,4,,CHEMBL617538,,Autocuration,,10062,,H,104686,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,
2332,,BAO_0000219,,,4,,CHEMBL617539,,Autocuration,In vitro,13427,,H,104686,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
2333,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617540,,Autocuration,,12280,,D,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,10116.0
2334,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617541,,Autocuration,,4101,,D,104686,1,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,10116.0
2335,,BAO_0000224,,,4,,CHEMBL617542,,Autocuration,,10062,,H,104686,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,
2336,,BAO_0000224,,,4,,CHEMBL617543,,Autocuration,,11147,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,
2337,Rattus norvegicus,BAO_0000219,,,5,,CHEMBL617544,,Autocuration,,2395,,D,104686,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0
2338,Rattus norvegicus,BAO_0000219,,,5,,CHEMBL617545,,Autocuration,,2395,,D,104686,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0
2339,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617413,,Autocuration,,9098,,D,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,10116.0
2340,,BAO_0000019,,,4,,CHEMBL617414,,Autocuration,,9098,,H,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,
2341,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617415,,Autocuration,,9098,,D,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,10116.0
2342,,BAO_0000224,,,4,,CHEMBL617416,,Autocuration,,9443,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2343,,BAO_0000224,,,4,,CHEMBL617417,,Autocuration,,9443,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,
2344,,BAO_0000019,,,4,,CHEMBL617418,,Autocuration,,9699,,H,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,
2345,,BAO_0000019,,,4,,CHEMBL617419,,Autocuration,,9699,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,
2346,,BAO_0000224,,,4,,CHEMBL617420,,Autocuration,,9098,,H,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
2347,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617421,,Autocuration,,3070,,D,104686,1,Affinity for 5-hydroxytryptamine 2 receptor,B,10116.0
2348,,BAO_0000224,,,4,,CHEMBL617422,,Autocuration,,9547,,H,104686,1,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,
2349,,BAO_0000019,,,4,,CHEMBL617423,,Autocuration,,10444,,H,104686,1,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,
2350,,BAO_0000019,,,4,,CHEMBL617424,,Autocuration,,14617,,H,104686,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,
2351,,BAO_0000019,,,4,,CHEMBL617425,,Autocuration,,14617,,H,104686,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,
2352,,BAO_0000224,,,4,,CHEMBL617426,,Autocuration,,11130,,H,104686,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,
2353,,BAO_0000218,,,4,,CHEMBL617427,,Autocuration,In vivo,11130,,H,104686,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,
2354,,BAO_0000221,955.0,,4,Brain,CHEMBL617428,,Autocuration,,14542,,H,104686,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,
2355,,BAO_0000224,,,4,,CHEMBL617429,,Autocuration,,2797,,H,104686,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,
2356,,BAO_0000019,,,4,,CHEMBL617430,,Autocuration,,11332,,H,104686,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,
2357,,BAO_0000019,,,4,,CHEMBL617431,,Autocuration,,11332,,H,104686,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,
2358,,BAO_0000019,1870.0,,4,Frontal cortex,CHEMBL617432,,Autocuration,,10752,,H,104686,1,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,
2359,,BAO_0000224,,,4,,CHEMBL617433,,Autocuration,,1185,,H,104686,1,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,
2360,,BAO_0000224,,,4,,CHEMBL617434,,Autocuration,,1185,,H,104686,1,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,
2361,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617435,,Autocuration,,11624,,D,104686,1,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,10116.0
2362,,BAO_0000019,,,4,,CHEMBL617436,,Autocuration,,1344,,H,104686,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,
2363,Rattus norvegicus,BAO_0000019,2435.0,,5,Striatum,CHEMBL617437,,Autocuration,,15453,,D,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,10116.0
2364,,BAO_0000019,,,4,,CHEMBL617438,,Autocuration,,11662,,H,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,
2365,,BAO_0000019,,,4,,CHEMBL617439,,Autocuration,,11662,,H,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2366,,BAO_0000224,,,4,,CHEMBL617440,,Autocuration,,10796,,H,104686,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,
2367,,BAO_0000224,,,4,,CHEMBL617441,,Autocuration,,9069,,H,104686,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,
2368,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL872918,,Autocuration,,8814,,D,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,10116.0
2369,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL617442,,Autocuration,,8908,,D,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,10116.0
2370,,BAO_0000019,,,4,,CHEMBL617443,,Autocuration,,9098,,H,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,
2371,,BAO_0000019,,,4,,CHEMBL617444,,Autocuration,,9098,,H,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,
2372,,BAO_0000019,,,4,,CHEMBL617445,,Autocuration,,9098,,H,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,
2373,,BAO_0000019,,,4,,CHEMBL617446,,Autocuration,,9098,,H,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,
2374,,BAO_0000249,,,4,,CHEMBL617447,,Autocuration,,9098,,H,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,
2375,,BAO_0000019,,,4,,CHEMBL617448,,Autocuration,,9098,,H,104686,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,
2376,,BAO_0000019,,,4,,CHEMBL617449,,Autocuration,,9098,,H,104686,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,
2377,,BAO_0000019,,,4,,CHEMBL617450,,Autocuration,,9161,,H,104686,1,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,
2378,,BAO_0000019,,,4,,CHEMBL617451,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,
2379,,BAO_0000019,,,4,,CHEMBL617452,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,
2380,,BAO_0000019,,,4,,CHEMBL617453,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,
2381,,BAO_0000019,,,4,,CHEMBL617660,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,
2382,,BAO_0000019,,,4,,CHEMBL617661,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,
2383,,BAO_0000019,,,4,,CHEMBL617662,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,
2384,,BAO_0000019,,,4,,CHEMBL872919,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,
2385,,BAO_0000019,,,4,,CHEMBL617663,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,
2386,,BAO_0000019,,,4,,CHEMBL617664,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,
2387,,BAO_0000019,,,4,,CHEMBL617665,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,
2388,,BAO_0000019,,,4,,CHEMBL617666,,Autocuration,,9161,,H,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,
2389,,BAO_0000019,,,4,,CHEMBL617667,,Autocuration,,12094,,H,104686,1,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,
2390,,BAO_0000249,,,4,,CHEMBL617668,,Autocuration,,12018,,H,104686,1,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,
2391,,BAO_0000249,,,4,,CHEMBL617669,,Autocuration,,10394,,H,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,
2392,,BAO_0000224,,,4,,CHEMBL617670,,Autocuration,,15260,,H,104686,1,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,
2393,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617671,,Autocuration,,11624,,D,104686,1,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,10116.0
2394,,BAO_0000224,,,4,,CHEMBL617672,,Autocuration,,13654,,H,104686,1,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,
2395,,BAO_0000019,,,4,,CHEMBL617673,,Autocuration,,9541,,H,104686,1,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,
2396,,BAO_0000224,,,4,,CHEMBL617674,,Autocuration,,11933,,H,104686,1,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,
2397,,BAO_0000019,,,4,,CHEMBL617675,,Autocuration,,15538,,H,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,
2398,,BAO_0000019,,,4,,CHEMBL617676,,Autocuration,,15538,,H,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,
2399,,BAO_0000019,,,4,,CHEMBL617677,,Autocuration,,15538,,H,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,
2400,,BAO_0000019,,,5,,CHEMBL617678,,Autocuration,,8841,,D,104686,1,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,
2401,,BAO_0000224,,,4,,CHEMBL617679,,Autocuration,,1455,,H,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,
2402,,BAO_0000224,,,4,,CHEMBL617680,,Autocuration,,1455,,H,104686,1,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,
2403,,BAO_0000019,,,4,,CHEMBL617681,,Autocuration,,11752,,H,104686,1,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,
2404,,BAO_0000221,955.0,,4,Brain,CHEMBL617682,,Autocuration,,11642,,H,104686,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,
2405,,BAO_0000224,,,4,,CHEMBL617683,,Autocuration,,12092,,H,104686,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,
2406,,BAO_0000224,,,4,,CHEMBL617684,,Autocuration,,3967,,H,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,
2407,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617685,,Autocuration,,12771,,D,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,10116.0
2408,,BAO_0000019,,,4,,CHEMBL617686,,Autocuration,,11642,,H,104686,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,
2409,,BAO_0000224,,,4,,CHEMBL617687,,Autocuration,,11628,,H,104686,1,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,
2410,,BAO_0000224,,,4,,CHEMBL617688,,Autocuration,,13654,,H,104686,1,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,
2411,,BAO_0000019,,,4,,CHEMBL617689,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2412,,BAO_0000019,,,4,,CHEMBL617690,,Autocuration,,11200,,H,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2413,,BAO_0000218,,,4,,CHEMBL617691,,Autocuration,In vivo,11200,,H,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,
2414,,BAO_0000218,,,4,,CHEMBL617692,,Autocuration,In vivo,11200,,H,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,
2415,,BAO_0000218,,,4,,CHEMBL617693,,Autocuration,In vivo,11200,,H,104686,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,
2416,,BAO_0000218,,,4,,CHEMBL617694,,Autocuration,In vivo,11200,,H,104686,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,
2417,,BAO_0000221,955.0,,8,Brain,CHEMBL857985,,Expert,,15436,,H,12687,1,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,
2418,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617695,,Expert,,15436,,D,12687,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0
2419,,BAO_0000019,,,8,,CHEMBL617696,,Autocuration,,14025,,H,12687,1,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,
2420,,BAO_0000357,,,8,,CHEMBL617697,,Autocuration,,4342,,H,12687,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,
2421,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617257,,Expert,,13735,,D,12687,1,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,10116.0
2422,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617258,,Expert,,5816,,D,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,10116.0
2423,,BAO_0000019,,,8,,CHEMBL617259,,Expert,,14287,,H,12687,1,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,
2424,,BAO_0000357,,,8,,CHEMBL617260,,Autocuration,,15738,,H,12687,1,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,
2425,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617261,,Expert,,15738,,D,12687,1,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,10116.0
2426,,BAO_0000019,,,8,,CHEMBL617262,,Autocuration,,15026,,H,12687,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,
2427,,BAO_0000019,,,8,,CHEMBL617263,,Expert,,16647,,H,12687,1,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,
2428,,BAO_0000019,,,8,,CHEMBL617264,,Autocuration,,16647,,H,12687,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,
2429,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617265,,Expert,,13345,,D,12687,1,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,10116.0
2430,,BAO_0000249,,,8,,CHEMBL617266,,Autocuration,,1543,,H,12687,1,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,
2431,,BAO_0000019,,,8,,CHEMBL617267,,Autocuration,,12444,,H,12687,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,
2432,,BAO_0000019,,,8,,CHEMBL617268,,Expert,,16404,,H,12687,1,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,
2433,,BAO_0000219,,,8,,CHEMBL617269,,Autocuration,,16404,,H,12687,1,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,
2434,,BAO_0000357,,,8,,CHEMBL617323,,Expert,,15577,,H,12687,1,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,
2435,,BAO_0000357,,,8,,CHEMBL617324,,Autocuration,,15577,,H,12687,1,Serotonergic activity of the compound.,B,
2436,,BAO_0000249,,,8,,CHEMBL617325,,Autocuration,,2495,,H,12687,1,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,
2437,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617326,,Expert,,15042,,D,12687,1,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,10116.0
2438,,BAO_0000249,,,8,,CHEMBL617327,,Expert,,15026,,H,12687,1,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,
2439,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617328,,Expert,,12919,,D,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0
2440,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617329,,Expert,,12919,,D,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0
2441,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617330,,Expert,,12919,,D,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0
2442,,BAO_0000357,,,8,,CHEMBL617331,,Autocuration,,15194,,H,12687,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2443,,BAO_0000357,,,8,,CHEMBL617332,,Autocuration,,15194,,H,12687,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,
2444,,BAO_0000357,,,8,,CHEMBL617333,,Expert,,4820,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2445,,BAO_0000357,,,8,,CHEMBL617334,,Autocuration,,6736,,H,107,1,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,
2446,,BAO_0000357,,,8,,CHEMBL617335,,Autocuration,,5163,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,
2447,,BAO_0000357,,,8,,CHEMBL617336,,Autocuration,,5163,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,
2448,,BAO_0000357,,,8,,CHEMBL617337,,Autocuration,,6011,,H,107,1,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,
2449,Homo sapiens,BAO_0000357,,,9,,CHEMBL617338,,Expert,,14294,,D,107,1,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,9606.0
2450,,BAO_0000357,,,8,,CHEMBL617339,,Autocuration,,5014,,H,107,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,
2451,,BAO_0000357,,,8,,CHEMBL617340,,Expert,,17066,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2452,,BAO_0000357,,,8,,CHEMBL617341,,Autocuration,,17515,,H,107,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,
2453,,BAO_0000357,,,8,,CHEMBL617342,,Expert,,6736,,H,107,1,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,
2454,,BAO_0000357,,,8,,CHEMBL617343,,Expert,,5163,,H,107,1,Affinity for 5-hydroxytryptamine 2A receptor,B,
2455,,BAO_0000219,,,8,,CHEMBL617344,,Expert,,16911,,H,107,1,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,
2456,,BAO_0000357,,,8,,CHEMBL617345,,Expert,,6841,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,
2457,,BAO_0000357,,,8,,CHEMBL617346,,Expert,,6119,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,
2458,,BAO_0000357,,,8,,CHEMBL617347,,Autocuration,,3962,,H,107,1,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,
2459,,BAO_0000357,,,8,,CHEMBL617348,,Autocuration,,4373,,H,107,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,
2460,,BAO_0000357,,,8,,CHEMBL617349,,Autocuration,,4373,,H,107,1,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,
2461,,BAO_0000019,,,8,,CHEMBL617350,,Autocuration,,3962,,H,107,1,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,
2462,,BAO_0000357,,,8,,CHEMBL872339,,Expert,,1633,,H,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,
2463,,BAO_0000357,,,8,,CHEMBL617351,,Autocuration,,4373,,H,107,1,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,
2464,,BAO_0000357,,,8,,CHEMBL617352,,Expert,,6576,,H,107,1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,
2465,,BAO_0000357,,,8,,CHEMBL617353,,Autocuration,,4687,,H,107,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2466,,BAO_0000357,,,8,,CHEMBL617354,,Autocuration,,16946,,H,107,1,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,
2467,,BAO_0000357,,,8,,CHEMBL617355,,Autocuration,,14159,,H,107,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,
2468,Mus musculus,BAO_0000219,,,8,,CHEMBL617356,,Expert,,3032,,H,107,1,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,10090.0
2469,,BAO_0000357,,,8,,CHEMBL617357,,Autocuration,,16655,,H,107,1,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,
2470,,BAO_0000357,,,8,,CHEMBL617358,,Autocuration,,13964,,H,107,1,Binding affinity at 5-hydroxytryptamine 2A receptor,B,
2471,,BAO_0000357,,,8,,CHEMBL617359,,Expert,,16989,,H,107,1,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,
2472,,BAO_0000357,,,8,,CHEMBL617360,,Autocuration,,16117,,H,107,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,
2473,,BAO_0000357,,,8,,CHEMBL875913,,Autocuration,,16700,,H,107,1,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,
2474,,BAO_0000357,,,8,,CHEMBL617361,,Autocuration,,3269,,H,107,1,Affinity against 5-hydroxytryptamine 2A receptor,B,
2475,Homo sapiens,BAO_0000357,,,9,,CHEMBL617362,,Expert,,1274,,D,107,1,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,9606.0
2476,,BAO_0000357,,,8,,CHEMBL617363,,Autocuration,,1317,,H,107,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,
2477,,BAO_0000357,,,8,,CHEMBL617364,,Autocuration,,12146,,H,107,1,Tested against 5-hydroxytryptamine 2A receptor,B,
2478,,BAO_0000224,,,4,,CHEMBL617365,,Autocuration,,12652,,H,105075,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,
2479,,BAO_0000224,,,4,,CHEMBL617366,,Autocuration,,12652,,H,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,
2480,,BAO_0000224,,,4,,CHEMBL617367,,Autocuration,,12652,,H,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,
2481,,BAO_0000224,,,4,,CHEMBL617368,,Autocuration,,12652,,H,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,
2482,,BAO_0000357,,,8,,CHEMBL617369,,Autocuration,,16647,,H,107,1,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,
2483,Homo sapiens,BAO_0000219,,,9,,CHEMBL617370,,Expert,,15851,,D,227,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,9606.0
2484,Homo sapiens,BAO_0000219,,,9,,CHEMBL617371,,Expert,,6857,,D,227,1,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0
2485,,BAO_0000357,,,8,,CHEMBL617372,,Autocuration,,3805,,H,227,1,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,
2486,Homo sapiens,BAO_0000357,,,9,,CHEMBL617373,,Expert,,6491,,D,227,1,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,9606.0
2487,,BAO_0000019,,,8,,CHEMBL617374,,Autocuration,,14093,,H,227,1,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,
2488,,BAO_0000019,,,8,,CHEMBL617375,,Autocuration,,13481,,H,227,1,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,
2489,,BAO_0000019,,,8,,CHEMBL617376,,Autocuration,,14093,,H,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,
2490,,BAO_0000019,,,8,,CHEMBL617377,,Autocuration,,14093,,H,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,
2491,,BAO_0000019,,,8,,CHEMBL617378,,Autocuration,,14093,,H,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,
2492,,BAO_0000019,,,8,,CHEMBL617379,,Autocuration,,13481,,H,227,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,
2493,,BAO_0000357,,,8,,CHEMBL617380,,Autocuration,,14442,,H,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,
2494,,BAO_0000357,,,8,,CHEMBL617381,,Autocuration,,14442,,H,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,
2495,,BAO_0000357,,,8,,CHEMBL617382,,Autocuration,,14442,,H,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,
2496,,BAO_0000357,,,8,,CHEMBL617383,,Autocuration,,12369,,H,107,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,
2497,,BAO_0000357,,,8,,CHEMBL617384,,Expert,,12369,,H,107,1,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,
2498,,BAO_0000357,,,8,,CHEMBL617385,,Expert,,12369,,H,107,1,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,
2499,,BAO_0000019,,,8,,CHEMBL617386,,Autocuration,,14447,,H,107,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,
2500,,BAO_0000019,,,8,,CHEMBL617387,,Autocuration,,14447,,H,107,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,
2501,,BAO_0000219,,,8,,CHEMBL617388,,Autocuration,,17451,,H,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2502,,BAO_0000219,,,8,,CHEMBL617389,,Autocuration,,6857,,H,107,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2503,Homo sapiens,BAO_0000219,,,9,,CHEMBL617390,,Expert,,6857,,D,107,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0
2504,,BAO_0000224,,,4,,CHEMBL617391,,Autocuration,,5635,,H,104817,1,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,
2505,,BAO_0000357,,,8,,CHEMBL617392,,Autocuration,,12861,,H,107,1,Binding activity radioligand.,B,
2506,,BAO_0000019,,,8,,CHEMBL617393,,Autocuration,,12861,,H,107,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
2507,,BAO_0000219,,,8,,CHEMBL617394,,Autocuration,,5105,,H,107,1,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,
2508,,BAO_0000219,,,8,,CHEMBL617395,,Expert,,5104,,H,107,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,
2509,,BAO_0000219,,,8,,CHEMBL617396,,Expert,,5105,,H,107,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,
2510,,BAO_0000219,,,8,,CHEMBL617397,,Autocuration,,5105,,H,107,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,
2511,,BAO_0000357,,,8,,CHEMBL617398,,Autocuration,,5254,,H,107,1,Binding affinity against 5-HT2A receptor,B,
2512,,BAO_0000357,,,8,,CHEMBL617399,,Autocuration,,5254,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor,B,
2513,,BAO_0000219,,,8,,CHEMBL617400,,Autocuration,,13267,,H,107,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,
2514,,BAO_0000219,,,8,,CHEMBL617401,,Autocuration,,13267,,H,107,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,
2515,Homo sapiens,BAO_0000219,,,9,,CHEMBL617402,,Expert,,14157,,D,107,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,9606.0
2516,Homo sapiens,BAO_0000219,,,9,,CHEMBL617403,,Expert,,12936,,D,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0
2517,,BAO_0000357,,,8,,CHEMBL617404,,Expert,,14068,,H,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,
2518,Homo sapiens,BAO_0000219,,,9,,CHEMBL857981,,Expert,,12936,,D,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0
2519,Homo sapiens,BAO_0000219,,,9,,CHEMBL617405,,Expert,,12936,,D,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0
2520,Homo sapiens,BAO_0000219,,,9,,CHEMBL617253,,Expert,,4540,,D,107,1,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,9606.0
2521,,BAO_0000357,,,8,,CHEMBL617254,,Expert,,6166,,H,107,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,
2522,,BAO_0000219,,,8,,CHEMBL617255,,Autocuration,,17296,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,
2523,,BAO_0000219,,,8,,CHEMBL617256,,Autocuration,,17296,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,
2524,,BAO_0000219,,,8,,CHEMBL616874,,Autocuration,,17296,,H,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,
2525,Homo sapiens,BAO_0000219,,,9,,CHEMBL616875,,Expert,,15779,,D,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,9606.0
2526,,BAO_0000219,,,8,,CHEMBL616876,,Expert,,14391,,H,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,
2527,,BAO_0000219,,,8,,CHEMBL616877,,Expert,,15851,,H,107,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,
2528,Homo sapiens,BAO_0000219,,,9,,CHEMBL616878,,Expert,,15851,,D,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,9606.0
2529,,BAO_0000219,,,8,,CHEMBL616879,,Expert,,3832,,H,107,1,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,
2530,,BAO_0000219,,,8,,CHEMBL616880,,Expert,,3833,,H,107,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,
2531,Homo sapiens,BAO_0000219,,,9,,CHEMBL616881,,Expert,,12936,,D,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0
2532,,BAO_0000219,,,8,,CHEMBL616882,,Autocuration,,17451,,H,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,
2533,,BAO_0000219,,,8,,CHEMBL616883,,Autocuration,,17451,,H,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2534,,BAO_0000219,,,8,,CHEMBL616884,,Autocuration,,17451,,H,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2535,,BAO_0000219,,,8,,CHEMBL616885,,Autocuration,,4199,,H,107,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,
2536,,BAO_0000219,,,8,,CHEMBL616886,,Autocuration,,1883,,H,107,1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,
2537,,BAO_0000219,,,8,,CHEMBL616887,,Expert,,1883,,H,107,1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,
2538,Homo sapiens,BAO_0000357,,,9,,CHEMBL616888,,Expert,,14875,,D,107,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0
2539,,BAO_0000219,,,8,,CHEMBL616889,,Autocuration,,15146,,H,107,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,
2540,,BAO_0000219,,,8,,CHEMBL616890,,Autocuration,,5213,,H,107,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,
2541,Homo sapiens,BAO_0000219,,,9,,CHEMBL616891,,Expert,,16404,,D,107,1,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,9606.0
2542,,BAO_0000219,,,8,,CHEMBL616892,,Autocuration,,14818,,H,107,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,
2543,,BAO_0000219,,,8,,CHEMBL616893,,Autocuration,,4829,,H,107,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,
2544,,BAO_0000219,,,8,,CHEMBL616894,,Autocuration,,12652,,H,10620,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,
2545,,BAO_0000219,,,8,,CHEMBL616895,,Expert,,4682,,H,107,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,
2546,,BAO_0000019,,,8,,CHEMBL616896,,Autocuration,,12652,,H,10620,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,
2547,,BAO_0000357,,,8,,CHEMBL617099,,Autocuration,,4921,,H,10621,1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,
2548,,BAO_0000357,,,8,,CHEMBL617100,,Autocuration,,4921,,H,10621,1,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,
2549,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL884532,,Autocuration,,16312,,H,107,1,Binding affinity against rabbit aorta 5-HT2A receptor,B,9986.0
2550,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL617101,,Expert,,14998,,H,107,1,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,9986.0
2551,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL617102,,Expert,,14025,,H,107,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,9986.0
2552,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL617103,,Autocuration,,13047,,H,107,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0
2553,Oryctolagus cuniculus,BAO_0000357,,,8,,CHEMBL617104,,Expert,,13047,,H,107,1,The compound was tested for binding affinity against 5-HT2A receptor,B,9986.0
2554,,BAO_0000219,,,8,,CHEMBL857979,,Autocuration,,1883,,H,10576,1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,
2555,,BAO_0000019,,,8,,CHEMBL857502,,Autocuration,,13463,,H,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,
2556,,BAO_0000019,,,8,,CHEMBL617105,,Autocuration,,13463,,H,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,
2557,,BAO_0000019,945.0,,8,Stomach,CHEMBL858021,,Autocuration,,13463,,H,12687,1,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,
2558,Rattus norvegicus,BAO_0000019,945.0,,9,Stomach,CHEMBL875910,,Expert,,13463,,D,12687,1,Binding affinity for 5-HT 2A in rat stomach fundus,B,10116.0
2559,,BAO_0000019,,,8,,CHEMBL617106,,Autocuration,,13463,,H,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,
2560,,BAO_0000219,,,8,,CHEMBL617107,,Expert,,16326,,H,12687,1,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,
2561,,BAO_0000019,,,8,,CHEMBL617108,,Autocuration,,14093,,H,12687,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,
2562,,BAO_0000019,,,8,,CHEMBL617109,,Autocuration,,14093,,H,12687,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,
2563,,BAO_0000357,,,8,,CHEMBL617110,,Autocuration,,15740,,H,12687,1,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,
2564,,BAO_0000357,,,8,,CHEMBL617111,,Autocuration,,16633,,H,12687,1,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,
2565,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617112,,Expert,,17200,,D,12687,1,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,10116.0
2566,,BAO_0000357,,,8,,CHEMBL617113,,Autocuration,,17133,,H,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2567,,BAO_0000357,,,8,,CHEMBL617114,,Autocuration,,17133,,H,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2568,,BAO_0000357,,,8,,CHEMBL617115,,Autocuration,,17133,,H,12687,1,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2569,,BAO_0000219,,,8,,CHEMBL617116,,Autocuration,,17200,,H,12687,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,
2570,,BAO_0000019,,,8,,CHEMBL617117,,Autocuration,,15363,,H,12687,1,Efficacy at 5-hydroxytryptamine 2A receptor,F,
2571,,BAO_0000357,,,8,,CHEMBL617118,,Autocuration,,17200,,H,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,
2572,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617119,,Expert,,17200,,D,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,10116.0
2573,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617120,,Expert,,17200,,D,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,10116.0
2574,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL617121,,Expert,,17200,,D,12687,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,10116.0
2575,,BAO_0000219,,,8,,CHEMBL617122,,Autocuration,,17200,,H,12687,1,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,
2576,,BAO_0000019,,,8,,CHEMBL617123,,Autocuration,,17211,,H,12687,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,
2577,,BAO_0000019,,,8,,CHEMBL617124,,Expert,,17331,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,
2578,,BAO_0000249,,,8,,CHEMBL617600,,Expert,,13565,,H,12687,1,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,
2579,,BAO_0000357,,,8,,CHEMBL617601,,Expert,,13730,,H,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,
2580,,BAO_0000019,,,8,,CHEMBL882923,,Expert,,12416,,H,12687,1,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,
2581,,BAO_0000357,,,8,,CHEMBL617602,,Autocuration,,15295,,H,12687,1,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2582,,BAO_0000019,,,8,,CHEMBL617603,,Autocuration,,1742,,H,12687,1,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,
2583,,BAO_0000357,,,8,,CHEMBL617604,,Autocuration,,15295,,H,12687,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,
2584,,BAO_0000019,,,8,,CHEMBL617605,,Expert,,14970,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,
2585,,BAO_0000019,,,8,,CHEMBL617606,,Expert,,16693,,H,12687,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,
2586,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617607,,Expert,,14776,,D,12687,1,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,10116.0
2587,,BAO_0000249,,,8,,CHEMBL617455,,Autocuration,,14286,,H,12687,1,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2588,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617456,,Expert,,17200,,D,12687,1,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0
2589,,BAO_0000357,,,8,,CHEMBL617457,,Expert,,15306,,H,12687,1,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,
2590,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617458,,Expert,,14178,,D,12687,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,10116.0
2591,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617459,,Expert,,14229,,D,12687,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,10116.0
2592,,BAO_0000357,,,8,,CHEMBL617460,,Expert,,12884,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,
2593,,BAO_0000357,,,8,,CHEMBL617461,,Expert,,13149,,H,12687,1,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,
2594,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617462,,Expert,,15295,,D,12687,1,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,10116.0
2595,,BAO_0000357,,,8,,CHEMBL617463,,Autocuration,,15740,,H,12687,1,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,
2596,,BAO_0000019,,,8,,CHEMBL617464,,Autocuration,,15185,,H,12687,1,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,
2597,,BAO_0000019,,,8,,CHEMBL617465,,Autocuration,,15185,,H,12687,1,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,
2598,,BAO_0000019,,,8,,CHEMBL617466,,Expert,,17529,,H,12687,1,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,
2599,,BAO_0000019,,,8,,CHEMBL617467,,Autocuration,,14826,,H,12687,1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,
2600,,BAO_0000019,,,8,,CHEMBL617468,,Expert,,17211,,H,12687,1,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,
2601,,BAO_0000019,,,8,,CHEMBL617469,,Autocuration,,14826,,H,12687,1,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,
2602,,BAO_0000019,,,8,,CHEMBL617470,,Autocuration,,14093,,H,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,
2603,,BAO_0000019,,,8,,CHEMBL617471,,Autocuration,,14093,,H,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,
2604,,BAO_0000219,,,8,,CHEMBL617472,,Expert,,13246,,H,12687,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,
2605,,BAO_0000357,,,8,,CHEMBL617473,,Expert,,13246,,H,12687,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,
2606,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617474,,Expert,,15436,,D,12687,1,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0
2607,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617475,,Expert,,15436,,D,12687,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0
2608,,BAO_0000221,955.0,,8,Brain,CHEMBL617476,,Autocuration,,14442,,H,12687,1,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,
2609,,BAO_0000357,,,8,,CHEMBL617477,,Expert,,12457,,H,12687,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,
2610,,BAO_0000219,,,8,,CHEMBL617478,,Expert,,12457,,H,12687,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,
2611,,BAO_0000221,,,8,,CHEMBL617479,,Autocuration,,14755,,H,12687,1,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,
2612,,BAO_0000357,,,8,,CHEMBL617480,,Autocuration,,4707,,H,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,
2613,,BAO_0000357,,,8,,CHEMBL617481,,Expert,,13297,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor,B,
2614,,BAO_0000019,,,8,,CHEMBL617482,,Expert,,17331,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,
2615,,BAO_0000019,,,8,,CHEMBL617483,,Autocuration,,4664,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,
2616,,BAO_0000357,,,8,,CHEMBL621528,,Autocuration,,16633,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2617,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL621529,,Expert,,4664,,D,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,10116.0
2618,,BAO_0000357,,,8,,CHEMBL621530,,Expert,,16133,,H,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2619,,BAO_0000357,,,8,,CHEMBL621531,,Expert,,16133,,H,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2620,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL621532,,Expert,,14060,,D,12687,1,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,10116.0
2621,,BAO_0000357,,,8,,CHEMBL621533,,Expert,,16326,,H,12687,1,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2622,,BAO_0000219,,,8,,CHEMBL621534,,Expert,,16659,,H,12687,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2623,,BAO_0000019,,,8,,CHEMBL621535,,Autocuration,,14776,,H,12687,1,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,
2624,,BAO_0000357,,,8,,CHEMBL621536,,Autocuration,,13481,,H,12687,1,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,
2625,,BAO_0000357,,,8,,CHEMBL621537,,Autocuration,,17386,,H,12687,1,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,
2626,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL621538,,Expert,,6611,,D,12687,1,Binding affinity for 5-hydroxytryptamine 2A receptor,B,10116.0
2627,,BAO_0000019,,,8,,CHEMBL621539,,Autocuration,,14423,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,
2628,,BAO_0000019,,,8,,CHEMBL621540,,Autocuration,,15412,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,
2629,,BAO_0000019,,,8,,CHEMBL621541,,Autocuration,,15412,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,
2630,,BAO_0000019,,,8,,CHEMBL621542,,Autocuration,,6238,,H,12687,1,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,
2631,,BAO_0000357,,,8,,CHEMBL621543,,Expert,,6648,,H,12687,1,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,
2632,,BAO_0000357,,,8,,CHEMBL621544,,Expert,,5667,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,
2633,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL621545,,Expert,,6611,,D,12687,1,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,10116.0
2634,,BAO_0000357,,,8,,CHEMBL621546,,Autocuration,,13481,,H,12687,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2635,,BAO_0000357,,,8,,CHEMBL621547,,Autocuration,,13481,,H,12687,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,
2636,,BAO_0000219,,,8,,CHEMBL618692,,Expert,,15558,,H,12687,1,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,
2637,,BAO_0000357,,,8,,CHEMBL618693,,Autocuration,,6013,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2638,,BAO_0000357,,,8,,CHEMBL872922,,Autocuration,,16633,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2639,,BAO_0000357,,,8,,CHEMBL618694,,Autocuration,,6013,,H,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,
2640,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL618695,,Expert,,6013,,D,12687,1,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,10116.0
2641,,BAO_0000357,,,8,,CHEMBL618696,,Autocuration,,6013,,H,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,
2642,,BAO_0000357,,,8,,CHEMBL618697,,Expert,,6013,,H,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,
2643,,BAO_0000357,,,8,,CHEMBL618892,,Autocuration,,6013,,H,12687,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,
2644,,BAO_0000357,,,8,,CHEMBL618893,,Autocuration,,6013,,H,12687,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,
2645,,BAO_0000357,,,8,,CHEMBL618894,,Autocuration,,16293,,H,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,
2646,,BAO_0000219,,,8,,CHEMBL618895,,Expert,,17175,,H,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,
2647,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL618896,,Expert,,13278,,D,12687,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0
2648,,BAO_0000019,5383.0,,8,Caudate-putamen,CHEMBL618897,,Autocuration,,3682,,H,12687,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,
2649,,BAO_0000357,,,8,,CHEMBL618898,,Autocuration,,2014,,H,12687,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,
2650,,BAO_0000357,,,8,,CHEMBL618899,,Autocuration,,2014,,H,12687,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,
2651,,BAO_0000357,,,8,,CHEMBL618900,,Autocuration,,4932,,H,12687,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,
2652,,BAO_0000019,,,8,,CHEMBL618901,,Autocuration,,4932,,H,12687,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,
2653,,BAO_0000357,,,8,,CHEMBL618902,,Autocuration,,3935,,H,12687,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,
2654,Rattus norvegicus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL618903,,Expert,,5432,,D,12687,1,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,10116.0
2655,,BAO_0000357,,,8,,CHEMBL618904,,Autocuration,,15818,,H,12687,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,
2656,,BAO_0000357,,,8,,CHEMBL618905,,Autocuration,,13672,,H,12687,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,
2657,,BAO_0000357,,,8,,CHEMBL618906,,Autocuration,,13672,,H,12687,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,
2658,,BAO_0000219,,,8,,CHEMBL618907,,Expert,,14749,,H,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,
2659,,BAO_0000019,,,8,,CHEMBL618908,,Autocuration,,13462,,H,12687,1,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,
2660,,BAO_0000357,,,8,,CHEMBL617909,,Autocuration,,15740,,H,12687,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,
2661,,BAO_0000019,,,8,,CHEMBL617910,,Expert,,16647,,H,12687,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,
2662,,BAO_0000221,955.0,,8,Brain,CHEMBL617911,,Autocuration,,13345,,H,12687,1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,
2663,,BAO_0000249,,,8,,CHEMBL872923,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2664,,BAO_0000249,,,8,,CHEMBL617912,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2665,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617913,,Expert,,15535,,D,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,10116.0
2666,,BAO_0000249,,,8,,CHEMBL617914,,Expert,,16740,,H,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2667,,BAO_0000249,,,8,,CHEMBL617915,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2668,,BAO_0000249,,,8,,CHEMBL617916,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2669,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617917,,Expert,,4795,,D,12687,1,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,10116.0
2670,,BAO_0000019,,,8,,CHEMBL617918,,Expert,,8,,H,12687,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,
2671,,BAO_0000019,,,8,,CHEMBL617919,,Autocuration,,8,,H,12687,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,
2672,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617920,,Expert,,17200,,D,12687,1,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0
2673,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617921,,Expert,,2148,,D,12687,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,10116.0
2674,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL617922,,Expert,,13345,,D,105102,1,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,10116.0
2675,,BAO_0000357,,,8,,CHEMBL617923,,Autocuration,,5088,,H,12687,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2676,,BAO_0000357,,,8,,CHEMBL617924,,Autocuration,,5088,,H,12687,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2677,,BAO_0000357,,,8,,CHEMBL617925,,Autocuration,,17133,,H,12687,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,
2678,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617926,,Expert,,17133,,D,12687,1,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,10116.0
2679,,BAO_0000357,,,8,,CHEMBL617927,,Autocuration,,16532,,H,12687,1,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,
2680,,BAO_0000357,,,8,,CHEMBL617928,,Autocuration,,15086,,H,12687,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,
2681,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617929,,Expert,,2309,,D,12687,1,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,10116.0
2682,,BAO_0000019,,,8,,CHEMBL617930,,Expert,,12953,,H,12687,1,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,
2683,,BAO_0000019,,,8,,CHEMBL617931,,Autocuration,,12953,,H,12687,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,
2684,,BAO_0000019,,,8,,CHEMBL617932,,Autocuration,,12953,,H,12687,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,
2685,,BAO_0000219,,,8,,CHEMBL617933,,Autocuration,,16659,,H,12687,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,
2686,,BAO_0000019,,,8,,CHEMBL617934,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,
2687,,BAO_0000019,,,8,,CHEMBL617935,,Autocuration,,16740,,H,12687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,
2688,,BAO_0000357,,,8,,CHEMBL617936,,Autocuration,,17133,,H,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,
2689,,BAO_0000019,,,8,,CHEMBL617937,,Autocuration,,17211,,H,12687,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,
2690,,BAO_0000019,,,8,,CHEMBL617938,,Autocuration,,17331,,H,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,
2691,,BAO_0000218,,,8,,CHEMBL617939,,Autocuration,,16633,,H,12687,1,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,
2692,,BAO_0000218,,,8,,CHEMBL617940,,Autocuration,,16633,,H,12687,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,
2693,,BAO_0000218,,,8,,CHEMBL617941,,Autocuration,,16633,,H,12687,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,
2694,,BAO_0000357,,,8,,CHEMBL617942,,Expert,,15026,,H,12687,1,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,
2695,,BAO_0000357,,,8,,CHEMBL617943,,Expert,,15026,,H,12687,1,Ratio of pKi of 5-HT2A to that of D2 receptor,B,
2696,,BAO_0000224,,,4,,CHEMBL617944,,Expert,,16404,,H,105093,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,
2697,,BAO_0000224,,,4,,CHEMBL617945,,Expert,,16404,,H,105093,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,
2698,,BAO_0000224,,,4,,CHEMBL617946,,Expert,,16404,,H,105075,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,
2699,,BAO_0000357,,,8,,CHEMBL617947,,Autocuration,,16404,,H,12687,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,
2700,,BAO_0000357,,,8,,CHEMBL617948,,Expert,,16326,,H,12687,1,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,
2701,,BAO_0000019,,,8,,CHEMBL858116,,Autocuration,,15847,,H,12687,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,
2702,,BAO_0000019,,,8,,CHEMBL617949,,Autocuration,,15847,,H,12687,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,
2703,,BAO_0000019,,,8,,CHEMBL617950,,Autocuration,,15329,,H,12687,1,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,
2704,,BAO_0000019,1515.0,,8,Thoracic aorta,CHEMBL617951,,Expert,,16404,,H,12687,1,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,
2705,,BAO_0000019,1515.0,,8,Thoracic aorta,CHEMBL617952,,Expert,,16404,,H,12687,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,
2706,,BAO_0000019,1515.0,,8,Thoracic aorta,CHEMBL617953,,Autocuration,,16404,,H,12687,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,
2707,,BAO_0000357,,,8,,CHEMBL617954,,Autocuration,,12861,,H,12687,1,Binding activity radioligand.,B,
2708,,BAO_0000019,,,8,,CHEMBL617955,,Expert,,12861,,H,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2709,,BAO_0000019,,,8,,CHEMBL857071,,Autocuration,,12861,,H,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,
2710,,BAO_0000019,,,8,,CHEMBL617270,,Expert,,12490,,H,12687,1,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,
2711,,BAO_0000219,,,8,,CHEMBL617271,,Autocuration,,12827,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,
2712,,BAO_0000219,,,8,,CHEMBL617272,,Autocuration,,12827,,H,12687,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,
2713,,BAO_0000019,,,8,,CHEMBL617273,,Autocuration,,12918,,H,12687,1,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,
2714,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617274,,Expert,,12919,,D,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,10116.0
2715,,BAO_0000357,,,8,,CHEMBL617275,,Autocuration,,17723,,H,108,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,
2716,,BAO_0000357,,,8,,CHEMBL617276,,Autocuration,,6013,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2717,,BAO_0000357,,,8,,CHEMBL617277,,Autocuration,,16293,,H,108,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,
2718,,BAO_0000019,,,8,,CHEMBL617278,,Expert,,3857,,H,108,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,
2719,,BAO_0000019,,,8,,CHEMBL617279,,Expert,,3857,,H,108,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,
2720,,BAO_0000019,,,8,,CHEMBL617280,,Expert,,3857,,H,108,1,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,
2721,,BAO_0000357,,,8,,CHEMBL617281,,Autocuration,,15363,,H,108,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,
2722,,BAO_0000357,,,8,,CHEMBL617282,,Autocuration,,15363,,H,108,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,
2723,,BAO_0000019,,,8,,CHEMBL617283,,Expert,,16441,,H,108,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,
2724,,BAO_0000019,,,8,,CHEMBL617284,,Expert,,16441,,H,108,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,
2725,,BAO_0000219,,,8,,CHEMBL617285,,Autocuration,,4176,,H,108,1,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,
2726,,BAO_0000019,,,8,,CHEMBL617286,,Autocuration,,17085,,H,108,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,
2727,Homo sapiens,BAO_0000357,,,9,,CHEMBL617287,,Expert,,17200,,D,108,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,9606.0
2728,,BAO_0000357,,,8,,CHEMBL617288,,Expert,,5088,,H,108,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,
2729,,BAO_0000357,,,8,,CHEMBL617289,,Autocuration,,5088,,H,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,
2730,,BAO_0000357,,,8,,CHEMBL872917,,Autocuration,,5088,,H,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2731,,BAO_0000357,,,8,,CHEMBL617290,,Autocuration,,5088,,H,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,
2732,,BAO_0000219,,,8,,CHEMBL617291,,Autocuration,,16659,,H,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2733,,BAO_0000219,,,8,,CHEMBL617292,,Autocuration,,16659,,H,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,
2734,,BAO_0000219,,,8,,CHEMBL617293,,Autocuration,,17451,,H,108,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2735,Homo sapiens,BAO_0000219,,,9,,CHEMBL617294,,Expert,,6857,,D,108,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0
2736,,BAO_0000019,,,8,,CHEMBL617295,,Expert,,3857,,H,108,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,
2737,,BAO_0000357,,,8,,CHEMBL617296,,Autocuration,,12861,,H,108,1,Binding activity radioligand.,B,
2738,,BAO_0000019,,,8,,CHEMBL617297,,Autocuration,,12861,,H,108,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
2739,,BAO_0000219,,,8,,CHEMBL617298,,Expert,,5104,,H,108,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,
2740,,BAO_0000219,,,8,,CHEMBL617299,,Expert,,5105,,H,108,1,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,
2741,,BAO_0000219,,,8,,CHEMBL617300,,Autocuration,,5105,,H,108,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,
2742,,BAO_0000357,,,8,,CHEMBL617454,,Autocuration,,5254,,H,108,1,Binding affinity against 5-HT2C receptor,B,
2743,,BAO_0000219,,,8,,CHEMBL617505,,Autocuration,,13267,,H,108,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,
2744,Homo sapiens,BAO_0000219,,,9,,CHEMBL617506,,Expert,,14157,,D,108,1,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,9606.0
2745,Homo sapiens,BAO_0000219,,,9,,CHEMBL617507,,Expert,,12936,,D,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0
2746,,BAO_0000357,,,8,,CHEMBL617508,,Expert,,14068,,H,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,
2747,Homo sapiens,BAO_0000219,,,9,,CHEMBL857982,,Expert,,12936,,D,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0
2748,Homo sapiens,BAO_0000219,,,9,,CHEMBL617509,,Expert,,4540,,D,108,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,9606.0
2749,Homo sapiens,BAO_0000219,,,9,,CHEMBL617510,,Expert,,4540,,D,108,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,9606.0
2750,,BAO_0000357,,,8,,CHEMBL617511,,Autocuration,,6166,,H,108,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,
2751,,BAO_0000219,,,8,,CHEMBL617512,,Autocuration,,17296,,H,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,
2752,,BAO_0000219,,,8,,CHEMBL617749,,Autocuration,,17296,,H,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,
2753,,BAO_0000219,,,8,,CHEMBL617750,,Autocuration,,15779,,H,108,1,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
2754,,BAO_0000219,,,8,,CHEMBL617751,,Autocuration,,15779,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
2755,,BAO_0000219,,,8,,CHEMBL617752,,Expert,,14391,,H,108,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,
2756,,BAO_0000219,,,8,,CHEMBL617753,,Autocuration,,15779,,H,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,
2757,,BAO_0000219,,,8,,CHEMBL617754,,Expert,,15851,,H,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,
2758,Homo sapiens,BAO_0000219,,,9,,CHEMBL617755,,Expert,,15851,,D,108,1,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,9606.0
2759,,BAO_0000219,,,8,,CHEMBL617756,,Autocuration,,15779,,H,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,
2760,,BAO_0000219,,,8,,CHEMBL617757,,Expert,,3832,,H,108,1,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,
2761,,BAO_0000219,,,8,,CHEMBL617758,,Expert,,3833,,H,108,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,
2762,,BAO_0000219,,,8,,CHEMBL617759,,Autocuration,,17451,,H,108,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,
2763,,BAO_0000219,,,8,,CHEMBL617760,,Autocuration,,4199,,H,108,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,
2764,,BAO_0000219,,,8,,CHEMBL617761,,Expert,,1883,,H,108,1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,
2765,Homo sapiens,BAO_0000357,,,9,,CHEMBL617762,,Expert,,4321,,D,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0
2766,,BAO_0000357,,,8,,CHEMBL617763,,Autocuration,,14875,,H,108,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,
2767,,BAO_0000219,,,8,,CHEMBL857983,,Autocuration,,15146,,H,108,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,
2768,,BAO_0000219,,,8,,CHEMBL617764,,Autocuration,,5213,,H,108,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,
2769,,BAO_0000219,,,8,,CHEMBL617765,,Autocuration,,16404,,H,108,1,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,
2770,,BAO_0000019,,,8,,CHEMBL617766,,Autocuration,,13267,,H,108,1,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,
2771,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL617767,,Autocuration,,13267,,H,108,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,
2772,,BAO_0000219,,,8,,CHEMBL617768,,Autocuration,,14818,,H,108,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,
2773,,BAO_0000219,,,8,,CHEMBL617769,,Autocuration,,4829,,H,108,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,
2774,,BAO_0000357,,,8,,CHEMBL858023,,Autocuration,,13463,,H,11864,1,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,
2775,,BAO_0000019,945.0,,8,Stomach,CHEMBL617770,,Autocuration,,13463,,H,11864,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,
2776,,BAO_0000019,945.0,,8,Stomach,CHEMBL617771,,Autocuration,,13463,,H,11864,1,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,
2777,,BAO_0000219,,,8,,CHEMBL617772,,Autocuration,,12652,,H,11864,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,
2778,,BAO_0000219,,,8,,CHEMBL617773,,Autocuration,,4682,,H,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,
2779,,BAO_0000219,,,8,,CHEMBL617850,,Autocuration,,4682,,H,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,
2780,,BAO_0000219,,,8,,CHEMBL617851,,Autocuration,,4682,,H,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,
2781,,BAO_0000019,,,8,,CHEMBL617852,,Autocuration,,12652,,H,11864,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,
2782,Mus musculus,BAO_0000019,945.0,,8,Stomach,CHEMBL858024,,Autocuration,,13463,,H,12689,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,10090.0
2783,Rattus norvegicus,BAO_0000019,945.0,,9,Stomach,CHEMBL617853,,Expert,,13463,,D,12689,1,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,10116.0
2784,,BAO_0000357,,,8,,CHEMBL617854,,Expert,,13969,,H,108,1,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,
2785,Sus scrofa,BAO_0000357,,,8,,CHEMBL873477,,Expert,,13392,,H,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor,B,9823.0
2786,,BAO_0000357,,,8,,CHEMBL617855,,Expert,,13392,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2787,,BAO_0000019,,,8,,CHEMBL617856,,Expert,,14430,,H,108,1,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,
2788,,BAO_0000019,,,8,,CHEMBL617857,,Autocuration,,1742,,H,108,1,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,
2789,,BAO_0000249,,,8,,CHEMBL617858,,Autocuration,,14286,,H,108,1,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,
2790,,BAO_0000357,,,8,,CHEMBL617859,,Autocuration,,5619,,H,108,1,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,
2791,,BAO_0000357,,,8,,CHEMBL617860,,Autocuration,,15086,,H,108,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,
2792,,BAO_0000357,,,8,,CHEMBL617861,,Autocuration,,12861,,H,108,1,Binding activity radioligand.,B,
2793,,BAO_0000019,,,8,,CHEMBL617862,,Expert,,12861,,H,108,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2794,,BAO_0000019,,,8,,CHEMBL617863,,Autocuration,,12861,,H,108,1,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,
2795,,BAO_0000249,,,8,,CHEMBL617864,,Autocuration,,12827,,H,108,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,
2796,,BAO_0000249,,,8,,CHEMBL617649,,Autocuration,,12827,,H,108,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,
2797,Sus scrofa,BAO_0000019,,,8,,CHEMBL617650,,Expert,,12919,,H,108,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0
2798,Sus scrofa,BAO_0000019,,,8,,CHEMBL617651,,Expert,,12919,,H,108,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0
2799,Sus scrofa,BAO_0000357,,,8,,CHEMBL617652,,Autocuration,,16429,,H,108,1,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,9823.0
2800,Sus scrofa,BAO_0000019,,,8,,CHEMBL857072,,Autocuration,,773,,H,108,1,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,9823.0
2801,Sus scrofa,BAO_0000357,,,8,,CHEMBL617653,,Autocuration,,5033,,H,108,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,9823.0
2802,,BAO_0000019,,,8,,CHEMBL617654,,Autocuration,,12861,,H,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2803,,BAO_0000019,,,8,,CHEMBL617655,,Autocuration,,14093,,H,12689,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,
2804,,BAO_0000357,,,8,,CHEMBL617656,,Expert,,14970,,H,12689,1,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,
2805,,BAO_0000357,,,8,,CHEMBL617657,,Autocuration,,14970,,H,12689,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,
2806,,BAO_0000357,,,8,,CHEMBL617658,,Autocuration,,14970,,H,12689,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,
2807,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617659,,Expert,,14178,,D,12689,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0
2808,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL617838,,Expert,,14178,,D,12689,1,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0
2809,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL617839,,Expert,,14229,,D,12689,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,10116.0
2810,,BAO_0000357,,,8,,CHEMBL617840,,Autocuration,,16532,,H,12689,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,
2811,,BAO_0000019,,,8,,CHEMBL617841,,Autocuration,,14826,,H,12689,1,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,
2812,,BAO_0000019,,,8,,CHEMBL875915,,Autocuration,,17211,,H,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,
2813,,BAO_0000219,,,8,,CHEMBL617842,,Expert,In vitro,17211,,H,12689,1,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,
2814,,BAO_0000219,,,8,,CHEMBL617843,,Expert,,13246,,H,12689,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,
2815,,BAO_0000357,,,8,,CHEMBL617844,,Expert,,13246,,H,12689,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,
2816,,BAO_0000357,,,8,,CHEMBL617845,,Expert,,12457,,H,12689,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,
2817,,BAO_0000219,,,8,,CHEMBL617846,,Expert,,12457,,H,12689,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,
2818,,BAO_0000357,,,8,,CHEMBL617847,,Autocuration,,4707,,H,12689,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,
2819,,BAO_0000357,,,8,,CHEMBL617848,,Expert,,13297,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor,B,
2820,,BAO_0000357,,,8,,CHEMBL617849,,Autocuration,,16633,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,
2821,,BAO_0000357,,,8,,CHEMBL621507,,Expert,,16133,,H,12689,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2822,,BAO_0000357,,,8,,CHEMBL621508,,Expert,,16326,,H,12689,1,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,
2823,,BAO_0000019,,,8,,CHEMBL621509,,Autocuration,,14423,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,
2824,,BAO_0000019,,,8,,CHEMBL621510,,Autocuration,,15412,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,
2825,,BAO_0000019,,,8,,CHEMBL621511,,Autocuration,,15412,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,
2826,,BAO_0000219,,,8,,CHEMBL621512,,Expert,,15558,,H,12689,1,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,
2827,,BAO_0000357,,,8,,CHEMBL621513,,Autocuration,,16633,,H,12689,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,
2828,,BAO_0000357,,,8,,CHEMBL621514,,Expert,,6013,,H,12689,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,
2829,,BAO_0000219,,,8,,CHEMBL621515,,Expert,In vitro,17175,,H,12689,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,
2830,,BAO_0000219,,,8,,CHEMBL621516,,Autocuration,,12469,,H,12689,1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,
2831,,BAO_0000019,5383.0,,8,Caudate-putamen,CHEMBL621517,,Autocuration,,3682,,H,12689,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,
2832,,BAO_0000357,,,8,,CHEMBL621518,,Autocuration,,4932,,H,12689,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,
2833,,BAO_0000019,,,8,,CHEMBL621519,,Autocuration,,4932,,H,12689,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,
2834,,BAO_0000357,,,8,,CHEMBL621520,,Autocuration,,3935,,H,12689,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,
2835,,BAO_0000357,,,8,,CHEMBL621521,,Autocuration,,15818,,H,12689,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,
2836,,BAO_0000357,,,8,,CHEMBL621522,,Autocuration,,15818,,H,12689,1,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,
2837,,BAO_0000219,,,8,,CHEMBL621523,,Expert,,14749,,H,12689,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,
2838,,BAO_0000357,,,8,,CHEMBL621524,,Autocuration,,15740,,H,12689,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,
2839,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL621525,,Expert,,17133,,D,12689,1,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,10116.0
2840,,BAO_0000357,,,8,,CHEMBL872921,,Autocuration,,16532,,H,12689,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,
2841,,BAO_0000357,,,8,,CHEMBL621526,,Autocuration,,12369,,H,12689,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,
2842,,BAO_0000219,,,8,,CHEMBL621527,,Expert,,12369,,H,12689,1,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,
2843,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617865,,Expert,,2309,,D,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,10116.0
2844,,BAO_0000357,,,8,,CHEMBL617866,,Autocuration,,12953,,H,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2845,,BAO_0000019,,,8,,CHEMBL617867,,Autocuration,,12953,,H,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,
2846,,BAO_0000357,,,8,,CHEMBL617487,,Autocuration,,12953,,H,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,
2847,,BAO_0000357,,,8,,CHEMBL617488,,Expert,,12953,,H,12689,1,Binding affinity for 5-hydroxytryptamine 2C receptor,B,
2848,,BAO_0000357,,,8,,CHEMBL617489,,Autocuration,,17133,,H,12689,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,
2849,,BAO_0000019,,,8,,CHEMBL617490,,Autocuration,,17211,,H,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,
2850,,BAO_0000019,,,8,,CHEMBL617491,,Autocuration,,17211,,H,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,
2851,,BAO_0000019,,,8,,CHEMBL617492,,Autocuration,,14025,,H,12689,1,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,
2852,,BAO_0000019,,,8,,CHEMBL617493,,Autocuration,,14998,,H,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,
2853,,BAO_0000357,,,8,,CHEMBL617494,,Autocuration,,4342,,H,12689,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,
2854,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL617495,,Expert,,13735,,D,12689,1,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,10116.0
2855,,BAO_0000357,,,8,,CHEMBL617496,,Autocuration,,13181,,H,12689,1,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,
2856,,BAO_0000219,,,8,,CHEMBL617497,,Autocuration,,1883,,H,12689,1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,
2857,,BAO_0000357,,,8,,CHEMBL617498,,Autocuration,,15194,,H,12689,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2858,,BAO_0000357,,,8,,CHEMBL617499,,Autocuration,,15194,,H,12689,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,
2859,,BAO_0000019,,,8,,CHEMBL617500,,Autocuration,,14579,,H,12689,1,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,
2860,,BAO_0000357,,,8,,CHEMBL617501,,Autocuration,,4639,,H,108,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,
2861,,BAO_0000357,,,8,,CHEMBL617502,,Expert,,4820,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2862,,BAO_0000357,,,8,,CHEMBL617503,,Autocuration,,14442,,H,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,
2863,,BAO_0000357,,,8,,CHEMBL617504,,Autocuration,,14755,,H,227,1,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,
2864,,BAO_0000357,,,8,,CHEMBL617406,,Autocuration,,14744,,H,227,1,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,
2865,Homo sapiens,BAO_0000019,,,9,,CHEMBL617407,,Expert,,6857,,D,227,1,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,9606.0
2866,,BAO_0000357,,,8,,CHEMBL617408,,Autocuration,,16209,,H,227,1,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,
2867,,BAO_0000357,,,8,,CHEMBL617409,,Autocuration,,15363,,H,227,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,
2868,,BAO_0000357,,,8,,CHEMBL617410,,Autocuration,,15363,,H,227,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,
2869,,BAO_0000357,,,8,,CHEMBL617411,,Autocuration,,15363,,H,227,1,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,
2870,,BAO_0000019,,,8,,CHEMBL617412,,Autocuration,,17085,,H,227,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,
2871,Homo sapiens,BAO_0000357,,,9,,CHEMBL617774,,Expert,,17200,,D,227,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,9606.0
2872,Homo sapiens,BAO_0000219,,,9,,CHEMBL617775,,Expert,,15851,,D,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0
2873,Homo sapiens,BAO_0000219,,,9,,CHEMBL617776,,Expert,,15851,,D,227,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0
2874,Homo sapiens,BAO_0000219,,,9,,CHEMBL617777,,Expert,,6857,,D,227,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0
2875,Homo sapiens,BAO_0000219,,,9,,CHEMBL617778,,Expert,,6857,,D,227,1,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0
2876,,BAO_0000219,,,8,,CHEMBL617779,,Autocuration,,15779,,H,227,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2877,,BAO_0000219,,,8,,CHEMBL617780,,Expert,,15851,,H,227,1,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,
2878,,BAO_0000219,,,8,,CHEMBL617781,,Autocuration,,15779,,H,227,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,
2879,Homo sapiens,BAO_0000219,,,9,,CHEMBL617782,,Expert,,14157,,D,227,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,9606.0
2880,Homo sapiens,BAO_0000219,,,9,,CHEMBL617783,,Expert,,4540,,D,227,1,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,9606.0
2881,,BAO_0000357,,,8,,CHEMBL617784,,Autocuration,,6166,,H,227,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,
2882,,BAO_0000219,,,8,,CHEMBL617785,,Autocuration,,15779,,H,227,1,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,
2883,,BAO_0000219,,,8,,CHEMBL857984,,Expert,,14391,,H,227,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,
2884,,BAO_0000219,,,8,,CHEMBL617786,,Expert,,3832,,H,227,1,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,
2885,,BAO_0000219,,,8,,CHEMBL617787,,Expert,,3833,,H,227,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,
2886,Homo sapiens,BAO_0000219,,,9,,CHEMBL617788,,Expert,,15851,,D,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,9606.0
2887,Homo sapiens,BAO_0000219,,,9,,CHEMBL617789,,Expert,,15851,,D,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,9606.0
2888,,BAO_0000219,,,8,,CHEMBL617790,,Autocuration,,4199,,H,227,1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,
2889,,BAO_0000219,,,8,,CHEMBL617791,,Expert,,1883,,H,227,1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,
2890,,BAO_0000357,,,8,,CHEMBL617608,,Expert,,4321,,H,227,1,Binding affinity against 5-hydroxytryptamine 2B receptor,B,
2891,,BAO_0000219,,,8,,CHEMBL617609,,Autocuration,,15146,,H,227,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,
2892,,BAO_0000219,,,8,,CHEMBL617610,,Autocuration,,5213,,H,227,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,
2893,,BAO_0000219,,,8,,CHEMBL617611,,Autocuration,,14818,,H,227,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,
2894,,BAO_0000219,,,8,,CHEMBL617612,,Autocuration,,4829,,H,227,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2895,,BAO_0000219,,,8,,CHEMBL617613,,Autocuration,,4829,,H,227,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2896,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL617614,,Autocuration,,14025,,H,227,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,9986.0
2897,,BAO_0000019,945.0,,8,Stomach,CHEMBL617615,,Expert,,13463,,H,12688,1,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,
2898,,BAO_0000357,945.0,,8,Stomach,CHEMBL858114,,Expert,,7259,,H,12688,1,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,
2899,,BAO_0000357,945.0,,8,Stomach,CHEMBL617616,,Autocuration,,7259,,H,12688,1,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,
2900,Rattus norvegicus,BAO_0000019,945.0,,9,Stomach,CHEMBL617617,,Expert,,7185,,D,12688,1,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,10116.0
2901,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL875914,,Expert,,7185,,D,12688,1,Antagonistic against 5-hydroxytryptamine 2B receptor,F,10116.0
2902,,BAO_0000019,945.0,,8,Stomach,CHEMBL617618,,Autocuration,,13267,,H,12688,1,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,
2903,Rattus norvegicus,BAO_0000357,945.0,,9,Stomach,CHEMBL617619,,Expert,,13735,,D,12688,1,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,10116.0
2904,,BAO_0000019,,,8,,CHEMBL617620,,Autocuration,,15738,,H,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,
2905,,BAO_0000019,,,8,,CHEMBL617621,,Autocuration,,15738,,H,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,
2906,,BAO_0000019,,,8,,CHEMBL617622,,Autocuration,,15738,,H,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,
2907,Rattus norvegicus,BAO_0000357,945.0,,9,Stomach,CHEMBL617623,,Expert,,12936,,D,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0
2908,Rattus norvegicus,BAO_0000357,945.0,,9,Stomach,CHEMBL617624,,Expert,,12936,,D,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0
2909,Rattus norvegicus,BAO_0000357,945.0,,9,Stomach,CHEMBL617625,,Expert,,12936,,D,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0
2910,Rattus norvegicus,BAO_0000357,945.0,,9,Stomach,CHEMBL617626,,Expert,,12936,,D,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0
2911,,BAO_0000019,945.0,,8,Stomach,CHEMBL617627,,Autocuration,,16404,,H,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,
2912,,BAO_0000019,945.0,,8,Stomach,CHEMBL617628,,Expert,,16404,,H,12688,1,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,
2913,,BAO_0000019,945.0,,8,Stomach,CHEMBL617629,,Autocuration,,16404,,H,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,
2914,,BAO_0000019,945.0,,8,Stomach,CHEMBL858115,,Autocuration,,16404,,H,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,
2915,Rattus norvegicus,BAO_0000019,945.0,,9,Stomach,CHEMBL617630,,Expert,,16404,,D,12688,1,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,10116.0
2916,,BAO_0000019,1515.0,,8,Thoracic aorta,CHEMBL617631,,Autocuration,,16404,,H,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,
2917,,BAO_0000357,,,8,,CHEMBL617632,,Autocuration,,7483,,H,12688,1,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,
2918,,BAO_0000357,,,8,,CHEMBL617633,,Expert,,7483,,H,12688,1,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,
2919,,BAO_0000357,,,8,,CHEMBL617634,,Autocuration,,7483,,H,12688,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,
2920,,BAO_0000357,,,8,,CHEMBL617635,,Autocuration,,7483,,H,12688,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,
2922,Rattus norvegicus,BAO_0000019,945.0,,9,Stomach,CHEMBL617637,,Autocuration,,16404,,D,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,10116.0
2923,,BAO_0000357,,,8,,CHEMBL617638,,Autocuration,,6347,,H,227,1,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
2924,,BAO_0000357,,,8,,CHEMBL617639,,Autocuration,,4373,,H,227,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,
2925,,BAO_0000357,,,8,,CHEMBL617640,,Autocuration,,4373,,H,227,1,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,
2926,,BAO_0000357,,,8,,CHEMBL617641,,Autocuration,,4687,,H,227,1,Evaluated for the binding affinity to 5-HT 2B receptor,B,
2927,,BAO_0000357,,,8,,CHEMBL617642,,Autocuration,,16946,,H,227,1,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,
2928,,BAO_0000357,,,8,,CHEMBL617643,,Autocuration,,16633,,H,227,1,Binding affinities against 5-hydroxytryptamine 2B receptor,B,
2929,,BAO_0000357,,,8,,CHEMBL617644,,Autocuration,,16633,,H,227,1,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,
2930,,BAO_0000357,,,8,,CHEMBL617645,,Autocuration,,16633,,H,227,1,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,
2931,,BAO_0000357,,,8,,CHEMBL617646,,Expert,,15026,,H,108,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,
2932,Bos taurus,BAO_0000357,,,8,,CHEMBL617647,,Autocuration,,15738,,H,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0
2933,Bos taurus,BAO_0000357,,,8,,CHEMBL617648,,Autocuration,,15738,,H,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,9913.0
2934,Bos taurus,BAO_0000357,,,8,,CHEMBL617875,,Autocuration,,15738,,H,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,9913.0
2935,Bos taurus,BAO_0000357,,,8,,CHEMBL617876,,Autocuration,,15738,,H,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,9913.0
2936,Bos taurus,BAO_0000357,,,8,,CHEMBL617877,,Expert,,16404,,H,108,1,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,9913.0
2937,Bos taurus,BAO_0000357,,,8,,CHEMBL617878,,Expert,,15026,,H,108,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,9913.0
2938,Bos taurus,BAO_0000357,,,8,,CHEMBL617879,,Autocuration,,15738,,H,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0
2939,Cavia porcellus,BAO_0000019,,,8,,CHEMBL617880,,Autocuration,,16312,,H,108,1,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,10141.0
2940,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL617881,,Intermediate,,5486,,D,20033,1,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,10141.0
2941,,BAO_0000357,,,8,,CHEMBL857073,,Autocuration,,5254,,H,51,1,Binding affinity against 5-HT1A receptor,B,
2942,,BAO_0000219,,,8,,CHEMBL617882,,Expert,,3857,,H,108,1,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,
2943,Homo sapiens,BAO_0000219,,,9,,CHEMBL617883,,Expert,,6857,,D,108,1,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0
2944,,BAO_0000219,,,8,,CHEMBL617884,,Autocuration,,4176,,H,108,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,
2945,,BAO_0000219,,,8,,CHEMBL617885,,Autocuration,,6347,,H,108,1,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,
2946,,BAO_0000219,,,8,,CHEMBL617886,,Autocuration,,6347,,H,108,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,
2947,Homo sapiens,BAO_0000357,,,9,,CHEMBL617887,,Expert,,16146,,D,108,1,Inhibition of human 5-hydroxytryptamine 2C receptor,B,9606.0
2948,,BAO_0000357,,,8,,CHEMBL617888,,Autocuration,,3805,,H,108,1,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,
2949,,BAO_0000019,,,8,,CHEMBL617889,,Autocuration,,3857,,H,108,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,
2950,,BAO_0000357,,,8,,CHEMBL617890,,Autocuration,,5635,,H,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,
2951,,BAO_0000357,,,8,,CHEMBL617891,,Autocuration,,5635,,H,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,
2952,,BAO_0000357,,,8,,CHEMBL617892,,Autocuration,,5635,,H,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,
2953,,BAO_0000219,,,8,,CHEMBL617893,,Expert,,4012,,H,108,1,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,
2954,,BAO_0000219,,,8,,CHEMBL617894,,Expert,,6366,,H,108,1,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,
2955,,BAO_0000219,,,8,,CHEMBL617895,,Expert,,15949,,H,108,1,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2956,,BAO_0000219,,,8,,CHEMBL617896,,Autocuration,,17211,,H,108,1,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,
2957,Homo sapiens,BAO_0000357,,,9,,CHEMBL617897,,Expert,,6491,,D,108,1,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,9606.0
2958,,BAO_0000019,,,8,,CHEMBL617898,,Autocuration,,14093,,H,108,1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,
2959,,BAO_0000019,,,8,,CHEMBL617899,,Autocuration,,13481,,H,108,1,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,
2960,Rattus norvegicus,BAO_0000219,,,8,,CHEMBL617900,,Expert,,6347,,H,108,1,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,10116.0
2961,,BAO_0000019,,,8,,CHEMBL617901,,Autocuration,,14093,,H,108,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,
2962,,BAO_0000019,,,8,,CHEMBL617902,,Autocuration,,14093,,H,108,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,
2963,,BAO_0000019,,,8,,CHEMBL617903,,Autocuration,,13481,,H,108,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,
2964,,BAO_0000357,,,8,,CHEMBL617904,,Autocuration,,14442,,H,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,
2965,,BAO_0000357,,,8,,CHEMBL617905,,Autocuration,,14442,,H,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,
2966,,BAO_0000357,,,8,,CHEMBL617906,,Autocuration,,14442,,H,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,
2967,,BAO_0000357,,,8,,CHEMBL617907,,Autocuration,,14755,,H,108,1,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,
2968,,BAO_0000357,,,8,,CHEMBL617908,,Autocuration,,14744,,H,108,1,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,
2969,,BAO_0000219,,,8,,CHEMBL620617,,Expert,,16659,,H,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2970,Homo sapiens,BAO_0000019,,,9,,CHEMBL620618,,Expert,,6857,,D,108,1,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,9606.0
2971,,BAO_0000357,,,8,,CHEMBL620619,,Expert,,5635,,H,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,
2972,Homo sapiens,BAO_0000357,,,9,,CHEMBL620620,,Expert,,4234,,D,108,1,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,9606.0
2973,,BAO_0000357,,,8,,CHEMBL620621,,Autocuration,,16209,,H,108,1,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,
2974,Rattus norvegicus,BAO_0000249,,,7,,CHEMBL872920,,Autocuration,,5778,,D,104698,1,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,10116.0
2975,,BAO_0000223,,,6,,CHEMBL620622,,Autocuration,,5094,,H,104698,1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,
2976,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL620623,,Autocuration,,809,,D,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,10116.0
2977,,BAO_0000019,,,6,,CHEMBL620624,,Autocuration,,1578,,H,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,
2978,,BAO_0000019,,,6,,CHEMBL620625,,Autocuration,,809,,H,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,
2979,,BAO_0000219,,,6,,CHEMBL620626,,Autocuration,,12469,,H,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,
2980,,BAO_0000019,,,6,,CHEMBL621307,,Autocuration,,14290,,H,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,
2981,,BAO_0000019,,,6,,CHEMBL621308,,Autocuration,,14290,,H,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,
2982,,BAO_0000223,,,6,,CHEMBL621309,,Autocuration,,10609,,H,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,
2983,,BAO_0000223,,,6,,CHEMBL621310,,Autocuration,,10609,,H,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,
2984,,BAO_0000223,,,6,,CHEMBL621311,,Autocuration,,10609,,H,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,
2985,,BAO_0000249,,,6,,CHEMBL621502,,Autocuration,,15253,,H,104698,1,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,
2986,,BAO_0000249,,,6,,CHEMBL621503,,Autocuration,,15253,,H,104698,1,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,
2987,,BAO_0000249,,,6,,CHEMBL621504,,Autocuration,,11683,,H,104698,1,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,
2988,,BAO_0000223,,,6,,CHEMBL621505,,Autocuration,,12092,,H,104698,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,
2989,,BAO_0000019,,,6,,CHEMBL621506,,Autocuration,,1946,,H,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,
2990,,BAO_0000223,,,6,,CHEMBL619781,,Autocuration,,11623,,H,104698,1,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,
2991,,BAO_0000223,,,6,,CHEMBL619782,,Autocuration,,11623,,H,104698,1,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,
2992,,BAO_0000019,,,6,,CHEMBL619783,,Autocuration,,14788,,H,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,
2993,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL619784,,Autocuration,,5432,,D,104698,1,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,10116.0
2994,,BAO_0000249,,,6,,CHEMBL619785,,Autocuration,,14826,,H,104698,1,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
2995,,BAO_0000223,,,6,,CHEMBL619786,,Autocuration,,2222,,H,104698,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,
2996,,BAO_0000019,,,6,,CHEMBL619787,,Autocuration,,11963,,H,104698,1,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,
2997,,BAO_0000019,,,6,,CHEMBL872925,,Autocuration,,14145,,H,104698,1,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,
2998,,BAO_0000019,,,6,,CHEMBL619788,,Autocuration,,17819,,H,104698,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,
2999,,BAO_0000249,,,6,,CHEMBL619789,,Autocuration,,10394,,H,104698,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,
3000,,BAO_0000249,,,6,,CHEMBL619790,,Autocuration,,10394,,H,104698,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,
3001,,BAO_0000019,,,6,,CHEMBL619791,,Autocuration,,15034,,H,104698,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,
3002,,BAO_0000019,,,6,,CHEMBL619792,,Autocuration,,691,,H,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,
3003,,BAO_0000249,,,6,,CHEMBL619793,,Autocuration,,12092,,H,104698,1,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,
3004,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL619794,,Autocuration,,11752,,D,104698,1,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,10116.0
3005,,BAO_0000221,955.0,,6,Brain,CHEMBL619795,,Autocuration,,11752,,H,104698,1,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,
3006,,BAO_0000019,,,6,,CHEMBL619796,,Autocuration,,301,,H,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,
3007,,BAO_0000223,,,6,,CHEMBL620448,,Autocuration,,16532,,H,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,
3008,,BAO_0000223,,,6,,CHEMBL620449,,Autocuration,,16532,,H,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,
3009,,BAO_0000223,,,6,,CHEMBL620450,,Autocuration,,12092,,H,104698,1,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,
3010,,BAO_0000223,,,6,,CHEMBL620451,,Autocuration,,11684,,H,104698,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,
3011,,BAO_0000223,,,6,,CHEMBL620631,,Autocuration,,11684,,H,104698,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,
3012,,BAO_0000019,,,6,,CHEMBL620632,,Autocuration,,12953,,H,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,
3013,,BAO_0000019,,,6,,CHEMBL620633,,Autocuration,,12953,,H,104698,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,
3014,,BAO_0000223,,,6,,CHEMBL620634,,Autocuration,,12953,,H,104698,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,
3015,,BAO_0000019,,,6,,CHEMBL620635,,Autocuration,,12861,,H,104698,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,
3016,,BAO_0000218,,,6,,CHEMBL620636,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3017,,BAO_0000218,,,6,,CHEMBL620637,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,
3018,,BAO_0000218,,,6,,CHEMBL620638,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,
3019,,BAO_0000218,,,6,,CHEMBL620639,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,
3020,,BAO_0000218,,,6,,CHEMBL620640,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3021,,BAO_0000218,,,6,,CHEMBL620641,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,
3022,,BAO_0000218,,,6,,CHEMBL620642,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,
3023,,BAO_0000218,,,6,,CHEMBL620643,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,
3024,,BAO_0000218,,,6,,CHEMBL620644,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,
3025,,BAO_0000218,,,6,,CHEMBL620645,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3026,,BAO_0000218,,,6,,CHEMBL620646,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,
3027,,BAO_0000218,,,6,,CHEMBL620647,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,
3028,,BAO_0000218,,,6,,CHEMBL620648,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,
3029,,BAO_0000218,,,6,,CHEMBL620649,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3030,,BAO_0000218,,,6,,CHEMBL620650,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,
3031,,BAO_0000218,,,6,,CHEMBL620651,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,
3032,,BAO_0000218,,,6,,CHEMBL872875,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,
3033,,BAO_0000218,,,6,,CHEMBL620652,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,
3034,,BAO_0000019,,,6,,CHEMBL620653,,Autocuration,,10609,,H,104698,1,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,
3035,,BAO_0000019,,,6,,CHEMBL857076,,Autocuration,,12861,,H,104698,1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,
3036,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL620654,,Autocuration,,12861,,D,104698,1,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0
3037,,BAO_0000223,,,6,,CHEMBL620655,,Autocuration,,12861,,H,104698,1,Binding activity radioligand.,B,
3038,,BAO_0000249,,,6,,CHEMBL620656,,Autocuration,,10728,,H,104698,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,
3039,,BAO_0000249,,,6,,CHEMBL620657,,Autocuration,,10728,,H,104698,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,
3040,,BAO_0000357,,,8,,CHEMBL620658,,Autocuration,,5163,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,
3041,,BAO_0000357,,,8,,CHEMBL620659,,Autocuration,,5163,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,
3042,,BAO_0000357,,,8,,CHEMBL620660,,Autocuration,,6011,,H,108,1,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,
3043,,BAO_0000357,,,8,,CHEMBL620661,,Autocuration,,5014,,H,108,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,
3044,,BAO_0000357,,,8,,CHEMBL620662,,Autocuration,,5635,,H,108,1,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,
3045,,BAO_0000357,,,8,,CHEMBL620663,,Expert,,5163,,H,108,1,Affinity for 5-hydroxytryptamine 2C receptor,B,
3046,,BAO_0000357,,,8,,CHEMBL620664,,Autocuration,,6841,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
3047,,BAO_0000357,,,8,,CHEMBL620665,,Expert,,6119,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,
3048,,BAO_0000357,,,8,,CHEMBL620666,,Autocuration,,4373,,H,108,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,
3049,,BAO_0000357,,,8,,CHEMBL620667,,Autocuration,,1633,,H,108,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,
3050,,BAO_0000357,,,8,,CHEMBL620668,,Expert,,1633,,H,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,
3051,,BAO_0000357,,,8,,CHEMBL620669,,Autocuration,,4373,,H,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,
3052,,BAO_0000357,,,8,,CHEMBL620670,,Expert,,6576,,H,108,1,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,
3053,,BAO_0000357,,,8,,CHEMBL620671,,Autocuration,,4687,,H,108,1,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,
3054,,BAO_0000357,,,8,,CHEMBL620672,,Autocuration,,12146,,H,108,1,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,
3055,,BAO_0000357,,,8,,CHEMBL620673,,Autocuration,,12146,,H,108,1,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,
3056,,BAO_0000357,,,8,,CHEMBL620674,,Autocuration,,16946,,H,108,1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,
3057,,BAO_0000357,,,8,,CHEMBL620675,,Autocuration,,14159,,H,108,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,
3058,,BAO_0000357,,,8,,CHEMBL620676,,Autocuration,,16700,,H,108,1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,
3059,,BAO_0000357,,,8,,CHEMBL621382,,Autocuration,,3269,,H,108,1,Affinity against 5-hydroxytryptamine 2C receptor,B,
3060,Homo sapiens,BAO_0000357,,,9,,CHEMBL621383,,Expert,,1274,,D,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0
3061,,BAO_0000357,,,8,,CHEMBL621384,,Autocuration,,1317,,H,108,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,
3062,Bos taurus,BAO_0000357,,,8,,CHEMBL621385,,Autocuration,,5834,,H,144,1,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,9913.0
3063,Bos taurus,BAO_0000357,,,8,,CHEMBL617989,,Autocuration,,11147,,H,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,9913.0
3064,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617990,,Expert,,14145,,H,104714,1,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,10141.0
3065,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL875085,,Autocuration,,10561,,H,104714,1,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0
3066,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617991,,Autocuration,,15847,,H,104714,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,10141.0
3067,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617992,,Autocuration,,15847,,H,104714,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,10141.0
3068,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617993,,Autocuration,,10561,,H,104714,1,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0
3069,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617994,,Autocuration,,11454,,H,104714,1,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,10141.0
3070,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617995,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,10141.0
3071,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617996,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,10141.0
3072,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617997,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,10141.0
3073,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617998,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,10141.0
3074,Cavia porcellus,BAO_0000019,,,4,,CHEMBL617999,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0
3075,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618000,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,10141.0
3076,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617815,,Autocuration,,15253,,H,104714,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,10141.0
3077,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617816,,Autocuration,,15253,,H,104714,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,10141.0
3078,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617817,,Autocuration,,11963,,H,104714,1,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,10141.0
3079,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617818,,Autocuration,,1946,,H,104714,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,10141.0
3080,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617819,,Autocuration,,1946,,H,104714,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,10141.0
3081,Cavia porcellus,BAO_0000223,,,4,,CHEMBL617820,,Autocuration,,12045,,H,104714,1,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,10141.0
3082,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617821,,Autocuration,,1559,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0
3083,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617822,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0
3084,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617823,,Autocuration,,273,,H,104714,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,10141.0
3085,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617824,,Autocuration,,188,,H,104714,1,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,10141.0
3086,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617825,,Autocuration,,12919,,H,104714,1,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,10141.0
3087,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617826,,Autocuration,,12918,,H,104714,1,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,10141.0
3088,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617827,,Autocuration,,1559,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0
3089,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617828,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0
3090,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617829,,Autocuration,,1559,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0
3091,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617830,,Autocuration,,1559,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,10141.0
3092,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617831,,Autocuration,,1559,,H,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,10141.0
3093,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617832,,Autocuration,,14424,,H,104714,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,10141.0
3094,Cavia porcellus,BAO_0000019,,,0,,CHEMBL617833,,Autocuration,,13181,,U,22226,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0
3095,,BAO_0000357,,,8,,CHEMBL617834,,Autocuration,,5486,,H,51,1,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,
3096,Homo sapiens,BAO_0000223,,,5,,CHEMBL617835,,Expert,,6491,,D,104714,1,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,9606.0
3097,,BAO_0000223,,,4,,CHEMBL617836,,Autocuration,,6013,,H,104714,1,Binding affinity towards 5-HT3 receptor,B,
3098,,BAO_0000223,,,4,,CHEMBL617837,,Autocuration,,12861,,H,104714,1,Binding activity radioligand.,B,
3099,,BAO_0000019,,,4,,CHEMBL620392,,Autocuration,,12861,,H,104714,1,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,
3100,,BAO_0000223,,,4,,CHEMBL620393,,Autocuration,,5104,,H,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,
3101,,BAO_0000223,,,4,,CHEMBL620394,,Autocuration,,5105,,H,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,
3102,,BAO_0000223,,,4,,CHEMBL620395,,Autocuration,,5104,,H,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,
3103,,BAO_0000019,,,0,,CHEMBL620396,,Autocuration,,3935,,U,22226,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,
3104,,BAO_0000219,,,4,,CHEMBL620582,,Expert,,13657,,H,105030,1,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,
3105,,BAO_0000218,,,4,,CHEMBL620583,,Autocuration,In vivo,10369,,H,105030,1,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,
3106,,BAO_0000019,,,4,,CHEMBL620584,,Autocuration,,10369,,H,105030,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,
3107,,BAO_0000224,,,4,,CHEMBL620585,,Autocuration,,12918,,H,105030,1,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,
3108,,BAO_0000224,,,4,,CHEMBL620586,,Autocuration,,12918,,H,105030,1,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,
3109,,BAO_0000019,,,4,,CHEMBL620587,,Autocuration,,10369,,H,105030,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,
3110,,BAO_0000019,,,4,,CHEMBL620588,,Autocuration,,773,,H,105030,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,
3111,,BAO_0000218,,,4,,CHEMBL620589,,Autocuration,,12918,,H,105030,1,5-hydroxytryptamine 3 receptor agonism in mouse,F,
3112,,BAO_0000219,,,4,,CHEMBL620590,,Autocuration,,10561,,H,105030,1,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,
3113,,BAO_0000019,,,4,,CHEMBL617956,,Autocuration,,12827,,H,105030,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,
3114,,BAO_0000019,,,4,,CHEMBL617957,,Autocuration,,12827,,H,105030,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,
3115,,BAO_0000224,,,4,,CHEMBL617958,,Autocuration,,12918,,H,105030,1,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,
3116,,BAO_0000219,,,4,,CHEMBL617959,,Autocuration,,273,,H,105030,1,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,
3117,,BAO_0000219,,,4,,CHEMBL617960,,Autocuration,,273,,H,105030,1,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,
3118,,BAO_0000224,,,4,,CHEMBL617961,,Autocuration,,10561,,H,105030,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,
3119,,BAO_0000219,,,4,,CHEMBL617962,,Autocuration,In vitro,5033,,H,105030,1,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,
3120,,BAO_0000219,,,4,,CHEMBL617963,,Autocuration,,16429,,H,105030,1,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,
3121,,BAO_0000019,,,8,,CHEMBL617964,,Autocuration,,10322,,H,11765,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,
3122,,BAO_0000219,,,8,,CHEMBL617965,,Autocuration,,14331,,H,11765,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,
3123,Mus musculus,BAO_0000357,,,9,,CHEMBL617966,,Autocuration,,13462,,D,10630,1,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,10090.0
3124,,BAO_0000019,,,8,,CHEMBL857074,,Autocuration,,12861,,H,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
3125,Sus scrofa,BAO_0000357,,,8,,CHEMBL617967,,Autocuration,,15086,,H,144,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,9823.0
3126,Sus scrofa,BAO_0000357,,,8,,CHEMBL617968,,Autocuration,,12861,,H,144,1,Binding activity radioligand.,B,9823.0
3127,Oryctolagus cuniculus,BAO_0000223,,,4,,CHEMBL617969,,Autocuration,,10561,,H,104714,1,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,9986.0
3128,Oryctolagus cuniculus,BAO_0000223,,,4,,CHEMBL617970,,Autocuration,,10561,,H,104714,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,9986.0
3129,Oryctolagus cuniculus,BAO_0000223,,,4,,CHEMBL617971,,Autocuration,,10561,,H,104714,1,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,9986.0
3130,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617972,,Autocuration,,10561,,H,104714,1,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,9986.0
3131,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617973,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0
3132,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617974,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0
3133,Oryctolagus cuniculus,BAO_0000221,2116.0,,4,Ileum,CHEMBL617975,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,9986.0
3134,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617976,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0
3135,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617977,,Autocuration,,273,,H,104714,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0
3136,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617978,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0
3137,Oryctolagus cuniculus,BAO_0000019,,,4,,CHEMBL617979,,Autocuration,,273,,H,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0
3138,Oryctolagus cuniculus,BAO_0000219,,,4,,CHEMBL617980,,Autocuration,,13047,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,9986.0
3139,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617981,,Autocuration,,1650,,D,104698,1,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,10116.0
3140,,BAO_0000019,,,8,,CHEMBL617982,,Autocuration,,16288,,H,12020,1,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,
3141,,BAO_0000357,,,8,,CHEMBL617983,,Autocuration,,16288,,H,12020,1,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,
3142,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617984,,Autocuration,,10254,,D,104698,1,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,10116.0
3143,,BAO_0000019,,,6,,CHEMBL617985,,Autocuration,,14532,,H,104698,1,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,
3144,,BAO_0000218,948.0,,6,Heart,CHEMBL617986,,Autocuration,In vivo,13392,,H,104698,1,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,
3145,,BAO_0000019,948.0,,6,Heart,CHEMBL617987,,Autocuration,,13392,,H,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,
3146,,BAO_0000019,948.0,,6,Heart,CHEMBL617988,,Autocuration,,13392,,H,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,
3147,,BAO_0000019,948.0,,6,Heart,CHEMBL617792,,Autocuration,,13392,,H,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,
3148,,BAO_0000019,948.0,,6,Heart,CHEMBL617793,,Autocuration,,13392,,H,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,
3149,,BAO_0000019,,,6,,CHEMBL617794,,Autocuration,,13392,,H,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,
3150,,BAO_0000019,,,6,,CHEMBL617795,,Autocuration,,13392,,H,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,
3151,,BAO_0000019,,,6,,CHEMBL617796,,Autocuration,,13392,,H,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,
3152,,BAO_0000019,,,6,,CHEMBL617797,,Autocuration,,13392,,H,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,
3153,Rattus norvegicus,BAO_0000218,,,7,,CHEMBL617798,,Autocuration,In vivo,1089,,D,104698,1,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,10116.0
3154,,BAO_0000218,,,6,,CHEMBL617799,,Autocuration,In vivo,1089,,H,104698,1,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,
3155,Rattus norvegicus,BAO_0000218,,,7,,CHEMBL617800,,Autocuration,In vivo,11454,,D,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,10116.0
3156,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617801,,Autocuration,,11454,,D,104698,1,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,10116.0
3157,Rattus norvegicus,BAO_0000218,,,7,,CHEMBL617802,,Autocuration,In vivo,12205,,D,104698,1,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,10116.0
3158,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617803,,Autocuration,,1089,,D,104698,1,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,10116.0
3159,,BAO_0000019,,,6,,CHEMBL617804,,Autocuration,,5094,,H,104698,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,
3160,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617805,,Autocuration,,2622,,D,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,10116.0
3161,,BAO_0000223,,,6,,CHEMBL617806,,Autocuration,,245,,H,104698,1,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,
3162,,BAO_0000019,,,6,,CHEMBL617807,,Autocuration,,14788,,H,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,
3163,,BAO_0000019,,,6,,CHEMBL617808,,Autocuration,,14788,,H,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,
3164,,BAO_0000249,,,6,,CHEMBL617809,,Autocuration,,3020,,H,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,
3165,,BAO_0000019,,,6,,CHEMBL617810,,Autocuration,,1742,,H,104698,1,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,
3166,,BAO_0000249,955.0,,6,Brain,CHEMBL617811,,Autocuration,,17394,,H,104698,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,
3167,,BAO_0000221,955.0,,6,Brain,CHEMBL617812,,Autocuration,,17394,,H,104698,1,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,
3168,,BAO_0000249,,,6,,CHEMBL617813,,Autocuration,,17394,,H,104698,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
3169,,BAO_0000249,,,6,,CHEMBL617814,,Autocuration,,14286,,H,104698,1,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
3170,,BAO_0000019,,,6,,CHEMBL617698,,Autocuration,,14178,,H,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,
3171,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617699,,Autocuration,,14178,,D,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,10116.0
3172,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617700,,Autocuration,,14178,,D,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,10116.0
3173,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL617701,,Autocuration,,14178,,D,104698,1,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,10116.0
3174,,BAO_0000019,,,6,,CHEMBL617702,,Autocuration,,15034,,H,104698,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,
3175,,BAO_0000249,,,6,,CHEMBL617703,,Autocuration,,1089,,H,104698,1,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,
3176,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617704,,Autocuration,,1089,,D,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,10116.0
3177,,BAO_0000223,,,6,,CHEMBL617705,,Autocuration,,16532,,H,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,
3178,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL617706,,Autocuration,,12801,,D,104698,1,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,10116.0
3179,,BAO_0000219,,,6,,CHEMBL617707,,Autocuration,,15194,,H,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,
3180,,BAO_0000219,,,6,,CHEMBL617708,,Autocuration,,15194,,H,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,
3181,,BAO_0000019,,,6,,CHEMBL617709,,Autocuration,,15194,,H,104698,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,
3182,,BAO_0000019,,,6,,CHEMBL617710,,Autocuration,,15194,,H,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,
3183,,BAO_0000019,,,6,,CHEMBL882925,,Autocuration,,15194,,H,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,
3184,,BAO_0000019,,,6,,CHEMBL617711,,Autocuration,,15194,,H,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,
3185,,BAO_0000019,,,6,,CHEMBL617712,,Autocuration,,10610,,H,104698,1,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,
3186,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL617713,,Autocuration,,10355,,D,104698,1,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,10116.0
3187,,BAO_0000019,,,6,,CHEMBL617714,,Autocuration,,691,,H,104698,1,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,
3188,,BAO_0000218,,,6,,CHEMBL617715,,Autocuration,,10611,,H,104698,1,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,
3189,,BAO_0000218,,,6,,CHEMBL617716,,Autocuration,In vivo,12801,,H,104698,1,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,
3190,,BAO_0000218,,,6,,CHEMBL617717,,Autocuration,,10609,,H,104698,1,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,
3191,,BAO_0000218,,,6,,CHEMBL617718,,Autocuration,In vivo,11454,,H,104698,1,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3192,,BAO_0000218,,,6,,CHEMBL617719,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,
3193,,BAO_0000218,,,6,,CHEMBL617720,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,
3194,Rattus norvegicus,BAO_0000218,,,7,,CHEMBL617721,,Autocuration,In vivo,11454,,D,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,10116.0
3195,,BAO_0000218,,,6,,CHEMBL617722,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3196,,BAO_0000218,,,6,,CHEMBL617723,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,
3197,,BAO_0000218,,,6,,CHEMBL617724,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,
3198,,BAO_0000218,,,6,,CHEMBL617725,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3199,,BAO_0000218,,,6,,CHEMBL617726,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,
3200,,BAO_0000218,,,6,,CHEMBL617727,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3201,,BAO_0000218,,,6,,CHEMBL617728,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3202,,BAO_0000218,,,6,,CHEMBL617729,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,
3203,,BAO_0000218,,,6,,CHEMBL617730,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,
3204,,BAO_0000218,,,6,,CHEMBL617731,,Autocuration,In vivo,11454,,H,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3205,,BAO_0000218,,,6,,CHEMBL617732,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,
3206,,BAO_0000218,,,6,,CHEMBL617733,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,
3207,,BAO_0000218,,,6,,CHEMBL617734,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3208,,BAO_0000218,,,6,,CHEMBL872874,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,
3209,,BAO_0000218,,,6,,CHEMBL617735,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,
3210,,BAO_0000218,,,6,,CHEMBL617736,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,
3211,,BAO_0000218,,,6,,CHEMBL617737,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,
3212,,BAO_0000218,,,6,,CHEMBL617738,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,
3213,,BAO_0000218,,,6,,CHEMBL617739,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3214,,BAO_0000218,,,6,,CHEMBL617740,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,
3215,,BAO_0000218,,,6,,CHEMBL617741,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3216,,BAO_0000218,,,6,,CHEMBL617742,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3217,,BAO_0000218,,,6,,CHEMBL617743,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,
3218,,BAO_0000218,,,6,,CHEMBL617744,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3219,,BAO_0000218,,,6,,CHEMBL617745,,Autocuration,In vivo,11454,,H,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,
3220,,BAO_0000218,,,6,,CHEMBL617746,,Autocuration,,670,,H,104698,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,
3221,,BAO_0000218,,,6,,CHEMBL617747,,Autocuration,,670,,H,104698,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,
3222,,BAO_0000218,,,6,,CHEMBL617748,,Autocuration,In vivo,10321,,H,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,
3223,,BAO_0000218,,,6,,CHEMBL618909,,Autocuration,In vivo,10321,,H,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,
3224,,BAO_0000218,,,6,,CHEMBL618910,,Autocuration,In vivo,10321,,H,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,
3225,,BAO_0000218,,,6,,CHEMBL618911,,Autocuration,In vivo,10321,,H,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,
3226,,BAO_0000218,,,6,,CHEMBL618912,,Autocuration,In vivo,10321,,H,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,
3227,,BAO_0000218,,,6,,CHEMBL618913,,Autocuration,In vivo,10322,,H,104698,1,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,
3228,,BAO_0000019,,,6,,CHEMBL618914,,Autocuration,,15412,,H,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,
3229,,BAO_0000019,,,6,,CHEMBL618915,,Autocuration,,15412,,H,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,
3230,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL618916,,Autocuration,,15412,,D,104698,1,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,10116.0
3231,,BAO_0000019,,,6,,CHEMBL618917,,Autocuration,,15412,,H,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,
3232,,BAO_0000221,10000000.0,,7,Hippocampus,CHEMBL618918,,Intermediate,,15412,,D,104698,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,
3233,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL618919,,Autocuration,,15412,,D,104698,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,10116.0
3234,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL618920,,Autocuration,,17394,,D,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,10116.0
3235,,BAO_0000223,,,6,,CHEMBL618921,,Autocuration,,12457,,H,104698,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,
3236,,BAO_0000019,,,6,,CHEMBL618922,,Autocuration,,12457,,H,104698,1,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,
3237,,BAO_0000019,,,6,,CHEMBL618923,,Autocuration,,12205,,H,104698,1,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,
3238,,BAO_0000019,,,6,,CHEMBL618924,,Autocuration,,14532,,H,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,
3239,,BAO_0000019,,,6,,CHEMBL618925,,Autocuration,,1122,,H,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,
3240,,BAO_0000019,,,6,,CHEMBL618926,,Autocuration,,5094,,H,104698,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,
3241,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL618927,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,10141.0
3242,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL618928,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,10141.0
3243,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL618929,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,10141.0
3244,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL618930,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0
3245,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL618931,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0
3246,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619594,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0
3247,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619595,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,10141.0
3248,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619596,,Intermediate,,13961,,D,20033,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,10141.0
3249,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619755,,Intermediate,,13961,,D,20033,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,10141.0
3250,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619756,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,10141.0
3251,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619757,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,10141.0
3252,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619758,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,10141.0
3253,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619759,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,10141.0
3254,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619760,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,10141.0
3255,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619761,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0
3256,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619762,,Intermediate,,14290,,D,20033,1,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,10141.0
3257,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619763,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0
3258,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL617868,,Intermediate,,14290,,D,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0
3259,Cavia porcellus,BAO_0000357,,,9,,CHEMBL617869,,Intermediate,,15034,,D,20033,1,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0
3260,Cavia porcellus,BAO_0000249,2435.0,,9,Striatum,CHEMBL882926,,Intermediate,,5094,,D,20033,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0
3261,Cavia porcellus,BAO_0000249,2435.0,,9,Striatum,CHEMBL617870,,Intermediate,,5094,,D,20033,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0
3262,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL617871,,Intermediate,,5399,,D,20033,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0
3263,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL617872,,Intermediate,,17394,,D,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0
3264,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL617873,,Intermediate,,17394,,D,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0
3265,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL617874,,Intermediate,,17394,,D,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0
3266,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619067,,Intermediate,,13961,,D,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,10141.0
3267,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619068,,Intermediate,,13961,,D,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,10141.0
3268,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619069,,Intermediate,,13961,,D,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0
3269,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619070,,Intermediate,,16946,,D,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,10141.0
3270,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619071,,Intermediate,,16946,,D,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,10141.0
3271,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619072,,Intermediate,,15034,,D,20033,1,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0
3272,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619073,,Intermediate,,15034,,D,20033,1,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,10141.0
3273,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619074,,Intermediate,,12918,,D,20033,1,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,10141.0
3274,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619075,,Intermediate,,16946,,D,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,10141.0
3275,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL619076,,Intermediate,,17394,,D,20033,1,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0
3276,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL619077,,Intermediate,,15034,,D,20033,1,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0
3277,Cavia porcellus,BAO_0000249,2435.0,,9,Striatum,CHEMBL619078,,Intermediate,,5094,,D,20033,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0
3278,Cavia porcellus,BAO_0000249,2435.0,,9,Striatum,CHEMBL619079,,Intermediate,,5094,,D,20033,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0
3279,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619080,,Intermediate,,17358,,D,20033,1,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,10141.0
3280,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619081,,Expert,,12953,,D,20033,1,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,10141.0
3281,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619082,,Intermediate,,12953,,D,20033,1,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0
3282,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619083,,Intermediate,,12953,,D,20033,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,10141.0
3283,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619084,,Intermediate,,12953,,D,20033,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0
3284,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL859397,,Intermediate,,273,,D,20033,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0
3285,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619085,,Intermediate,,12918,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,10141.0
3286,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619086,,Intermediate,,12919,,D,20033,1,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,10141.0
3287,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619087,,Intermediate,,273,,D,20033,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,10141.0
3288,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619088,,Intermediate,,273,,D,20033,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0
3289,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619089,,Intermediate,,13181,,D,20033,1,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,10141.0
3290,Cavia porcellus,BAO_0000357,,,8,,CHEMBL619090,,Autocuration,,13181,,H,168,1,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,10141.0
3291,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619091,,Intermediate,,15034,,D,20033,1,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0
3292,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619092,,Intermediate,,5033,,D,20033,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0
3293,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619093,,Intermediate,,1980,,D,20033,1,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,10141.0
3294,Cavia porcellus,BAO_0000219,,,8,,CHEMBL619094,,Autocuration,,13181,,H,168,1,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,10141.0
3295,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619095,,Intermediate,,14287,,D,20033,1,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,10141.0
3296,Cavia porcellus,BAO_0000357,,,9,,CHEMBL857988,,Intermediate,,1317,,D,20033,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,10141.0
3297,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619096,,Intermediate,,15316,,D,20033,1,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,10141.0
3298,Cavia porcellus,BAO_0000357,2435.0,,9,Striatum,CHEMBL619097,,Intermediate,,16429,,D,20033,1,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,10141.0
3299,Cavia porcellus,BAO_0000221,10000000.0,,9,Hippocampus,CHEMBL619098,,Intermediate,,14818,,D,20033,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,10141.0
3300,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619751,,Intermediate,,15194,,D,20033,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,10141.0
3301,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619752,,Intermediate,,15194,,D,20033,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,10141.0
3302,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL875096,,Intermediate,,13961,,D,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0
3303,,BAO_0000357,,,8,,CHEMBL619004,,Autocuration,,5486,,H,108,1,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,
3304,,BAO_0000357,,,8,,CHEMBL619005,,Autocuration,,16209,,H,168,1,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,
3305,,BAO_0000019,,,8,,CHEMBL619006,,Autocuration,,17085,,H,168,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,
3306,,BAO_0000219,,,8,,CHEMBL619007,,Autocuration,,4199,,H,168,1,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,
3307,,BAO_0000357,,,8,,CHEMBL619008,,Autocuration,,15146,,H,168,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,
3308,,BAO_0000357,,,8,,CHEMBL619009,,Autocuration,,5213,,H,168,1,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,
3309,,BAO_0000219,,,8,,CHEMBL619010,,Autocuration,,4829,,H,168,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,
3310,,BAO_0000357,,,8,,CHEMBL619011,,Autocuration,,17358,,H,10622,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,
3311,,BAO_0000357,,,8,,CHEMBL619012,,Autocuration,,17358,,H,10622,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,
3312,,BAO_0000219,,,8,,CHEMBL619013,,Autocuration,,16946,,H,10622,1,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,
3313,,BAO_0000357,,,8,,CHEMBL619014,,Autocuration,,17358,,H,10622,1,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,
3314,,BAO_0000019,2081.0,,8,Cardiac atrium,CHEMBL857503,,Autocuration,,268,,H,11249,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,
3315,,BAO_0000019,2081.0,,8,Cardiac atrium,CHEMBL619015,,Autocuration,,268,,H,11249,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,
3316,,BAO_0000357,,,8,,CHEMBL619016,,Autocuration,,15086,,H,11249,1,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,
3317,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL619017,,Autocuration,,14875,,H,11249,1,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,
3318,Sus scrofa,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL619018,,Autocuration,,13267,,H,168,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,9823.0
3319,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL619019,,Autocuration,,13047,,H,168,1,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,9986.0
3320,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL619020,,Expert,,1650,,D,10623,1,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,10116.0
3321,,BAO_0000019,,,8,,CHEMBL619021,,Autocuration,,567,,H,10623,1,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,
3322,,BAO_0000357,,,8,,CHEMBL619022,,Autocuration,,17358,,H,10623,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,
3323,,BAO_0000357,,,8,,CHEMBL619023,,Autocuration,,188,,H,10623,1,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,
3324,,BAO_0000019,,,8,,CHEMBL619024,,Autocuration,,670,,H,10623,1,lntrinsic activity relative to 5-HT receptor,F,
3325,,BAO_0000019,,,8,,CHEMBL619025,,Autocuration,,204,,H,10623,1,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,
3326,,BAO_0000019,,,8,,CHEMBL619026,,Expert,,1946,,H,10623,1,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,
3327,,BAO_0000019,,,8,,CHEMBL619027,,Autocuration,,6398,,H,10623,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,
3328,,BAO_0000019,,,8,,CHEMBL619028,,Autocuration,,6398,,H,10623,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,
3329,,BAO_0000019,,,8,,CHEMBL619029,,Autocuration,,17358,,H,10623,1,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,
3330,,BAO_0000019,,,8,,CHEMBL619030,,Autocuration,,6398,,H,10623,1,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,
3331,,BAO_0000357,,,8,,CHEMBL619031,,Expert,,11752,,H,10623,1,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,
3332,,BAO_0000019,,,8,,CHEMBL619032,,Autocuration,,809,,H,10623,1,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,
3333,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL619033,,Expert,,14178,,D,10623,1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,10116.0
3334,,BAO_0000357,,,8,,CHEMBL619034,,Autocuration,,567,,H,10623,1,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,
3335,,BAO_0000357,,,8,,CHEMBL619035,,Autocuration,,1946,,H,10623,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,
3336,,BAO_0000357,,,8,,CHEMBL619036,,Autocuration,,1946,,H,10623,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,
3337,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL619037,,Expert,,13961,,D,10623,1,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,10116.0
3338,,BAO_0000249,2435.0,,8,Striatum,CHEMBL619038,,Autocuration,,6238,,H,10623,1,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,
3339,,BAO_0000249,,,8,,CHEMBL619039,,Autocuration,,14290,,H,10623,1,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,
3340,,BAO_0000249,,,8,,CHEMBL619040,,Expert,,14290,,H,10623,1,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,
3341,Rattus norvegicus,BAO_0000019,2435.0,,9,Striatum,CHEMBL619041,,Expert,,809,,D,10623,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,10116.0
3342,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619042,,Autocuration,,1578,,H,10623,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,
3343,,BAO_0000249,2435.0,,8,Striatum,CHEMBL619043,,Expert,,16709,,H,10623,1,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,
3344,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619044,,Expert,,1946,,H,10623,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,
3345,,BAO_0000249,2435.0,,8,Striatum,CHEMBL619045,,Expert,,15253,,H,10623,1,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,
3346,,BAO_0000249,2435.0,,8,Striatum,CHEMBL619046,,Expert,,4535,,H,10623,1,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,
3347,,BAO_0000249,,,8,,CHEMBL619047,,Expert,,13961,,H,10623,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,
3348,,BAO_0000221,955.0,,8,Brain,CHEMBL619048,,Autocuration,,17358,,H,10623,1,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,
3349,,BAO_0000019,,,8,,CHEMBL859398,,Autocuration,,15847,,H,10623,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,
3350,,BAO_0000019,,,8,,CHEMBL619049,,Autocuration,,15847,,H,10623,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,
3351,,BAO_0000019,,,8,,CHEMBL857886,,Autocuration,,670,,H,10623,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,
3352,,BAO_0000019,,,8,,CHEMBL619050,,Autocuration,,670,,H,10623,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,
3353,,BAO_0000019,,,8,,CHEMBL620591,,Autocuration,,1317,,H,10623,1,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,
3354,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620592,,Expert,,12936,,D,10623,1,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,10116.0
3355,,BAO_0000249,2435.0,,8,Striatum,CHEMBL620593,,Expert,,4535,,H,10623,1,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,
3356,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL620594,,Expert,,14424,,D,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,10116.0
3357,,BAO_0000019,,,8,,CHEMBL875079,,Expert,,14424,,H,10623,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,
3358,,BAO_0000019,,,8,,CHEMBL620595,,Expert,,14424,,H,10623,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,
3359,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL620596,,Expert,,14424,,D,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,10116.0
3360,,BAO_0000019,,,8,,CHEMBL620597,,Autocuration,,14424,,H,10623,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,
3361,,BAO_0000019,,,8,,CHEMBL620598,,Expert,,14424,,H,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,
3362,,BAO_0000218,,,8,,CHEMBL620599,,Expert,,14424,,H,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,
3363,,BAO_0000019,,,8,,CHEMBL620600,,Autocuration,,14424,,H,10623,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,
3364,Rattus norvegicus,BAO_0000019,,,8,,CHEMBL620601,,Autocuration,,1980,,H,168,1,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,10116.0
3365,,BAO_0000019,,,8,,CHEMBL620602,,Autocuration,,4639,,H,168,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,
3366,,BAO_0000357,,,8,,CHEMBL620603,,Autocuration,,17358,,H,168,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,
3367,,BAO_0000357,,,8,,CHEMBL620604,,Autocuration,,17358,,H,168,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,
3368,,BAO_0000357,,,8,,CHEMBL620605,,Autocuration,,17358,,H,168,1,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,
3369,,BAO_0000357,,,8,,CHEMBL620606,,Autocuration,,1558,,H,168,1,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,
3370,,BAO_0000019,,,8,,CHEMBL620607,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3371,,BAO_0000357,,,8,,CHEMBL620608,,Autocuration,,16117,,H,168,1,In vitro binding affinity towards 5-HT4 receptor was determined,B,
3372,,BAO_0000019,,,8,,CHEMBL620609,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3373,,BAO_0000019,,,8,,CHEMBL620610,,Autocuration,,17358,,H,168,1,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,
3374,,BAO_0000357,,,8,,CHEMBL620611,,Autocuration,,17358,,H,168,1,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,
3375,,BAO_0000357,,,8,,CHEMBL620612,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,
3376,,BAO_0000357,,,8,,CHEMBL620613,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,
3377,,BAO_0000357,,,8,,CHEMBL620614,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,
3378,,BAO_0000357,,,8,,CHEMBL620615,,Expert,,1274,,H,168,1,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,
3379,,BAO_0000249,,,6,,CHEMBL857075,,Autocuration,,10728,,H,104698,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,
3380,,BAO_0000249,,,6,,CHEMBL620616,,Autocuration,,11695,,H,104698,1,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,
3381,,BAO_0000249,,,6,,CHEMBL619411,,Autocuration,,11695,,H,104698,1,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,
3382,,BAO_0000019,,,6,,CHEMBL619412,,Autocuration,,12490,,H,104698,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,
3383,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL619413,,Autocuration,,11828,,D,104698,1,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0
3384,,BAO_0000221,10000000.0,,6,Hippocampus,CHEMBL619414,,Autocuration,,12253,,H,104698,1,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,
3385,,BAO_0000019,,,6,,CHEMBL619415,,Autocuration,,10561,,H,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,
3386,,BAO_0000019,,,6,,CHEMBL619416,,Autocuration,,10561,,H,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,
3387,,BAO_0000019,,,6,,CHEMBL619417,,Autocuration,,14432,,H,104698,1,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,
3388,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL619418,,Autocuration,,12936,,D,104698,1,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,10116.0
3389,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL619419,,Autocuration,,1274,,D,104698,1,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,10116.0
3390,,BAO_0000019,,,6,,CHEMBL619420,,Autocuration,,1980,,H,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,
3391,,BAO_0000249,,,6,,CHEMBL619421,,Autocuration,,670,,H,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,
3392,Rattus norvegicus,BAO_0000019,,,7,,CHEMBL619422,,Autocuration,,968,,D,104698,1,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,10116.0
3393,,BAO_0000019,,,6,,CHEMBL619423,,Autocuration,,14287,,H,104698,1,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,
3394,,BAO_0000019,,,6,,CHEMBL875080,,Autocuration,,567,,H,104698,1,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,
3395,,BAO_0000019,,,6,,CHEMBL619424,,Autocuration,,13267,,H,104698,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,
3396,,BAO_0000249,,,6,,CHEMBL619425,,Autocuration,,14826,,H,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,
3397,,BAO_0000223,,,6,,CHEMBL619426,,Autocuration,,15194,,H,104698,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,
3398,,BAO_0000223,,,6,,CHEMBL619427,,Autocuration,,15194,,H,104698,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,
3399,Rattus norvegicus,BAO_0000223,,,7,,CHEMBL619645,,Autocuration,,10394,,D,104698,1,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,10116.0
3400,,BAO_0000249,,,9,,CHEMBL619646,,Expert,,13657,,D,10576,1,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,
3401,,BAO_0000221,955.0,,8,Brain,CHEMBL619647,,Autocuration,,1879,,H,12020,1,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,
3402,,BAO_0000019,,,8,,CHEMBL619648,,Autocuration,,1879,,H,12020,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,
3403,,BAO_0000019,,,8,,CHEMBL619165,,Autocuration,,1879,,H,12020,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,
3404,,BAO_0000218,,,8,,CHEMBL620719,,Autocuration,In vivo,204,,H,12020,1,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,
3405,,BAO_0000019,,,8,,CHEMBL872924,,Autocuration,,1879,,H,12020,1,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,
3406,,BAO_0000357,,,8,,CHEMBL620720,,Autocuration,,1879,,H,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3407,,BAO_0000019,,,8,,CHEMBL620721,,Autocuration,,1879,,H,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,
3408,,BAO_0000019,,,8,,CHEMBL620722,,Autocuration,,1879,,H,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,
3409,,BAO_0000019,,,6,,CHEMBL620723,,Autocuration,,10641,,H,104698,1,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,
3410,,BAO_0000019,,,8,,CHEMBL620724,,Autocuration,,773,,H,12020,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,
3411,,BAO_0000249,,,6,,CHEMBL620725,,Autocuration,,11952,,H,104698,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,
3412,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL620726,,Autocuration,,14145,,D,12020,1,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,10116.0
3413,,BAO_0000357,,,8,,CHEMBL620727,,Expert,,17066,,H,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3414,,BAO_0000223,,,4,,CHEMBL620728,,Autocuration,,6398,,H,104714,1,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,
3415,,BAO_0000019,,,0,,CHEMBL620729,,Autocuration,,10321,,U,22226,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,
3416,,BAO_0000019,,,4,,CHEMBL858288,,Autocuration,,511,,H,104714,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,
3417,,BAO_0000223,,,4,,CHEMBL620730,,Autocuration,,4639,,H,104714,1,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3418,,BAO_0000223,,,4,,CHEMBL620731,,Autocuration,,4639,,H,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3419,Cavia porcellus,BAO_0000019,,,4,,CHEMBL620732,,Autocuration,,4639,,H,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,10141.0
3420,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618042,,Autocuration,,4639,,H,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0
3421,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618043,,Autocuration,,4639,,H,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,10141.0
3422,,BAO_0000223,,,4,,CHEMBL618044,,Autocuration,,1558,,H,104714,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,
3423,,BAO_0000019,,,4,,CHEMBL618045,,Autocuration,,268,,H,104714,1,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,
3424,,BAO_0000223,,,4,,CHEMBL618046,,Autocuration,,2474,,H,104714,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,
3425,,BAO_0000019,,,4,,CHEMBL618047,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,
3426,,BAO_0000019,,,4,,CHEMBL875084,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,
3427,,BAO_0000019,,,4,,CHEMBL618048,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,
3428,,BAO_0000223,,,4,,CHEMBL618049,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,
3429,,BAO_0000019,,,4,,CHEMBL619764,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,
3430,,BAO_0000019,,,4,,CHEMBL619765,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,
3431,,BAO_0000019,,,4,,CHEMBL619766,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,
3432,,BAO_0000223,,,4,,CHEMBL619767,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,
3433,,BAO_0000223,,,4,,CHEMBL619768,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,
3434,,BAO_0000019,,,4,,CHEMBL619769,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,
3435,,BAO_0000223,,,4,,CHEMBL619770,,Autocuration,,5067,,H,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,
3436,,BAO_0000223,,,4,,CHEMBL619771,,Autocuration,,5067,,H,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3437,,BAO_0000219,,,4,,CHEMBL619772,,Autocuration,,14331,,H,104714,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,
3438,,BAO_0000223,,,4,,CHEMBL619773,,Autocuration,,5067,,H,104714,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,
3439,,BAO_0000219,,,4,,CHEMBL619774,,Autocuration,,6179,,H,104714,1,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,
3440,,BAO_0000019,,,4,,CHEMBL875083,,Autocuration,,4265,,H,104714,1,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,
3441,,BAO_0000219,,,4,,CHEMBL620718,,Autocuration,,4265,,H,104714,1,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,
3442,,BAO_0000223,,,4,,CHEMBL618127,,Autocuration,,17358,,H,104714,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,
3443,,BAO_0000223,,,4,,CHEMBL618128,,Autocuration,,17358,,H,104714,1,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,
3444,,BAO_0000219,,,4,,CHEMBL618129,,Autocuration,In vitro,13628,,H,104714,1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,
3445,,BAO_0000223,,,4,,CHEMBL618130,,Autocuration,,4612,,H,104714,1,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,
3446,,BAO_0000019,,,4,,CHEMBL618131,,Autocuration,,17358,,H,104714,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,
3447,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618132,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,10141.0
3448,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618133,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,10141.0
3449,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618134,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,10141.0
3450,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618135,,Autocuration,,4639,,H,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0
3451,,BAO_0000223,,,4,,CHEMBL618136,,Autocuration,,511,,H,104714,1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,
3452,,BAO_0000223,,,4,,CHEMBL618137,,Autocuration,,1479,,H,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3453,,BAO_0000223,,,4,,CHEMBL618138,,Autocuration,,1317,,H,104714,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,
3454,,BAO_0000223,,,4,,CHEMBL618139,,Autocuration,,12146,,H,104714,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,
3455,,BAO_0000223,,,4,,CHEMBL618140,,Autocuration,,12146,,H,104714,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,
3456,,BAO_0000223,,,4,,CHEMBL618141,,Autocuration,,13969,,H,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,
3457,,BAO_0000357,,,8,,CHEMBL873478,,Expert,,13392,,H,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor,B,
3458,,BAO_0000223,,,6,,CHEMBL618142,,Autocuration,,13392,,H,104698,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3459,,BAO_0000357,,,8,,CHEMBL618143,,Autocuration,,14159,,H,144,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,
3460,,BAO_0000357,,,8,,CHEMBL618144,,Autocuration,,1558,,H,144,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,
3461,,BAO_0000357,,,8,,CHEMBL618145,,Autocuration,,16655,,H,144,1,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,
3462,,BAO_0000223,,,4,,CHEMBL618146,,Autocuration,,13020,,H,104714,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,
3463,,BAO_0000223,,,4,,CHEMBL618147,,Autocuration,,13021,,H,104714,1,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,
3464,,BAO_0000223,,,4,,CHEMBL618148,,Autocuration,,13020,,H,104714,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,
3465,,BAO_0000019,,,8,,CHEMBL618149,,Autocuration,,10321,,H,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,
3466,,BAO_0000357,,,8,,CHEMBL872927,,Autocuration,,15818,,H,144,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3467,,BAO_0000357,,,8,,CHEMBL618150,,Autocuration,,15818,,H,144,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3468,,BAO_0000357,,,8,,CHEMBL618151,,Autocuration,,17358,,H,144,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,
3469,,BAO_0000357,,,8,,CHEMBL875094,,Autocuration,,2222,,H,144,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,
3470,,BAO_0000019,,,8,,CHEMBL618152,,Autocuration,,10322,,H,144,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,
3471,,BAO_0000357,,,8,,CHEMBL618153,,Autocuration,,16117,,H,144,1,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,
3472,,BAO_0000357,,,8,,CHEMBL618888,,Autocuration,,17200,,H,144,1,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,
3473,,BAO_0000019,,,8,,CHEMBL618889,,Autocuration,,17358,,H,144,1,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,
3474,,BAO_0000357,,,8,,CHEMBL618890,,Autocuration,,16700,,H,144,1,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,
3475,,BAO_0000019,,,8,,CHEMBL618891,,Autocuration,,1980,,H,144,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,
3476,,BAO_0000019,,,8,,CHEMBL619054,,Autocuration,,1980,,H,144,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,
3477,,BAO_0000223,,,4,,CHEMBL619055,,Autocuration,,12409,,H,104714,1,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,
3478,,BAO_0000357,,,8,,CHEMBL619056,,Autocuration,,4365,,H,144,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,
3479,,BAO_0000019,,,8,,CHEMBL619057,,Autocuration,,4365,,H,144,1,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,
3480,,BAO_0000357,,,8,,CHEMBL619058,,Autocuration,,4365,,H,144,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,
3481,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619059,,Expert,,6769,,D,12020,1,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,10116.0
3482,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619060,,Expert,,6769,,D,12020,1,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,10116.0
3483,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL875095,,Expert,,6769,,D,12020,1,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,10116.0
3484,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619061,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,10141.0
3485,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619062,,Intermediate,,809,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,10141.0
3486,Cavia porcellus,BAO_0000019,,,9,,CHEMBL619063,,Intermediate,,14290,,D,20033,1,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,10141.0
3487,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619064,,Intermediate,,17358,,D,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,10141.0
3488,Cavia porcellus,BAO_0000357,,,9,,CHEMBL619065,,Intermediate,,17358,,D,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,10141.0
3489,Cavia porcellus,BAO_0000221,2116.0,,9,Ileum,CHEMBL619066,,Intermediate,,17358,,D,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,10141.0
3490,,BAO_0000221,2116.0,,8,Ileum,CHEMBL619775,,Autocuration,,17386,,H,10209,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,
3491,,BAO_0000357,,,8,,CHEMBL619776,,Autocuration,,3269,,H,10209,1,Affinity against 5-hydroxytryptamine 7 receptor,B,
3492,Cavia porcellus,BAO_0000224,,,4,,CHEMBL619777,,Autocuration,,7721,,H,104841,1,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0
3493,Cavia porcellus,BAO_0000224,,,4,,CHEMBL619778,,Autocuration,,7721,,H,104841,1,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0
3494,Cavia porcellus,BAO_0000221,2116.0,,4,Ileum,CHEMBL619779,,Autocuration,,9117,,H,104841,1,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,10141.0
3495,Cavia porcellus,BAO_0000224,,,4,,CHEMBL619780,,Autocuration,,7721,,H,104841,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0
3496,Cavia porcellus,BAO_0000224,,,4,,CHEMBL619166,,Autocuration,,7721,,H,104841,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0
3497,Cavia porcellus,BAO_0000019,,,4,,CHEMBL619167,,Autocuration,,15796,,H,104841,1,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0
3498,Cavia porcellus,BAO_0000019,,,4,,CHEMBL619168,,Autocuration,,15796,,H,104841,1,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0
3499,Homo sapiens,BAO_0000219,2081.0,,9,Cardiac atrium,CHEMBL619169,,Expert,,15650,,D,168,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,9606.0
3500,Homo sapiens,BAO_0000219,2081.0,,9,Cardiac atrium,CHEMBL619170,,Expert,,15650,,D,168,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,9606.0
3501,Homo sapiens,BAO_0000019,,,5,,CHEMBL619171,,Autocuration,,6866,,D,104841,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,9606.0
3502,Homo sapiens,BAO_0000219,2081.0,,9,Cardiac atrium,CHEMBL619172,,Expert,,15650,,D,168,1,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,9606.0
3503,Mus musculus,BAO_0000019,,,0,,CHEMBL619173,,Autocuration,,10063,,U,22226,1,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,10090.0
3504,Mus musculus,BAO_0000019,,,0,,CHEMBL619174,,Autocuration,,12665,,U,22226,1,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,10090.0
3505,,BAO_0000019,,,4,,CHEMBL619175,,Autocuration,,7504,,H,104705,1,5-hydroxytryptamine receptor binding affinity was determined in rats,B,
3506,,BAO_0000224,,,4,,CHEMBL619176,,Autocuration,,7504,,H,104705,1,Binding affinity at rat 5-hydroxytryptamine receptor.,B,
3507,,BAO_0000019,,,4,,CHEMBL619177,,Autocuration,,7038,,H,104705,1,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,
3508,,BAO_0000224,,,4,,CHEMBL619178,,Autocuration,,7626,,H,104705,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,
3509,,BAO_0000224,,,4,,CHEMBL619179,,Autocuration,,7626,,H,104705,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,
3510,,BAO_0000019,945.0,,4,Stomach,CHEMBL619180,,Autocuration,,7185,,H,104705,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,
3511,,BAO_0000019,945.0,,4,Stomach,CHEMBL619181,,Autocuration,,7185,,H,104705,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,
3512,,BAO_0000019,,,4,,CHEMBL619182,,Autocuration,,7185,,H,104705,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,
3513,,BAO_0000224,,,4,,CHEMBL619183,,Autocuration,,6960,,H,104705,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,
3514,,BAO_0000224,,,4,,CHEMBL619184,,Autocuration,,6960,,H,104705,1,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,
3515,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL619185,,Autocuration,,12416,,H,10576,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,
3516,,BAO_0000357,,,8,,CHEMBL619186,,Expert,,15753,,H,12198,1,Binding affinity for rat 5-hydroxytryptamine transporter.,B,
3517,,BAO_0000019,,,4,,CHEMBL619187,,Autocuration,,8062,,H,104705,1,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,
3518,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL619188,,Autocuration,,9036,,D,104705,1,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,10116.0
3519,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL619189,,Autocuration,,15067,,D,104705,1,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,10116.0
3520,Rattus norvegicus,BAO_0000019,955.0,,9,Brain,CHEMBL619190,,Expert,,15753,,D,12198,1,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,10116.0
3521,Rattus norvegicus,BAO_0000221,2037.0,,9,Cerebellum,CHEMBL619191,,Expert,,15753,,D,12198,1,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,10116.0
3522,Rattus norvegicus,BAO_0000019,,,5,,CHEMBL619192,,Autocuration,,15295,,D,104705,1,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,10116.0
3523,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL619193,,Autocuration,,6347,,D,104705,1,Percent binding affinity against 5-hydroxytryptamine receptor,B,10116.0
3524,,BAO_0000019,,,0,,CHEMBL619194,,Autocuration,,6763,,U,22226,1,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,
3525,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL619195,,Autocuration,,12092,,D,104705,1,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,10116.0
3526,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL619196,,Autocuration,,1579,,D,104705,1,Affinity against 5-hydroxytryptamine receptor was determined,B,10116.0
3527,Rattus norvegicus,BAO_0000019,945.0,,5,Stomach,CHEMBL619197,,Autocuration,,1579,,D,104705,1,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,10116.0
3528,Homo sapiens,BAO_0000219,,,9,,CHEMBL619198,,Expert,In vitro,5963,,D,121,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0
3529,Homo sapiens,BAO_0000219,,,9,,CHEMBL875081,,Expert,In vitro,5963,,D,121,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0
3530,,BAO_0000357,,,8,,CHEMBL884712,,Autocuration,,5030,,H,18065,1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,
3531,,BAO_0000357,,,8,,CHEMBL884710,,Expert,,15796,,H,121,1,Inhibition of 5-hydroxytryptamine reuptake,B,
3532,,BAO_0000019,,,8,,CHEMBL619199,,Autocuration,,15413,,H,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,
3533,,BAO_0000019,,,8,,CHEMBL619200,,Autocuration,,15413,,H,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,
3534,,BAO_0000019,,,8,,CHEMBL619201,,Autocuration,,15413,,H,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,
3535,,BAO_0000019,,,8,,CHEMBL619202,,Autocuration,,12409,,H,18065,1,Tested for 5-hydroxytryptamine receptor uptake,F,
3536,Homo sapiens,BAO_0000219,,,9,,CHEMBL619203,,Expert,,16909,,D,51,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0
3537,Homo sapiens,BAO_0000019,,,9,,CHEMBL619204,,Expert,,16909,,D,51,1,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,9606.0
3538,Homo sapiens,BAO_0000249,,,8,,CHEMBL619205,,Autocuration,,15629,,H,10576,1,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,9606.0
3539,,BAO_0000357,,,8,,CHEMBL619206,,Autocuration,,15629,,H,10576,1,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,
3540,,BAO_0000249,,,8,,CHEMBL619207,,Expert,,15629,,H,10576,1,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,
3541,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619208,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,
3542,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619209,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,
3543,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619210,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,
3544,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619211,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,
3545,,BAO_0000019,2435.0,,8,Striatum,CHEMBL619212,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,
3546,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620681,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,
3547,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620682,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,
3548,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620683,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,
3549,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620684,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,
3550,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620685,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,
3551,,BAO_0000019,2435.0,,8,Striatum,CHEMBL620686,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,
3552,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620687,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,
3553,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620688,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,
3554,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620689,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,
3555,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620690,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,
3556,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620691,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,
3557,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620692,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,
3558,,BAO_0000019,349.0,,8,Limbic system,CHEMBL620693,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,
3559,,BAO_0000357,,,8,,CHEMBL620694,,Expert,,1274,,H,168,1,Binding affinity against 5-hydroxytryptamine 4 receptor,B,
3560,,BAO_0000019,,,8,,CHEMBL857986,,Autocuration,,17358,,H,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3561,,BAO_0000357,,,8,,CHEMBL620695,,Autocuration,,14532,,H,168,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,
3562,,BAO_0000357,,,8,,CHEMBL620696,,Expert,,16989,,H,168,1,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,
3563,,BAO_0000357,,,8,,CHEMBL620697,,Autocuration,,17200,,H,168,1,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,
3564,,BAO_0000357,,,8,,CHEMBL620698,,Autocuration,,15779,,H,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,
3565,,BAO_0000357,,,8,,CHEMBL620699,,Autocuration,,15779,,H,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,
3566,,BAO_0000357,,,8,,CHEMBL620700,,Autocuration,,15779,,H,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,
3567,,BAO_0000219,,,8,,CHEMBL620701,,Autocuration,,15650,,H,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,
3568,,BAO_0000219,,,8,,CHEMBL875082,,Autocuration,,15650,,H,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,
3569,,BAO_0000219,,,8,,CHEMBL620702,,Autocuration,,15650,,H,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,
3570,,BAO_0000219,,,8,,CHEMBL620703,,Autocuration,,15650,,H,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,
3571,,BAO_0000219,,,8,,CHEMBL620704,,Autocuration,,17046,,H,168,1,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,
3572,,BAO_0000219,,,8,,CHEMBL620705,,Expert,,17046,,H,168,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,
3573,,BAO_0000219,,,8,,CHEMBL620706,,Expert,,15650,,H,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,
3574,,BAO_0000219,,,8,,CHEMBL620707,,Expert,,17046,,H,168,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,
3575,,BAO_0000357,,,8,,CHEMBL620708,,Expert,,17066,,H,10624,1,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,
3576,,BAO_0000357,,,8,,CHEMBL620709,,Autocuration,,17200,,H,105,1,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,
3577,Homo sapiens,BAO_0000357,,,9,,CHEMBL620710,,Expert,,16146,,D,10624,1,Binding affinity against 5-hydroxytryptamine 5A receptor,B,9606.0
3578,,BAO_0000219,,,8,,CHEMBL620711,,Autocuration,,15250,,H,10624,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,
3579,Homo sapiens,BAO_0000357,,,9,,CHEMBL620712,,Expert,,6491,,D,10624,1,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,9606.0
3580,Homo sapiens,BAO_0000357,,,9,,CHEMBL620713,,Expert,,17066,,D,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,9606.0
3581,Homo sapiens,BAO_0000357,,,9,,CHEMBL620714,,Expert,,17066,,D,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,9606.0
3582,Homo sapiens,BAO_0000357,,,9,,CHEMBL620715,,Expert,,4234,,D,10624,1,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,9606.0
3583,,BAO_0000357,,,8,,CHEMBL620716,,Autocuration,,6013,,H,10624,1,Binding affinity towards 5-HT5A receptor,B,
3584,,BAO_0000357,,,8,,CHEMBL620717,,Expert,,17175,,H,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,
3585,,BAO_0000357,,,8,,CHEMBL618072,,Autocuration,,15818,,H,10624,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,
3586,,BAO_0000357,,,8,,CHEMBL857987,,Autocuration,,6166,,H,10624,1,Binding affinity towards cloned human 5-HT5A receptor was determined,B,
3587,,BAO_0000219,,,8,,CHEMBL618073,,Autocuration,,15779,,H,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
3588,,BAO_0000219,,,8,,CHEMBL618074,,Autocuration,,15779,,H,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,
3589,,BAO_0000219,,,8,,CHEMBL618075,,Autocuration,,5213,,H,10624,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,
3590,Mus musculus,BAO_0000357,,,9,,CHEMBL618076,,Expert,,17066,,D,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,10090.0
3591,Mus musculus,BAO_0000357,,,9,,CHEMBL618077,,Expert,,17066,,D,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,10090.0
3592,Mus musculus,BAO_0000357,,,9,,CHEMBL618078,,Expert,,17066,,D,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,10090.0
3593,Mus musculus,BAO_0000357,,,9,,CHEMBL881821,,Expert,,17066,,D,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,10090.0
3594,Mus musculus,BAO_0000357,,,9,,CHEMBL618079,,Expert,,17066,,D,10625,1,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,10090.0
3595,,BAO_0000357,,,8,,CHEMBL618080,,Expert,,17175,,H,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,
3596,,BAO_0000219,,,8,,CHEMBL618081,,Autocuration,,16190,,H,10576,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,
3597,,BAO_0000219,,,8,,CHEMBL618082,,Autocuration,,16190,,H,10626,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,
3598,,BAO_0000357,,,8,,CHEMBL618083,,Expert,,4820,,H,10624,1,Binding affinity towards 5-HT5a receptor,B,
3599,Homo sapiens,BAO_0000357,,,9,,CHEMBL618084,,Expert,,17066,,D,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,9606.0
3600,,BAO_0000357,,,8,,CHEMBL618085,,Expert,,17066,,H,10624,1,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,
3601,,BAO_0000357,,,8,,CHEMBL618086,,Expert,,17175,,H,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,
3602,,BAO_0000357,,,8,,CHEMBL875092,,Autocuration,,16633,,H,10624,1,Binding affinities against 5-hydroxytryptamine 5A receptor,B,
3603,,BAO_0000357,,,8,,CHEMBL618087,,Autocuration,,16633,,H,10624,1,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,
3604,,BAO_0000357,,,8,,CHEMBL872926,,Autocuration,,16700,,H,10624,1,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,
3605,Cavia porcellus,BAO_0000019,,,4,,CHEMBL618088,,Autocuration,,4639,,H,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0
3606,,BAO_0000223,,,4,,CHEMBL618089,,Autocuration,,5486,,H,104714,1,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,
3607,Homo sapiens,BAO_0000357,,,9,,CHEMBL618090,,Expert,,16146,,D,10627,1,Inhibition of human 5-hydroxytryptamine 6 receptor,B,9606.0
3608,Homo sapiens,BAO_0000357,,,9,,CHEMBL618091,,Expert,,17273,,D,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,9606.0
3609,,BAO_0000357,,,8,,CHEMBL618092,,Autocuration,,17687,,H,10627,1,Inhibition against human 5-hydroxytryptamine 6 receptor,B,
3610,Homo sapiens,BAO_0000357,,,9,,CHEMBL618093,,Expert,,6491,,D,10627,1,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,9606.0
3611,,BAO_0000219,,,8,,CHEMBL618094,,Expert,,16190,,H,10627,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,
3612,Homo sapiens,BAO_0000357,,,9,,CHEMBL618095,,Expert,,17066,,D,10627,1,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,9606.0
3613,Homo sapiens,BAO_0000357,,,9,,CHEMBL875093,,Expert,,17066,,D,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,9606.0
3614,Homo sapiens,BAO_0000357,,,9,,CHEMBL618096,,Expert,,17066,,D,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,9606.0
3615,Homo sapiens,BAO_0000357,,,9,,CHEMBL618118,,Expert,,17066,,D,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,9606.0
3616,Homo sapiens,BAO_0000357,,,9,,CHEMBL618119,,Expert,,3555,,D,10627,1,Binding affinity against 5-hydroxytryptamine 6 receptor,B,9606.0
3617,,BAO_0000357,,,8,,CHEMBL618120,,Expert,,5808,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3618,,BAO_0000357,,,8,,CHEMBL618121,,Autocuration,,6013,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3619,,BAO_0000219,,,8,,CHEMBL618122,,Expert,,15818,,H,10627,1,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,
3620,,BAO_0000357,,,8,,CHEMBL618123,,Autocuration,,16209,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,
3621,,BAO_0000219,,,8,,CHEMBL618124,,Expert,,3935,,H,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,
3622,,BAO_0000357,,,8,,CHEMBL618125,,Autocuration,,15818,,H,10627,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3623,Homo sapiens,BAO_0000219,,,9,,CHEMBL618126,,Expert,,3805,,D,10627,1,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,9606.0
3624,,BAO_0000019,,,8,,CHEMBL618236,,Expert,,16441,,H,10627,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,
3625,,BAO_0000019,,,8,,CHEMBL618237,,Expert,,16441,,H,10627,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,
3626,,BAO_0000219,,,8,,CHEMBL618238,,Expert,,6786,,H,10627,1,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,
3627,Homo sapiens,BAO_0000357,,,9,,CHEMBL618239,,Expert,,4234,,D,10627,1,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,9606.0
3628,,BAO_0000019,,,8,,CHEMBL618240,,Autocuration,,17085,,H,10627,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,
3629,,BAO_0000357,,,8,,CHEMBL618241,,Autocuration,,17200,,H,10627,1,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,
3630,,BAO_0000219,,,8,,CHEMBL859399,,Autocuration,,17451,,H,10627,1,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,
3631,,BAO_0000019,,,8,,CHEMBL618242,,Autocuration,,3935,,H,10627,1,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,
3632,,BAO_0000357,,,8,,CHEMBL857991,,Autocuration,,5033,,H,10627,1,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,
3633,,BAO_0000357,,,8,,CHEMBL619951,,Expert,,4540,,H,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,
3634,Homo sapiens,BAO_0000219,,,9,,CHEMBL619952,,Expert,,4540,,D,10627,1,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0
3635,Homo sapiens,BAO_0000219,,,9,,CHEMBL619953,,Expert,,4540,,D,10627,1,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0
3636,,BAO_0000219,,,8,,CHEMBL619954,,Autocuration,,17296,,H,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,
3637,,BAO_0000219,,,8,,CHEMBL619955,,Autocuration,,17296,,H,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,
3638,,BAO_0000219,,,8,,CHEMBL619956,,Autocuration,,17296,,H,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,
3639,,BAO_0000219,,,8,,CHEMBL619957,,Autocuration,,15779,,H,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
3640,,BAO_0000219,,,8,,CHEMBL619958,,Autocuration,,15779,,H,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
3641,,BAO_0000219,,,8,,CHEMBL620627,,Autocuration,,15779,,H,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,
3642,,BAO_0000219,,,8,,CHEMBL620628,,Autocuration,,15779,,H,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,
3643,,BAO_0000219,,,8,,CHEMBL620629,,Autocuration,,15779,,H,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,
3644,,BAO_0000357,,,8,,CHEMBL620630,,Autocuration,,6166,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3645,,BAO_0000219,,,8,,CHEMBL620782,,Autocuration,,17451,,H,10627,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,
3646,,BAO_0000357,,,8,,CHEMBL620783,,Autocuration,,15316,,H,10627,1,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,
3647,,BAO_0000357,,,8,,CHEMBL620784,,Expert,,4199,,H,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,
3648,,BAO_0000219,,,8,,CHEMBL620785,,Expert,,15146,,H,10627,1,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,
3649,,BAO_0000357,,,8,,CHEMBL857992,,Autocuration,,5213,,H,10627,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,
3650,,BAO_0000219,,,8,,CHEMBL620786,,Autocuration,,16429,,H,10627,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,
3651,,BAO_0000219,,,8,,CHEMBL620787,,Autocuration,,14818,,H,10627,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,
3652,,BAO_0000219,,,8,,CHEMBL620788,,Autocuration,,4829,,H,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,
3653,,BAO_0000219,,,8,,CHEMBL620789,,Autocuration,,4829,,H,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,
3654,,BAO_0000219,,,8,,CHEMBL620790,,Autocuration,,4829,,H,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,
3655,,BAO_0000219,,,8,,CHEMBL620791,,Autocuration,,15250,,H,10628,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,
3656,,BAO_0000019,,,8,,CHEMBL620792,,Autocuration,,14423,,H,10628,1,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,
3657,,BAO_0000357,,,8,,CHEMBL620793,,Autocuration,,15086,,H,10628,1,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,
3658,,BAO_0000357,,,8,,CHEMBL620794,,Autocuration,,4342,,H,10628,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,
3659,Homo sapiens,BAO_0000219,,,9,,CHEMBL620795,,Autocuration,,16190,,D,10627,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,9606.0
3660,,BAO_0000357,,,8,,CHEMBL620796,,Expert,,4820,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3661,,BAO_0000357,,,8,,CHEMBL620797,,Autocuration,,4639,,H,10627,1,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,
3662,Homo sapiens,BAO_0000019,,,9,,CHEMBL620798,,Expert,,17066,,D,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,9606.0
3663,,BAO_0000357,,,8,,CHEMBL620799,,Autocuration,,6011,,H,10627,1,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,
3664,,BAO_0000357,,,8,,CHEMBL620800,,Expert,,17066,,H,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3665,,BAO_0000357,,,8,,CHEMBL620801,,Autocuration,,17515,,H,10627,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,
3666,,BAO_0000357,,,8,,CHEMBL875100,,Autocuration,,5014,,H,10627,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,
3667,,BAO_0000357,,,8,,CHEMBL620802,,Autocuration,,4373,,H,10627,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,
3668,,BAO_0000019,,,8,,CHEMBL620803,,Expert,,17066,,H,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,
3669,,BAO_0000019,,,8,,CHEMBL620804,,Expert,,17066,,H,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,
3670,,BAO_0000357,,,8,,CHEMBL620805,,Autocuration,,4373,,H,10627,1,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,
3671,,BAO_0000357,,,8,,CHEMBL620806,,Autocuration,,4687,,H,10627,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,
3672,,BAO_0000357,,,8,,CHEMBL620807,,Autocuration,,16946,,H,10627,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,
3673,,BAO_0000357,,,8,,CHEMBL620808,,Autocuration,,16946,,H,10627,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,
3674,,BAO_0000357,,,8,,CHEMBL620809,,Autocuration,,16633,,H,10627,1,Binding affinities against 5-hydroxytryptamine 6 receptor,B,
3675,,BAO_0000357,,,8,,CHEMBL620810,,Autocuration,,16633,,H,10627,1,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,
3676,Homo sapiens,BAO_0000357,,,9,,CHEMBL620811,,Expert,,17066,,D,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,9606.0
3677,,BAO_0000357,,,8,,CHEMBL620812,,Autocuration,,16700,,H,10627,1,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,
3678,,BAO_0000357,,,8,,CHEMBL620813,,Autocuration,,3269,,H,10627,1,Affinity against 5-hydroxytryptamine 6 receptor,B,
3679,,BAO_0000357,,,8,,CHEMBL620814,,Autocuration,,5486,,H,10627,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,
3680,Homo sapiens,BAO_0000357,,,9,,CHEMBL620815,,Expert,,16146,,D,10209,1,Inhibition of human 5-hydroxytryptamine 7 receptor,B,9606.0
3681,,BAO_0000219,,,8,,CHEMBL620816,,Autocuration,,5014,,H,10209,1,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,
3682,,BAO_0000357,,,8,,CHEMBL620817,,Autocuration,,15463,,H,10209,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,
3683,,BAO_0000357,,,8,,CHEMBL620818,,Autocuration,,3805,,H,10209,1,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,
3684,,BAO_0000219,,,8,,CHEMBL620819,,Expert,,5014,,H,10209,1,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,
3685,Homo sapiens,BAO_0000357,,,9,,CHEMBL620820,,Expert,,6491,,D,10209,1,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,9606.0
3686,,BAO_0000219,,,8,,CHEMBL620821,,Autocuration,,16190,,H,10209,1,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,
3687,Homo sapiens,BAO_0000357,,,9,,CHEMBL620822,,Expert,,17066,,D,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,9606.0
3688,Homo sapiens,BAO_0000357,,,9,,CHEMBL620823,,Expert,,17066,,D,10209,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,9606.0
3689,Homo sapiens,BAO_0000357,,,9,,CHEMBL620824,,Expert,,3555,,D,10209,1,Binding affinity against 5-hydroxytryptamine 7 receptor,B,9606.0
3690,,BAO_0000219,,,8,,CHEMBL620825,,Expert,,6588,,H,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,
3691,,BAO_0000357,,,8,,CHEMBL872930,,Autocuration,,15463,,H,10209,1,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,
3692,,BAO_0000357,,,8,,CHEMBL620826,,Autocuration,,6013,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3693,,BAO_0000357,,,8,,CHEMBL620827,,Autocuration,,16209,,H,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,
3694,,BAO_0000357,,,8,,CHEMBL620828,,Autocuration,,3935,,H,10209,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,
3695,,BAO_0000357,,,8,,CHEMBL620829,,Autocuration,,15818,,H,10209,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,
3696,,BAO_0000219,,,8,,CHEMBL620830,,Expert,,5014,,H,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,
3697,,BAO_0000019,,,8,,CHEMBL620831,,Expert,,16441,,H,10209,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,
3698,,BAO_0000019,,,8,,CHEMBL620832,,Expert,,16441,,H,10209,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,
3699,Homo sapiens,BAO_0000357,,,9,,CHEMBL621548,,Expert,,4234,,D,10209,1,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,9606.0
3700,,BAO_0000019,,,8,,CHEMBL621549,,Autocuration,,17085,,H,10209,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,
3701,,BAO_0000357,,,8,,CHEMBL621550,,Autocuration,,17200,,H,10209,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,
3702,,BAO_0000219,,,8,,CHEMBL621551,,Autocuration,,17451,,H,10209,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,
3703,,BAO_0000019,,,8,,CHEMBL621552,,Autocuration,,17085,,H,10209,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,
3704,,BAO_0000357,,,8,,CHEMBL857077,,Autocuration,,5104,,H,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,
3705,,BAO_0000357,,,8,,CHEMBL618158,,Autocuration,,5104,,H,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,
3706,Homo sapiens,BAO_0000219,,,9,,CHEMBL618159,,Expert,,5033,,D,10209,1,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,9606.0
3707,,BAO_0000219,,,8,,CHEMBL875101,,Autocuration,,5486,,H,10209,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,
3708,Homo sapiens,BAO_0000219,,,9,,CHEMBL618160,,Expert,,4540,,D,10209,1,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,9606.0
3709,,BAO_0000357,,,8,,CHEMBL618161,,Expert,,6166,,H,10209,1,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,
3710,,BAO_0000219,,,8,,CHEMBL618162,,Expert,,17342,,H,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,
3711,,BAO_0000357,,,8,,CHEMBL618163,,Expert,,17342,,H,10209,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,
3712,,BAO_0000357,,,8,,CHEMBL618164,,Autocuration,,17296,,H,10209,1,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,
3713,,BAO_0000219,,,8,,CHEMBL618165,,Expert,,16429,,H,10209,1,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,
3714,,BAO_0000219,,,8,,CHEMBL618166,,Autocuration,,15779,,H,10209,1,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,
3715,,BAO_0000219,,,8,,CHEMBL857989,,Autocuration,,15779,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3716,,BAO_0000219,,,8,,CHEMBL619888,,Autocuration,,15779,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3717,,BAO_0000219,,,8,,CHEMBL619889,,Autocuration,,15779,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3718,,BAO_0000219,,,8,,CHEMBL619890,,Autocuration,,15779,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,
3719,,BAO_0000219,,,8,,CHEMBL619891,,Autocuration,,17451,,H,10209,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,
3720,,BAO_0000219,,,8,,CHEMBL619892,,Autocuration,,4199,,H,10209,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,
3721,,BAO_0000219,,,9,,CHEMBL619893,,Expert,,4199,,D,10209,1,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,
3722,,BAO_0000219,,,8,,CHEMBL619894,,Autocuration,,4199,,H,10209,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,
3723,,BAO_0000219,,,9,,CHEMBL619895,,Intermediate,,3680,,D,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,
3724,,BAO_0000357,,,9,,CHEMBL619896,,Intermediate,,3680,,D,10209,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,
3725,,BAO_0000219,,,8,,CHEMBL619897,,Autocuration,,15316,,H,10209,1,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,
3726,,BAO_0000219,,,8,,CHEMBL619898,,Autocuration,,15146,,H,10209,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,
3727,,BAO_0000219,,,8,,CHEMBL619899,,Expert,,5213,,H,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,
3728,,BAO_0000219,,,8,,CHEMBL619900,,Autocuration,,5213,,H,10209,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,
3729,Homo sapiens,BAO_0000219,,,9,,CHEMBL619901,,Expert,,14818,,D,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,9606.0
3730,,BAO_0000219,,,8,,CHEMBL620580,,Autocuration,,14818,,H,10209,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,
3731,,BAO_0000219,,,8,,CHEMBL620581,,Autocuration,,14818,,H,10209,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,
3732,,BAO_0000219,,,8,,CHEMBL620733,,Autocuration,,4829,,H,10209,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,
3733,Homo sapiens,BAO_0000357,,,9,,CHEMBL620734,,Autocuration,,17200,,D,10209,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,9606.0
3734,Mus musculus,BAO_0000357,,,9,,CHEMBL620735,,Expert,,17066,,D,10022,1,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10090.0
3735,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL620736,,Autocuration,,14025,,H,10209,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,9986.0
3736,,BAO_0000219,,,8,,CHEMBL620737,,Autocuration,,15250,,H,11923,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,
3737,,BAO_0000219,,,8,,CHEMBL620738,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,
3738,,BAO_0000219,,,8,,CHEMBL620739,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,
3739,,BAO_0000219,,,8,,CHEMBL620740,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,
3740,,BAO_0000219,,,8,,CHEMBL620741,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,
3741,,BAO_0000219,,,8,,CHEMBL620742,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,
3742,,BAO_0000219,,,8,,CHEMBL620743,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,
3743,,BAO_0000219,,,8,,CHEMBL620744,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,
3744,,BAO_0000219,,,8,,CHEMBL620745,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,
3745,,BAO_0000219,,,8,,CHEMBL620746,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,
3746,,BAO_0000219,,,8,,CHEMBL620747,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,
3747,,BAO_0000219,,,8,,CHEMBL620748,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,
3748,,BAO_0000219,,,8,,CHEMBL620749,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,
3749,,BAO_0000357,,,8,,CHEMBL620750,,Expert,,17066,,H,11923,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,
3750,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620751,,Expert,,17066,,D,11923,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10116.0
3751,,BAO_0000357,,,8,,CHEMBL620752,,Expert,,17386,,H,11923,1,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,
3752,,BAO_0000019,,,8,,CHEMBL872929,,Autocuration,,14423,,H,11923,1,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,
3753,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620753,,Expert,,15874,,D,11923,1,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,10116.0
3754,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620754,,Expert,,15874,,D,11923,1,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,10116.0
3755,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL620755,,Expert,,16372,,D,11923,1,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,10116.0
3756,,BAO_0000357,,,8,,CHEMBL620756,,Autocuration,,4622,,H,11923,1,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,
3757,,BAO_0000357,,,8,,CHEMBL620757,,Autocuration,,15086,,H,11923,1,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,
3758,,BAO_0000219,,,8,,CHEMBL620758,,Autocuration,,16372,,H,11923,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,
3759,,BAO_0000219,,,8,,CHEMBL620759,,Autocuration,,16372,,H,11923,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,
3760,,BAO_0000219,,,8,,CHEMBL620760,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,
3761,,BAO_0000219,,,8,,CHEMBL620761,,Autocuration,,16372,,H,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,
3762,,BAO_0000221,2116.0,,8,Ileum,CHEMBL620762,,Autocuration,,17386,,H,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,
3763,,BAO_0000221,2116.0,,8,Ileum,CHEMBL620763,,Autocuration,,17386,,H,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,
3764,,BAO_0000221,2116.0,,8,Ileum,CHEMBL620764,,Autocuration,,17386,,H,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,
3765,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL857990,,Expert,,5831,,D,11923,1,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,10116.0
3766,,BAO_0000357,,,8,,CHEMBL620765,,Autocuration,,4342,,H,11923,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,
3767,,BAO_0000357,,,8,,CHEMBL620766,,Expert,,17319,,H,11923,1,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,
3768,,BAO_0000019,1898.0,,8,Hypothalamus,CHEMBL620767,,Expert,,17342,,H,11923,1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,
3769,,BAO_0000357,,,8,,CHEMBL620768,,Autocuration,,17342,,H,11923,1,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,
3770,,BAO_0000249,1898.0,,8,Hypothalamus,CHEMBL619051,,Expert,,3680,,H,11923,1,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,
3771,,BAO_0000357,,,8,,CHEMBL619052,,Expert,,3680,,H,11923,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3772,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619053,,Expert,,17319,,D,11923,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,10116.0
3773,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619703,,Expert,,17319,,D,11923,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,10116.0
3774,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619704,,Autocuration,,17319,,D,11923,1,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,10116.0
3775,,BAO_0000357,,,8,,CHEMBL619851,,Expert,,4820,,H,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3776,,BAO_0000357,,,8,,CHEMBL619852,,Autocuration,,4639,,H,10209,1,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,
3777,,BAO_0000357,,,8,,CHEMBL619853,,Autocuration,,6011,,H,10209,1,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,
3778,Homo sapiens,BAO_0000357,,,9,,CHEMBL619854,,Expert,,17066,,D,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,9606.0
3779,,BAO_0000357,,,8,,CHEMBL619855,,Expert,,17066,,H,10209,1,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,
3780,,BAO_0000357,,,8,,CHEMBL619856,,Autocuration,,17515,,H,10209,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,
3781,,BAO_0000357,,,8,,CHEMBL619857,,Autocuration,,4373,,H,10209,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,
3782,,BAO_0000019,,,8,,CHEMBL619858,,Expert,,17066,,H,10209,1,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,
3783,,BAO_0000357,,,8,,CHEMBL619859,,Autocuration,,4373,,H,10209,1,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,
3784,,BAO_0000357,,,8,,CHEMBL619860,,Autocuration,,4373,,H,10209,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,
3785,,BAO_0000357,,,8,,CHEMBL619861,,Autocuration,,4687,,H,10209,1,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,
3786,,BAO_0000357,,,8,,CHEMBL619862,,Expert,,17342,,H,10209,1,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,
3787,,BAO_0000357,,,8,,CHEMBL619863,,Autocuration,,16946,,H,10209,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,
3788,,BAO_0000357,,,8,,CHEMBL619864,,Autocuration,,16946,,H,10209,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,
3789,,BAO_0000357,,,8,,CHEMBL872928,,Autocuration,,16633,,H,10209,1,Binding affinities against 5-hydroxytryptamine 7 receptor,B,
3790,,BAO_0000357,,,8,,CHEMBL619865,,Autocuration,,16633,,H,10209,1,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,
3791,,BAO_0000357,,,8,,CHEMBL619866,,Expert,,17066,,H,10209,1,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,
3792,,BAO_0000357,,,8,,CHEMBL619867,,Autocuration,,16700,,H,10209,1,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,
3793,,BAO_0000221,2116.0,,8,Ileum,CHEMBL619868,,Autocuration,,17386,,H,10209,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,
3794,,BAO_0000019,,,8,,CHEMBL619869,,Autocuration,,14080,,H,55,1,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,
3795,Homo sapiens,BAO_0000019,,,9,,CHEMBL619870,,Expert,,14080,,D,55,1,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,9606.0
3796,,BAO_0000357,,,8,,CHEMBL619871,,Autocuration,,409,,H,55,1,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,
3797,,BAO_0000357,,,8,,CHEMBL619872,,Autocuration,,409,,H,55,1,In vitro inhibition of human recombinant lipoxygenase enzyme,B,
3798,,BAO_0000357,,,8,,CHEMBL619873,,Autocuration,,409,,H,55,1,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,
3799,,BAO_0000357,178.0,,8,Blood,CHEMBL619874,,Expert,,11090,,H,55,1,Inhibition of 5-lipoxygenase in human whole blood.,B,
3800,,BAO_0000357,178.0,,8,Blood,CHEMBL619875,,Expert,,11090,,H,55,1,Inhibition of 5-lipoxygenase in human whole blood.,B,
3801,,BAO_0000357,,,8,,CHEMBL619876,,Autocuration,,948,,H,55,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,
3802,,BAO_0000357,,,8,,CHEMBL619877,,Autocuration,,948,,H,55,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,
3803,,BAO_0000219,,,8,,CHEMBL619878,,Expert,,13622,,H,55,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,
3804,,BAO_0000019,178.0,,8,Blood,CHEMBL619879,,Autocuration,,13622,,H,55,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,
3805,,BAO_0000357,,,8,,CHEMBL619880,,Autocuration,,9637,,H,55,1,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,
3806,,BAO_0000357,,,8,,CHEMBL619881,,Autocuration,,11320,,H,55,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,
3807,,BAO_0000357,,,8,,CHEMBL619882,,Expert,,11320,,H,55,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,
3808,,BAO_0000357,,,8,,CHEMBL619883,,Autocuration,,6838,,H,55,1,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,
3809,Homo sapiens,BAO_0000357,178.0,,9,Blood,CHEMBL619884,,Expert,,17667,,D,55,1,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,9606.0
3810,,BAO_0000357,,,8,,CHEMBL619885,,Autocuration,,12703,,H,55,1,In vitro potency against human 5-Lipoxygenase,B,
3811,Homo sapiens,BAO_0000019,,,9,,CHEMBL619886,,Expert,,14312,,D,55,1,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,9606.0
3812,,BAO_0000019,178.0,,8,Blood,CHEMBL619887,,Autocuration,,14312,,H,55,1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,
3813,,BAO_0000019,,,8,,CHEMBL875097,,Autocuration,,5364,,H,55,1,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,
3814,,BAO_0000219,,,8,,CHEMBL618001,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,
3815,,BAO_0000219,,,8,,CHEMBL618002,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,
3816,,BAO_0000219,,,8,,CHEMBL618003,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,
3817,,BAO_0000219,,,8,,CHEMBL618004,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,
3818,,BAO_0000219,,,8,,CHEMBL618005,,Autocuration,,12365,,H,55,1,Inhibition of human 5-lipoxygenase in human cells,B,
3819,,BAO_0000357,,,8,,CHEMBL618006,,Expert,,10603,,H,55,1,Inhibition of human neutrophil 5-lipoxygenase,B,
3820,,BAO_0000019,,,8,,CHEMBL875086,,Autocuration,,10501,,H,55,1,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,
3821,,BAO_0000357,178.0,,8,Blood,CHEMBL618007,,Expert,,12281,,H,55,1,Inhibition of 5-lipoxygenase from human whole blood,B,
3822,,BAO_0000357,,,8,,CHEMBL618008,,Autocuration,,2567,,H,55,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,
3823,,BAO_0000219,,,8,,CHEMBL618009,,Autocuration,,2567,,H,55,1,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,
3824,,BAO_0000357,,,8,,CHEMBL618010,,Expert,,10193,,H,55,1,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,
3825,,BAO_0000357,,,8,,CHEMBL618011,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3826,,BAO_0000357,,,8,,CHEMBL618012,,Expert,,13623,,H,55,1,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,
3827,,BAO_0000357,,,8,,CHEMBL882927,,Autocuration,,12780,,H,55,1,Tested against 5-lipoxygenase,B,
3828,,BAO_0000357,,,8,,CHEMBL618013,,Autocuration,,12780,,H,55,1,Tested for activity against 5-Lipoxygenase (5-LO),B,
3829,,BAO_0000357,,,8,,CHEMBL618014,,Autocuration,,12780,,H,55,1,Tested for activity against 5-lipoxygenase,B,
3830,,BAO_0000357,,,8,,CHEMBL618015,,Autocuration,,11966,,H,55,1,Tested for inhibition of 5-HPETE production by human 5-LO,B,
3831,,BAO_0000019,,,8,,CHEMBL618016,,Autocuration,,5364,,H,55,1,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,
3832,,BAO_0000357,,,8,,CHEMBL618017,,Expert,,13165,,H,55,1,Inhibition of Human 5-lipoxygenase,B,
3833,,BAO_0000019,,,8,,CHEMBL618018,,Autocuration,,5364,,H,55,1,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,
3834,,BAO_0000219,,,8,,CHEMBL875087,,Autocuration,,11311,,H,55,1,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,
3835,,BAO_0000219,,,8,,CHEMBL618019,,Autocuration,,11311,,H,55,1,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,
3836,,BAO_0000019,,,8,,CHEMBL618020,,Autocuration,,14863,,H,55,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,
3837,,BAO_0000019,,,8,,CHEMBL618021,,Autocuration,,14863,,H,55,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,
3838,,BAO_0000357,178.0,,8,Blood,CHEMBL618022,,Autocuration,,11087,,H,55,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,
3839,,BAO_0000357,,,8,,CHEMBL618023,,Autocuration,,455,,H,55,1,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,
3840,,BAO_0000357,,,8,,CHEMBL618024,,Autocuration,,13183,,H,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
3841,,BAO_0000019,,,8,,CHEMBL873950,,Expert,,10319,,H,55,1,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,
3842,,BAO_0000357,,,8,,CHEMBL618025,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3843,,BAO_0000219,,,8,,CHEMBL618026,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,
3844,,BAO_0000219,,,8,,CHEMBL618027,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,
3845,,BAO_0000219,,,8,,CHEMBL618028,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,
3846,,BAO_0000219,,,8,,CHEMBL618029,,Autocuration,,951,,H,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,
3847,,BAO_0000357,,,8,,CHEMBL618030,,Expert,,9859,,H,55,1,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,
3848,,BAO_0000357,,,8,,CHEMBL618031,,Expert,,9859,,H,55,1,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,
3849,,BAO_0000357,,,8,,CHEMBL618032,,Autocuration,,9859,,H,55,1,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,
3850,,BAO_0000357,,,8,,CHEMBL618033,,Autocuration,,2567,,H,55,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,
3851,,BAO_0000357,,,8,,CHEMBL618034,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,
3852,,BAO_0000357,,,8,,CHEMBL875088,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3853,,BAO_0000019,,,8,,CHEMBL618035,,Autocuration,,949,,H,55,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,
3854,,BAO_0000019,,,8,,CHEMBL618036,,Autocuration,,949,,H,55,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,
3855,,BAO_0000357,,,8,,CHEMBL618037,,Expert,,10603,,H,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,
3856,,BAO_0000357,,,8,,CHEMBL618038,,Expert,,10603,,H,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,
3857,,BAO_0000019,,,8,,CHEMBL618761,,Autocuration,,10603,,H,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,
3858,,BAO_0000357,,,8,,CHEMBL618762,,Expert,,10603,,H,55,1,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,
3859,,BAO_0000357,,,8,,CHEMBL618763,,Expert,,10603,,H,55,1,Inhibition of lipoxygenase at the concentration of 1 uM,B,
3860,,BAO_0000357,,,8,,CHEMBL618764,,Autocuration,,10193,,H,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,
3861,Homo sapiens,BAO_0000357,,,9,,CHEMBL618765,,Expert,,14580,,D,55,1,Inhibition of 5-Lipoxygenase (5-LOX),B,9606.0
3862,,BAO_0000357,,,8,,CHEMBL618766,,Expert,,11090,,H,17087,1,Inhibition of 5-lipoxygenase in mouse macrophages.,B,
3863,,BAO_0000357,,,8,,CHEMBL618767,,Expert,,11090,,H,17087,1,Inhibition of 5-lipoxygenase in mouse macrophages.,B,
3864,,BAO_0000357,,,8,,CHEMBL619380,,Autocuration,,6339,,H,17087,1,Inhibitory activity against lipoxygenase-2 in mice,B,
3865,,BAO_0000357,,,8,,CHEMBL619381,,Expert,,6339,,H,17087,1,Inhibitory activity against murine lipoxygenase-2.,B,
3866,Mus musculus,BAO_0000357,,,9,,CHEMBL619382,,Expert,,12281,,D,17087,1,Inhibition of 5-lipoxygenase from mouse macrophage,B,10090.0
3867,,BAO_0000357,,,8,,CHEMBL619383,,Autocuration,,11311,,H,17087,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,
3868,Sus scrofa,BAO_0000019,,,8,,CHEMBL619384,,Autocuration,,11089,,H,55,1,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,9823.0
3869,Sus scrofa,BAO_0000019,,,8,,CHEMBL619385,,Autocuration,,10091,,H,55,1,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,9823.0
3870,Oryctolagus cuniculus,BAO_0000019,,,8,,CHEMBL882928,,Autocuration,,14352,,H,55,1,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,9986.0
3871,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL619386,,Expert,,13329,,D,12166,1,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,10116.0
3872,,BAO_0000019,,,8,,CHEMBL619387,,Autocuration,,13329,,H,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,
3873,,BAO_0000019,,,8,,CHEMBL619388,,Autocuration,,13329,,H,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,
3874,,BAO_0000019,,,8,,CHEMBL619389,,Autocuration,,13329,,H,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,
3875,,BAO_0000019,,,8,,CHEMBL619390,,Expert,,13329,,H,12166,1,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,
3876,,BAO_0000019,,,8,,CHEMBL619391,,Expert,,13329,,H,12166,1,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,
3877,,BAO_0000019,,,8,,CHEMBL619392,,Autocuration,,13329,,H,12166,1,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,
3878,,BAO_0000019,,,8,,CHEMBL619393,,Autocuration,,11311,,H,12166,1,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,
3879,,BAO_0000019,,,8,,CHEMBL619394,,Autocuration,,11311,,H,12166,1,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,
3880,,BAO_0000219,,,8,,CHEMBL619395,,Autocuration,,105,,H,12166,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,
3881,,BAO_0000219,,,8,,CHEMBL619396,,Autocuration,,105,,H,12166,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,
3882,,BAO_0000357,,,8,,CHEMBL619397,,Autocuration,,9138,,H,12166,1,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,
3883,,BAO_0000357,,,8,,CHEMBL619398,,Autocuration,,9138,,H,12166,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,
3884,,BAO_0000357,,,8,,CHEMBL619399,,Autocuration,,9138,,H,12166,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,
3885,,BAO_0000357,,,8,,CHEMBL619400,,Autocuration,,14427,,H,12166,1,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,
3886,,BAO_0000019,,,8,,CHEMBL619401,,Autocuration,,13329,,H,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,
3887,,BAO_0000019,,,8,,CHEMBL619402,,Autocuration,,13329,,H,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,
3888,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619403,,Expert,,14427,,D,12166,1,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,10116.0
3889,,BAO_0000357,,,8,,CHEMBL619404,,Autocuration,,14427,,H,12166,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,
3890,,BAO_0000357,,,8,,CHEMBL619405,,Autocuration,,14427,,H,12166,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,
3891,,BAO_0000219,,,8,,CHEMBL619406,,Expert,,10293,,H,12166,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,
3892,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL619407,,Expert,,338,,D,12166,1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,10116.0
3893,,BAO_0000357,,,8,,CHEMBL619408,,Autocuration,,303,,H,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,
3894,,BAO_0000219,,,8,,CHEMBL619409,,Autocuration,,303,,H,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,
3895,,BAO_0000219,,,8,,CHEMBL619410,,Expert,,9247,,H,12166,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,
3896,,BAO_0000219,,,8,,CHEMBL619753,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,
3897,,BAO_0000219,,,8,,CHEMBL619754,,Autocuration,,137,,H,12166,1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,
3898,,BAO_0000357,,,8,,CHEMBL619903,,Expert,,11481,,H,12166,1,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,
3899,,BAO_0000357,,,8,,CHEMBL619904,,Expert,,11481,,H,12166,1,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,
3900,,BAO_0000357,,,8,,CHEMBL619905,,Expert,,9029,,H,12166,1,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,
3901,,BAO_0000019,,,8,,CHEMBL619906,,Autocuration,,1701,,H,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,
3902,,BAO_0000019,,,8,,CHEMBL619907,,Autocuration,,1701,,H,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,
3903,,BAO_0000019,,,8,,CHEMBL619908,,Autocuration,,1701,,H,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,
3904,,BAO_0000019,,,8,,CHEMBL619909,,Autocuration,,1701,,H,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,
3905,,BAO_0000219,,,8,,CHEMBL619910,,Expert,,13358,,H,12166,1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,
3906,,BAO_0000219,,,8,,CHEMBL882929,,Expert,,1175,,H,12166,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,
3907,,BAO_0000219,,,8,,CHEMBL619911,,Expert,,8797,,H,12166,1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,
3908,,BAO_0000019,,,8,,CHEMBL619912,,Autocuration,,8797,,H,12166,1,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,
3909,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL619913,,Expert,,577,,D,12166,1,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,10116.0
3910,,BAO_0000219,,,8,,CHEMBL619914,,Expert,,9295,,H,12166,1,In vitro inhibitory activity against RBL-1 5-LO,B,
3911,,BAO_0000219,,,8,,CHEMBL619915,,Autocuration,,9295,,H,12166,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,
3912,,BAO_0000219,,,8,,CHEMBL619916,,Autocuration,,9295,,H,12166,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,
3913,,BAO_0000218,,,8,,CHEMBL619917,,Autocuration,,9295,,H,12166,1,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,
3914,,BAO_0000357,,,8,,CHEMBL619918,,Autocuration,,9295,,H,12166,1,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,
3915,,BAO_0000218,,,8,,CHEMBL619919,,Autocuration,,216,,H,12166,1,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,
3916,,BAO_0000219,,,8,,CHEMBL883710,,Autocuration,,11090,,H,12166,1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,
3917,,BAO_0000019,178.0,,8,Blood,CHEMBL619920,,Autocuration,,11090,,H,12166,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,
3918,,BAO_0000357,,,8,,CHEMBL619921,,Expert,,10091,,H,12166,1,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,
3919,,BAO_0000019,,,8,,CHEMBL619922,,Autocuration,,10274,,H,12166,1,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,
3920,,BAO_0000219,,,8,,CHEMBL619923,,Autocuration,,13622,,H,12166,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,
3921,,BAO_0000219,,,8,,CHEMBL619924,,Expert,,12118,,H,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,
3922,,BAO_0000357,,,8,,CHEMBL619925,,Expert,,12576,,H,12166,1,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,
3923,,BAO_0000219,,,8,,CHEMBL619926,,Expert,,9546,,H,12166,1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,
3924,,BAO_0000219,,,8,,CHEMBL619927,,Autocuration,,9521,,H,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,
3925,,BAO_0000219,,,8,,CHEMBL619928,,Expert,,10626,,H,12166,1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,
3926,,BAO_0000219,,,8,,CHEMBL619929,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase,B,
3927,,BAO_0000219,,,8,,CHEMBL875089,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,
3928,,BAO_0000219,,,8,,CHEMBL619930,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,
3929,,BAO_0000219,,,8,,CHEMBL619931,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,
3930,,BAO_0000219,,,8,,CHEMBL619932,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,
3931,,BAO_0000219,,,8,,CHEMBL619933,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,
3932,,BAO_0000219,,,8,,CHEMBL619934,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,
3933,,BAO_0000219,,,8,,CHEMBL619935,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,
3934,,BAO_0000219,,,8,,CHEMBL619936,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,
3935,,BAO_0000219,,,8,,CHEMBL619937,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,
3936,,BAO_0000219,,,8,,CHEMBL619938,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,
3937,,BAO_0000219,,,8,,CHEMBL619939,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,
3938,,BAO_0000219,,,8,,CHEMBL619940,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,
3939,,BAO_0000219,,,8,,CHEMBL875090,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,
3940,,BAO_0000219,,,8,,CHEMBL619941,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,
3941,,BAO_0000219,,,8,,CHEMBL619942,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,
3942,,BAO_0000219,,,8,,CHEMBL883711,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,
3943,,BAO_0000219,,,8,,CHEMBL619943,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,
3944,,BAO_0000219,,,8,,CHEMBL619944,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,
3945,,BAO_0000219,,,8,,CHEMBL619945,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,
3946,,BAO_0000219,,,8,,CHEMBL619946,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,
3947,,BAO_0000219,,,8,,CHEMBL619947,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,
3948,,BAO_0000219,,,8,,CHEMBL619948,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,
3949,,BAO_0000219,,,8,,CHEMBL619949,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,
3950,,BAO_0000019,,,8,,CHEMBL619950,,Expert,,9401,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,
3951,,BAO_0000019,,,8,,CHEMBL618050,,Autocuration,,10325,,H,12166,1,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,
3952,,BAO_0000219,,,8,,CHEMBL875091,,Expert,,1556,,H,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,
3953,,BAO_0000219,,,8,,CHEMBL618051,,Expert,,1556,,H,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,
3954,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618052,,Expert,,961,,D,12166,1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,10116.0
3955,,BAO_0000019,,,8,,CHEMBL618053,,Autocuration,,6838,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,
3956,,BAO_0000019,,,8,,CHEMBL618054,,Expert,,10325,,H,12166,1,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,
3957,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618055,,Expert,,9209,,D,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,10116.0
3958,,BAO_0000219,,,8,,CHEMBL618056,,Expert,,11520,,H,12166,1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,
3959,,BAO_0000357,,,8,,CHEMBL618057,,Autocuration,,137,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined,B,
3960,,BAO_0000219,,,8,,CHEMBL618058,,Autocuration,,4717,,H,12166,1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,
3961,,BAO_0000219,,,8,,CHEMBL618059,,Expert,,10636,,H,12166,1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,
3962,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL618060,,Expert,,14312,,D,12166,1,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,10116.0
3963,,BAO_0000219,,,8,,CHEMBL618061,,Autocuration,,1203,,H,12166,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,
3964,,BAO_0000019,,,8,,CHEMBL618062,,Autocuration,,1203,,H,12166,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,
3965,,BAO_0000219,,,8,,CHEMBL618063,,Expert,,13622,,H,12166,1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,
3966,,BAO_0000357,,,8,,CHEMBL618064,,Autocuration,,9793,,H,12166,1,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,
3967,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618065,,Expert,,1143,,D,12166,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,10116.0
3968,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618066,,Expert,,11854,,D,12166,1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,10116.0
3969,,BAO_0000219,,,8,,CHEMBL618067,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
3970,,BAO_0000219,,,8,,CHEMBL618068,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,
3971,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618069,,Expert,,10501,,D,12166,1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,10116.0
3972,,BAO_0000219,,,8,,CHEMBL618070,,Expert,,12526,,H,12166,1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
3973,,BAO_0000019,349.0,,8,Limbic system,CHEMBL618071,,Autocuration,,10034,,H,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,
3974,,BAO_0000019,349.0,,8,Limbic system,CHEMBL619247,,Autocuration,,10034,,H,10825,1,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,
3975,,BAO_0000019,,,8,,CHEMBL619248,,Autocuration,,10034,,H,10825,1,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,
3976,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL619249,,Autocuration,,10046,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,
3977,,BAO_0000221,10000000.0,,8,Hippocampus,CHEMBL619250,,Autocuration,,10046,,H,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,
3978,,BAO_0000019,,,8,,CHEMBL619251,,Autocuration,,10046,,H,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,
3979,Canis lupus familiaris,BAO_0000019,178.0,,8,Blood,CHEMBL619252,,Autocuration,,12079,,H,55,1,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,9615.0
3980,,BAO_0000019,178.0,,8,Blood,CHEMBL619253,,Autocuration,,12079,,H,55,1,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,
3981,,BAO_0000219,,,8,,CHEMBL619254,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,
3982,,BAO_0000219,,,8,,CHEMBL619255,,Expert,,12338,,H,17140,1,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,
3983,,BAO_0000219,,,8,,CHEMBL619256,,Expert,,12143,,H,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,
3984,,BAO_0000219,,,8,,CHEMBL875418,,Autocuration,,12143,,H,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,
3985,,BAO_0000219,,,8,,CHEMBL619257,,Expert,,12143,,H,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,
3986,,BAO_0000219,,,8,,CHEMBL619258,,Autocuration,,12143,,H,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,
3987,,BAO_0000357,,,8,,CHEMBL619259,,Expert,,12365,,H,17140,1,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,
3988,,BAO_0000357,,,8,,CHEMBL619260,,Expert,,13500,,H,17140,1,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,
3989,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619261,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3990,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619263,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3991,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619264,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3992,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619265,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3993,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619266,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3994,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619902,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3995,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620058,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3996,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620059,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3997,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620060,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3998,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620061,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
3999,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620062,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4000,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620063,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4001,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620064,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4002,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620065,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4003,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620066,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4004,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620067,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4005,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620068,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4006,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620069,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4007,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620070,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4008,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620071,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4009,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620072,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4010,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620036,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4011,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL857702,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4012,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620037,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4013,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620038,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4014,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620039,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4015,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620040,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4016,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620041,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4017,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620042,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4018,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620043,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4019,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620044,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4020,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620045,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4021,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620046,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4022,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620047,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4023,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620048,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0
4024,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL857703,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4025,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620049,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0
4026,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620050,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4027,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL620051,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4028,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619213,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4029,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619214,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4030,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619804,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4031,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619805,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0
4032,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619806,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4033,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619807,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4034,Canis lupus familiaris,BAO_0000218,178.0,,8,Blood,CHEMBL619808,,Autocuration,In vivo,12832,,H,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0
4035,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL619809,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,9615.0
4036,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL619810,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,9615.0
4037,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL619811,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,9615.0
4038,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL620769,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,9615.0
4039,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL620770,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,9615.0
4040,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL620771,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,9615.0
4041,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL620772,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,9615.0
4042,Canis lupus familiaris,BAO_0000218,,,8,,CHEMBL620773,,Autocuration,,3595,,H,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,9615.0
4043,Cavia porcellus,BAO_0000357,,,8,,CHEMBL620774,,Autocuration,,9203,,H,55,1,Ability to inhibit 5-lipoxygenase in guinea pig,B,10141.0
4044,Cavia porcellus,BAO_0000357,,,8,,CHEMBL620775,,Expert,,82,,H,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,10141.0
4045,Cavia porcellus,BAO_0000357,,,8,,CHEMBL620776,,Autocuration,,11090,,H,55,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,10141.0
4046,Cavia porcellus,BAO_0000218,178.0,,8,Blood,CHEMBL620777,,Autocuration,,12832,,H,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,10141.0
4047,Cavia porcellus,BAO_0000357,,,8,,CHEMBL620778,,Autocuration,,1065,,H,55,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,10141.0
4048,Cavia porcellus,BAO_0000357,,,8,,CHEMBL620779,,Autocuration,,1065,,H,55,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,10141.0
4049,Cavia porcellus,BAO_0000019,,,8,,CHEMBL621500,,Expert,,12832,,H,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0
4050,Cavia porcellus,BAO_0000019,,,8,,CHEMBL621501,,Expert,,12832,,H,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0
4051,Cavia porcellus,BAO_0000019,,,8,,CHEMBL618098,,Autocuration,,12832,,H,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0
4052,Cavia porcellus,BAO_0000019,,,8,,CHEMBL618099,,Autocuration,,10504,,H,55,1,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,10141.0
4053,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618100,,Autocuration,,7788,,H,55,1,Inhibitory activity against 5-lipoxygenase,B,10141.0
4054,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618101,,Autocuration,,10001,,H,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,10141.0
4055,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618102,,Autocuration,,10193,,H,55,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,10141.0
4056,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618103,,Autocuration,,13243,,H,55,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,10141.0
4057,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618104,,Autocuration,,13243,,H,55,1,Inhibitory activity uM,B,10141.0
4058,Cavia porcellus,BAO_0000219,,,8,,CHEMBL883712,,Autocuration,,969,,H,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,10141.0
4059,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618105,,Autocuration,,10001,,H,55,1,Inhibitory activity against 5-lipoxygenase at 10 uM,B,10141.0
4060,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618106,,Autocuration,,7788,,H,55,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,10141.0
4061,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618107,,Autocuration,,10001,,H,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,10141.0
4062,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618108,,Autocuration,,10193,,H,55,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,10141.0
4063,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618109,,Autocuration,,13243,,H,55,1,Inhibitory activity uM,B,10141.0
4064,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618110,,Autocuration,,13243,,H,55,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,10141.0
4065,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618111,,Expert,,13243,,H,55,1,Inhibitory activity uM,B,10141.0
4066,Cavia porcellus,BAO_0000019,,,8,,CHEMBL618112,,Autocuration,,13243,,H,55,1,Inhibitory activity uM,F,10141.0
4067,Cavia porcellus,BAO_0000019,,,8,,CHEMBL618113,,Autocuration,,10504,,H,55,1,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,10141.0
4068,Cavia porcellus,BAO_0000357,,,8,,CHEMBL618114,,Autocuration,,7788,,H,55,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,10141.0
4069,Cavia porcellus,BAO_0000221,2116.0,,8,Ileum,CHEMBL620871,,Expert,,10546,,H,55,1,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,10141.0
4070,,BAO_0000357,,,8,,CHEMBL620872,,Autocuration,,13183,,H,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
4071,,BAO_0000357,,,8,,CHEMBL620873,,Autocuration,,13183,,H,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
4072,,BAO_0000357,,,8,,CHEMBL620874,,Autocuration,,2578,,H,55,1,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,
4073,,BAO_0000357,,,8,,CHEMBL620875,,Expert,,12780,,H,55,1,In vitro inhibition of human 5-Lipoxygenase.,B,
4074,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620876,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,10116.0
4075,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620877,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,10116.0
4076,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL857854,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,10116.0
4077,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620878,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,10116.0
4078,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620879,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,10116.0
4079,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620880,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0
4080,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620881,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0
4081,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620882,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,10116.0
4082,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620883,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,10116.0
4083,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620884,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,10116.0
4084,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620885,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,10116.0
4085,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620886,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,10116.0
4086,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620887,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,10116.0
4087,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618039,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0
4088,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618040,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,10116.0
4089,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618041,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0
4090,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618216,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0
4091,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618217,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0
4092,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618218,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,10116.0
4093,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618219,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,10116.0
4094,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618220,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,10116.0
4095,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618221,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,10116.0
4096,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618222,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,10116.0
4097,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618223,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,10116.0
4098,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618224,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,10116.0
4099,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618225,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,10116.0
4100,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618226,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,10116.0
4101,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618227,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0
4102,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618228,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,10116.0
4103,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618229,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,10116.0
4104,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618230,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,10116.0
4105,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618231,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,10116.0
4106,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618232,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,10116.0
4107,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618233,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,10116.0
4108,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618234,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0
4109,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618235,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,10116.0
4110,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618115,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,10116.0
4111,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618116,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,10116.0
4112,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL618117,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,10116.0
4113,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619968,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,10116.0
4114,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619969,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0
4115,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619970,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,10116.0
4116,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619971,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,10116.0
4117,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619972,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,10116.0
4118,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619973,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,10116.0
4119,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619974,,Autocuration,,7411,,U,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,10116.0
4120,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619975,,Autocuration,,7411,,U,22226,1,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0
4121,Rattus norvegicus,BAO_0000251,,,0,,CHEMBL619976,,Autocuration,,7411,,U,22226,1,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,10116.0
4122,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619977,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0
4123,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619978,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0
4124,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619979,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,10116.0
4125,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619980,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0
4126,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619981,,Autocuration,,7411,,U,22226,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0
4127,Homo sapiens,BAO_0000219,,,1,,CHEMBL619982,,Intermediate,,10797,,N,80433,1,In vitro inhibition of 7226/S myeloma cancer cell line,F,9606.0
4128,Homo sapiens,BAO_0000219,,,1,,CHEMBL619983,,Intermediate,,6881,,N,80698,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,9606.0
4129,Homo sapiens,BAO_0000219,,,1,,CHEMBL620031,,Intermediate,,3838,,N,80640,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,9606.0
4130,Homo sapiens,BAO_0000219,,,1,,CHEMBL620032,,Intermediate,,3838,,N,80640,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,9606.0
4131,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL620033,,Expert,,12981,,N,81264,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,10029.0
4132,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL620034,,Expert,,12981,,N,81264,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,10029.0
4133,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL620035,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,10116.0
4134,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618318,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,10116.0
4135,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618319,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,10116.0
4136,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618320,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,10116.0
4137,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618321,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,10116.0
4138,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL883118,,Intermediate,,7653,,N,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,10116.0
4139,Homo sapiens,BAO_0000219,,,1,,CHEMBL883795,,Intermediate,,17229,,N,80640,1,In vitro antitumor activity against renal 786-0 tumor cell lines,F,9606.0
4140,Homo sapiens,BAO_0000219,,,1,,CHEMBL618322,,Intermediate,,12858,,N,80640,1,Cytotoxic activity against 786-0 Renal cancer cell line,F,9606.0
4141,Homo sapiens,BAO_0000219,,,1,,CHEMBL618323,,Intermediate,,16325,,N,80640,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,9606.0
4142,Homo sapiens,BAO_0000219,,,1,,CHEMBL618324,,Intermediate,,16325,,N,80640,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,9606.0
4143,Homo sapiens,BAO_0000219,,,1,,CHEMBL618325,,Intermediate,,5858,,N,80640,1,In vitro antitumor activity against human renal 786-0 cell line,F,9606.0
4144,Homo sapiens,BAO_0000219,,,1,,CHEMBL875416,,Intermediate,,16325,,N,80640,1,Inhibition of Renal cancer in 786-0 cancer cell lines,F,9606.0
4145,Homo sapiens,BAO_0000219,,,1,,CHEMBL618326,,Intermediate,,14696,,N,80640,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,9606.0
4146,Homo sapiens,BAO_0000219,,,1,,CHEMBL618327,,Intermediate,,3786,,N,80640,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,9606.0
4147,Homo sapiens,BAO_0000219,,,1,,CHEMBL619215,,Intermediate,,14696,,N,80640,1,inhibition of the growth of renal cancer(786-0) cell line,F,9606.0
4148,Homo sapiens,BAO_0000219,,,1,,CHEMBL619216,,Intermediate,,14769,,N,80640,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,9606.0
4149,Homo sapiens,BAO_0000219,,,1,,CHEMBL619217,,Intermediate,,15354,,N,80640,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,9606.0
4150,Homo sapiens,BAO_0000219,,,1,,CHEMBL619218,,Intermediate,,14255,,N,80640,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,9606.0
4151,Homo sapiens,BAO_0000219,,,1,,CHEMBL619219,,Intermediate,,14255,,N,80640,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,9606.0
4152,Homo sapiens,BAO_0000219,,,1,,CHEMBL619220,,Intermediate,,14255,,N,80640,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,9606.0
4153,Homo sapiens,BAO_0000219,,,1,,CHEMBL619221,,Intermediate,,14696,,N,80640,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,9606.0
4154,Homo sapiens,BAO_0000219,,,1,,CHEMBL619222,,Intermediate,,12016,,N,80640,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,9606.0
4155,Homo sapiens,BAO_0000219,,,1,,CHEMBL857454,,Intermediate,,2597,,N,80640,1,Compound was tested for growth inhibitory activity against 786-0 cell line,F,9606.0
4156,,BAO_0000219,,,8,,CHEMBL619223,,Autocuration,,12526,,H,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,
4157,,BAO_0000219,,,8,,CHEMBL619224,,Autocuration,,12526,,H,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,
4158,,BAO_0000019,,,8,,CHEMBL619225,,Autocuration,,14799,,H,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,
4159,,BAO_0000219,,,8,,CHEMBL619226,,Expert,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
4160,,BAO_0000219,,,8,,CHEMBL619227,,Expert,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,
4161,,BAO_0000357,,,8,,CHEMBL619228,,Autocuration,,12767,,H,12166,1,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,
4162,,BAO_0000219,,,8,,CHEMBL619229,,Autocuration,,10997,,H,12166,1,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,
4163,,BAO_0000219,,,8,,CHEMBL619230,,Autocuration,,11388,,H,12166,1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,
4164,,BAO_0000357,,,8,,CHEMBL619231,,Autocuration,,167,,H,12166,1,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,
4165,,BAO_0000357,,,8,,CHEMBL619232,,Autocuration,,167,,H,12166,1,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,
4166,,BAO_0000357,,,8,,CHEMBL619233,,Expert,,13744,,H,12166,1,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,
4167,,BAO_0000357,,,8,,CHEMBL619234,,Autocuration,,1630,,H,12166,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,
4168,,BAO_0000357,,,8,,CHEMBL619235,,Autocuration,,1630,,H,12166,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,
4169,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL619236,,Expert,,969,,D,12166,1,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,10116.0
4170,,BAO_0000219,,,8,,CHEMBL619237,,Autocuration,,13621,,H,12166,1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,
4171,,BAO_0000357,,,8,,CHEMBL619238,,Autocuration,,10089,,H,12166,1,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,
4172,,BAO_0000357,,,8,,CHEMBL619239,,Expert,,10193,,H,12166,1,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,
4173,,BAO_0000357,,,8,,CHEMBL619240,,Autocuration,,11966,,H,12166,1,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,
4174,,BAO_0000019,,,8,,CHEMBL875417,,Autocuration,,12251,,H,12166,1,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,
4175,,BAO_0000219,,,8,,CHEMBL619241,,Autocuration,,211,,H,12166,1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,
4176,,BAO_0000019,,,8,,CHEMBL619242,,Expert,,12251,,H,12166,1,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,
4177,,BAO_0000219,,,8,,CHEMBL883796,,Autocuration,,12495,,H,12166,1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,
4178,,BAO_0000357,,,8,,CHEMBL619243,,Autocuration,,414,,H,12166,1,Tested for its inhibitory activity against 5-lipoxygenase,B,
4179,,BAO_0000357,,,8,,CHEMBL619244,,Autocuration,,414,,H,12166,1,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,
4180,,BAO_0000019,,,8,,CHEMBL619245,,Expert,,10325,,H,12166,1,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,
4181,,BAO_0000019,,,8,,CHEMBL619246,,Expert,,11966,,H,12166,1,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,
4182,,BAO_0000219,,,8,,CHEMBL619984,,Expert,,165,,H,12166,1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4183,,BAO_0000219,,,8,,CHEMBL619985,,Autocuration,,165,,H,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,
4184,,BAO_0000219,,,8,,CHEMBL619986,,Autocuration,,165,,H,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4185,,BAO_0000219,,,8,,CHEMBL619987,,Expert,,165,,H,12166,1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4186,,BAO_0000218,,,8,,CHEMBL619988,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,
4187,,BAO_0000219,,,8,,CHEMBL619989,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,
4188,,BAO_0000219,,,8,,CHEMBL619990,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,
4189,,BAO_0000219,,,8,,CHEMBL619991,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,
4190,,BAO_0000219,,,8,,CHEMBL619992,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,
4191,,BAO_0000218,,,8,,CHEMBL619993,,Autocuration,In vivo,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,
4192,,BAO_0000219,,,8,,CHEMBL619994,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,
4193,,BAO_0000219,,,8,,CHEMBL619995,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,
4194,,BAO_0000019,,,8,,CHEMBL619996,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,
4195,,BAO_0000019,,,8,,CHEMBL619997,,Autocuration,,11732,,H,12166,1,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,
4196,,BAO_0000019,,,8,,CHEMBL619998,,Expert,,11732,,H,12166,1,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,
4197,,BAO_0000019,,,8,,CHEMBL619999,,Expert,,11087,,H,12166,1,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,
4198,,BAO_0000019,,,8,,CHEMBL620000,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,
4199,,BAO_0000219,,,8,,CHEMBL620001,,Autocuration,,11087,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,
4200,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620002,,Expert,,11087,,D,12166,1,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,10116.0
4201,,BAO_0000219,,,8,,CHEMBL620003,,Autocuration,,496,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,
4202,,BAO_0000219,,,8,,CHEMBL620004,,Expert,,13986,,H,12166,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,
4203,,BAO_0000357,,,8,,CHEMBL874063,,Autocuration,,11520,,H,12166,1,Compound was evaluated for the inhibition of 5-lipoxygenase,B,
4204,,BAO_0000219,,,8,,CHEMBL620005,,Autocuration,,10293,,H,12166,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,
4205,,BAO_0000219,,,8,,CHEMBL620006,,Autocuration,,303,,H,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,
4206,,BAO_0000219,,,8,,CHEMBL620007,,Autocuration,,303,,H,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,
4207,,BAO_0000219,,,8,,CHEMBL620008,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,
4208,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL620009,,Expert,,9247,,D,12166,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,10116.0
4209,,BAO_0000219,,,8,,CHEMBL620010,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,
4210,,BAO_0000219,,,8,,CHEMBL620011,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,
4211,,BAO_0000219,,,8,,CHEMBL620677,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,
4212,,BAO_0000219,,,8,,CHEMBL620678,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,
4213,,BAO_0000219,,,8,,CHEMBL620679,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,
4214,,BAO_0000219,,,8,,CHEMBL620680,,Autocuration,,9247,,H,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,
4215,Rattus norvegicus,BAO_0000357,,,9,,CHEMBL620838,,Expert,,11481,,D,12166,1,Inhibitory activity against 5-lipoxygenase at 10 uM,B,10116.0
4216,,BAO_0000357,,,8,,CHEMBL620839,,Autocuration,,105,,H,12166,1,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,
4217,,BAO_0000357,,,8,,CHEMBL620840,,Expert,,9029,,H,12166,1,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,
4218,,BAO_0000219,,,8,,CHEMBL620841,,Expert,,1175,,H,12166,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,
4219,,BAO_0000219,,,8,,CHEMBL620842,,Autocuration,,12118,,H,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,
4220,,BAO_0000219,,,8,,CHEMBL620843,,Autocuration,,12118,,H,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,
4221,,BAO_0000219,,,8,,CHEMBL620844,,Autocuration,,12118,,H,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,
4222,,BAO_0000219,,,8,,CHEMBL620845,,Autocuration,,9225,,H,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,
4223,,BAO_0000019,,,8,,CHEMBL620846,,Autocuration,,9401,,H,12166,1,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,
4224,,BAO_0000357,,,8,,CHEMBL873951,,Autocuration,,137,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,
4225,,BAO_0000357,,,8,,CHEMBL620847,,Autocuration,,137,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,
4226,,BAO_0000219,,,8,,CHEMBL620848,,Autocuration,,4717,,H,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,
4227,,BAO_0000219,,,8,,CHEMBL620849,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,
4228,,BAO_0000219,,,8,,CHEMBL620850,,Autocuration,,10501,,H,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,
4229,,BAO_0000219,,,8,,CHEMBL620851,,Autocuration,,10501,,H,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,
4230,,BAO_0000219,,,8,,CHEMBL620852,,Autocuration,,10501,,H,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,
4231,,BAO_0000219,,,8,,CHEMBL875098,,Autocuration,,12526,,H,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4232,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL620853,,Expert,,14799,,D,12166,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,10116.0
4233,,BAO_0000019,,,8,,CHEMBL620854,,Autocuration,,14799,,H,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,
4234,,BAO_0000219,,,8,,CHEMBL620855,,Autocuration,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,
4235,,BAO_0000219,,,8,,CHEMBL839884,,Expert,,3595,,H,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,
4236,,BAO_0000219,,,8,,CHEMBL620856,,Autocuration,,12526,,H,12166,1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4237,,BAO_0000219,,,8,,CHEMBL620857,,Autocuration,,12526,,H,12166,1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4238,,BAO_0000019,,,8,,CHEMBL620858,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,
4239,,BAO_0000019,,,8,,CHEMBL620859,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,
4240,,BAO_0000019,,,8,,CHEMBL620860,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,
4241,,BAO_0000019,,,8,,CHEMBL620861,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,
4242,,BAO_0000357,,,8,,CHEMBL620862,,Expert,,9138,,H,12166,1,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,
4243,,BAO_0000357,,,8,,CHEMBL620863,,Autocuration,,9138,,H,12166,1,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,
4244,,BAO_0000019,,,8,,CHEMBL620864,,Autocuration,,11966,,H,12166,1,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,
4245,,BAO_0000219,,,8,,CHEMBL620865,,Autocuration,,165,,H,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,
4246,,BAO_0000219,,,8,,CHEMBL620866,,Autocuration,,165,,H,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,
4247,,BAO_0000219,,,8,,CHEMBL620867,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,
4248,,BAO_0000219,,,8,,CHEMBL620868,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,
4249,,BAO_0000219,,,8,,CHEMBL620869,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,
4250,,BAO_0000019,,,8,,CHEMBL873952,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,
4251,,BAO_0000357,,,8,,CHEMBL875099,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of isolated 5-lipoxygenase,B,
4252,,BAO_0000219,,,8,,CHEMBL620870,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,
4253,,BAO_0000019,,,8,,CHEMBL618261,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,
4254,,BAO_0000019,,,8,,CHEMBL618262,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,
4255,,BAO_0000019,,,8,,CHEMBL619428,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,
4256,,BAO_0000019,,,8,,CHEMBL619429,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,
4257,,BAO_0000019,,,8,,CHEMBL619430,,Autocuration,,11087,,H,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,
4258,,BAO_0000219,,,8,,CHEMBL620017,,Autocuration,,496,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,
4259,,BAO_0000219,,,8,,CHEMBL620018,,Autocuration,,496,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,
4260,,BAO_0000219,,,8,,CHEMBL620019,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,
4261,,BAO_0000219,,,8,,CHEMBL620020,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,
4262,,BAO_0000219,,,8,,CHEMBL620021,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,
4263,,BAO_0000219,,,8,,CHEMBL620022,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,
4264,,BAO_0000219,,,8,,CHEMBL620023,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,
4265,,BAO_0000219,,,8,,CHEMBL620024,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,
4266,,BAO_0000219,,,8,,CHEMBL620025,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,
4267,,BAO_0000219,,,8,,CHEMBL620026,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,
4268,,BAO_0000219,,,8,,CHEMBL620027,,Autocuration,,13986,,H,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,
4269,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL620028,,Expert,,13986,,D,12166,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,10116.0
4270,,BAO_0000357,,,8,,CHEMBL620029,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,
4271,,BAO_0000357,,,8,,CHEMBL620030,,Autocuration,,9295,,H,12166,1,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,
4272,,BAO_0000219,,,8,,CHEMBL875415,,Autocuration,,4717,,H,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,
4273,,BAO_0000219,,,8,,CHEMBL618256,,Autocuration,,4717,,H,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,
4274,,BAO_0000219,,,8,,CHEMBL618257,,Autocuration,,11854,,H,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,
4275,,BAO_0000219,,,8,,CHEMBL618258,,Autocuration,,11854,,H,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,
4276,,BAO_0000219,,,8,,CHEMBL618259,,Autocuration,,11854,,H,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,
4277,,BAO_0000019,,,8,,CHEMBL618260,,Autocuration,,10193,,H,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,
4278,,BAO_0000219,,,8,,CHEMBL618215,,Autocuration,,9295,,H,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,
4279,,BAO_0000219,,,8,,CHEMBL618390,,Autocuration,,9295,,H,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,
4280,,BAO_0000219,,,8,,CHEMBL618391,,Autocuration,,9295,,H,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,
4281,,BAO_0000219,,,8,,CHEMBL618392,,Autocuration,,9295,,H,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,
4282,,BAO_0000219,,,8,,CHEMBL618393,,Autocuration,,165,,H,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,
4283,,BAO_0000219,,,8,,CHEMBL618394,,Autocuration,,11311,,H,12166,1,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,
4284,Homo sapiens,BAO_0000219,,,8,,CHEMBL618395,,Expert,,10489,,H,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,9606.0
4285,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL618396,,Expert,,10489,,D,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,10116.0
4286,Rattus norvegicus,BAO_0000219,,,9,,CHEMBL858253,,Expert,,10489,,D,12166,1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,10116.0
4287,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL618397,,Autocuration,,14799,,D,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,10116.0
4288,Glycine max,BAO_0000357,,,8,,CHEMBL618398,,Autocuration,,9295,,H,12054,1,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,3847.0
4289,,BAO_0000019,,,0,,CHEMBL618399,,Autocuration,,16811,,U,22226,1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,
4290,,BAO_0000357,,,8,,CHEMBL618400,,Expert,,168,,H,55,1,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,
4291,,BAO_0000357,,,8,,CHEMBL618401,,Autocuration,,6309,,H,55,1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,
4292,,BAO_0000357,,,8,,CHEMBL618402,,Autocuration,,6309,,H,55,1,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,
4293,,BAO_0000219,,,8,,CHEMBL876400,,Autocuration,,3092,,H,55,1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,
4294,,BAO_0000357,,,8,,CHEMBL618403,,Expert,,168,,H,55,1,Inhibitory activity against 5-lipoxygenase.,B,
4295,,BAO_0000357,,,8,,CHEMBL618404,,Autocuration,,168,,H,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,
4296,,BAO_0000357,,,8,,CHEMBL618405,,Autocuration,,168,,H,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,
4297,,BAO_0000357,,,8,,CHEMBL618406,,Autocuration,,168,,H,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,
4298,,BAO_0000019,,,8,,CHEMBL618407,,Expert,,12338,,H,55,1,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,
4299,,BAO_0000357,,,8,,CHEMBL618408,,Autocuration,,4501,,H,55,1,Tested for the inhibitory activity against 5-lipoxygenase,B,
4300,,BAO_0000357,,,8,,CHEMBL618409,,Autocuration,,1132,,H,55,1,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,
4301,,BAO_0000357,,,8,,CHEMBL618410,,Autocuration,,2117,,H,55,1,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,
4302,,BAO_0000357,,,8,,CHEMBL618411,,Autocuration,,168,,H,55,1,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,
4303,,BAO_0000357,,,8,,CHEMBL618412,,Autocuration,,168,,H,55,1,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,
4304,,BAO_0000219,,,8,,CHEMBL618413,,Autocuration,,13575,,H,12166,1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,
4305,,BAO_0000357,,,8,,CHEMBL618414,,Autocuration,,11089,,H,12166,1,,B,
4306,,BAO_0000357,,,8,,CHEMBL618415,,Autocuration,,216,,H,10102,1,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,
4307,,BAO_0000019,,,8,,CHEMBL618416,,Autocuration,,13165,,H,10102,1,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,
4308,,BAO_0000357,,,8,,CHEMBL876401,,Autocuration,,3278,,H,10102,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,
4309,,BAO_0000357,,,8,,CHEMBL618417,,Expert,,3278,,H,10102,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,
4310,,BAO_0000357,,,8,,CHEMBL618418,,Autocuration,,11966,,H,10102,1,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,
4311,,BAO_0000357,,,8,,CHEMBL618419,,Autocuration,,175,,H,10102,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,
4312,,BAO_0000357,,,8,,CHEMBL618420,,Autocuration,,175,,H,10102,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,
4313,,BAO_0000357,,,8,,CHEMBL618421,,Autocuration,,13449,,H,10102,1,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,
4314,,BAO_0000019,,,8,,CHEMBL618422,,Autocuration,,12014,,H,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,
4315,,BAO_0000019,,,8,,CHEMBL618423,,Autocuration,,12014,,H,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,
4316,,BAO_0000019,,,8,,CHEMBL618424,,Autocuration,,12014,,H,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,
4317,,BAO_0000220,,,2,,CHEMBL618425,,Intermediate,,99,,S,100284,1,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,
4318,Homo sapiens,BAO_0000019,,,0,,CHEMBL618426,,Autocuration,,4349,,U,22226,1,The dark toxicity against 543 human galactophore carcinoma cells,F,9606.0
4319,Homo sapiens,BAO_0000219,,,1,,CHEMBL618427,,Expert,,4071,,N,80623,1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,9606.0
4320,Homo sapiens,BAO_0000219,,,1,,CHEMBL618428,,Expert,,17589,,N,80008,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,9606.0
4321,Homo sapiens,BAO_0000219,,,1,,CHEMBL618429,,Intermediate,,15002,,N,80008,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,9606.0
4322,Homo sapiens,BAO_0000219,,,1,,CHEMBL618430,,Intermediate,,13958,,N,80008,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,9606.0
4323,Homo sapiens,BAO_0000219,,,1,,CHEMBL618431,,Expert,,17589,,N,80008,1,Growth inhibition against human 5637 cell lines,F,9606.0
4324,Homo sapiens,BAO_0000219,,,1,,CHEMBL883799,,Expert,,16748,,N,80008,1,Antitumor activity against human bladder carcinoma 5637 cells.,F,9606.0
4325,Homo sapiens,BAO_0000219,,,1,,CHEMBL618432,,Intermediate,,16747,,N,80008,1,Antitumor activity against human bladder carcinoma 5637 cells,F,9606.0
4326,Homo sapiens,BAO_0000219,,,1,,CHEMBL618433,,Intermediate,,16747,,N,80008,1,Antitumor activity against human bladder carcinoma 5637 cells,F,9606.0
4327,Bos taurus,BAO_0000357,,,9,,CHEMBL618434,,Expert,,15285,,D,10443,1,In vitro inhibition of bovine trypsin(Trp).,B,9913.0
4328,Cercopithecidae,BAO_0000219,,,8,,CHEMBL618435,,Expert,,3726,,H,240,1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,9527.0
4329,,BAO_0000357,,,8,,CHEMBL876402,,Autocuration,,5033,,H,10577,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,
4330,,BAO_0000019,,,6,,CHEMBL618436,,Autocuration,,11756,,H,104698,1,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,
4331,,BAO_0000218,,,0,,CHEMBL618437,,Autocuration,In vivo,11953,,U,22226,1,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,
4332,Cavia porcellus,BAO_0000357,,,9,,CHEMBL618438,,Intermediate,,5033,,D,20033,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,10141.0
4333,Rattus norvegicus,BAO_0000251,,,8,,CHEMBL883800,,Expert,,11347,,H,17045,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,10116.0
4334,Rattus norvegicus,BAO_0000251,,,8,,CHEMBL618439,,Expert,,11347,,H,17045,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,10116.0
4335,,BAO_0000019,,,0,,CHEMBL618440,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,
4336,,BAO_0000019,,,0,,CHEMBL618441,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,
4337,Trypanosoma brucei,BAO_0000019,,,8,,CHEMBL618442,,Expert,,17588,,H,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,5691.0
4338,Trypanosoma brucei,BAO_0000019,,,8,,CHEMBL618443,,Autocuration,,17588,,H,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,5691.0
4339,Ovis aries,BAO_0000019,,,8,,CHEMBL619158,,Expert,,17588,,H,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,9940.0
4340,Ovis aries,BAO_0000019,,,8,,CHEMBL620974,,Autocuration,,17588,,H,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,9940.0
4341,,BAO_0000357,,,8,,CHEMBL620975,,Autocuration,,16485,,H,11938,1,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,
4342,Homo sapiens,BAO_0000019,,,0,,CHEMBL620976,,Intermediate,,4337,,U,22226,1,Average inhibitory concentration against 60 human cell lines was reported,F,9606.0
4343,Homo sapiens,BAO_0000019,,,0,,CHEMBL620977,,Expert,,4112,,U,22226,1,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,9606.0
4344,Homo sapiens,BAO_0000219,,,1,,CHEMBL620978,,Intermediate,,16160,,N,80315,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,9606.0
4345,Homo sapiens,BAO_0000219,,,1,,CHEMBL620979,,Intermediate,,16160,,N,80315,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,9606.0
4346,,BAO_0000219,,,1,,CHEMBL620980,,Expert,,17376,,N,80315,1,In vitro mean growth inhibitory activity against 60-cell panel,F,
4347,,BAO_0000219,,,1,,CHEMBL620981,,Expert,,17376,,N,80315,1,In vitro mean growth lethal concentration against 60-cell panel,F,
4348,,BAO_0000219,,,1,,CHEMBL620982,,Expert,,17376,,N,80315,1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,
4349,,BAO_0000219,,,1,,CHEMBL620983,,Expert,,17376,,N,80315,1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,
4350,,BAO_0000019,,,4,,CHEMBL620984,,Autocuration,,3241,,H,104775,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,
4351,,BAO_0000019,,,4,,CHEMBL620985,,Autocuration,,3241,,H,104775,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,
4352,,BAO_0000357,,,8,,CHEMBL620986,,Expert,,3725,,H,275,1,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,
4353,Plasmodium falciparum,BAO_0000218,,,1,,CHEMBL620987,,Expert,,10805,,N,50425,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,5833.0
4354,Plasmodium falciparum,BAO_0000218,,,1,,CHEMBL620988,,Expert,,10805,,N,50425,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,5833.0
4355,Plasmodium falciparum,BAO_0000218,,,1,,CHEMBL620989,,Expert,,10805,,N,50425,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,5833.0
4356,Plasmodium falciparum,BAO_0000218,,,1,,CHEMBL620990,,Expert,,10805,,N,50425,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,5833.0
4357,Plasmodium falciparum,BAO_0000218,,,1,,CHEMBL620991,,Intermediate,,10805,,N,50425,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,5833.0
4358,Mus musculus,BAO_0000218,,,1,,CHEMBL620992,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,10090.0
4359,Mus musculus,BAO_0000218,,,1,,CHEMBL620993,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,10090.0
4360,Mus musculus,BAO_0000218,,,1,,CHEMBL620994,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,10090.0
4361,Mus musculus,BAO_0000218,,,1,,CHEMBL620995,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,10090.0
4362,Mus musculus,BAO_0000218,,,1,,CHEMBL620996,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,10090.0
4363,Mus musculus,BAO_0000218,,,1,,CHEMBL875581,,Intermediate,,10144,,N,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,10090.0
4364,Mus musculus,BAO_0000218,,,0,,CHEMBL620997,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,10090.0
4365,Mus musculus,BAO_0000218,,,0,,CHEMBL620998,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,10090.0
4366,Mus musculus,BAO_0000218,,,0,,CHEMBL620999,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,10090.0
4367,Mus musculus,BAO_0000218,,,0,,CHEMBL621000,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,10090.0
4368,Mus musculus,BAO_0000218,,,0,,CHEMBL621001,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,10090.0
4369,Mus musculus,BAO_0000218,,,0,,CHEMBL621002,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,10090.0
4370,Mus musculus,BAO_0000218,,,0,,CHEMBL621003,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,10090.0
4371,Mus musculus,BAO_0000218,,,0,,CHEMBL621004,,Autocuration,In vivo,10685,,U,22224,1,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,10090.0
4372,Mus musculus,BAO_0000218,,,0,,CHEMBL621005,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,10090.0
4373,Mus musculus,BAO_0000218,,,0,,CHEMBL621006,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,10090.0
4374,Mus musculus,BAO_0000218,,,0,,CHEMBL621007,,Autocuration,In vivo,10685,,U,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,10090.0
4375,Mus musculus,BAO_0000218,,,0,,CHEMBL621008,,Autocuration,,10144,,U,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,10090.0
4376,Mus musculus,BAO_0000218,,,0,,CHEMBL621009,,Autocuration,,10144,,U,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,10090.0
4377,Mus musculus,BAO_0000218,,,0,,CHEMBL857705,,Autocuration,,10144,,U,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,10090.0
4378,Mus musculus,BAO_0000218,,,0,,CHEMBL619828,,Autocuration,,10144,,U,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,10090.0
4379,Mus musculus,BAO_0000218,,,0,,CHEMBL619829,,Autocuration,,10685,,U,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0
4380,Mus musculus,BAO_0000218,,,0,,CHEMBL619830,,Autocuration,,10685,,U,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,10090.0
4381,Mus musculus,BAO_0000218,,,0,,CHEMBL619831,,Autocuration,,10685,,U,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0
4382,Mus musculus,BAO_0000218,,,0,,CHEMBL619832,,Autocuration,,10685,,U,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0
4383,Mus musculus,BAO_0000218,,,0,,CHEMBL619833,,Autocuration,,10685,,U,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,10090.0
4384,Mus musculus,BAO_0000218,,,0,,CHEMBL619834,,Autocuration,,10685,,U,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,10090.0
4385,Mus musculus,BAO_0000218,,,0,,CHEMBL619835,,Autocuration,,10685,,U,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,10090.0
4386,Mus musculus,BAO_0000218,,,0,,CHEMBL619836,,Autocuration,,10685,,U,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,10090.0
4387,Mus musculus,BAO_0000218,,,1,,CHEMBL619837,,Intermediate,,8831,,N,80628,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,10090.0
4388,,BAO_0000218,,,0,,CHEMBL619838,,Autocuration,In vivo,11704,,U,22224,1,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,
4389,Mus musculus,BAO_0000218,,,1,,CHEMBL619839,,Intermediate,,11704,,N,50594,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,10090.0
4390,Mus musculus,BAO_0000218,,,1,,CHEMBL619840,,Intermediate,In vivo,10685,,N,80628,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,10090.0
4391,Mus musculus,BAO_0000218,,,1,,CHEMBL619841,,Intermediate,In vivo,10685,,N,80628,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,10090.0
4392,Mus musculus,BAO_0000218,,,1,,CHEMBL857704,,Expert,,11368,,N,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,10090.0
4393,Mus musculus,BAO_0000218,,,1,,CHEMBL619842,,Intermediate,,11368,,N,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,10090.0
4394,Mus musculus,BAO_0000218,,,1,,CHEMBL619843,,Expert,,11368,,N,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,10090.0
4395,Staphylococcus aureus,BAO_0000019,,,0,,CHEMBL619844,,Autocuration,,17763,,U,22226,1,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,1280.0
4396,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL857855,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,10116.0
4397,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619845,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,10116.0
4398,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619846,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,10116.0
4399,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619847,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,10116.0
4400,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL619848,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,10116.0
4401,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620893,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,10116.0
4402,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620894,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,10116.0
4403,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620895,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,10116.0
4404,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620896,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,10116.0
4405,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620897,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0
4406,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620898,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,10116.0
4407,Rattus norvegicus,BAO_0000251,2107.0,,0,Liver,CHEMBL620899,,Autocuration,,7411,,U,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,10116.0
4408,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620900,,Autocuration,In vivo,347,,U,22224,1,The apparent total plasma clearance in monkey,A,9527.0
4409,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620901,,Autocuration,In vivo,3341,,U,22224,1,Compound was evaluated for Hepatic clearance in monkey,A,9527.0
4410,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620902,,Autocuration,In vivo,17853,,U,22224,1,Lower clearance in monkey (i.v.) at 0.5 mpk,A,9527.0
4411,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620903,,Autocuration,In vivo,4514,,U,22224,1,Plasma clearance in rhesus monkey,A,9527.0
4412,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620904,,Autocuration,In vivo,6062,,U,22224,1,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,9527.0
4413,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620905,,Autocuration,In vivo,6821,,U,22224,1,Plasma clearance of compound was determined in monkey,A,9527.0
4414,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620906,,Autocuration,In vivo,6057,,U,22224,1,Plasma clearance was calculated in rhesus monkey,A,9527.0
4415,Cercopithecidae,BAO_0000218,,,0,,CHEMBL875420,,Autocuration,In vivo,5145,,U,22224,1,Plasma clearance in rhesus monkey,A,9527.0
4416,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620907,,Autocuration,In vivo,6641,,U,22224,1,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0
4417,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620908,,Autocuration,In vivo,5472,,U,22224,1,Plasma clearance was evaluated in rhesus,A,9527.0
4418,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620909,,Autocuration,In vivo,4257,,U,22224,1,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,9527.0
4419,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620910,,Autocuration,In vivo,5546,,U,22224,1,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0
4420,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620911,,Autocuration,In vivo,5334,,U,22224,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0
4421,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620912,,Autocuration,In vivo,5334,,U,22224,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0
4422,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620913,,Autocuration,In vivo,17509,,U,22224,1,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,9527.0
4423,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620914,,Autocuration,In vivo,6535,,U,22224,1,Cmax in monkey after administration of 1 mg/kg iv,A,9527.0
4424,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620915,,Autocuration,In vivo,5668,,U,22224,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,9527.0
4425,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620916,,Autocuration,In vivo,5922,,U,22224,1,Cmax in cynomolgus monkey by iv administration,A,9527.0
4426,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620917,,Autocuration,In vivo,5922,,U,22224,1,Cmax in cynomolgus monkey by po administration,A,9527.0
4427,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620918,,Autocuration,In vivo,6078,,U,22224,1,Cmax value evaluated in monkey,A,9527.0
4428,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620919,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0
4429,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620920,,Autocuration,In vivo,3249,,U,22224,1,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,9527.0
4430,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620921,,Autocuration,In vivo,3249,,U,22224,1,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,9527.0
4431,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620922,,Autocuration,In vivo,5553,,U,22224,1,Maximal plasma concentration in squirrel monkeys,A,9527.0
4432,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620923,,Autocuration,In vivo,1916,,U,22224,1,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0
4433,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620924,,Autocuration,In vivo,6227,,U,22224,1,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,9527.0
4434,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620925,,Autocuration,In vivo,4809,,U,22224,1,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0
4435,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620926,,Autocuration,In vivo,5355,,U,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,9527.0
4436,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620927,,Autocuration,In vivo,5355,,U,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,9527.0
4437,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620928,,Autocuration,In vivo,5355,,U,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,9527.0
4438,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620929,,Autocuration,In vivo,5355,,U,22224,1,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,9527.0
4439,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL620930,,Autocuration,In vivo,6221,,U,22224,1,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,9527.0
4440,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620931,,Autocuration,,167,,U,22224,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,9527.0
4441,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620932,,Autocuration,,167,,U,22224,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,9527.0
4442,monkey,BAO_0000218,,,0,,CHEMBL620933,,Autocuration,In vivo,4257,,U,22224,1,Absolute bioavailability was evaluated in monkey,A,9443.0
4443,monkey,BAO_0000218,,,0,,CHEMBL620934,,Autocuration,In vivo,6221,,U,22224,1,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,9443.0
4444,monkey,BAO_0000218,,,0,,CHEMBL620935,,Autocuration,In vivo,17667,,U,22224,1,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,9443.0
4445,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620936,,Autocuration,In vivo,17267,,U,22224,1,Bioavailability of compound was determined in rhesus monkey,A,9544.0
4446,marmosets,BAO_0000218,,,0,,CHEMBL620937,,Autocuration,In vivo,4256,,U,22224,1,Bioavailability determined after oral administration in marmoset,A,38020.0
4447,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL620938,,Autocuration,In vivo,4256,,U,22224,1,Oral bioavailability in cynomolgus monkey,A,9541.0
4448,monkey,BAO_0000218,,,0,,CHEMBL620939,,Autocuration,In vivo,17853,,U,22224,1,Bioavailability in monkey (p.o.) at 2.0 mpk,A,9443.0
4449,monkey,BAO_0000218,,,0,,CHEMBL620940,,Autocuration,In vivo,16365,,U,22224,1,Bioavailability was evaluated after oral administration in monkey,A,9443.0
4450,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL620941,,Autocuration,In vivo,1916,,U,22224,1,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9541.0
4451,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620942,,Autocuration,In vivo,5334,,U,22224,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9544.0
4452,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620943,,Autocuration,In vivo,5334,,U,22224,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9544.0
4453,monkey,BAO_0000218,,,0,,CHEMBL620944,,Autocuration,In vivo,17592,,U,22224,1,Bioavailability of the compound was determined in monkey,A,9443.0
4454,Saimiri sciureus,BAO_0000218,,,0,,CHEMBL620945,,Autocuration,In vivo,1399,,U,22224,1,Bioavailability in squirrel monkey (dose 5 mg/kg),A,9521.0
4455,monkey,BAO_0000218,,,0,,CHEMBL620946,,Autocuration,In vivo,4809,,U,22224,1,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9443.0
4456,monkey,BAO_0000218,,,0,,CHEMBL620947,,Autocuration,In vivo,3341,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4457,Saimiri sciureus,BAO_0000218,,,0,,CHEMBL620948,,Autocuration,In vivo,64,,U,22224,1,Compound was tested for bioavailability in squirrel monkey,A,9521.0
4458,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620949,,Autocuration,In vivo,5005,,U,22224,1,Oral bioavailability in Rhesus monkey,A,9544.0
4459,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620950,,Autocuration,In vivo,5005,,U,22224,1,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,9544.0
4460,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL620951,,Autocuration,In vivo,5237,,U,22224,1,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,9541.0
4461,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL620952,,Autocuration,In vivo,5237,,U,22224,1,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,9541.0
4462,monkey,BAO_0000218,,,0,,CHEMBL875421,,Autocuration,In vivo,5302,,U,22224,1,Oral bioavailability in monkey (dose 5 mg/kg),A,9443.0
4463,monkey,BAO_0000218,,,0,,CHEMBL620953,,Autocuration,In vivo,17667,,U,22224,1,Oral bioavailability of compound at 5 mg/kg in monkey,A,9443.0
4464,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873491,,Intermediate,In vivo,6161,,N,50588,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,9615.0
4465,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620954,,Intermediate,In vivo,6161,,N,50588,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,9615.0
4466,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620955,,Intermediate,,3854,,N,50588,1,Plasma half life determined,A,9615.0
4467,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618097,,Intermediate,,993,,N,50588,1,Plasma half life in dog,A,9615.0
4468,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618268,,Intermediate,,4514,,N,50588,1,Plasma half-life in Beagle dogs,A,9615.0
4469,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618269,,Intermediate,In vivo,5334,,N,50588,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0
4470,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618270,,Intermediate,In vivo,5334,,N,50588,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,9615.0
4471,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618271,,Intermediate,In vivo,1466,,N,50588,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0
4472,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873493,,Intermediate,In vivo,1466,,N,50588,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0
4473,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621031,,Intermediate,,5313,,N,50588,1,Tested for the half life period in dog,A,9615.0
4474,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621032,,Intermediate,In vivo,5313,,N,50588,1,Tested for the half life period in dog at dosage of 10 mpk,A,9615.0
4475,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621033,,Intermediate,,3880,,N,50588,1,The compound was tested for half life in dog,A,9615.0
4476,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621034,,Intermediate,,3639,,N,50588,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,9615.0
4477,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621035,,Intermediate,,3880,,N,50588,1,The half life was determined,A,9615.0
4478,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621036,,Intermediate,,3918,,N,50588,1,The plasma half-life in dogs,A,9615.0
4479,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621037,,Intermediate,,16452,,N,50588,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,9615.0
4480,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619812,,Intermediate,,17796,,N,50588,1,Half life in dog,A,9615.0
4481,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619813,,Intermediate,In vivo,5983,,N,50588,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,9615.0
4482,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873335,,Intermediate,In vivo,1466,,N,50588,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0
4483,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619814,,Intermediate,In vivo,16456,,N,50588,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0
4484,Mustela putorius furo,BAO_0000218,,,1,,CHEMBL619815,,Expert,In vivo,6113,,N,50506,1,Cmax in ferrets after 30 mg/kg oral dose,A,9669.0
4485,Mustela putorius furo,BAO_0000218,,,1,,CHEMBL619816,,Expert,In vivo,6113,,N,50506,1,Emesis in ferrets at 30 mg/kg oral dose,F,9669.0
4486,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL619817,,Autocuration,In vivo,17796,,U,22224,1,Bioavailability in cynomolgus monkey,A,9541.0
4487,Macaca fascicularis,BAO_0000218,,,1,,CHEMBL619818,,Intermediate,In vivo,17796,,N,100710,1,Volume of distribution in cynomolgus,A,9541.0
4488,Cavia porcellus,BAO_0000218,1969.0,,0,Plasma,CHEMBL619819,,Autocuration,,5308,,U,22224,1,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,10141.0
4489,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619820,,Autocuration,,4877,,U,22224,1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,10141.0
4490,Cavia porcellus,BAO_0000218,,,0,,CHEMBL875419,,Autocuration,,4876,,U,22224,1,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,10141.0
4491,Cavia porcellus,BAO_0000218,1969.0,,0,Plasma,CHEMBL619821,,Autocuration,In vivo,4878,,U,22224,1,AUC in guinea pig after 3mg/kg oral dose,A,10141.0
4492,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619822,,Autocuration,In vivo,5308,,U,22224,1,Bioavailability in guinea pig was tested,A,10141.0
4493,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619823,,Autocuration,In vivo,4877,,U,22224,1,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,10141.0
4494,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619824,,Autocuration,In vivo,4876,,U,22224,1,Tested for the oral bioavailability of the compound,A,10141.0
4495,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619825,,Autocuration,In vivo,4876,,U,22224,1,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,10141.0
4496,Cavia porcellus,BAO_0000218,,,0,,CHEMBL619826,,Autocuration,In vivo,5308,,U,22224,1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,10141.0
4497,Cavia porcellus,BAO_0000218,2048.0,,0,Lung,CHEMBL619827,,Autocuration,In vivo,4877,,U,22224,1,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,10141.0
4498,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618167,,Autocuration,In vivo,4878,,U,22224,1,Cmax in guinea pig after 3mg/kg oral dose,A,10141.0
4499,Cavia porcellus,BAO_0000019,178.0,,0,Blood,CHEMBL618168,,Autocuration,,5689,,U,22224,1,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4500,Cavia porcellus,BAO_0000019,955.0,,0,Brain,CHEMBL618169,,Autocuration,,5689,,U,22224,1,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4501,Cavia porcellus,BAO_0000019,,,0,,CHEMBL618170,,Autocuration,,5689,,U,22224,1,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4502,Cavia porcellus,BAO_0000019,160.0,,0,Intestine,CHEMBL618171,,Autocuration,,5689,,U,22224,1,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4503,Cavia porcellus,BAO_0000019,2113.0,,0,Kidney,CHEMBL618172,,Autocuration,,5689,,U,22224,1,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4504,Cavia porcellus,BAO_0000019,2107.0,,0,Liver,CHEMBL618173,,Autocuration,,5689,,U,22224,1,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4505,Cavia porcellus,BAO_0000019,,,0,,CHEMBL618174,,Autocuration,,5689,,U,22224,1,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4506,Cavia porcellus,BAO_0000019,2106.0,,0,Spleen,CHEMBL875408,,Autocuration,,5689,,U,22224,1,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0
4507,Cavia porcellus,BAO_0000218,,,0,,CHEMBL839827,,Autocuration,In vivo,14465,,U,22224,1,Elimination T1/2 in Guinea pig (PO dose),A,10141.0
4508,Cavia porcellus,BAO_0000019,,,0,,CHEMBL618175,,Autocuration,,5689,,U,22224,1,Partition coefficient was measured as -log (counts per min ),A,10141.0
4509,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618176,,Autocuration,In vivo,611,,U,22224,1,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,10141.0
4510,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618177,,Autocuration,In vivo,611,,U,22224,1,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,10141.0
4511,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618178,,Autocuration,In vivo,14465,,U,22224,1,Elimination T1/2 in Guinea pig (PO dose),A,10141.0
4512,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618179,,Autocuration,In vivo,4876,,U,22224,1,"Tested for the half life period of the compound, intravenously",A,10141.0
4513,Cavia porcellus,BAO_0000019,,,0,,CHEMBL873489,,Autocuration,,5689,,U,22224,1,Half-life was measured,A,10141.0
4514,Cavia porcellus,BAO_0000019,,,0,,CHEMBL618180,,Autocuration,,7515,,U,22224,1,The time required for onset of inotropy after addition of a single dose of delta F75,A,10141.0
4515,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618181,,Autocuration,In vivo,17667,,U,22224,1,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,10141.0
4516,Cavia porcellus,BAO_0000218,,,0,,CHEMBL618182,,Autocuration,In vivo,17667,,U,22224,1,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,10141.0
4517,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL618183,,Autocuration,In vivo,4727,,U,22224,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,10029.0
4518,Mus musculus,BAO_0000218,,,1,,CHEMBL618184,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
4519,Mus musculus,BAO_0000218,,,1,,CHEMBL618185,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
4520,Mus musculus,BAO_0000218,,,1,,CHEMBL618186,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
4521,Mus musculus,BAO_0000218,,,1,,CHEMBL618187,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
4522,Mus musculus,BAO_0000218,,,1,,CHEMBL618188,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,10090.0
4523,Mus musculus,BAO_0000218,,,1,,CHEMBL875409,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
4524,Mus musculus,BAO_0000218,,,1,,CHEMBL618189,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
4525,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL618190,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,10090.0
4526,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL618191,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,10090.0
4527,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL618192,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,10090.0
4528,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL618193,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,10090.0
4529,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL618194,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,10090.0
4530,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL618195,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,10090.0
4531,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL618196,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,10090.0
4532,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL618197,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,10090.0
4533,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL618198,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,10090.0
4534,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL618199,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,10090.0
4535,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL618200,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,10090.0
4536,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL618201,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,10090.0
4537,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL618202,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,10090.0
4538,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL618203,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,10090.0
4539,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL618204,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,10090.0
4540,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL618205,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,10090.0
4541,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL618206,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,10090.0
4542,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL618207,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,10090.0
4543,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL618208,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,10090.0
4544,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL618932,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,10090.0
4545,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL618933,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,10090.0
4546,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL618934,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,10090.0
4547,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL618935,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,10090.0
4548,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL618936,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,10090.0
4549,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL618937,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,10090.0
4550,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL618938,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,10090.0
4551,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL619104,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,10090.0
4552,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL619105,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,10090.0
4553,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL619106,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,10090.0
4554,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL619107,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,10090.0
4555,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL875410,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,10090.0
4556,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL619108,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,10090.0
4557,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL619109,,Intermediate,In vivo,3655,,N,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,10090.0
4558,Mus musculus,BAO_0000218,,,1,,CHEMBL619110,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,10090.0
4559,Mus musculus,BAO_0000218,,,1,,CHEMBL619111,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,10090.0
4560,Mus musculus,BAO_0000218,,,1,,CHEMBL619112,,Intermediate,In vivo,16597,,N,50594,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
4561,Mus musculus,BAO_0000218,,,1,,CHEMBL619113,,Intermediate,In vivo,16597,,N,50594,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
4562,Mus musculus,BAO_0000218,,,1,,CHEMBL619114,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,10090.0
4563,Mus musculus,BAO_0000218,,,1,,CHEMBL619115,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,10090.0
4564,Homo sapiens,BAO_0000219,,,1,,CHEMBL619116,,Intermediate,,3830,,N,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,9606.0
4565,Homo sapiens,BAO_0000219,,,1,,CHEMBL619117,,Intermediate,,3829,,N,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,9606.0
4566,Homo sapiens,BAO_0000219,,,1,,CHEMBL619118,,Intermediate,,2040,,N,81034,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,9606.0
4567,Homo sapiens,BAO_0000219,,,1,,CHEMBL619119,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,9606.0
4568,Homo sapiens,BAO_0000219,,,1,,CHEMBL619120,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,9606.0
4569,Homo sapiens,BAO_0000219,,,1,,CHEMBL619121,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,9606.0
4570,Homo sapiens,BAO_0000219,,,1,,CHEMBL619122,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,9606.0
4571,Homo sapiens,BAO_0000219,,,1,,CHEMBL619123,,Intermediate,,15684,,N,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,9606.0
4572,Homo sapiens,BAO_0000219,,,1,,CHEMBL619124,,Intermediate,,15684,,N,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,9606.0
4573,Homo sapiens,BAO_0000219,,,1,,CHEMBL619125,,Intermediate,,2859,,N,81034,1,Compound was evaluated for cytotoxicity against A2780 cell line,F,9606.0
4574,Homo sapiens,BAO_0000219,,,1,,CHEMBL875411,,Intermediate,,5618,,N,81034,1,In vitro inhibitory activity against human tumor cell line A2780,F,9606.0
4575,Homo sapiens,BAO_0000219,,,1,,CHEMBL619126,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,9606.0
4576,Homo sapiens,BAO_0000219,,,1,,CHEMBL619127,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,9606.0
4577,Homo sapiens,BAO_0000219,,,1,,CHEMBL619128,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,9606.0
4578,Homo sapiens,BAO_0000219,,,1,,CHEMBL619129,,Intermediate,,15684,,N,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,9606.0
4579,Homo sapiens,BAO_0000219,,,1,,CHEMBL619130,,Intermediate,,2113,,N,81034,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,9606.0
4580,Homo sapiens,BAO_0000219,,,1,,CHEMBL619131,,Intermediate,,2113,,N,81034,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,9606.0
4581,Homo sapiens,BAO_0000219,,,1,,CHEMBL619132,,Intermediate,,16745,,N,81034,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,9606.0
4582,Homo sapiens,BAO_0000218,,,1,,CHEMBL619133,,Expert,,16597,,N,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0
4583,Homo sapiens,BAO_0000219,,,1,,CHEMBL619134,,Intermediate,,15684,,N,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,9606.0
4584,Homo sapiens,BAO_0000219,,,1,,CHEMBL619135,,Intermediate,,15684,,N,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,9606.0
4585,Homo sapiens,BAO_0000219,,,1,,CHEMBL619136,,Intermediate,,2040,,N,81034,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,9606.0
4586,Homo sapiens,BAO_0000219,,,1,,CHEMBL619137,,Intermediate,,2040,,N,81034,1,Relative resistance factor in A2780 cisplatin-resistant line,F,9606.0
4587,Homo sapiens,BAO_0000219,,,1,,CHEMBL883713,,Intermediate,,16165,,N,81034,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,9606.0
4588,Homo sapiens,BAO_0000219,,,1,,CHEMBL875412,,Intermediate,,16165,,N,81034,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,9606.0
4589,Homo sapiens,BAO_0000218,,,1,,CHEMBL619138,,Expert,,16597,,N,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0
4590,Homo sapiens,BAO_0000218,,,1,,CHEMBL619262,,Expert,,16597,,N,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0
4591,Homo sapiens,BAO_0000219,,,1,,CHEMBL619139,,Intermediate,,3992,,N,81034,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,9606.0
4592,Homo sapiens,BAO_0000219,,,1,,CHEMBL619140,,Intermediate,,10553,,N,81034,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,9606.0
4593,Homo sapiens,BAO_0000219,,,1,,CHEMBL619141,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,9606.0
4594,Homo sapiens,BAO_0000219,,,1,,CHEMBL619142,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,9606.0
4595,Homo sapiens,BAO_0000219,,,1,,CHEMBL619143,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,9606.0
4596,Homo sapiens,BAO_0000219,,,1,,CHEMBL619144,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,9606.0
4597,Homo sapiens,BAO_0000219,,,1,,CHEMBL619145,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,9606.0
4598,Homo sapiens,BAO_0000219,,,1,,CHEMBL619146,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,9606.0
4599,Homo sapiens,BAO_0000219,,,1,,CHEMBL619147,,Intermediate,,15569,,N,81034,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,9606.0
4600,Homo sapiens,BAO_0000219,,,1,,CHEMBL619148,,Intermediate,,17420,,N,81034,1,Antiproliferative effect of compound on A2780/DX cell line,F,9606.0
4601,Homo sapiens,BAO_0000219,,,1,,CHEMBL619149,,Intermediate,,17420,,N,81034,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,9606.0
4602,Homo sapiens,BAO_0000219,,,1,,CHEMBL619150,,Intermediate,,15099,,N,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,9606.0
4603,Homo sapiens,BAO_0000219,,,1,,CHEMBL619151,,Intermediate,,15099,,N,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,9606.0
4604,Homo sapiens,BAO_0000219,,,1,,CHEMBL883794,,Intermediate,,17672,,N,81034,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,9606.0
4605,Homo sapiens,BAO_0000219,,,1,,CHEMBL619152,,Intermediate,,17672,,N,81034,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,9606.0
4606,Homo sapiens,BAO_0000219,,,1,,CHEMBL619153,,Intermediate,,17270,,N,81034,1,In vitro cytotoxicity against A2780ADR cell line,F,9606.0
4607,Homo sapiens,BAO_0000219,,,1,,CHEMBL619154,,Intermediate,,17270,,N,81034,1,In vitro cytotoxicity against A2780CIS cell line,F,9606.0
4608,Homo sapiens,BAO_0000219,,,1,,CHEMBL619155,,Intermediate,,5574,,N,81034,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,9606.0
4609,Homo sapiens,BAO_0000219,,,1,,CHEMBL619156,,Intermediate,,2113,,N,81034,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,9606.0
4610,Homo sapiens,BAO_0000219,,,1,,CHEMBL619157,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0
4611,Homo sapiens,BAO_0000219,,,1,,CHEMBL619797,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0
4612,Macaca mulatta,BAO_0000218,,,0,,CHEMBL619798,,Autocuration,In vivo,17839,,U,22224,1,Oral bioavailability of compound in rhesus macaques,A,9544.0
4613,monkey,BAO_0000218,,,0,,CHEMBL619799,,Autocuration,In vivo,6821,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4614,monkey,BAO_0000218,,,0,,CHEMBL619800,,Autocuration,In vivo,6078,,U,22224,1,Oral bioavailability evaluated in monkey,A,9443.0
4615,monkey,BAO_0000218,,,0,,CHEMBL619801,,Autocuration,In vivo,6535,,U,22224,1,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,9443.0
4616,Macaca mulatta,BAO_0000218,,,0,,CHEMBL619802,,Autocuration,In vivo,4449,,U,22224,1,Oral bioavailability in Rhesus monkey,A,9544.0
4617,Macaca mulatta,BAO_0000218,,,0,,CHEMBL619803,,Autocuration,In vivo,6057,,U,22224,1,Oral bioavailability was calculated in rhesus monkey,A,9544.0
4618,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL619965,,Autocuration,In vivo,5922,,U,22224,1,Oral bioavailability in cynomolgus monkey,A,9541.0
4619,monkey,BAO_0000218,,,0,,CHEMBL619966,,Autocuration,In vivo,5940,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4620,monkey,BAO_0000218,,,0,,CHEMBL619967,,Autocuration,In vivo,6265,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4621,monkey,BAO_0000218,,,0,,CHEMBL620073,,Autocuration,In vivo,6265,,U,22224,1,Oral bioavailability in monkey (dose 1 mg/kg),A,9443.0
4622,monkey,BAO_0000218,,,0,,CHEMBL620074,,Autocuration,In vivo,6265,,U,22224,1,Oral bioavailability in monkey (dose 5 mg/kg),A,9443.0
4623,monkey,BAO_0000218,,,0,,CHEMBL620075,,Autocuration,In vivo,5940,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4624,monkey,BAO_0000218,,,0,,CHEMBL620076,,Autocuration,In vivo,5940,,U,22224,1,Oral bioavailability in monkey,A,9443.0
4625,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620077,,Autocuration,In vivo,4514,,U,22224,1,Oral bioavailability in rhesus monkey,A,9544.0
4626,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620078,,Autocuration,In vivo,5546,,U,22224,1,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,9544.0
4627,Saimiri sciureus,BAO_0000218,,,0,,CHEMBL620079,,Autocuration,In vivo,5553,,U,22224,1,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,9521.0
4628,monkey,BAO_0000218,,,0,,CHEMBL620080,,Autocuration,In vivo,6641,,U,22224,1,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9443.0
4629,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620081,,Autocuration,In vivo,5472,,U,22224,1,Oral bioavailability in Rhesus monkey,A,9544.0
4630,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620082,,Autocuration,In vivo,5668,,U,22224,1,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,9544.0
4631,monkey,BAO_0000218,,,0,,CHEMBL620083,,Autocuration,In vivo,5711,,U,22224,1,Oral bioavailability in monkey at 10 mg/kg of the compound,A,9443.0
4632,Macaca mulatta,BAO_0000218,,,0,,CHEMBL620084,,Autocuration,In vivo,5145,,U,22224,1,Bioavailability in Rhesus monkey,A,9544.0
4633,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620085,,Autocuration,,3443,,U,22224,1,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4634,Cercopithecidae,BAO_0000218,,,0,,CHEMBL874595,,Autocuration,,3443,,U,22224,1,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4635,Cercopithecidae,BAO_0000218,,,0,,CHEMBL873352,,Autocuration,In vivo,3249,,U,22224,1,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,9527.0
4636,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620086,,Autocuration,In vivo,3249,,U,22224,1,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,9527.0
4637,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620087,,Autocuration,In vivo,5355,,U,22224,1,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,9527.0
4638,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620088,,Autocuration,In vivo,5355,,U,22224,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0
4639,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620089,,Autocuration,In vivo,5355,,U,22224,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0
4640,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620090,,Autocuration,In vivo,4809,,U,22224,1,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0
4641,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620091,,Autocuration,In vivo,4809,,U,22224,1,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0
4642,Cercopithecidae,BAO_0000251,,,0,,CHEMBL620092,,Autocuration,,14294,,U,22224,1,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,9527.0
4643,Cercopithecidae,BAO_0000251,,,0,,CHEMBL620093,,Autocuration,,14294,,U,22224,1,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,9527.0
4644,Cercopithecidae,BAO_0000251,,,0,,CHEMBL620094,,Autocuration,,14294,,U,22224,1,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,9527.0
4645,Cercopithecidae,BAO_0000251,,,0,,CHEMBL620095,,Autocuration,,14294,,U,22224,1,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,9527.0
4646,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620096,,Autocuration,In vivo,3443,,U,22224,1,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4647,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620097,,Autocuration,In vivo,3443,,U,22224,1,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4648,Cercopithecidae,BAO_0000019,,,0,,CHEMBL620098,,Autocuration,,11271,,U,22224,1,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,9527.0
4649,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620099,,Autocuration,,3443,,U,22224,1,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4650,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620100,,Autocuration,,3443,,U,22224,1,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4651,Cercopithecidae,BAO_0000019,,,0,,CHEMBL620101,,Autocuration,,6821,,U,22224,1,Elimination Half-life of compound was determined in monkey,A,9527.0
4652,Cercopithecidae,BAO_0000019,,,0,,CHEMBL620102,,Autocuration,,17267,,U,22224,1,Half life of compound was determined in rhesus monkey,A,9527.0
4653,Cercopithecidae,BAO_0000366,1969.0,,0,Plasma,CHEMBL620103,,Autocuration,,5819,,U,22224,1,Half life in monkey plasma,A,9527.0
4654,Cercopithecidae,BAO_0000366,1969.0,,0,Plasma,CHEMBL620104,,Autocuration,,5819,,U,22224,1,Half life in monkey plasma; Not detected,A,9527.0
4655,Cercopithecidae,BAO_0000218,,,0,,CHEMBL874596,,Autocuration,In vivo,1916,,U,22224,1,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0
4656,Cercopithecidae,BAO_0000218,,,0,,CHEMBL873490,,Autocuration,In vivo,17509,,U,22224,1,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,9527.0
4657,Cercopithecidae,BAO_0000019,,,0,,CHEMBL620105,,Autocuration,,1399,,U,22224,1,Terminal half life of the compound.,A,9527.0
4658,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620780,,Autocuration,In vivo,1916,,U,22224,1,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0
4659,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620781,,Autocuration,In vivo,4809,,U,22224,1,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0
4660,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620956,,Autocuration,,5546,,U,22224,1,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0
4661,Cercopithecidae,BAO_0000218,1088.0,,0,Urine,CHEMBL620957,,Autocuration,,3443,,U,22224,1,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4662,Cercopithecidae,BAO_0000218,1088.0,,0,Urine,CHEMBL620958,,Autocuration,,3443,,U,22224,1,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4663,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620959,,Autocuration,In vivo,4257,,U,22224,1,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,9527.0
4664,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620960,,Autocuration,In vivo,6221,,U,22224,1,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0
4665,Cercopithecidae,BAO_0000218,,,0,,CHEMBL620961,,Autocuration,In vivo,5472,,U,22224,1,Volume of distribution was evaluated in rhesus,A,9527.0
4666,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL620962,,Autocuration,In vivo,4727,,U,22224,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,10029.0
4667,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL620963,,Autocuration,In vivo,4727,,U,22224,1,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,10029.0
4668,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL620964,,Autocuration,In vivo,4727,,U,22224,1,Bioavailability in hamster was determined,A,10029.0
4669,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL620965,,Autocuration,In vivo,4727,,U,22224,1,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,10029.0
4670,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL620966,,Autocuration,In vivo,4727,,U,22224,1,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,10029.0
4671,Cricetulus griseus,BAO_0000221,178.0,,0,Blood,CHEMBL620967,,Autocuration,,4727,,U,22224,1,Half life of compound was determined in hamster blood,A,10029.0
4672,Sus scrofa,BAO_0000019,,,0,,CHEMBL620968,,Autocuration,,1452,,U,22224,1,Michaelis-Menten constant of the compound.,A,9823.0
4673,Sus scrofa,BAO_0000019,,,0,,CHEMBL874597,,Autocuration,,1452,,U,22224,1,Vmax value was measured at 0 uM concentration of silyl ether.,A,9823.0
4674,Sus scrofa,BAO_0000019,,,0,,CHEMBL620969,,Autocuration,,1452,,U,22224,1,Vmax value was measured at 10 uM concentration of silyl ether.,A,9823.0
4675,Sus scrofa,BAO_0000019,,,0,,CHEMBL620970,,Autocuration,,1452,,U,22224,1,Vmax value was measured at 5 uM concentration of silyl ether.,A,9823.0
4676,Homo sapiens,BAO_0000357,,,9,,CHEMBL620971,,Expert,,11706,,D,235,1,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,9606.0
4677,Homo sapiens,BAO_0000218,,,0,,CHEMBL620972,,Autocuration,,1916,,U,22224,1,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0
4678,Homo sapiens,BAO_0000019,,,0,,CHEMBL620973,,Autocuration,,17791,,U,22224,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,9606.0
4679,Homo sapiens,BAO_0000019,,,0,,CHEMBL618243,,Autocuration,,7766,,U,22224,1,Active metabolite of ifosfamide determined in humans; A-Active,A,9606.0
4680,Homo sapiens,BAO_0000019,,,0,,CHEMBL618244,,Autocuration,,6567,,U,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,9606.0
4681,Homo sapiens,BAO_0000019,,,0,,CHEMBL618245,,Autocuration,,6567,,U,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,9606.0
4682,Homo sapiens,BAO_0000019,,,0,,CHEMBL618246,,Autocuration,,6567,,U,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,9606.0
4683,Homo sapiens,BAO_0000019,,,0,,CHEMBL618247,,Autocuration,,6567,,U,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,9606.0
4684,Homo sapiens,BAO_0000218,,,0,,CHEMBL618248,,Autocuration,,17791,,U,22224,1,Compound was evaluated for oral bioavailability in human,A,9606.0
4685,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618249,,Autocuration,,7766,,U,22224,1,Metabolite of ifosfamide determined in urine; NF-Not found,A,9606.0
4686,Homo sapiens,BAO_0000019,,,0,,CHEMBL618250,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,9606.0
4687,Homo sapiens,BAO_0000019,,,0,,CHEMBL874598,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,9606.0
4688,Homo sapiens,BAO_0000019,,,0,,CHEMBL618251,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,9606.0
4689,Homo sapiens,BAO_0000019,,,0,,CHEMBL618252,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,9606.0
4690,Homo sapiens,BAO_0000019,,,0,,CHEMBL618253,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,9606.0
4691,Homo sapiens,BAO_0000019,,,0,,CHEMBL618254,,Autocuration,,6852,,U,22224,1,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,9606.0
4692,Homo sapiens,BAO_0000019,,,0,,CHEMBL618255,,Autocuration,,6852,,U,22224,1,Percent of compound in healthy individuals (Group D),A,9606.0
4693,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618983,,Autocuration,,4397,,U,22224,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,9606.0
4694,Homo sapiens,BAO_0000019,,,0,,CHEMBL618984,,Autocuration,,17409,,U,22224,1,Binding towards human plasma protein at 10 uM,A,9606.0
4695,Homo sapiens,BAO_0000019,,,0,,CHEMBL618985,,Autocuration,,17409,,U,22224,1,Binding towards human plasma protein at 100 uM,A,9606.0
4696,Homo sapiens,BAO_0000019,,,0,,CHEMBL618986,,Autocuration,,17176,,U,22224,1,Human plasma protein binding activity was determined,A,9606.0
4697,Homo sapiens,BAO_0000019,,,0,,CHEMBL618987,,Autocuration,,15444,,U,22224,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,9606.0
4698,Homo sapiens,BAO_0000019,,,0,,CHEMBL618988,,Autocuration,,17267,,U,22224,1,Percent binding of compound towards human plasma protein was determined,A,9606.0
4699,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618989,,Autocuration,In vitro,5944,,U,22224,1,Plasma clearance in human liver microsomes,A,9606.0
4700,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618990,,Autocuration,In vitro,5668,,U,22224,1,In vitro intrinsic clearance in human liver microsome,A,9606.0
4701,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618991,,Autocuration,In vitro,5669,,U,22224,1,In vitro intrinsic clearance in human liver microsome,A,9606.0
4702,Homo sapiens,BAO_0000251,,,0,,CHEMBL876725,,Autocuration,In vitro,5041,,U,22224,1,In vitro microsome metabolism clearance in human was determined,A,9606.0
4703,Homo sapiens,BAO_0000251,,,0,,CHEMBL618992,,Autocuration,In vitro,5041,,U,22224,1,In vitro microsome metabolism clearance in human was determined; High,A,9606.0
4704,Homo sapiens,BAO_0000251,,,0,,CHEMBL618993,,Autocuration,In vitro,5041,,U,22224,1,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,9606.0
4705,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618994,,Autocuration,In vitro,5676,,U,22224,1,Pharmacokinetic property (clearance) in human liver microsome,A,9606.0
4706,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618995,,Autocuration,In vitro,5944,,U,22224,1,Plasma clearance in human liver microsomes,A,9606.0
4707,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618996,,Autocuration,In vitro,17538,,U,22224,1,In vitro clearance in human liver microsomes,A,9606.0
4708,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618997,,Autocuration,In vitro,6331,,U,22224,1,Intrinsic clearance in human liver microsomes was determined,A,9606.0
4709,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618998,,Autocuration,In vitro,5948,,U,22224,1,Intrinsic clearance in human liver microsomes was determined,A,9606.0
4710,Homo sapiens,BAO_0000218,,,0,,CHEMBL618999,,Autocuration,In vivo,5965,,U,22224,1,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,9606.0
4711,Homo sapiens,BAO_0000218,,,0,,CHEMBL620223,,Autocuration,In vivo,1916,,U,22224,1,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0
4712,Homo sapiens,BAO_0000218,,,0,,CHEMBL620224,,Autocuration,,5965,,U,22224,1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,9606.0
4713,Homo sapiens,BAO_0000019,,,0,,CHEMBL620225,,Autocuration,,1299,,U,22224,1,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,9606.0
4714,Homo sapiens,BAO_0000019,,,0,,CHEMBL620226,,Autocuration,,1299,,U,22224,1,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,9606.0
4715,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL620227,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4716,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL876726,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4717,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL620228,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4718,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL620229,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4719,Mus musculus,BAO_0000218,,,1,,CHEMBL620230,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,10090.0
4720,Mus musculus,BAO_0000218,,,1,,CHEMBL620231,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,10090.0
4721,Mus musculus,BAO_0000218,,,1,,CHEMBL620232,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,10090.0
4722,Mus musculus,BAO_0000218,,,1,,CHEMBL620233,,Intermediate,In vivo,17764,,N,50594,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,10090.0
4723,Mus musculus,BAO_0000218,,,1,,CHEMBL620234,,Intermediate,,14294,,N,50594,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,10090.0
4724,Mus musculus,BAO_0000218,,,1,,CHEMBL620235,,Intermediate,,14294,,N,50594,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,10090.0
4725,Mus musculus,BAO_0000218,,,1,,CHEMBL620236,,Intermediate,,14294,,N,50594,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,10090.0
4726,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL620237,,Intermediate,,6251,,N,50594,1,In vitro metabolic potential in mouse liver microsomes,A,10090.0
4727,Mus musculus,BAO_0000218,,,1,,CHEMBL620238,,Intermediate,,17582,,N,50594,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,10090.0
4728,Mus musculus,BAO_0000218,2369.0,,1,Adrenal gland,CHEMBL620239,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,10090.0
4729,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL620240,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,10090.0
4730,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL620241,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,10090.0
4731,Mus musculus,BAO_0000218,,,1,,CHEMBL876727,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,10090.0
4732,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL620242,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,10090.0
4733,Mus musculus,BAO_0000218,,,1,,CHEMBL620243,,Intermediate,,17811,,N,50594,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,10090.0
4734,Mus musculus,BAO_0000218,,,1,,CHEMBL620244,,Intermediate,,5288,,N,50594,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,10090.0
4735,Mus musculus,BAO_0000218,1977.0,,1,Serum,CHEMBL620245,,Intermediate,,2717,,N,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,10090.0
4736,Mus musculus,BAO_0000218,1977.0,,1,Serum,CHEMBL620246,,Intermediate,,2717,,N,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,10090.0
4737,Mus musculus,BAO_0000218,1977.0,,1,Serum,CHEMBL620247,,Intermediate,,2717,,N,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,10090.0
4738,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL620248,,Intermediate,In vivo,17753,,N,50594,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,10090.0
4739,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL873497,,Intermediate,In vivo,17753,,N,50594,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,10090.0
4740,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL620249,,Intermediate,In vivo,17753,,N,50594,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,10090.0
4741,Mus musculus,BAO_0000218,,,1,,CHEMBL620250,,Intermediate,In vivo,17764,,N,50594,1,Half life after intraperitoneal administration in mice at 18 uM/kg,F,10090.0
4742,Mus musculus,BAO_0000218,,,1,,CHEMBL620251,,Intermediate,In vivo,17764,,N,50594,1,Half life after intraperitoneal administration in mice at 23 uM/kg,F,10090.0
4743,Mus musculus,BAO_0000218,,,1,,CHEMBL620252,,Intermediate,In vivo,17764,,N,50594,1,Half life after intraperitoneal administration in mice at 25 uM/kg,F,10090.0
4744,Mus musculus,BAO_0000218,,,1,,CHEMBL620253,,Intermediate,In vivo,17764,,N,50594,1,Half life after intraperitoneal administration in mice at 26 uM/kg,F,10090.0
4745,Mus musculus,BAO_0000218,,,1,,CHEMBL620254,,Intermediate,In vivo,17764,,N,50594,1,Half life after intravenous administration in mice at 23 uM/kg,F,10090.0
4746,Mus musculus,BAO_0000218,,,1,,CHEMBL620255,,Intermediate,In vivo,17764,,N,50594,1,Half life after intravenous administration in mice at 24 uM/kg,A,10090.0
4747,Mus musculus,BAO_0000218,,,1,,CHEMBL620256,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,10090.0
4748,Mus musculus,BAO_0000218,,,1,,CHEMBL876728,,Intermediate,In vivo,2675,,N,50594,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,10090.0
4749,Mus musculus,BAO_0000218,,,1,,CHEMBL620257,,Intermediate,In vivo,2675,,N,50594,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,10090.0
4750,Mus musculus,BAO_0000218,,,1,,CHEMBL620258,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,10090.0
4751,Mus musculus,BAO_0000218,,,1,,CHEMBL620259,,Intermediate,In vivo,4890,,N,50594,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,10090.0
4752,Mus musculus,BAO_0000218,,,1,,CHEMBL620260,,Intermediate,In vivo,429,,N,50594,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,10090.0
4753,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL620261,,Intermediate,In vivo,17837,,N,50594,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0
4754,Mus musculus,BAO_0000218,,,1,,CHEMBL620262,,Intermediate,In vivo,16597,,N,50594,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
4755,Mus musculus,BAO_0000218,,,1,,CHEMBL620263,,Intermediate,In vivo,16597,,N,50594,1,Half life at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
4756,Mus musculus,BAO_0000218,,,1,,CHEMBL620264,,Intermediate,,6619,,N,50594,1,Half life in ob/ob mice,A,10090.0
4757,Mus musculus,BAO_0000218,,,1,,CHEMBL620265,,Intermediate,In vivo,4066,,N,50594,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0
4758,Mus musculus,BAO_0000218,,,1,,CHEMBL620266,,Intermediate,,4239,,N,50594,1,Half-life was measured in mouse,A,10090.0
4759,Mus musculus,BAO_0000218,,,1,,CHEMBL620267,,Intermediate,In vivo,5969,,N,50594,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,10090.0
4760,Mus musculus,BAO_0000218,,,1,,CHEMBL619364,,Intermediate,,8999,,N,50594,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,10090.0
4761,Mus musculus,BAO_0000218,,,1,,CHEMBL619365,,Intermediate,,8999,,N,50594,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,10090.0
4762,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL619366,,Intermediate,,17641,,N,50594,1,T2 in brain of mice at the oral dose of 50 mg/kg,A,10090.0
4763,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL619367,,Intermediate,,17641,,N,50594,1,T2 in kidney of mice at the oral dose of 50 mg/kg,A,10090.0
4764,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL619368,,Intermediate,,17641,,N,50594,1,T2 in liver of mice at the oral dose of 50 mg/kg,A,10090.0
4765,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL619369,,Intermediate,,17641,,N,50594,1,T2 in lungs of mice at the oral dose of 50 mg/kg,A,10090.0
4766,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL876729,,Intermediate,,17641,,N,50594,1,T2 in spleen of mice at the oral dose of 50 mg/kg,A,10090.0
4767,Mus musculus,BAO_0000218,,,1,,CHEMBL619370,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,10090.0
4768,Mus musculus,BAO_0000218,,,1,,CHEMBL619371,,Intermediate,In vivo,4890,,N,50594,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,10090.0
4769,Mus musculus,BAO_0000218,,,1,,CHEMBL619372,,Intermediate,In vivo,429,,N,50594,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,10090.0
4770,Mus musculus,BAO_0000218,,,1,,CHEMBL620012,,Intermediate,In vivo,429,,N,50594,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,10090.0
4771,Mus musculus,BAO_0000218,,,1,,CHEMBL620013,,Intermediate,In vivo,5969,,N,50594,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,10090.0
4772,Homo sapiens,BAO_0000219,,,1,,CHEMBL620014,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0
4773,Homo sapiens,BAO_0000219,,,1,,CHEMBL620015,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0
4774,Homo sapiens,BAO_0000219,,,1,,CHEMBL621010,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0
4775,Homo sapiens,BAO_0000219,,,1,,CHEMBL621011,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0
4776,Homo sapiens,BAO_0000219,,,1,,CHEMBL621012,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0
4777,Homo sapiens,BAO_0000219,,,1,,CHEMBL621013,,Intermediate,,16913,,N,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0
4778,Homo sapiens,BAO_0000219,,,1,,CHEMBL621014,,Intermediate,,17270,,N,81034,1,In vitro cytotoxicity against A2780TAX cell line,F,9606.0
4779,Homo sapiens,BAO_0000219,,,1,,CHEMBL618154,,Intermediate,,5618,,N,80017,1,In vitro inhibitory activity against human tumor cell line A2780cis,F,9606.0
4780,Homo sapiens,BAO_0000219,,,1,,CHEMBL618155,,Expert,,17777,,N,81034,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,9606.0
4781,Homo sapiens,BAO_0000219,,,1,,CHEMBL618156,,Intermediate,,16112,,N,80017,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,9606.0
4782,Homo sapiens,BAO_0000219,,,1,,CHEMBL618157,,Intermediate,,15748,,N,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,9606.0
4783,Homo sapiens,BAO_0000219,,,1,,CHEMBL618328,,Intermediate,,6633,,N,81034,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,9606.0
4784,Homo sapiens,BAO_0000219,,,1,,CHEMBL618329,,Intermediate,,16930,,N,81034,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,9606.0
4785,Homo sapiens,BAO_0000219,,,1,,CHEMBL618330,,Intermediate,,17496,,N,81034,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,9606.0
4786,Homo sapiens,BAO_0000219,,,1,,CHEMBL618331,,Expert,,12989,,N,81034,1,In vitro antitumor activity against A2780cisR cell line.,F,9606.0
4787,Homo sapiens,BAO_0000219,,,1,,CHEMBL618332,,Intermediate,,4840,,N,81034,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,9606.0
4788,Homo sapiens,BAO_0000219,,,1,,CHEMBL618333,,Expert,,12989,,N,81034,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,9606.0
4789,Homo sapiens,BAO_0000219,,,1,,CHEMBL618334,,Intermediate,,16745,,N,80017,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,9606.0
4790,Homo sapiens,BAO_0000219,,,1,,CHEMBL618335,,Expert,,16597,,N,81034,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,9606.0
4791,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL618336,,Expert,,16547,,D,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,10116.0
4792,,BAO_0000019,,,8,,CHEMBL618337,,Expert,,16547,,H,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,
4793,Rattus norvegicus,BAO_0000019,,,9,,CHEMBL618338,,Expert,,16547,,D,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,10116.0
4794,Homo sapiens,BAO_0000219,,,9,,CHEMBL618339,,Expert,,15856,,D,278,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,9606.0
4795,Homo sapiens,BAO_0000219,,,9,,CHEMBL618340,,Expert,,15856,,D,278,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,9606.0
4796,Mus musculus,BAO_0000019,,,9,,CHEMBL618341,,Expert,,16547,,D,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,10090.0
4797,,BAO_0000019,,,8,,CHEMBL618342,,Expert,,16547,,H,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,
4798,Mus musculus,BAO_0000019,,,9,,CHEMBL618343,,Expert,,16547,,D,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,10090.0
4799,,BAO_0000357,,,8,,CHEMBL621038,,Expert,,17402,,H,280,1,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,
4800,Homo sapiens,BAO_0000219,,,0,,CHEMBL621039,,Autocuration,,11746,,U,22226,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,9606.0
4801,Homo sapiens,BAO_0000219,,,0,,CHEMBL621040,,Autocuration,,11746,,U,22226,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,9606.0
4802,Homo sapiens,BAO_0000219,,,1,,CHEMBL621041,,Intermediate,,5455,,N,80018,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,9606.0
4803,Homo sapiens,BAO_0000219,,,1,,CHEMBL621042,,Intermediate,,2068,,N,80018,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,9606.0
4804,Homo sapiens,BAO_0000219,,,1,,CHEMBL621043,,Intermediate,,2683,,N,80018,1,In vitro antitumor activity against A375cell line extracted form melanoma,F,9606.0
4805,Homo sapiens,BAO_0000219,,,1,,CHEMBL621044,,Expert,,15313,,N,80018,1,Inhibition of cell growth in (A375) melan cell line,F,9606.0
4806,Homo sapiens,BAO_0000219,,,1,,CHEMBL621045,,Intermediate,,13739,,N,80018,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,9606.0
4807,Homo sapiens,BAO_0000219,,,1,,CHEMBL621046,,Intermediate,,13739,,N,80018,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,9606.0
4808,Homo sapiens,BAO_0000219,,,1,,CHEMBL621047,,Intermediate,,14750,,N,80018,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,9606.0
4809,Homo sapiens,BAO_0000219,,,1,,CHEMBL621048,,Intermediate,,14777,,N,80019,1,Antiproliferative activity measured against A427 human lung carcinoma,F,9606.0
4810,Homo sapiens,BAO_0000219,,,1,,CHEMBL883798,,Intermediate,,14777,,N,80019,1,Antiproliferative activity measured against A427 human lung carcinoma,F,9606.0
4811,Homo sapiens,BAO_0000219,,,1,,CHEMBL621049,,Intermediate,,17672,,N,80019,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,9606.0
4812,Homo sapiens,BAO_0000219,,,1,,CHEMBL621050,,Intermediate,,14368,,N,80019,1,Inhibition of large cell lung carcinoma (A427),F,9606.0
4813,Homo sapiens,BAO_0000219,,,1,,CHEMBL621051,,Intermediate,,14368,,N,80019,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,9606.0
4814,Homo sapiens,BAO_0000219,,,1,,CHEMBL621052,,Intermediate,,13866,,N,80019,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,9606.0
4815,Homo sapiens,BAO_0000219,,,1,,CHEMBL621053,,Intermediate,,2545,,N,80019,1,Inhibitory concentration in human lung carcinoma A427 cell line,F,9606.0
4816,Homo sapiens,BAO_0000219,,,1,,CHEMBL621054,,Intermediate,,2545,,N,80019,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,9606.0
4817,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621055,,Autocuration,In vivo,6062,,U,22224,1,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,9527.0
4818,Cercopithecidae,BAO_0000218,,,0,,CHEMBL876398,,Autocuration,In vivo,4578,,U,22224,1,Tested for volume of distribution upon iv administration to african green monkey,A,9527.0
4819,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621056,,Autocuration,In vivo,17592,,U,22224,1,Volume of distribution in monkey,A,9527.0
4820,Macaca mulatta,BAO_0000218,,,0,,CHEMBL621057,,Autocuration,In vivo,5005,,U,22224,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0
4821,Macaca mulatta,BAO_0000218,,,0,,CHEMBL621058,,Autocuration,In vivo,5005,,U,22224,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,9544.0
4822,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621059,,Autocuration,In vivo,5922,,U,22224,1,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,9527.0
4823,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621060,,Autocuration,In vivo,5355,,U,22224,1,The distribution volume after intravenous administration in cynomolgus monkeys,A,9527.0
4824,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621061,,Autocuration,In vivo,5355,,U,22224,1,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0
4825,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621062,,Autocuration,In vivo,5355,,U,22224,1,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0
4826,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621063,,Autocuration,In vivo,6057,,U,22224,1,Volume displacement was calculated in rhesus monkey,A,9527.0
4827,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621064,,Autocuration,In vivo,5145,,U,22224,1,Volume of distribution in steady state was determined in rhesus monkey,A,9527.0
4828,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621065,,Autocuration,In vivo,6821,,U,22224,1,Volume of distribution of compound was determined in monkey,A,9527.0
4829,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621066,,Autocuration,In vivo,5334,,U,22224,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0
4830,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621067,,Autocuration,In vivo,5334,,U,22224,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0
4831,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621068,,Autocuration,In vivo,6641,,U,22224,1,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0
4832,Cercopithecidae,BAO_0000218,,,0,,CHEMBL876399,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0
4833,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621069,,Autocuration,In vivo,6535,,U,22224,1,Volume distribution in monkey after administration of 1 mg/kg iv,A,9527.0
4834,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621070,,Autocuration,In vivo,4809,,U,22224,1,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0
4835,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621071,,Autocuration,In vivo,6062,,U,22224,1,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,9527.0
4836,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621072,,Autocuration,In vivo,3443,,U,22224,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
4837,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618209,,Autocuration,In vivo,4578,,U,22224,1,Oral systemic bioavailability upon iv administration to african green monkey,A,9527.0
4838,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618210,,Autocuration,In vivo,4809,,U,22224,1,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0
4839,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618211,,Autocuration,,11271,,U,22224,1,Baboon plasma free fraction. ,A,9527.0
4840,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618212,,Autocuration,,6057,,U,22224,1,Area under the curve was calculated in rhesus monkey after iv administration,A,9527.0
4841,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618213,,Autocuration,,6057,,U,22224,1,Area under the curve was calculated in rhesus monkey after peroral administration,A,9527.0
4842,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618214,,Autocuration,,17853,,U,22224,1,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,9527.0
4843,Cercopithecidae,BAO_0000218,,,0,,CHEMBL873492,,Autocuration,In vivo,5302,,U,22224,1,Half life period in monkey after 5 mg/kg dose,A,9527.0
4844,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618272,,Autocuration,In vivo,4257,,U,22224,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,9527.0
4845,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618273,,Autocuration,In vivo,4257,,U,22224,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,9527.0
4846,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL618274,,Autocuration,In vivo,13501,,U,22224,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,9527.0
4847,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618275,,Autocuration,In vivo,5394,,U,22224,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,9527.0
4848,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618276,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0
4849,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618277,,Autocuration,,3341,,U,22224,1,Compound was evaluated for terminal half life in monkey,A,9527.0
4850,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618278,,Autocuration,In vivo,3045,,U,22224,1,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,9527.0
4851,Macaca mulatta,BAO_0000218,1969.0,,0,Plasma,CHEMBL618279,,Autocuration,In vivo,5005,,U,22224,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0
4852,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618280,,Autocuration,,4847,,U,22224,1,Half life of compound was determined in squirrel monkey,A,9527.0
4853,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL618281,,Autocuration,In vivo,4256,,U,22224,1,Half life after iv administration in cynomolgus monkey,A,9541.0
4854,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL618282,,Autocuration,In vivo,6535,,U,22224,1,Half life in monkey plasma after administration of 1 mg/kg iv,A,9527.0
4855,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618283,,Autocuration,,6057,,U,22224,1,Half life was calculated in rhesus monkey,A,9527.0
4856,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618284,,Autocuration,,17592,,U,22224,1,Half life in monkey,A,9527.0
4857,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618285,,Autocuration,In vivo,6641,,U,22224,1,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0
4858,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618286,,Autocuration,,5472,,U,22224,1,Half life was evaluated in rhesus,A,9527.0
4859,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618287,,Autocuration,In vivo,6221,,U,22224,1,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0
4860,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618288,,Autocuration,In vivo,5668,,U,22224,1,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,9527.0
4861,Cercopithecidae,BAO_0000218,,,0,,CHEMBL876393,,Autocuration,In vivo,4809,,U,22224,1,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0
4862,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618289,,Autocuration,In vivo,5546,,U,22224,1,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0
4863,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618290,,Autocuration,In vivo,5553,,U,22224,1,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,9527.0
4864,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618291,,Autocuration,,6078,,U,22224,1,Half-life was calculated in monkey,A,9527.0
4865,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618292,,Autocuration,,5147,,U,22224,1,Half-life in Squirrel monkey,A,9527.0
4866,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618293,,Autocuration,,5145,,U,22224,1,Half-life in rhesus monkey,A,9527.0
4867,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618294,,Autocuration,In vivo,6062,,U,22224,1,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,9527.0
4868,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618295,,Autocuration,In vivo,5355,,U,22224,1,Half-life period after intravenous administration in cynomolgus monkeys,A,9527.0
4869,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618296,,Autocuration,In vivo,5355,,U,22224,1,Half-life period after oral administration in cynomolgus monkeys,A,9527.0
4870,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618297,,Autocuration,In vivo,5355,,U,22224,1,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,9527.0
4871,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618298,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4872,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618299,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4873,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618300,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4874,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618301,,Autocuration,,7766,,U,22224,1,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0
4875,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618302,,Autocuration,,7766,,U,22224,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,9606.0
4876,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL876394,,Autocuration,,7766,,U,22224,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,9606.0
4877,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618303,,Autocuration,,7766,,U,22224,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,9606.0
4878,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618304,,Autocuration,,7766,,U,22224,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,9606.0
4879,Homo sapiens,BAO_0000218,,,0,,CHEMBL618305,,Autocuration,In vivo,1916,,U,22224,1,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,9606.0
4880,Homo sapiens,BAO_0000218,,,0,,CHEMBL618306,,Autocuration,In vivo,16643,,U,22224,1,Oral bioavailability in human,A,9606.0
4881,Homo sapiens,BAO_0000019,,,0,,CHEMBL618307,,Autocuration,,17248,,U,22224,1,Compound was tested for human plasma protein binding,A,9606.0
4882,Homo sapiens,BAO_0000019,,,0,,CHEMBL618308,,Autocuration,,17248,,U,22224,1,Compound was tested for human plasma protein binding; Not determined,A,9606.0
4883,Homo sapiens,BAO_0000019,,,0,,CHEMBL618309,,Autocuration,,6241,,U,22224,1,Protein binding activity of compound in human plasma; % Free,A,9606.0
4884,Homo sapiens,BAO_0000019,,,0,,CHEMBL618310,,Autocuration,,17716,,U,22224,1,Unbound fraction (plasma),A,9606.0
4885,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL873353,,Autocuration,,17605,,U,22224,1,Half life for the hydrolysis of compound in human blood serum,A,9606.0
4886,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618311,,Autocuration,,17625,,U,22224,1,Half life period in human plasma using phosphate buffer (0.08 M),A,9606.0
4887,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618312,,Autocuration,,17625,,U,22224,1,Half life period in human plasma using phosphate buffer (0.1 M),A,9606.0
4888,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618313,,Autocuration,,17747,,U,22224,1,Half-life in human plasma was determined,A,9606.0
4889,Homo sapiens,BAO_0000019,,,0,,CHEMBL618314,,Autocuration,,15613,,U,22224,1,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,9606.0
4890,Homo sapiens,BAO_0000019,,,0,,CHEMBL618315,,Autocuration,,354,,U,22224,1,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,9606.0
4891,Homo sapiens,BAO_0000019,,,0,,CHEMBL618316,,Autocuration,,3741,,U,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,9606.0
4892,Homo sapiens,BAO_0000019,,,0,,CHEMBL618317,,Autocuration,,3741,,U,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,9606.0
4893,Homo sapiens,BAO_0000019,,,0,,CHEMBL620138,,Autocuration,,3741,,U,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,9606.0
4894,Homo sapiens,BAO_0000019,,,0,,CHEMBL858280,,Autocuration,,17599,,U,22224,1,Partition coefficient (logP),A,9606.0
4895,Homo sapiens,BAO_0000019,,,0,,CHEMBL620139,,Autocuration,,5486,,U,22224,1,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,9606.0
4896,Homo sapiens,BAO_0000251,,,0,,CHEMBL620140,,Autocuration,,5600,,U,22224,1,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,9606.0
4897,Homo sapiens,BAO_0000019,,,0,,CHEMBL620141,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,9606.0
4898,Homo sapiens,BAO_0000019,,,0,,CHEMBL620142,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,9606.0
4899,Homo sapiens,BAO_0000019,,,0,,CHEMBL620143,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,9606.0
4900,Homo sapiens,BAO_0000251,,,0,,CHEMBL620144,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,9606.0
4901,Homo sapiens,BAO_0000251,,,0,,CHEMBL620145,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,9606.0
4902,Homo sapiens,BAO_0000251,,,0,,CHEMBL620146,,Autocuration,,14294,,U,22224,1,Metabolism of compound in human microsomes; Trace,A,9606.0
4903,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL620147,,Autocuration,,6260,,U,22224,1,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,9606.0
4904,Homo sapiens,BAO_0000251,,,0,,CHEMBL620148,,Autocuration,,6187,,U,22224,1,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,9606.0
4905,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL620149,,Autocuration,,6251,,U,22224,1,In vitro metabolic potential in human liver microsomes,A,9606.0
4906,Homo sapiens,BAO_0000019,,,0,,CHEMBL876412,,Autocuration,,3246,,U,22224,1,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,9606.0
4907,Homo sapiens,BAO_0000019,,,0,,CHEMBL619352,,Autocuration,,17313,,U,22224,1,Tested for human plasma protein binding of the compound; Not tested,A,9606.0
4908,Homo sapiens,BAO_0000019,,,0,,CHEMBL619353,,Autocuration,,6227,,U,22224,1,Compound was tested for percent protein binding (PB) in human,A,9606.0
4909,Homo sapiens,BAO_0000019,1969.0,,0,Plasma,CHEMBL619354,,Autocuration,,5530,,U,22224,1,Protein binding in human plasma,A,9606.0
4910,Homo sapiens,BAO_0000019,,,0,,CHEMBL619355,,Autocuration,,6108,,U,22224,1,Permeability coefficient (B to A) in Caco-2 cell,A,9606.0
4911,Homo sapiens,BAO_0000019,,,0,,CHEMBL619356,,Autocuration,,6108,,U,22224,1,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,9606.0
4912,Homo sapiens,BAO_0000019,,,0,,CHEMBL619357,,Autocuration,,2774,,U,22224,1,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,9606.0
4913,Homo sapiens,BAO_0000019,,,0,,CHEMBL619358,,Autocuration,,16643,,U,22224,1,In vitro rate of absorption observed as Caco-2 permeability in humans,A,9606.0
4914,Homo sapiens,BAO_0000219,,,0,,CHEMBL619359,,Autocuration,,17582,,U,22224,1,Cellular permeability of compound was determined in Caco-2 cells; High,A,9606.0
4915,Homo sapiens,BAO_0000219,,,0,,CHEMBL619360,,Autocuration,,6838,,U,22224,1,Permeability in Caco-2 cells of compound,A,9606.0
4916,Homo sapiens,BAO_0000019,,,0,,CHEMBL619361,,Autocuration,,6108,,U,22224,1,Permeability coefficient (A to B) in Caco-2 cell,A,9606.0
4917,Homo sapiens,BAO_0000019,,,0,,CHEMBL619362,,Autocuration,,6108,,U,22224,1,Permeability coefficient (B to A) in Caco-2 cell,A,9606.0
4918,Homo sapiens,BAO_0000019,,,0,,CHEMBL619363,,Autocuration,,6108,,U,22224,1,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,9606.0
4919,Homo sapiens,BAO_0000019,,,0,,CHEMBL618942,,Autocuration,,2146,,U,22224,1,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,9606.0
4920,Homo sapiens,BAO_0000019,,,0,,CHEMBL618943,,Autocuration,,4514,,U,22224,1,Compound was tested for protein binding in human plasma,A,9606.0
4921,Homo sapiens,BAO_0000019,,,0,,CHEMBL618944,,Autocuration,,6108,,U,22224,1,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,9606.0
4922,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL618945,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,9606.0
4923,Mus musculus,BAO_0000218,,,1,,CHEMBL618946,,Intermediate,In vivo,5969,,N,50594,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,10090.0
4924,Mus musculus,BAO_0000218,,,1,,CHEMBL876413,,Intermediate,In vivo,3277,,N,50594,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0
4925,Mus musculus,BAO_0000218,,,1,,CHEMBL618947,,Intermediate,In vivo,3802,,N,50594,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,10090.0
4926,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL618948,,Intermediate,In vivo,2862,,N,50594,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,10090.0
4927,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL618949,,Intermediate,In vivo,6348,,N,50594,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0
4928,Mus musculus,BAO_0000218,,,1,,CHEMBL618950,,Intermediate,In vivo,17764,,N,50594,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,10090.0
4929,Mus musculus,BAO_0000218,,,1,,CHEMBL618951,,Intermediate,In vivo,5781,,N,50594,1,Tmax after oral administration at 30 mg/kg in ICR mouse,A,10090.0
4930,Mus musculus,BAO_0000218,,,1,,CHEMBL618952,,Intermediate,In vivo,17764,,N,50594,1,Tmax after peroral administration in mice at 2.4 uM/kg,A,10090.0
4931,Mus musculus,BAO_0000218,,,1,,CHEMBL618953,,Intermediate,In vivo,4066,,N,50594,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0
4932,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL618954,,Intermediate,In vivo,17641,,N,50594,1,Tmax in brain of mice at the oral dose of 50 mg/kg,A,10090.0
4933,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL618955,,Intermediate,In vivo,17641,,N,50594,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,10090.0
4934,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL618956,,Intermediate,In vivo,17641,,N,50594,1,Tmax in liver of mice at the oral dose of 50 mg/kg,A,10090.0
4935,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL618957,,Intermediate,In vivo,17641,,N,50594,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,10090.0
4936,Mus musculus,BAO_0000218,,,1,,CHEMBL618958,,Intermediate,In vivo,17764,,N,50594,1,Tmax in mice at 18 uM/kg i.p. administration,F,10090.0
4937,Mus musculus,BAO_0000218,,,1,,CHEMBL618959,,Intermediate,In vivo,17764,,N,50594,1,Tmax in mice at 23 uM/kg i.v. administration,F,10090.0
4938,Mus musculus,BAO_0000218,,,1,,CHEMBL618960,,Intermediate,In vivo,17764,,N,50594,1,Tmax in mice at 25 uM/kg i.p. administration,F,10090.0
4939,Mus musculus,BAO_0000218,,,1,,CHEMBL876723,,Intermediate,In vivo,17764,,N,50594,1,Tmax in mice at 26 uM/kg i.p. administration,F,10090.0
4940,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618961,,Intermediate,In vivo,17641,,N,50594,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,10090.0
4941,Mus musculus,BAO_0000218,,,1,,CHEMBL618962,,Intermediate,In vivo,16597,,N,50594,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
4942,Mus musculus,BAO_0000218,,,1,,CHEMBL618963,,Intermediate,In vivo,16597,,N,50594,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
4943,Mus musculus,BAO_0000218,,,1,,CHEMBL618964,,Intermediate,,5951,,N,50594,1,Tmax value in IRC mice,A,10090.0
4944,Mus musculus,BAO_0000218,,,1,,CHEMBL618965,,Intermediate,In vivo,5506,,N,50594,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0
4945,Mus musculus,BAO_0000218,,,1,,CHEMBL618966,,Intermediate,In vivo,5506,,N,50594,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0
4946,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL618967,,Intermediate,,429,,N,50594,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,10090.0
4947,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL618968,,Intermediate,,429,,N,50594,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,10090.0
4948,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL618969,,Intermediate,,4066,,N,50594,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,10090.0
4949,Mus musculus,BAO_0000218,,,1,,CHEMBL618970,,Intermediate,,17734,,N,50594,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
4950,Mus musculus,BAO_0000218,,,1,,CHEMBL618971,,Intermediate,,17734,,N,50594,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
4951,Mus musculus,BAO_0000218,,,1,,CHEMBL618972,,Intermediate,In vivo,6062,,N,50594,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,10090.0
4952,Mus musculus,BAO_0000218,,,1,,CHEMBL618973,,Intermediate,In vivo,5969,,N,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,10090.0
4953,Mus musculus,BAO_0000218,,,1,,CHEMBL618974,,Intermediate,In vivo,5969,,N,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,10090.0
4954,Mus musculus,BAO_0000218,,,1,,CHEMBL618975,,Intermediate,In vivo,5969,,N,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0
4955,Mus musculus,BAO_0000218,,,1,,CHEMBL618976,,Intermediate,In vivo,5980,,N,50594,1,Vd in mice,A,10090.0
4956,Mus musculus,BAO_0000218,,,1,,CHEMBL618977,,Intermediate,In vivo,17592,,N,50594,1,Volume of distribution in mouse,A,10090.0
4957,Mus musculus,BAO_0000218,,,1,,CHEMBL876724,,Intermediate,In vivo,6348,,N,50594,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0
4958,Mus musculus,BAO_0000218,,,1,,CHEMBL618978,,Intermediate,In vivo,17753,,N,50594,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,10090.0
4959,Mus musculus,BAO_0000218,,,1,,CHEMBL618979,,Intermediate,In vivo,17753,,N,50594,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,10090.0
4960,Mus musculus,BAO_0000218,,,1,,CHEMBL618980,,Intermediate,In vivo,17753,,N,50594,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,10090.0
4961,Mus musculus,BAO_0000218,,,1,,CHEMBL618981,,Intermediate,In vivo,4239,,N,50594,1,Pharmacokinetic property (vdss) was measured in mouse,A,10090.0
4962,Mus musculus,BAO_0000218,,,1,,CHEMBL618982,,Intermediate,In vivo,2862,,N,50594,1,Value distribution upon iv administration in mouse,A,10090.0
4963,Mus musculus,BAO_0000218,,,1,,CHEMBL620150,,Intermediate,In vivo,17734,,N,50594,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
4964,Mus musculus,BAO_0000218,,,1,,CHEMBL620151,,Intermediate,In vivo,2675,,N,50594,1,Volume of distribution was evaluated in mice after intravenous administration,A,10090.0
4965,Mus musculus,BAO_0000218,,,1,,CHEMBL620152,,Intermediate,In vivo,2675,,N,50594,1,Volume of distribution was evaluated in mice after oral administration,A,10090.0
4966,Mus musculus,BAO_0000218,,,1,,CHEMBL620153,,Intermediate,In vivo,17837,,N,50594,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0
4967,Mus musculus,BAO_0000218,,,1,,CHEMBL876395,,Intermediate,In vivo,5727,,N,50594,1,Steady state volume of distribution was determined in mice,A,10090.0
4968,Mus musculus,BAO_0000218,,,1,,CHEMBL620154,,Intermediate,In vivo,17852,,N,50594,1,Volume distribution (steady state) of compound was determined in mouse,A,10090.0
4969,Mus musculus,BAO_0000218,,,1,,CHEMBL620155,,Intermediate,In vivo,17764,,N,50594,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,10090.0
4970,Mus musculus,BAO_0000218,,,1,,CHEMBL620156,,Intermediate,In vivo,16597,,N,50594,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
4971,Mus musculus,BAO_0000218,,,1,,CHEMBL620157,,Intermediate,In vivo,6062,,N,50594,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,10090.0
4972,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL620158,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution of compound (oxidized form) in in kidney tissue,A,10090.0
4973,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL620159,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0
4974,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL620160,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0
4975,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL620161,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
4976,Homo sapiens,BAO_0000219,,,1,,CHEMBL620162,,Intermediate,,10708,,N,80019,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,9606.0
4977,Homo sapiens,BAO_0000219,,,1,,CHEMBL620163,,Expert,,16597,,N,80852,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,9606.0
4978,Homo sapiens,BAO_0000219,,,1,,CHEMBL620833,,Expert,,16062,,N,80852,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,9606.0
4979,Homo sapiens,BAO_0000219,,,1,,CHEMBL876396,,Expert,,16062,,N,80852,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,9606.0
4980,Homo sapiens,BAO_0000219,,,1,,CHEMBL620834,,Expert,,16958,,N,80852,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,9606.0
4981,Homo sapiens,BAO_0000219,,,1,,CHEMBL620835,,Expert,,6700,,N,80852,1,Inhibition of A431 human carcinoma cell proliferation,F,9606.0
4982,Homo sapiens,BAO_0000219,,,1,,CHEMBL620836,,Expert,,17226,,N,80852,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,9606.0
4983,Homo sapiens,BAO_0000219,,,1,,CHEMBL620837,,Intermediate,,6828,,N,80852,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,9606.0
4984,Homo sapiens,BAO_0000219,,,1,,CHEMBL621017,,Intermediate,,12314,,N,80852,1,In vitro cytotoxicity against epidermoid carcinoma cell line,F,9606.0
4985,Homo sapiens,BAO_0000218,,,9,,CHEMBL621018,,Expert,,13412,,D,9,1,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,9606.0
4986,Homo sapiens,BAO_0000219,,,1,,CHEMBL621019,,Intermediate,,13299,,N,80852,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,9606.0
4987,Homo sapiens,BAO_0000219,,,1,,CHEMBL621020,,Intermediate,,17420,,N,80852,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,9606.0
4988,Homo sapiens,BAO_0000219,,,1,,CHEMBL621021,,Intermediate,,13678,,N,80852,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,9606.0
4989,,BAO_0000219,,,8,,CHEMBL621022,,Expert,,14171,,H,9,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,
4990,Homo sapiens,BAO_0000219,,,1,,CHEMBL621023,,Expert,,6333,,N,80852,1,Tested for antiproliferative activity against human A431 cells,F,9606.0
4991,Homo sapiens,BAO_0000219,,,9,,CHEMBL621024,,Expert,,2356,,D,9,1,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,9606.0
4992,Homo sapiens,BAO_0000219,,,1,,CHEMBL621025,,Expert,,15578,,N,80852,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,9606.0
4993,Homo sapiens,BAO_0000219,,,1,,CHEMBL621026,,Expert,,5126,,N,80852,1,Inhibition of A431 cell proliferation,F,9606.0
4994,Homo sapiens,BAO_0000219,,,1,,CHEMBL621027,,Expert,,6844,,N,80852,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,9606.0
4995,Homo sapiens,BAO_0000219,,,1,,CHEMBL876397,,Expert,,6844,,N,80852,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,9606.0
4996,Homo sapiens,BAO_0000219,,,1,,CHEMBL883797,,Intermediate,,4925,,N,80852,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,9606.0
4997,Homo sapiens,BAO_0000219,,,1,,CHEMBL621028,,Intermediate,,4925,,N,80852,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,9606.0
4998,Homo sapiens,BAO_0000219,,,1,,CHEMBL621029,,Intermediate,,13978,,N,80852,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,9606.0
4999,Homo sapiens,BAO_0000219,,,1,,CHEMBL621030,,Intermediate,,16786,,N,80852,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,9606.0
5000,,BAO_0000219,,,8,,CHEMBL621147,,Expert,,13412,,H,9,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,
5001,Homo sapiens,BAO_0000218,,,1,,CHEMBL621148,,Intermediate,,17824,,N,80852,1,In vivo antiproliferative activity against A431 cell line,F,9606.0
5002,Homo sapiens,BAO_0000219,,,9,,CHEMBL621149,,Expert,,12751,,D,9,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,9606.0
5003,Homo sapiens,BAO_0000219,,,1,,CHEMBL621150,,Expert,,12380,,N,80852,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,9606.0
5004,Homo sapiens,BAO_0000219,,,9,,CHEMBL621151,,Expert,,4959,,D,9,1,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,9606.0
5005,Homo sapiens,BAO_0000219,,,1,,CHEMBL621152,,Intermediate,,6333,,N,80852,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,9606.0
5006,Homo sapiens,BAO_0000219,,,1,,CHEMBL621153,,Intermediate,,6333,,N,80852,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,9606.0
5007,Homo sapiens,BAO_0000219,,,1,,CHEMBL884000,,Intermediate,,6333,,N,80852,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,9606.0
5008,Homo sapiens,BAO_0000019,,,9,,CHEMBL621154,,Expert,,5296,,D,9,1,Inhibition of EGFR overexpressing A431 cell proliferation,F,9606.0
5009,Homo sapiens,BAO_0000219,,,1,,CHEMBL621155,,Expert,,12624,,N,80852,1,Inhibition of A431 cell proliferation,F,9606.0
5010,Homo sapiens,BAO_0000219,,,9,,CHEMBL621156,,Expert,,14926,,D,9,1,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,9606.0
5011,Homo sapiens,BAO_0000219,,,9,,CHEMBL621157,,Expert,,14926,,D,9,1,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,9606.0
5012,,BAO_0000219,,,8,,CHEMBL621158,,Expert,,14926,,H,9,1,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,
5013,Homo sapiens,BAO_0000219,,,1,,CHEMBL621159,,Intermediate,,15144,,N,80852,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,9606.0
5014,Homo sapiens,BAO_0000219,,,1,,CHEMBL621160,,Intermediate,,15144,,N,80852,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,9606.0
5015,Homo sapiens,BAO_0000219,,,1,,CHEMBL621161,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,9606.0
5016,Homo sapiens,BAO_0000219,,,1,,CHEMBL621162,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,9606.0
5017,Homo sapiens,BAO_0000219,,,1,,CHEMBL621163,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,9606.0
5018,Homo sapiens,BAO_0000219,,,1,,CHEMBL621164,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,9606.0
5019,Homo sapiens,BAO_0000219,,,1,,CHEMBL621165,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,9606.0
5020,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619159,,Autocuration,,5922,,U,22224,1,Half-life period in cynomolgus monkey,A,9527.0
5021,Cercopithecidae,BAO_0000366,1969.0,,0,Plasma,CHEMBL619160,,Autocuration,In vitro,1116,,U,22224,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,9527.0
5022,Cercopithecidae,BAO_0000218,,,0,,CHEMBL619161,,Autocuration,In vivo,17853,,U,22224,1,Longer half-life in monkey (i.v.) at 0.5 mpk,A,9527.0
5023,Cercopithecidae,BAO_0000366,1969.0,,0,Plasma,CHEMBL619162,,Autocuration,,993,,U,22224,1,Plasma half life in monkey,A,9527.0
5024,Cercopithecidae,BAO_0000366,1969.0,,0,Plasma,CHEMBL619163,,Autocuration,,4514,,U,22224,1,Plasma half-life in rhesus monkey,A,9527.0
5025,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL619164,,Autocuration,In vivo,5334,,U,22224,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0
5026,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL619320,,Autocuration,In vivo,5334,,U,22224,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0
5027,Cercopithecidae,BAO_0000218,,,0,,CHEMBL619321,,Autocuration,In vivo,4578,,U,22224,1,Tested for half life upon iv administration to african green monkey,A,9527.0
5028,Cercopithecidae,BAO_0000218,,,0,,CHEMBL873336,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0
5029,Cercopithecidae,BAO_0000218,,,0,,CHEMBL619322,,Autocuration,In vivo,5355,,U,22224,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,9527.0
5030,Cercopithecidae,BAO_0000218,,,0,,CHEMBL619323,,Autocuration,In vivo,5355,,U,22224,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,9527.0
5031,Cercopithecidae,BAO_0000218,,,0,,CHEMBL619324,,Autocuration,In vivo,5355,,U,22224,1,The time for peak concentration value after oral administration in cynomolgus monkeys,A,9527.0
5032,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619325,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,9527.0
5033,Cercopithecidae,BAO_0000019,,,0,,CHEMBL876411,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,9527.0
5034,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619326,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,9527.0
5035,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619327,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,9527.0
5036,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619328,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,9527.0
5037,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619329,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,9527.0
5038,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619330,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,9527.0
5039,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619331,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,9527.0
5040,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619332,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,9527.0
5041,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619333,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,9527.0
5042,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619334,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,9527.0
5043,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619335,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,9527.0
5044,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619336,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,9527.0
5045,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619337,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,9527.0
5046,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619338,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,9527.0
5047,Cercopithecidae,BAO_0000019,,,0,,CHEMBL619339,,Autocuration,,11271,,U,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,9527.0
5048,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619340,,Intermediate,In vivo,5809,,N,50597,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,10116.0
5049,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL873496,,Intermediate,In vivo,17720,,N,50597,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,10116.0
5050,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL619341,,Intermediate,,3546,,N,50597,1,AUC value in rat after IV administration at a dose of 10 mg/kg,A,10116.0
5051,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL619342,,Intermediate,,3546,,N,50597,1,AUC value in rat after oral administration at a dose of 10 mg/kg,A,10116.0
5052,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619343,,Intermediate,In vivo,3546,,N,50597,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,10116.0
5053,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619344,,Intermediate,In vivo,3546,,N,50597,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,10116.0
5054,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619345,,Intermediate,In vivo,3546,,N,50597,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,10116.0
5055,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619346,,Intermediate,,3546,,N,50597,1,Vc value in rat after IV administration at a dose of 10 mg/kg,A,10116.0
5056,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL619347,,Intermediate,In vivo,3546,,N,50597,1,Half life period in rat after IV administration at a dose of 10 mg/kg,A,10116.0
5057,Papio hamadryas,BAO_0000019,,,0,,CHEMBL619348,,Autocuration,,10625,,U,22224,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,9557.0
5058,Papio hamadryas,BAO_0000019,,,0,,CHEMBL619349,,Autocuration,,10625,,U,22224,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,9557.0
5059,Papio hamadryas,BAO_0000019,,,0,,CHEMBL619350,,Autocuration,,10625,,U,22224,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,9557.0
5060,Papio hamadryas,BAO_0000019,,,0,,CHEMBL619351,,Autocuration,,10625,,U,22224,1,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,9557.0
5061,Papio hamadryas,BAO_0000019,,,0,,CHEMBL875953,,Autocuration,,10625,,U,22224,1,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,9557.0
5062,Papio hamadryas,BAO_0000019,,,0,,CHEMBL621716,,Autocuration,,10625,,U,22224,1,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,9557.0
5063,Papio hamadryas,BAO_0000019,,,0,,CHEMBL621717,,Autocuration,,10625,,U,22224,1,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,9557.0
5064,Papio hamadryas,BAO_0000019,,,0,,CHEMBL621718,,Autocuration,,10625,,U,22224,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,9557.0
5065,beagle,BAO_0000019,,,0,,CHEMBL621719,,Autocuration,,3510,,U,22224,1,Area under curve after 1 mpk peroral administration to beagles,A,9615.0
5066,beagle,BAO_0000019,,,0,,CHEMBL621720,,Autocuration,,3510,,U,22224,1,Area under curve after 2 mpk peroral administration to beagles,A,9615.0
5067,beagle,BAO_0000218,,,0,,CHEMBL621721,,Autocuration,In vivo,3510,,U,22224,1,Cmax value after 1 mpk peroral administration to beagles,A,9615.0
5068,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL621722,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,9606.0
5069,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL621723,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,9606.0
5070,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL621724,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,9606.0
5071,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL623443,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,9606.0
5072,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL623444,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,9606.0
5073,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL623445,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,9606.0
5074,Homo sapiens,BAO_0000019,1088.0,,0,Urine,CHEMBL623446,,Autocuration,,7766,,U,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,9606.0
5075,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL623447,,Autocuration,,16643,,U,22224,1,Metabolic stability observed at 30 min after administration in human liver microsomes,A,9606.0
5076,Homo sapiens,BAO_0000019,,,0,,CHEMBL623448,,Autocuration,,6852,,U,22224,1,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,9606.0
5077,Homo sapiens,BAO_0000019,,,0,,CHEMBL623449,,Autocuration,,6852,,U,22224,1,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,9606.0
5078,Homo sapiens,BAO_0000019,,,0,,CHEMBL623450,,Autocuration,,6852,,U,22224,1,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,9606.0
5079,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL623451,,Autocuration,,6567,,U,22224,1,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,9606.0
5080,Homo sapiens,BAO_0000019,,,0,,CHEMBL623452,,Autocuration,,6570,,U,22224,1,Metabolic stability (% remaining at 30 mins) in human S9.,A,9606.0
5081,Homo sapiens,BAO_0000019,,,0,,CHEMBL623453,,Autocuration,,6570,,U,22224,1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,9606.0
5082,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL623454,,Autocuration,,5237,,U,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,9606.0
5083,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL623455,,Autocuration,,5237,,U,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,9606.0
5084,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL624371,,Autocuration,,5237,,U,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,9606.0
5085,Homo sapiens,BAO_0000218,,,0,,CHEMBL624372,,Autocuration,,5202,,U,22224,1,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,9606.0
5086,Homo sapiens,BAO_0000019,,,0,,CHEMBL624373,,Autocuration,,5481,,U,22224,1,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,9606.0
5087,Homo sapiens,BAO_0000019,,,0,,CHEMBL624374,,Autocuration,,5481,,U,22224,1,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,9606.0
5088,Homo sapiens,BAO_0000019,,,0,,CHEMBL624556,,Autocuration,,3956,,U,22224,1,The percent remaining in human plasma after 30 min was determined,A,9606.0
5089,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL624557,,Autocuration,,5074,,U,22224,1,Conversion rate of the prodrug in human plasma,A,9606.0
5090,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL624558,,Autocuration,,5074,,U,22224,1,Conversion rate of the prodrug in human plasma; ND means no data,A,9606.0
5091,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL624559,,Autocuration,,4727,,U,22224,1,Half life of compound was determined in human blood,A,9606.0
5092,Homo sapiens,BAO_0000019,,,0,,CHEMBL624560,,Autocuration,,5965,,U,22224,1,Half life of compound was determined in man with once daily dosing,A,9606.0
5093,Homo sapiens,BAO_0000251,,,0,,CHEMBL624561,,Autocuration,In vitro,5732,,U,22224,1,Half life in human microsomes,A,9606.0
5094,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL624562,,Autocuration,,5819,,U,22224,1,Half life in human plasma,A,9606.0
5095,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL624563,,Autocuration,,5819,,U,22224,1,Half life in human plasma; Not detected,A,9606.0
5096,Homo sapiens,BAO_0000218,,,0,,CHEMBL624564,,Autocuration,In vivo,1916,,U,22224,1,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0
5097,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL624565,,Autocuration,In vitro,6597,,U,22224,1,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,9606.0
5098,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL875152,,Autocuration,,5229,,U,22224,1,Half-life in human plasma,A,9606.0
5099,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL624566,,Autocuration,,5229,,U,22224,1,Half-life of the parent prodrug in plasma,A,9606.0
5100,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL873805,,Autocuration,In vitro,2192,,U,22224,1,In vitro half life in human plasma was determined,A,9606.0
5101,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL624567,,Autocuration,In vitro,3032,,U,22224,1,The compound was tested In Vitro for half life in human liver microsomes.,A,9606.0
5102,Homo sapiens,BAO_0000218,,,0,,CHEMBL624568,,Autocuration,In vivo,1916,,U,22224,1,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0
5103,Homo sapiens,BAO_0000218,,,0,,CHEMBL624569,,Autocuration,In vivo,17716,,U,22224,1,Observed volume of distribution,A,9606.0
5104,Homo sapiens,BAO_0000218,,,0,,CHEMBL624570,,Autocuration,In vivo,15778,,U,22224,1,Oral bioavailability in human,A,9606.0
5105,Homo sapiens,BAO_0000019,,,0,,CHEMBL624571,,Autocuration,,17313,,U,22224,1,Tested for human plasma protein binding of the compound,A,9606.0
5106,Homo sapiens,BAO_0000019,,,0,,CHEMBL624572,,Autocuration,,4231,,U,22224,1,"First order rate constant, k was determined in human plasma",A,9606.0
5107,Homo sapiens,BAO_0000019,,,0,,CHEMBL624573,,Autocuration,,4755,,U,22224,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,9606.0
5108,Homo sapiens,BAO_0000019,,,0,,CHEMBL875153,,Autocuration,,4755,,U,22224,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,9606.0
5109,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL624574,,Autocuration,,16907,,U,22224,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,9606.0
5110,Homo sapiens,BAO_0000019,,,0,,CHEMBL624575,,Autocuration,,10839,,U,22224,1,The compound was tested for the plasma binding in human,A,9606.0
5111,Homo sapiens,BAO_0000019,,,0,,CHEMBL624576,,Autocuration,,10839,,U,22224,1,Plasma protein binding (human),A,9606.0
5112,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL624577,,Autocuration,In vitro,3199,,U,22224,1,Compound was evaluated for half-life in human liver microsomes,A,9606.0
5113,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL624578,,Autocuration,In vitro,1345,,U,22224,1,Half life measured in vitro for its stability in human blood,A,9606.0
5114,Homo sapiens,BAO_0000019,1977.0,,0,Serum,CHEMBL622796,,Autocuration,,4297,,U,22224,1,Half life in human serum,A,9606.0
5115,Homo sapiens,BAO_0000019,1977.0,,0,Serum,CHEMBL622797,,Autocuration,,4297,,U,22224,1,Half life in human serum; ND=not determined,A,9606.0
5116,Homo sapiens,BAO_0000019,,,0,,CHEMBL622798,,Autocuration,,4297,,U,22224,1,Half life were determined in CEM-SS cell extract in decomposition step 1,A,9606.0
5117,Homo sapiens,BAO_0000019,,,0,,CHEMBL622799,,Autocuration,,4297,,U,22224,1,Half life were determined in CEM-SS cell extract in decomposition step 2,A,9606.0
5118,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL622800,,Autocuration,,4231,,U,22224,1,Half life of the in human plasma,A,9606.0
5119,Homo sapiens,BAO_0000220,,,0,,CHEMBL622801,,Autocuration,In vitro,5633,,U,22224,1,Half life period in human hepatic S9 fraction was determined,A,9606.0
5120,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL622802,,Autocuration,In vitro,5633,,U,22224,1,Half life period in human liver microsome was determined,A,9606.0
5121,Homo sapiens,BAO_0000019,,,0,,CHEMBL622803,,Autocuration,,17791,,U,22224,1,Half life period was determined; 6-7,A,9606.0
5122,Homo sapiens,BAO_0000019,,,0,,CHEMBL875154,,Autocuration,,17791,,U,22224,1,Half life period was evaluated in human,A,9606.0
5123,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL622804,,Autocuration,,3160,,U,22224,1,Half life time in human plasma,A,9606.0
5124,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622805,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5125,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622611,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5126,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622612,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5127,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL875160,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5128,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL622613,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0
5129,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL622614,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5130,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL622615,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5131,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL622616,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0
5132,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL622617,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5133,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL622618,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0
5134,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL622619,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0
5135,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL622620,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5136,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622621,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5137,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622622,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution of compound (oxidized form) in blood tissue,A,10090.0
5138,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622623,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5139,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622624,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0
5140,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622625,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5141,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622626,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5142,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622627,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0
5143,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622628,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution of compound (oxidized form) in brain tissue of mice,A,10090.0
5144,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622629,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5145,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622630,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5146,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622631,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5147,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622632,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0
5148,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622633,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0
5149,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622634,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution of compound (oxidized form) in heart tissue of mice,A,10090.0
5150,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622635,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5151,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL875161,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5152,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622636,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5153,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL623335,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5154,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL623336,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0
5155,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623337,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5156,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623338,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0
5157,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623339,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5158,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623524,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0
5159,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623525,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0
5160,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623526,,Intermediate,In vivo,16438,,N,50594,1,Biodistribution of compound (oxidized form) in liver tissue,A,10090.0
5161,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623527,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0
5162,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623528,,Intermediate,In vivo,16438,,N,50594,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0
5163,Homo sapiens,BAO_0000219,,,1,,CHEMBL624615,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,9606.0
5164,Homo sapiens,BAO_0000219,,,1,,CHEMBL621672,,Intermediate,,5245,,N,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,9606.0
5165,,BAO_0000218,,,1,,CHEMBL621673,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,
5166,,BAO_0000218,,,1,,CHEMBL621674,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,
5167,Homo sapiens,BAO_0000219,,,9,,CHEMBL884002,,Expert,,16093,,D,9,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,9606.0
5168,Homo sapiens,BAO_0000219,,,1,,CHEMBL621850,,Intermediate,,16825,,N,80852,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,9606.0
5169,Homo sapiens,BAO_0000219,,,1,,CHEMBL621851,,Intermediate,,4848,,N,80852,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,9606.0
5170,Homo sapiens,BAO_0000219,,,9,,CHEMBL621852,,Expert,,14827,,D,9,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,9606.0
5171,Homo sapiens,BAO_0000219,,,9,,CHEMBL621853,,Expert,,14827,,D,9,1,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,9606.0
5172,,BAO_0000218,,,1,,CHEMBL621854,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,
5173,,BAO_0000218,,,1,,CHEMBL621855,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,
5174,,BAO_0000218,,,1,,CHEMBL623724,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,
5175,,BAO_0000218,,,1,,CHEMBL623725,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,
5176,,BAO_0000218,,,1,,CHEMBL623726,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,
5177,Homo sapiens,BAO_0000219,,,9,,CHEMBL623727,,Expert,,16289,,D,9,1,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,9606.0
5178,,BAO_0000219,,,8,,CHEMBL623728,,Expert,,16289,,H,9,1,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,
5179,,BAO_0000218,,,1,,CHEMBL623729,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,
5180,,BAO_0000218,,,1,,CHEMBL623730,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,
5181,,BAO_0000218,,,1,,CHEMBL623731,,Expert,,16289,,N,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,
5182,Mus musculus,BAO_0000218,,,1,,CHEMBL623732,,Expert,,14555,,N,80852,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0
5183,Mus musculus,BAO_0000218,,,1,,CHEMBL623733,,Expert,,14555,,N,80852,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0
5184,Mus musculus,BAO_0000218,,,1,,CHEMBL623734,,Expert,,14555,,N,80852,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0
5185,Mus musculus,BAO_0000218,,,1,,CHEMBL623735,,Expert,,14555,,N,80852,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0
5186,Homo sapiens,BAO_0000219,,,1,,CHEMBL623736,,Expert,,1937,,N,80852,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,9606.0
5187,Homo sapiens,BAO_0000219,,,1,,CHEMBL623737,,Intermediate,,13739,,N,80852,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,9606.0
5188,Homo sapiens,BAO_0000219,,,1,,CHEMBL623738,,Intermediate,,3558,,N,80852,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,9606.0
5189,Homo sapiens,BAO_0000219,,,1,,CHEMBL875168,,Intermediate,,3558,,N,80852,1,Dose giving a 50% decrease in the living cell number (A437 cells),F,9606.0
5190,Homo sapiens,BAO_0000219,,,1,,CHEMBL623739,,Expert,,17686,,N,80682,1,In vitro inhibitory concentration against proliferation of A459 cell line.,F,9606.0
5191,Homo sapiens,BAO_0000219,,,1,,CHEMBL623740,,Intermediate,,5305,,N,80682,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,9606.0
5192,Homo sapiens,BAO_0000219,,,1,,CHEMBL624424,,Intermediate,,3614,,N,80682,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,9606.0
5193,Homo sapiens,BAO_0000219,,,1,,CHEMBL624425,,Intermediate,,17229,,N,80021,1,In vitro antitumor activity against renal A498 tumor cell lines,F,9606.0
5194,Homo sapiens,BAO_0000219,,,1,,CHEMBL624426,,Intermediate,,15935,,N,80021,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,9606.0
5195,Homo sapiens,BAO_0000219,,,1,,CHEMBL624427,,Intermediate,,15935,,N,80021,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,9606.0
5196,Homo sapiens,BAO_0000219,,,1,,CHEMBL624428,,Intermediate,,15560,,N,80021,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,9606.0
5197,Homo sapiens,BAO_0000219,,,1,,CHEMBL624429,,Intermediate,,13891,,N,80021,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,9606.0
5198,Homo sapiens,BAO_0000219,,,1,,CHEMBL624620,,Intermediate,,13891,,N,80021,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,9606.0
5199,Homo sapiens,BAO_0000219,,,1,,CHEMBL624621,,Intermediate,,13788,,N,80021,1,Cytotoxicity on kidney carcinoma (A-498) cell line,F,9606.0
5200,Homo sapiens,BAO_0000219,,,1,,CHEMBL624622,,Intermediate,,15403,,N,80021,1,Compound was evaluated against Human cell line renal A498,F,9606.0
5201,Homo sapiens,BAO_0000219,,,1,,CHEMBL624623,,Intermediate,,1009,,N,80021,1,Compound was tested for inhibition of A498 human renal cancer cell line,F,9606.0
5202,Homo sapiens,BAO_0000219,,,1,,CHEMBL874365,,Intermediate,,1043,,N,80021,1,Growth inhibitory activity against A498 human cancer cell line,F,9606.0
5203,Homo sapiens,BAO_0000219,,,1,,CHEMBL624624,,Intermediate,,5858,,N,80021,1,In vitro antitumor activity against human renal A498 cell line,F,9606.0
5204,Homo sapiens,BAO_0000219,,,1,,CHEMBL624625,,Intermediate,,5958,,N,80021,1,In vitro cytotoxic activity against renal (A498) cell line,F,9606.0
5205,Homo sapiens,BAO_0000219,,,1,,CHEMBL624626,,Intermediate,,5506,,N,80021,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,9606.0
5206,Homo sapiens,BAO_0000219,,,1,,CHEMBL624627,,Intermediate,,12781,,N,80021,1,Tested for cytostatic activity against renal A498 cell line,F,9606.0
5207,Homo sapiens,BAO_0000219,,,1,,CHEMBL883157,,Intermediate,,14399,,N,80021,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,9606.0
5208,Homo sapiens,BAO_0000219,,,1,,CHEMBL624628,,Expert,,5958,,N,80021,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,9606.0
5209,beagle,BAO_0000218,,,0,,CHEMBL624629,,Autocuration,In vivo,3510,,U,22224,1,Cmax value after 2 mpk peroral administration to beagles,A,9615.0
5210,Canis lupus familiaris,BAO_0000218,,,0,,CHEMBL623551,,Autocuration,In vivo,3510,,U,22224,1,Bioavailability,A,9615.0
5211,Canis lupus familiaris,BAO_0000218,,,0,,CHEMBL623552,,Autocuration,In vivo,3510,,U,22224,1,Bioavailability after 1 mpk peroral administration to beagles,A,9615.0
5212,Canis lupus familiaris,BAO_0000218,,,0,,CHEMBL623553,,Autocuration,In vivo,3510,,U,22224,1,Bioavailability after 2 mpk peroral administration to beagles,A,9615.0
5213,Bos taurus,BAO_0000019,,,0,,CHEMBL623554,,Autocuration,,3085,,U,22224,1,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,9913.0
5214,Bos taurus,BAO_0000019,,,0,,CHEMBL623555,,Autocuration,,3085,,U,22224,1,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,9913.0
5215,Bos taurus,BAO_0000019,,,0,,CHEMBL623556,,Autocuration,,3085,,U,22224,1,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,9913.0
5216,Bos taurus,BAO_0000019,,,0,,CHEMBL623557,,Autocuration,,9372,,U,22224,1,Solubility against bovine alpha-chymotrypsin,A,9913.0
5217,Bos taurus,BAO_0000019,,,0,,CHEMBL623558,,Autocuration,,3085,,U,22224,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,9913.0
5218,Bos taurus,BAO_0000019,,,0,,CHEMBL623559,,Autocuration,,3085,,U,22224,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,9913.0
5219,Bos taurus,BAO_0000221,2106.0,,0,Spleen,CHEMBL623560,,Autocuration,,1469,,U,22224,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,9913.0
5220,Bos taurus,BAO_0000019,,,0,,CHEMBL623561,,Autocuration,,4297,,U,22224,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,9913.0
5221,Bos taurus,BAO_0000019,,,0,,CHEMBL623562,,Autocuration,,4297,,U,22224,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,9913.0
5222,Bos taurus,BAO_0000019,,,0,,CHEMBL623563,,Autocuration,,17585,,U,22224,1,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,9913.0
5223,Bos taurus,BAO_0000221,2106.0,,0,Spleen,CHEMBL623564,,Autocuration,,1336,,U,22224,1,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,9913.0
5224,Bos taurus,BAO_0000019,,,0,,CHEMBL873806,,Autocuration,,3085,,U,22224,1,Half life in presence of 2 mg/mL BSA at pH 8.8,A,9913.0
5225,Bos taurus,BAO_0000019,,,0,,CHEMBL623565,,Autocuration,,2857,,U,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,9913.0
5226,Bos taurus,BAO_0000019,,,0,,CHEMBL623566,,Autocuration,,2857,,U,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,9913.0
5227,Bos taurus,BAO_0000019,,,0,,CHEMBL623567,,Autocuration,,2857,,U,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,9913.0
5228,Bos taurus,BAO_0000019,,,0,,CHEMBL623568,,Autocuration,,1540,,U,22224,1,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,9913.0
5229,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623569,,Intermediate,,6316,,N,50588,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,9615.0
5230,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623570,,Intermediate,,17594,,N,50588,1,AUC after administration at 100 mg/kg/day in dogs,A,9615.0
5231,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624254,,Intermediate,,4953,,N,50588,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,9615.0
5232,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624255,,Intermediate,,16907,,N,50588,1,AUC value after 15 mg/kg iv dose in Dogs,A,9615.0
5233,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624256,,Intermediate,,16907,,N,50588,1,AUC value after 30 mg/kg po dose in Dogs,A,9615.0
5234,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624257,,Intermediate,,2959,,N,50588,1,AUC value after administration of 4 mg/Kg oral dose in dog,A,9615.0
5235,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624258,,Intermediate,,17594,,N,50588,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,9615.0
5236,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875277,,Intermediate,,5356,,N,50588,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,9615.0
5237,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622667,,Intermediate,,16807,,N,50588,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,9615.0
5238,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622668,,Intermediate,,4527,,N,50588,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,9615.0
5239,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622669,,Intermediate,,4527,,N,50588,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0
5240,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622670,,Intermediate,,15660,,N,50588,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,9615.0
5241,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622671,,Intermediate,,15660,,N,50588,1,Area under curve determined in dogs after oral administration of 10 mg/kg,A,9615.0
5242,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622672,,Intermediate,,5802,,N,50588,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0
5243,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622673,,Expert,,3598,,N,50588,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
5244,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622674,,Expert,,3598,,N,50588,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
5245,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622675,,Intermediate,,5944,,N,50588,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0
5246,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622676,,Intermediate,,5944,,N,50588,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,9615.0
5247,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622677,,Intermediate,,5944,,N,50588,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0
5248,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622678,,Intermediate,,5944,,N,50588,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,9615.0
5249,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622679,,Intermediate,,4186,,N,50588,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,9615.0
5250,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622680,,Intermediate,,5007,,N,50588,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0
5251,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622681,,Intermediate,,5668,,N,50588,1,Area under curve was determine after peroral administration at 10 mpk in dog,A,9615.0
5252,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875278,,Intermediate,,5668,,N,50588,1,Area under curve was determine after peroral administration at 5 mpk in dog,A,9615.0
5253,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622682,,Intermediate,,5006,,N,50588,1,Area under curve was determined,A,9615.0
5254,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622683,,Intermediate,,5006,,N,50588,1,Area under curve in dogs,A,9615.0
5255,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622684,,Intermediate,,3771,,N,50588,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,9615.0
5256,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622685,,Intermediate,,3771,,N,50588,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,9615.0
5257,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622686,,Intermediate,,3771,,N,50588,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,9615.0
5258,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618344,,Intermediate,,1916,,N,50588,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0
5259,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875582,,Intermediate,,5302,,N,50588,1,Area under curve value in dog at a dose of 5 mg/kg,A,9615.0
5260,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618345,,Intermediate,,5600,,N,50588,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,9615.0
5261,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618346,,Intermediate,,5600,,N,50588,1,Area under curve was determined after 0.3 mg/kg po administration in dog,A,9615.0
5262,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618347,,Intermediate,,17764,,N,50588,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
5263,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618348,,Intermediate,,4368,,N,50588,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,9615.0
5264,Homo sapiens,BAO_0000019,,,0,,CHEMBL618349,,Autocuration,,5318,,U,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,9606.0
5265,Homo sapiens,BAO_0000019,,,0,,CHEMBL618350,,Autocuration,,5318,,U,22224,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,9606.0
5266,Homo sapiens,BAO_0000019,,,0,,CHEMBL618351,,Autocuration,,5318,,U,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,9606.0
5267,Homo sapiens,BAO_0000019,,,0,,CHEMBL618352,,Autocuration,,5318,,U,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,9606.0
5268,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL873494,,Autocuration,,14518,,U,22224,1,Time taken to reduce 50% of the concentration of compound in blood plasma,A,9606.0
5269,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618353,,Autocuration,,2209,,U,22224,1,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,9606.0
5270,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618354,,Autocuration,,6787,,U,22224,1,Half life in human plasma,A,9606.0
5271,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL875583,,Autocuration,,4898,,U,22224,1,Half life in human plasma was reported,A,9606.0
5272,Homo sapiens,BAO_0000019,1977.0,,0,Serum,CHEMBL618355,,Autocuration,,6072,,U,22224,1,Half life in human serum,A,9606.0
5273,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618356,,Autocuration,,16907,,U,22224,1,Half life upon exposure to human plasma,A,9606.0
5274,Homo sapiens,BAO_0000251,,,0,,CHEMBL618357,,Autocuration,In vitro,5656,,U,22224,1,t1/2 in human microsomes,A,9606.0
5275,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618358,,Autocuration,,4755,,U,22224,1,Half life period in 80% human plasma at 37 degree Centigrade,A,9606.0
5276,Homo sapiens,BAO_0000221,14.0,,0,Zone of skin,CHEMBL618359,,Autocuration,,17503,,U,22224,1,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,9606.0
5277,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618360,,Autocuration,In vitro,12357,,U,22224,1,Half-life measured in in vitro Cathepsin B assay in human plasma,A,9606.0
5278,Homo sapiens,BAO_0000019,,,0,,CHEMBL618361,,Autocuration,,3076,,U,22224,1,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,9606.0
5279,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618362,,Autocuration,In vitro,6410,,U,22224,1,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,9606.0
5280,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618363,,Autocuration,,3741,,U,22224,1,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,9606.0
5281,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618364,,Autocuration,,3741,,U,22224,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,9606.0
5282,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL875584,,Autocuration,,3741,,U,22224,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,9606.0
5283,Homo sapiens,BAO_0000019,,,0,,CHEMBL618365,,Autocuration,,1540,,U,22224,1,Half-life in the CEM cell extracts,A,9606.0
5284,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL873495,,Autocuration,,2905,,U,22224,1,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,9606.0
5285,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618366,,Autocuration,,2905,,U,22224,1,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,9606.0
5286,Homo sapiens,BAO_0000019,,,0,,CHEMBL618367,,Autocuration,,5523,,U,22224,1,Half-life was determined,A,9606.0
5287,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL618368,,Autocuration,,1499,,U,22224,1,Half-life (human blood stability),A,9606.0
5288,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL618369,,Autocuration,,1499,,U,22224,1,Half-life (human blood stability); no data,A,9606.0
5289,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618370,,Autocuration,,17065,,U,22224,1,Half-life in human plasma,A,9606.0
5290,Homo sapiens,BAO_0000019,,,0,,CHEMBL618371,,Autocuration,,6861,,U,22224,1,CYP3A4 metabolism half-life (t1/2),A,9606.0
5291,Homo sapiens,BAO_0000221,178.0,,0,Blood,CHEMBL618372,,Autocuration,,1499,,U,22224,1,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,9606.0
5292,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618373,,Autocuration,In vitro,530,,U,22224,1,In vitro half life in human plasma,A,9606.0
5293,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618374,,Autocuration,In vitro,1116,,U,22224,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,9606.0
5294,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618375,,Autocuration,In vitro,6695,,U,22224,1,In vitro hydrolysis in human plasma,A,9606.0
5295,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618376,,Autocuration,In vitro,6695,,U,22224,1,In vitro hydrolysis in human plasma; no data,A,9606.0
5296,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL618377,,Autocuration,In vitro,10,,U,22224,1,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,9606.0
5297,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618378,,Autocuration,,993,,U,22224,1,Plasma half life in human,A,9606.0
5298,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618379,,Autocuration,,15429,,U,22224,1,Stability after incubation with human plasma (at 37 degree C),A,9606.0
5299,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618380,,Autocuration,,1675,,U,22224,1,T1/2 was evaluated in human plasma,A,9606.0
5300,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618381,,Autocuration,,2209,,U,22224,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,9606.0
5301,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL618382,,Autocuration,,2209,,U,22224,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,9606.0
5302,Homo sapiens,BAO_0000019,,,0,,CHEMBL618383,,Autocuration,,5318,,U,22224,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,9606.0
5303,Homo sapiens,BAO_0000019,,,0,,CHEMBL618384,,Autocuration,In vitro,2412,,U,22224,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,9606.0
5304,Homo sapiens,BAO_0000019,,,0,,CHEMBL618385,,Autocuration,In vitro,2412,,U,22224,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,9606.0
5305,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL619099,,Autocuration,,2906,,U,22224,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,9606.0
5306,Homo sapiens,BAO_0000366,1969.0,,0,Plasma,CHEMBL619100,,Autocuration,,2906,,U,22224,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,9606.0
5307,Homo sapiens,BAO_0000019,,,0,,CHEMBL619101,,Autocuration,,5495,,U,22224,1,Time taken for 50% to be consumed by serum PON1 was determined,A,9606.0
5308,Homo sapiens,BAO_0000019,,,0,,CHEMBL619102,,Autocuration,,5495,,U,22224,1,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,9606.0
5309,Homo sapiens,BAO_0000251,2107.0,,0,Liver,CHEMBL619103,,Autocuration,,4397,,U,22224,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,9606.0
5310,Mus sp.,BAO_0000218,,,0,,CHEMBL619268,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5311,Mus sp.,BAO_0000218,,,0,,CHEMBL619269,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5312,Mus sp.,BAO_0000218,,,0,,CHEMBL619270,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5313,Mus sp.,BAO_0000218,,,0,,CHEMBL619271,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5314,Mus sp.,BAO_0000218,,,0,,CHEMBL875585,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5315,Mus sp.,BAO_0000218,,,0,,CHEMBL619272,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0
5316,Homo sapiens,BAO_0000219,,,1,,CHEMBL619273,,Intermediate,,6058,,N,80640,1,Compound tested for growth inhibition of renal cancer cell line 786-0,F,9606.0
5317,Homo sapiens,BAO_0000219,,,1,,CHEMBL619274,,Intermediate,,17708,,N,80640,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,9606.0
5318,Homo sapiens,BAO_0000219,,,1,,CHEMBL619275,,Expert,,14017,,N,80640,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,9606.0
5319,Homo sapiens,BAO_0000219,,,1,,CHEMBL619276,,Intermediate,,16818,,N,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,9606.0
5320,Homo sapiens,BAO_0000219,,,1,,CHEMBL619277,,Intermediate,,16818,,N,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,9606.0
5321,Homo sapiens,BAO_0000219,,,1,,CHEMBL619278,,Intermediate,,16818,,N,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,9606.0
5322,Homo sapiens,BAO_0000219,,,1,,CHEMBL619279,,Intermediate,,11970,,N,80640,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,9606.0
5323,Homo sapiens,BAO_0000219,,,1,,CHEMBL858458,,Intermediate,,12400,,N,80640,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,9606.0
5324,Homo sapiens,BAO_0000219,,,1,,CHEMBL619280,,Expert,,12888,,N,80640,1,Cytotoxic effect on renal cancer line 786-0,F,9606.0
5325,Homo sapiens,BAO_0000219,,,1,,CHEMBL619281,,Intermediate,,15300,,N,80640,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,9606.0
5326,Homo sapiens,BAO_0000219,,,1,,CHEMBL619282,,Intermediate,,14769,,N,80640,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,9606.0
5327,Homo sapiens,BAO_0000219,,,1,,CHEMBL619283,,Intermediate,,15895,,N,80640,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,9606.0
5328,Homo sapiens,BAO_0000219,,,1,,CHEMBL619284,,Intermediate,,17376,,N,80640,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,9606.0
5329,Homo sapiens,BAO_0000219,,,1,,CHEMBL619285,,Intermediate,,14882,,N,80640,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,9606.0
5330,Homo sapiens,BAO_0000219,,,1,,CHEMBL619286,,Intermediate,,14882,,N,80640,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,9606.0
5331,Homo sapiens,BAO_0000219,,,1,,CHEMBL619287,,Intermediate,,15176,,N,80640,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,9606.0
5332,Homo sapiens,BAO_0000219,,,1,,CHEMBL857455,,Intermediate,,12696,,N,80640,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,9606.0
5333,Homo sapiens,BAO_0000219,,,1,,CHEMBL883801,,Intermediate,,2496,,N,80640,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,9606.0
5334,Homo sapiens,BAO_0000219,,,1,,CHEMBL619288,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,9606.0
5335,Homo sapiens,BAO_0000219,,,1,,CHEMBL619289,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,9606.0
5336,Homo sapiens,BAO_0000219,,,1,,CHEMBL619290,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,9606.0
5337,Homo sapiens,BAO_0000219,,,1,,CHEMBL619291,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,9606.0
5338,Homo sapiens,BAO_0000219,,,1,,CHEMBL619292,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,9606.0
5339,Homo sapiens,BAO_0000219,,,1,,CHEMBL619293,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,9606.0
5340,Homo sapiens,BAO_0000219,,,1,,CHEMBL619294,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,9606.0
5341,Homo sapiens,BAO_0000219,,,1,,CHEMBL619295,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,9606.0
5342,Homo sapiens,BAO_0000219,,,1,,CHEMBL619296,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,9606.0
5343,Homo sapiens,BAO_0000219,,,1,,CHEMBL619297,,Intermediate,,11831,,N,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,9606.0
5344,Homo sapiens,BAO_0000219,,,1,,CHEMBL619298,,Intermediate,,12782,,N,80640,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,9606.0
5345,,BAO_0000019,,,0,,CHEMBL619299,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,
5346,Homo sapiens,BAO_0000219,,,1,,CHEMBL619300,,Expert,,15313,,N,80433,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,9606.0
5347,Homo sapiens,BAO_0000219,,,1,,CHEMBL619301,,Expert,,15313,,N,80433,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,9606.0
5348,Homo sapiens,BAO_0000219,,,1,,CHEMBL619302,,Intermediate,,11544,,N,80433,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,9606.0
5349,Homo sapiens,BAO_0000219,,,1,,CHEMBL619303,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0
5350,Homo sapiens,BAO_0000219,,,1,,CHEMBL619304,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0
5351,Homo sapiens,BAO_0000219,,,1,,CHEMBL857706,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0
5352,Homo sapiens,BAO_0000219,,,1,,CHEMBL619305,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0
5353,Homo sapiens,BAO_0000219,,,1,,CHEMBL619306,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0
5354,Homo sapiens,BAO_0000219,,,1,,CHEMBL619307,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0
5355,Homo sapiens,BAO_0000219,,,1,,CHEMBL619308,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0
5356,Homo sapiens,BAO_0000219,,,1,,CHEMBL619309,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0
5357,Homo sapiens,BAO_0000219,,,1,,CHEMBL619310,,Intermediate,,9424,,N,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0
5358,Homo sapiens,BAO_0000219,,,1,,CHEMBL619311,,Intermediate,,14769,,N,80021,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,9606.0
5359,Homo sapiens,BAO_0000219,,,1,,CHEMBL619312,,Intermediate,,15354,,N,80021,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,9606.0
5360,Homo sapiens,BAO_0000219,,,1,,CHEMBL619313,,Intermediate,,17445,,N,80021,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,9606.0
5361,Homo sapiens,BAO_0000219,,,1,,CHEMBL619314,,Intermediate,,4337,,N,80021,1,In vitro inhibitory concentration against renal cancer cell line A498,F,9606.0
5362,Homo sapiens,BAO_0000219,,,1,,CHEMBL619959,,Intermediate,,15277,,N,80021,1,Cytotoxicity against A 498 tumor cell line,F,9606.0
5363,Homo sapiens,BAO_0000219,,,1,,CHEMBL619960,,Intermediate,,4812,,N,80021,1,In vitro antitumor activity against A498 human cancer cell line,F,9606.0
5364,Homo sapiens,BAO_0000219,,,1,,CHEMBL619961,,Intermediate,,4812,,N,80021,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,9606.0
5365,Homo sapiens,BAO_0000219,,,1,,CHEMBL619962,,Intermediate,,4995,,N,80021,1,Inhibitory dose required against A498 human tumor cell lines,F,9606.0
5366,Homo sapiens,BAO_0000219,,,1,,CHEMBL875586,,Intermediate,,5847,,N,80021,1,Anticancer activity against one renal cancer (A498 cell line),F,9606.0
5367,Homo sapiens,BAO_0000219,,,1,,CHEMBL619963,,Intermediate,,6557,,N,80021,1,In vitro cytotoxicity against melanoma A498 cell line,F,9606.0
5368,Homo sapiens,BAO_0000219,,,1,,CHEMBL619964,,Intermediate,,2597,,N,80021,1,Compound was tested for growth inhibitory activity against A498 cell line,F,9606.0
5369,Homo sapiens,BAO_0000219,,,1,,CHEMBL620108,,Intermediate,,6058,,N,80021,1,Compound tested for growth inhibition of renal cancer cell line A498,F,9606.0
5370,Homo sapiens,BAO_0000219,,,1,,CHEMBL620109,,Intermediate,,17708,,N,80021,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,9606.0
5371,Homo sapiens,BAO_0000219,,,1,,CHEMBL620110,,Intermediate,,15176,,N,80021,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,9606.0
5372,Homo sapiens,BAO_0000219,,,1,,CHEMBL620111,,Intermediate,,15300,,N,80021,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,9606.0
5373,Homo sapiens,BAO_0000219,,,1,,CHEMBL620112,,Intermediate,,11970,,N,80021,1,Tested for cytotoxicity against A498 cell lines in renal cancer,F,9606.0
5374,Homo sapiens,BAO_0000219,,,1,,CHEMBL620113,,Intermediate,,12400,,N,80021,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,9606.0
5375,Homo sapiens,BAO_0000219,,,1,,CHEMBL620114,,Expert,,12888,,N,80021,1,Cytotoxic effect on renal cancer lines A498,F,9606.0
5376,Homo sapiens,BAO_0000219,,,1,,CHEMBL620115,,Intermediate,,3030,,N,80021,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,9606.0
5377,Homo sapiens,BAO_0000219,,,1,,CHEMBL620116,,Intermediate,,14769,,N,80021,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,9606.0
5378,Homo sapiens,BAO_0000219,,,1,,CHEMBL620117,,Intermediate,,17376,,N,80021,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,9606.0
5379,Homo sapiens,BAO_0000219,,,1,,CHEMBL620118,,Intermediate,,16558,,N,80021,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,9606.0
5380,Homo sapiens,BAO_0000219,,,1,,CHEMBL620119,,Intermediate,,5194,,N,80021,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,9606.0
5381,Homo sapiens,BAO_0000219,,,1,,CHEMBL620120,,Intermediate,,10708,,N,80021,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,9606.0
5382,Homo sapiens,BAO_0000219,,,1,,CHEMBL620121,,Expert,,16880,,N,80682,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,9606.0
5383,Homo sapiens,BAO_0000219,,,1,,CHEMBL620122,,Intermediate,,10196,,N,80682,1,Antitumor activity against A549 human lung carcinoma cell line,F,9606.0
5384,Homo sapiens,BAO_0000219,,,1,,CHEMBL620123,,Intermediate,,10196,,N,80682,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,9606.0
5385,Homo sapiens,BAO_0000219,,,1,,CHEMBL620124,,Intermediate,,10196,,N,80682,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,9606.0
5386,Homo sapiens,BAO_0000219,,,1,,CHEMBL620125,,Intermediate,,12083,,N,80682,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,9606.0
5387,Homo sapiens,BAO_0000219,,,1,,CHEMBL620126,,Expert,,16464,,N,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,9606.0
5388,Homo sapiens,BAO_0000219,,,1,,CHEMBL883027,,Intermediate,,16464,,N,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5389,Homo sapiens,BAO_0000219,,,1,,CHEMBL620127,,Expert,,16470,,N,80682,1,In vitro cytotoxic activity against human lung A549 cell line,F,9606.0
5390,Homo sapiens,BAO_0000219,,,1,,CHEMBL620128,,Intermediate,,16470,,N,80682,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,9606.0
5391,Homo sapiens,BAO_0000219,,,1,,CHEMBL620129,,Intermediate,,16470,,N,80682,1,In vitro cytotoxic activity against human lung A549 cell line),F,9606.0
5392,Homo sapiens,BAO_0000219,,,1,,CHEMBL620130,,Intermediate,,16470,,N,80682,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,9606.0
5393,Homo sapiens,BAO_0000219,,,1,,CHEMBL620131,,Expert,,16582,,N,80682,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,9606.0
5394,Homo sapiens,BAO_0000219,,,1,,CHEMBL620132,,Intermediate,,15935,,N,80682,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,9606.0
5395,Homo sapiens,BAO_0000219,,,1,,CHEMBL620133,,Intermediate,,15935,,N,80682,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,9606.0
5396,Homo sapiens,BAO_0000219,,,1,,CHEMBL620134,,Expert,,16597,,N,80682,1,Inhibition of A549 human lung carcinoma cell proliferation,F,9606.0
5397,Homo sapiens,BAO_0000219,,,1,,CHEMBL620135,,Intermediate,,17376,,N,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line,F,9606.0
5398,Homo sapiens,BAO_0000219,,,1,,CHEMBL620136,,Intermediate,,16496,,N,80682,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,9606.0
5399,Homo sapiens,BAO_0000219,,,1,,CHEMBL620137,,Intermediate,,16152,,N,80682,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,9606.0
5400,Homo sapiens,BAO_0000219,,,1,,CHEMBL620268,,Intermediate,,16152,,N,80682,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,9606.0
5401,Homo sapiens,BAO_0000219,,,1,,CHEMBL620269,,Intermediate,,16464,,N,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5402,Homo sapiens,BAO_0000219,,,1,,CHEMBL620270,,Intermediate,,2288,,N,80682,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,9606.0
5403,Homo sapiens,BAO_0000219,,,1,,CHEMBL620271,,Intermediate,,17350,,N,80682,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,9606.0
5404,Homo sapiens,BAO_0000219,,,1,,CHEMBL620272,,Expert,,4090,,N,80682,1,Inhibition of A549 cancer cell proliferation,F,9606.0
5405,Homo sapiens,BAO_0000219,,,1,,CHEMBL620273,,Expert,,4090,,N,80682,1,Inhibition of A549 cancer cell proliferation (Not tested),F,9606.0
5406,Homo sapiens,BAO_0000219,,,1,,CHEMBL620274,,Intermediate,,17350,,N,80682,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,9606.0
5407,Homo sapiens,BAO_0000219,,,1,,CHEMBL620275,,Intermediate,,4197,,N,80682,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,9606.0
5408,Homo sapiens,BAO_0000219,,,1,,CHEMBL620276,,Intermediate,,17072,,N,80682,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,9606.0
5409,Homo sapiens,BAO_0000219,,,1,,CHEMBL620277,,Intermediate,,17072,,N,80682,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,9606.0
5410,Homo sapiens,BAO_0000219,,,1,,CHEMBL620278,,Intermediate,,5194,,N,80682,1,Cytotoxicity against Renal cell lines A549 was determined,F,9606.0
5411,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620279,,Intermediate,,4257,,N,50588,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,9615.0
5412,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620280,,Intermediate,,6123,,N,50588,1,Area under curve was determined in dog after oral administration at 1 mg/kg,A,9615.0
5413,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620281,,Intermediate,,1337,,N,50588,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
5414,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620282,,Intermediate,,1337,,N,50588,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
5415,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621134,,Intermediate,,8833,,N,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,9615.0
5416,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621135,,Intermediate,,8833,,N,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,9615.0
5417,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621136,,Intermediate,,8833,,N,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,9615.0
5418,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621137,,Intermediate,,8833,,N,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,9615.0
5419,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621138,,Intermediate,,17657,,N,50588,1,Area under plasma concentration time curve in dog upon oral administration,A,9615.0
5420,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL875587,,Intermediate,,17650,,N,50588,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,9615.0
5421,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621139,,Intermediate,,1977,,N,50588,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,9615.0
5422,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621140,,Intermediate,,1977,,N,50588,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,9615.0
5423,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621141,,Intermediate,,3132,,N,50588,1,Area under the curve for the compound was obtained when tested in dog,A,9615.0
5424,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621142,,Intermediate,,5473,,N,50588,1,Area under the curve at a dose of 1 mg/kg,A,9615.0
5425,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621143,,Intermediate,,5474,,N,50588,1,Area under the curve at a dose of 1 mg/kg (oral),A,9615.0
5426,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621144,,Intermediate,,5474,,N,50588,1,Area under the curve at i.v. dose of 0.2 mg/kg,A,9615.0
5427,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621145,,Intermediate,,6062,,N,50588,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,9615.0
5428,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621146,,Intermediate,,4709,,N,50588,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,9615.0
5429,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622567,,Intermediate,,2652,,N,50588,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,9615.0
5430,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622568,,Intermediate,,2652,,N,50588,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,9615.0
5431,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622569,,Intermediate,,2877,,N,50588,1,Compound was evaluated for area under the curve in dog blood.,A,9615.0
5432,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622570,,Intermediate,,5444,,N,50588,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,9615.0
5433,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622571,,Intermediate,,5130,,N,50588,1,AUC in dog after oral dose (1 mg/kg),A,9615.0
5434,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622572,,Intermediate,,6265,,N,50588,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,9615.0
5435,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622573,,Intermediate,,4657,,N,50588,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,9615.0
5436,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622574,,Intermediate,,16367,,N,50588,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,9615.0
5437,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622575,,Intermediate,,16367,,N,50588,1,Pharmacokinetic parameter AUC after oral administration to dogs,A,9615.0
5438,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622576,,Intermediate,,9579,,N,50588,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,9615.0
5439,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622577,,Intermediate,,9579,,N,50588,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,9615.0
5440,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622578,,Intermediate,,5983,,N,50588,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,9615.0
5441,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622579,,Intermediate,,6241,,N,50588,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,9615.0
5442,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622580,,Intermediate,,5313,,N,50588,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,9615.0
5443,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622581,,Intermediate,,5313,,N,50588,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,9615.0
5444,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622582,,Intermediate,,6642,,N,50588,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0
5445,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622583,,Intermediate,,6642,,N,50588,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0
5446,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622584,,Intermediate,,6641,,N,50588,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,9615.0
5447,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622585,,Intermediate,,6642,,N,50588,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,9615.0
5448,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622586,,Intermediate,,17791,,N,50588,1,Compound was evaluated for oral bioavailability in dog; 90-100,A,9615.0
5449,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623281,,Intermediate,,17655,,N,50588,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,9615.0
5450,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623282,,Intermediate,,17655,,N,50588,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,9615.0
5451,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623283,,Intermediate,,6596,,N,50588,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,9615.0
5452,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623284,,Intermediate,,3880,,N,50588,1,Oral bioavailability in dog,A,9615.0
5453,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623285,,Intermediate,,16367,,N,50588,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,9615.0
5454,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623463,,Intermediate,,17409,,N,50588,1,Plasma protein binding towards dog plasma at 10 uM,A,9615.0
5455,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL875952,,Intermediate,,17409,,N,50588,1,Plasma protein binding towards dog plasma at 100 uM,A,9615.0
5456,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621705,,Intermediate,In vivo,2959,,N,50588,1,Bioavailability in dog (dose 4 mg/kg p.o.),A,9615.0
5457,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621706,,Intermediate,In vivo,13501,,N,50588,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,9615.0
5458,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621707,,Intermediate,In vivo,4527,,N,50588,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0
5459,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621708,,Intermediate,In vivo,15145,,N,50588,1,Bioavailability in dogs,A,9615.0
5460,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621709,,Intermediate,In vivo,4219,,N,50588,1,Bioavailability,A,9615.0
5461,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621710,,Intermediate,In vivo,17538,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0
5462,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621711,,Intermediate,In vivo,17538,,N,50588,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,9615.0
5463,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621712,,Intermediate,In vivo,1466,,N,50588,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,9615.0
5464,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621713,,Intermediate,In vivo,17650,,N,50588,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,9615.0
5465,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621714,,Intermediate,In vivo,3132,,N,50588,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,9615.0
5466,Mus sp.,BAO_0000218,,,0,,CHEMBL621715,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5467,Mus sp.,BAO_0000218,2107.0,,0,Liver,CHEMBL623717,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5468,Mus sp.,BAO_0000218,2107.0,,0,Liver,CHEMBL623718,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0
5469,Mus sp.,BAO_0000218,2107.0,,0,Liver,CHEMBL623719,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5470,Mus sp.,BAO_0000218,,,0,,CHEMBL623720,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5471,Mus sp.,BAO_0000218,,,0,,CHEMBL623721,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5472,Mus sp.,BAO_0000218,2385.0,,0,Muscle tissue,CHEMBL623722,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5473,Mus sp.,BAO_0000218,2385.0,,0,Muscle tissue,CHEMBL623723,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0
5474,Mus sp.,BAO_0000218,2385.0,,0,Muscle tissue,CHEMBL618543,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5475,Mus sp.,BAO_0000218,2106.0,,0,Spleen,CHEMBL618544,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5476,Mus sp.,BAO_0000218,2106.0,,0,Spleen,CHEMBL875155,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5477,Mus sp.,BAO_0000218,,,0,,CHEMBL618545,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0
5478,Mus sp.,BAO_0000218,,,0,,CHEMBL618546,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0
5479,Mus sp.,BAO_0000218,,,0,,CHEMBL623529,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5480,Mus sp.,BAO_0000218,,,0,,CHEMBL623530,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0
5481,Mus sp.,BAO_0000218,,,0,,CHEMBL621764,,Autocuration,,2413,,U,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0
5482,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621765,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,9527.0
5483,Cercopithecidae,BAO_0000019,2037.0,,0,Cerebellum,CHEMBL621766,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,9527.0
5484,Cercopithecidae,BAO_0000019,1870.0,,0,Frontal cortex,CHEMBL621767,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,9527.0
5485,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621768,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,9527.0
5486,Cercopithecidae,BAO_0000019,2435.0,,0,Striatum,CHEMBL621769,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,9527.0
5487,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621770,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,9527.0
5488,Cercopithecidae,BAO_0000019,2037.0,,0,Cerebellum,CHEMBL621771,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,9527.0
5489,Cercopithecidae,BAO_0000019,1870.0,,0,Frontal cortex,CHEMBL621772,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,9527.0
5490,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621773,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,9527.0
5491,Cercopithecidae,BAO_0000019,2435.0,,0,Striatum,CHEMBL621774,,Autocuration,,17827,,U,22224,1,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,9527.0
5492,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621775,,Autocuration,,17791,,U,22224,1,Compound was evaluated for oral bioavailability in rats,A,9527.0
5493,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL621776,,Autocuration,In vivo,17667,,U,22224,1,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,9527.0
5494,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621777,,Autocuration,,17791,,U,22224,1,Half life period was evaluated in monkey,A,9527.0
5495,Cercopithecidae,BAO_0000218,,,0,,CHEMBL875162,,Autocuration,In vivo,110,,U,22224,1,Half-life in rhesus monkeys by intravenous administration of dose,A,9527.0
5496,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL621778,,Intermediate,,5781,,N,50594,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,10090.0
5497,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL621779,,Intermediate,,17734,,N,50594,1,AUC after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
5498,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622479,,Intermediate,,17718,,N,50594,1,AUC value was determined after oral administration,A,10090.0
5499,Mus musculus,BAO_0000218,,,1,,CHEMBL622480,,Intermediate,,4573,,N,50594,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,10090.0
5500,Mus musculus,BAO_0000218,,,1,,CHEMBL622481,,Intermediate,,3277,,N,50594,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0
5501,Mus musculus,BAO_0000218,,,1,,CHEMBL622482,,Intermediate,,2862,,N,50594,1,Area under curve by ioral administration in mouse,A,10090.0
5502,Mus musculus,BAO_0000218,,,1,,CHEMBL622483,,Intermediate,,2862,,N,50594,1,Area under curve by iv administration in mouse,A,10090.0
5503,Mus musculus,BAO_0000218,,,1,,CHEMBL622484,,Intermediate,,5951,,N,50594,1,Area under curve at 0-8 hr in IRC mice after peroral administration,A,10090.0
5504,Mus musculus,BAO_0000218,,,1,,CHEMBL622641,,Intermediate,,17729,,N,50594,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,10090.0
5505,Mus musculus,BAO_0000218,,,1,,CHEMBL622642,,Intermediate,,17728,,N,50594,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,10090.0
5506,Mus musculus,BAO_0000218,,,1,,CHEMBL622643,,Intermediate,,17728,,N,50594,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,10090.0
5507,Mus musculus,BAO_0000218,,,1,,CHEMBL622644,,Intermediate,,17729,,N,50594,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,10090.0
5508,Homo sapiens,BAO_0000219,,,1,,CHEMBL622645,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0
5509,Homo sapiens,BAO_0000219,,,1,,CHEMBL622646,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0
5510,Homo sapiens,BAO_0000219,,,1,,CHEMBL621238,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0
5511,Homo sapiens,BAO_0000219,,,1,,CHEMBL621239,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0
5512,Homo sapiens,BAO_0000219,,,1,,CHEMBL621240,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0
5513,Homo sapiens,BAO_0000219,,,1,,CHEMBL621241,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0
5514,Homo sapiens,BAO_0000219,,,1,,CHEMBL621242,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0
5515,Homo sapiens,BAO_0000219,,,1,,CHEMBL620350,,Intermediate,,9424,,N,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0
5516,Homo sapiens,BAO_0000219,,,1,,CHEMBL620351,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0
5517,Homo sapiens,BAO_0000219,,,1,,CHEMBL620352,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0
5518,Homo sapiens,BAO_0000219,,,1,,CHEMBL620353,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0
5519,Homo sapiens,BAO_0000219,,,1,,CHEMBL620354,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0
5520,Homo sapiens,BAO_0000219,,,1,,CHEMBL620355,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0
5521,Homo sapiens,BAO_0000219,,,1,,CHEMBL620356,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0
5522,Homo sapiens,BAO_0000219,,,1,,CHEMBL620357,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0
5523,Homo sapiens,BAO_0000219,,,1,,CHEMBL620358,,Intermediate,,9424,,N,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0
5524,Homo sapiens,BAO_0000219,,,1,,CHEMBL620359,,Expert,,9424,,N,80433,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,9606.0
5525,Homo sapiens,BAO_0000219,,,1,,CHEMBL620360,,Intermediate,,11544,,N,80433,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,9606.0
5526,Homo sapiens,BAO_0000219,,,1,,CHEMBL620361,,Intermediate,,17378,,N,80433,1,Cytotoxicity of compound against 8226/DOX1V cells,F,9606.0
5527,Homo sapiens,BAO_0000219,,,1,,CHEMBL620362,,Intermediate,,17378,,N,80433,1,Cytotoxicity of compound against 8226/S cells,F,9606.0
5528,Homo sapiens,BAO_0000219,,,1,,CHEMBL620363,,Intermediate,,17079,,N,80433,1,Inhibitory concentration against 8226 myeloma cancer cell line,F,9606.0
5529,Homo sapiens,BAO_0000219,,,1,,CHEMBL620364,,Intermediate,,17079,,N,80433,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,9606.0
5530,Homo sapiens,BAO_0000219,,,1,,CHEMBL620365,,Intermediate,,13466,,N,80647,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,9606.0
5531,Homo sapiens,BAO_0000219,,,1,,CHEMBL620366,,Intermediate,,13466,,N,80647,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,9606.0
5532,Homo sapiens,BAO_0000219,,,1,,CHEMBL620367,,Expert,,2392,,N,80647,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,9606.0
5533,Homo sapiens,BAO_0000219,,,1,,CHEMBL620368,,Intermediate,,2392,,N,80647,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,9606.0
5534,,BAO_0000019,,,0,,CHEMBL620369,,Autocuration,,6608,,U,22226,1,Inhibitory activity against caspase-1,B,
5535,Enterococcus faecalis,BAO_0000357,,,8,,CHEMBL620370,,Autocuration,,10199,,H,45,1,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,1351.0
5536,Homo sapiens,BAO_0000219,,,1,,CHEMBL620371,,Intermediate,,17749,,N,80648,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,9606.0
5537,Homo sapiens,BAO_0000219,,,1,,CHEMBL620372,,Intermediate,,17749,,N,80648,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,9606.0
5538,,BAO_0000019,,,0,,CHEMBL876492,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,
5539,,BAO_0000019,,,0,,CHEMBL620373,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,
5540,,BAO_0000019,,,0,,CHEMBL620374,,Intermediate,,1229,,U,22226,1,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,
5541,,BAO_0000019,,,0,,CHEMBL620375,,Autocuration,,6390,,U,22226,1,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,
5542,Streptococcus pyogenes,BAO_0000019,,,0,,CHEMBL857902,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1314.0
5543,Streptococcus pyogenes,BAO_0000019,,,0,,CHEMBL620376,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1314.0
5544,,BAO_0000357,,,8,,CHEMBL620377,,Autocuration,,17043,,H,11922,1,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,
5545,Homo sapiens,BAO_0000219,,,1,,CHEMBL620378,,Intermediate,,6929,,N,81115,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,9606.0
5546,Homo sapiens,BAO_0000219,,,1,,CHEMBL620379,,Intermediate,,6929,,N,81115,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,9606.0
5547,Homo sapiens,BAO_0000219,,,0,,CHEMBL620380,,Autocuration,,7083,,U,22226,1,In vitro cytotoxicity of compound was tested against 9KB cells.,F,9606.0
5548,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL884006,,Intermediate,,12446,,N,80653,1,Cytotoxic concentration against 9L cells was determined on day 3,F,10116.0
5549,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL620381,,Expert,,15345,,N,80653,1,Tested in vitro for anticancer activity against 9L cells,F,10116.0
5550,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL620382,,Expert,,15345,,N,80653,1,Tested in vitro for anticancer activity against 9L cells; Not determined,F,10116.0
5551,Homo sapiens,BAO_0000219,,,1,,CHEMBL620383,,Intermediate,,6301,,N,80682,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,9606.0
5552,Homo sapiens,BAO_0000219,,,1,,CHEMBL876493,,Intermediate,,4833,,N,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,9606.0
5553,Homo sapiens,BAO_0000219,,,1,,CHEMBL620384,,Intermediate,,4833,,N,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,9606.0
5554,Homo sapiens,BAO_0000219,,,1,,CHEMBL620385,,Intermediate,,4833,,N,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,9606.0
5555,Homo sapiens,BAO_0000219,,,1,,CHEMBL620386,,Expert,,13330,,N,80682,1,Cytotoxicity against human lung carcinoma A549 cell line,F,9606.0
5556,Homo sapiens,BAO_0000219,,,9,,CHEMBL620387,,Expert,,17517,,D,25,1,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,9606.0
5557,Homo sapiens,BAO_0000219,,,9,,CHEMBL621404,,Expert,,17517,,D,25,1,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,9606.0
5558,Homo sapiens,BAO_0000219,,,1,,CHEMBL621405,,Intermediate,,14425,,N,80682,1,"In vitro growth inhibition of A549, lung carcinoma",F,9606.0
5559,Homo sapiens,BAO_0000219,,,1,,CHEMBL621406,,Intermediate,,14425,,N,80682,1,"In vitro growth inhibition of A549, lung carcinoma.",F,9606.0
5560,Homo sapiens,BAO_0000219,,,1,,CHEMBL621407,,Expert,,5228,,N,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0
5561,Homo sapiens,BAO_0000219,,,1,,CHEMBL621408,,Intermediate,,5351,,N,80682,1,Cytotoxic activity against human lung cancer A549 cell line was determined,F,9606.0
5562,Homo sapiens,BAO_0000219,,,1,,CHEMBL885345,,Expert,,12198,,N,80682,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,9606.0
5563,Homo sapiens,BAO_0000219,,,1,,CHEMBL621409,,Intermediate,,13891,,N,80682,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,9606.0
5564,Homo sapiens,BAO_0000219,,,1,,CHEMBL876034,,Expert,,5677,,N,80682,1,Cytotoxicity in A549 (human carcinoma) cell line.,F,9606.0
5565,Homo sapiens,BAO_0000219,,,1,,CHEMBL621410,,Intermediate,,13788,,N,80682,1,Cytotoxicity on lung carcinoma (A-549) cell line,F,9606.0
5566,Homo sapiens,BAO_0000219,,,1,,CHEMBL621411,,Expert,,13384,,N,80682,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,9606.0
5567,Homo sapiens,BAO_0000219,,,1,,CHEMBL621412,,Intermediate,,6726,,N,80682,1,Effective dose of compound against replication of A549 cell line was evaluated,F,9606.0
5568,Homo sapiens,BAO_0000219,,,1,,CHEMBL621413,,Expert,,3455,,N,80682,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,9606.0
5569,Homo sapiens,BAO_0000219,,,1,,CHEMBL621414,,Intermediate,,5726,,N,80682,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,9606.0
5570,Homo sapiens,BAO_0000219,,,1,,CHEMBL621415,,Intermediate,,5726,,N,80682,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,9606.0
5571,Homo sapiens,BAO_0000219,,,1,,CHEMBL621416,,Intermediate,,3936,,N,80682,1,The compound was evaluated for antiproliferative activity against A549 cell line,F,9606.0
5572,Homo sapiens,BAO_0000219,,,1,,CHEMBL621417,,Intermediate,,14991,,N,80682,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,9606.0
5573,Homo sapiens,BAO_0000219,,,1,,CHEMBL621418,,Intermediate,,5243,,N,80682,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,9606.0
5574,Homo sapiens,BAO_0000219,,,1,,CHEMBL621419,,Intermediate,,12858,,N,80682,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,9606.0
5575,Homo sapiens,BAO_0000219,,,1,,CHEMBL621420,,Intermediate,,6776,,N,80682,1,Growth inhibition against A549 cell line was evaluated,F,9606.0
5576,Homo sapiens,BAO_0000219,,,1,,CHEMBL875823,,Intermediate,,16558,,N,80682,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,9606.0
5577,Homo sapiens,BAO_0000219,,,1,,CHEMBL621421,,Expert,,4583,,N,80682,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,9606.0
5578,Homo sapiens,BAO_0000219,,,1,,CHEMBL621422,,Intermediate,,13514,,N,80682,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,9606.0
5579,Homo sapiens,BAO_0000219,,,1,,CHEMBL884014,,Expert,,15166,,N,80682,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,9606.0
5580,Homo sapiens,BAO_0000219,,,1,,CHEMBL621423,,Intermediate,,13873,,N,80682,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,9606.0
5581,Homo sapiens,BAO_0000219,,,1,,CHEMBL621424,,Expert,,6447,,N,80682,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,9606.0
5582,Homo sapiens,BAO_0000219,,,1,,CHEMBL621425,,Intermediate,,2068,,N,80682,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,9606.0
5583,Homo sapiens,BAO_0000219,,,1,,CHEMBL621426,,Expert,,1863,,N,80682,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,9606.0
5584,Homo sapiens,BAO_0000219,,,1,,CHEMBL621427,,Intermediate,,13873,,N,80682,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,9606.0
5585,Homo sapiens,BAO_0000219,,,1,,CHEMBL621428,,Intermediate,,13873,,N,80682,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,9606.0
5586,Homo sapiens,BAO_0000219,,,1,,CHEMBL621429,,Expert,,13873,,N,80682,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,9606.0
5587,Homo sapiens,BAO_0000219,,,1,,CHEMBL621430,,Intermediate,,579,,N,80682,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,9606.0
5588,Homo sapiens,BAO_0000219,,,1,,CHEMBL621431,,Intermediate,,579,,N,80682,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,9606.0
5589,Homo sapiens,BAO_0000219,,,1,,CHEMBL621432,,Intermediate,,4584,,N,80682,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,9606.0
5590,Homo sapiens,BAO_0000219,,,1,,CHEMBL621433,,Expert,,5421,,N,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,9606.0
5591,Homo sapiens,BAO_0000219,,,1,,CHEMBL875824,,Intermediate,,5421,,N,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,9606.0
5592,Homo sapiens,BAO_0000219,,,1,,CHEMBL621434,,Intermediate,,5421,,N,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,9606.0
5593,Homo sapiens,BAO_0000219,,,1,,CHEMBL621435,,Intermediate,,5421,,N,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,9606.0
5594,Homo sapiens,BAO_0000219,,,1,,CHEMBL621436,,Intermediate,,14188,,N,80682,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,9606.0
5595,Homo sapiens,BAO_0000219,,,1,,CHEMBL621437,,Intermediate,,14188,,N,80682,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,9606.0
5596,Homo sapiens,BAO_0000219,,,1,,CHEMBL621438,,Intermediate,,15354,,N,80682,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,9606.0
5597,Homo sapiens,BAO_0000219,,,1,,CHEMBL621439,,Expert,,14253,,N,80682,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,9606.0
5598,Homo sapiens,BAO_0000219,,,1,,CHEMBL621440,,Intermediate,,13873,,N,80682,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,9606.0
5599,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621441,,Intermediate,In vivo,3043,,N,50588,1,Oral bioavailability in dog (conscious),A,9615.0
5600,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621442,,Intermediate,In vivo,3045,,N,50588,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,9615.0
5601,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621443,,Intermediate,In vivo,3022,,N,50588,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,9615.0
5602,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621444,,Intermediate,In vivo,4453,,N,50588,1,Oral bioavailability in dog,A,9615.0
5603,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625133,,Intermediate,In vivo,1696,,N,50588,1,Oral bioavailability in dog,A,9615.0
5604,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625134,,Intermediate,In vivo,5045,,N,50588,1,Oral bioavailability in dog,A,9615.0
5605,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625135,,Intermediate,In vivo,5356,,N,50588,1,Oral bioavailability in dog (fasted),A,9615.0
5606,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625136,,Intermediate,In vivo,17764,,N,50588,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
5607,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625137,,Intermediate,In vivo,6448,,N,50588,1,Oral bioavailability in dog,A,9615.0
5608,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625138,,Intermediate,In vivo,1475,,N,50588,1,Oral bioavailability in dog,A,9615.0
5609,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625139,,Intermediate,In vivo,3788,,N,50588,1,Percent bioavailability in dog,A,9615.0
5610,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL872264,,Intermediate,In vivo,3639,,N,50588,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,9615.0
5611,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625140,,Intermediate,In vivo,13397,,N,50588,1,Oral bioavailability in dog,A,9615.0
5612,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624436,,Intermediate,In vivo,2137,,N,50588,1,The compound was evaluated for bioavailability in dogs; 34-44,A,9615.0
5613,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624437,,Intermediate,In vivo,2959,,N,50588,1,Bioavailability in dog (dose 4 mg/kg p.o.),A,9615.0
5614,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL872261,,Intermediate,In vivo,6448,,N,50588,1,Oral bioavailability in dog,A,9615.0
5615,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624438,,Intermediate,,6084,,N,50588,1,8 hour trough Blood level in dog was measured after administration of compound,A,9615.0
5616,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624439,,Intermediate,In vivo,3639,,N,50588,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,9615.0
5617,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624440,,Intermediate,,6316,,N,50588,1,C24 after oral administration at 5 mg/kg,A,9615.0
5618,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624441,,Intermediate,,5238,,N,50588,1,Clearance after oral and iv dosing in dogs,A,9615.0
5619,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624442,,Intermediate,,17796,,N,50588,1,Clearance of the drug was measured in the plasma of dog,A,9615.0
5620,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624443,,Intermediate,,2652,,N,50588,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,9615.0
5621,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624444,,Intermediate,In vivo,5654,,N,50588,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0
5622,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624445,,Intermediate,In vivo,6621,,N,50588,1,Clearance of compound was determined in dogs,A,9615.0
5623,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624446,,Intermediate,In vivo,6505,,N,50588,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,9615.0
5624,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624447,,Intermediate,In vivo,5802,,N,50588,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0
5625,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624448,,Intermediate,In vivo,17267,,N,50588,1,Plasma clearance in dog was determined,A,9615.0
5626,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624449,,Intermediate,In vivo,4521,,N,50588,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0
5627,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624450,,Intermediate,In vivo,6535,,N,50588,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,9615.0
5628,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875942,,Intermediate,In vivo,6535,,N,50588,1,Plasma clearance in dog after administration of 1 mg/kg iv,A,9615.0
5629,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624451,,Intermediate,In vivo,6535,,N,50588,1,Plasma clearance in dogs,A,9615.0
5630,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624452,,Intermediate,In vivo,5542,,N,50588,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,9615.0
5631,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624453,,Intermediate,In vivo,5199,,N,50588,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,9615.0
5632,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624454,,Intermediate,In vivo,16907,,N,50588,1,Plasma clearance after 15 mg/kg iv dose in Dogs,A,9615.0
5633,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624455,,Intermediate,In vivo,16907,,N,50588,1,Plasma clearance after 30 mg/kg po dose in Dogs,A,9615.0
5634,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624456,,Intermediate,In vivo,16367,,N,50588,1,Plasma administration to dogs,A,9615.0
5635,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624457,,Intermediate,In vivo,5505,,N,50588,1,Plasma clearance was determined,A,9615.0
5636,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624458,,Intermediate,In vivo,6215,,N,50588,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0
5637,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624459,,Intermediate,In vivo,1466,,N,50588,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0
5638,Homo sapiens,BAO_0000251,2107.0,,2,Liver,CHEMBL624460,,Intermediate,In vitro,5007,,S,102164,1,Intrinsic clearance in human liver microsomes,A,9606.0
5639,Homo sapiens,BAO_0000251,2107.0,,2,Liver,CHEMBL624461,,Intermediate,In vitro,5007,,S,102164,1,Intrinsic clearance in human liver microsomes,A,9606.0
5640,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875943,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0
5641,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624462,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0
5642,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624463,,Intermediate,In vivo,16452,,N,50588,1,Clearance in dog (dose 1 mg/kg i.v.),A,9615.0
5643,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624464,,Intermediate,In vivo,6221,,N,50588,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,9615.0
5644,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624465,,Intermediate,In vivo,5007,,N,50588,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0
5645,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624466,,Intermediate,In vivo,5668,,N,50588,1,Plasma clearance after peroral administration at 10 mpk in dog,A,9615.0
5646,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624467,,Intermediate,In vivo,5668,,N,50588,1,Plasma clearance after peroral administration at 5 mpk in dog,A,9615.0
5647,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624468,,Intermediate,In vivo,5668,,N,50588,1,Plasma clearance after peroral administration at 5 mg/kg in dog,A,9615.0
5648,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624469,,Intermediate,In vivo,15660,,N,50588,1,Plasma clearance was measured in dog,A,9615.0
5649,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624470,,Intermediate,In vivo,15660,,N,50588,1,Plasma clearance was measured in dog,A,9615.0
5650,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624471,,Intermediate,In vivo,5983,,N,50588,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,9615.0
5651,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624472,,Intermediate,In vivo,5600,,N,50588,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,9615.0
5652,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622775,,Intermediate,In vivo,17764,,N,50588,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
5653,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622776,,Intermediate,In vivo,6039,,N,50588,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,9615.0
5654,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622777,,Intermediate,In vivo,6039,,N,50588,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,9615.0
5655,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622778,,Intermediate,In vivo,6039,,N,50588,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,9615.0
5656,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622779,,Intermediate,In vivo,4368,,N,50588,1,Clearance by intravenous administration of 1.2 mg/kg in dog,A,9615.0
5657,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622780,,Intermediate,In vivo,4305,,N,50588,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,9615.0
5658,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622781,,Intermediate,In vivo,1918,,N,50588,1,Clearance value was evaluated in dog plasma,A,9615.0
5659,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622782,,Intermediate,In vivo,6005,,N,50588,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,9615.0
5660,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622783,,Intermediate,In vivo,4839,,N,50588,1,Compound was tested for plasma clearance in dog,A,9615.0
5661,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622784,,Intermediate,In vivo,4239,,N,50588,1,Pharmacokinetic property (Plasma clearance) was measured in dog,A,9615.0
5662,Mus musculus,BAO_0000218,,,1,,CHEMBL622785,,Intermediate,,17729,,N,50594,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,10090.0
5663,Mus musculus,BAO_0000218,,,1,,CHEMBL622786,,Intermediate,,17728,,N,50594,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,10090.0
5664,Mus musculus,BAO_0000218,,,1,,CHEMBL622787,,Intermediate,,5302,,N,50594,1,Area under curve value in mouse at a dose of 10 mg/kg,A,10090.0
5665,Mus musculus,BAO_0000218,,,1,,CHEMBL875949,,Intermediate,,5506,,N,50594,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0
5666,Mus musculus,BAO_0000218,,,1,,CHEMBL622788,,Intermediate,,5506,,N,50594,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0
5667,Mus musculus,BAO_0000218,,,1,,CHEMBL622789,,Intermediate,,17764,,N,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,10090.0
5668,Mus musculus,BAO_0000218,,,1,,CHEMBL622790,,Intermediate,,17764,,N,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,10090.0
5669,Mus musculus,BAO_0000218,,,1,,CHEMBL622791,,Intermediate,,17764,,N,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,10090.0
5670,Mus musculus,BAO_0000218,,,1,,CHEMBL622792,,Intermediate,,17764,,N,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,10090.0
5671,Mus musculus,BAO_0000218,,,1,,CHEMBL622793,,Intermediate,,17764,,N,50594,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,10090.0
5672,Mus musculus,BAO_0000218,,,1,,CHEMBL622794,,Intermediate,,17753,,N,50594,1,Area under curve was determined for the compound at 24 mg/Kg,A,10090.0
5673,Mus musculus,BAO_0000218,,,1,,CHEMBL622795,,Intermediate,,17753,,N,50594,1,Area under curve was determined for the compound at 40 mg/Kg,A,10090.0
5674,Mus musculus,BAO_0000218,,,1,,CHEMBL621803,,Intermediate,,17753,,N,50594,1,Area under curve was determined for the compound at 5 mg/Kg,A,10090.0
5675,Mus musculus,BAO_0000218,,,1,,CHEMBL621804,,Intermediate,,3132,,N,50594,1,Area under the curve for the compound is obtained at dose 25 mg/kg,A,10090.0
5676,Mus musculus,BAO_0000218,,,1,,CHEMBL621805,,Intermediate,,3132,,N,50594,1,Area under the curve for the compound was obtained when tested in mouse,A,10090.0
5677,Mus musculus,BAO_0000218,,,1,,CHEMBL621806,,Intermediate,,17837,,N,50594,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0
5678,Mus musculus,BAO_0000218,,,1,,CHEMBL621807,,Intermediate,,17837,,N,50594,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,10090.0
5679,Mus musculus,BAO_0000218,,,1,,CHEMBL621808,,Intermediate,,6062,,N,50594,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,10090.0
5680,Mus musculus,BAO_0000218,,,1,,CHEMBL621809,,Intermediate,,4066,,N,50594,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0
5681,Mus musculus,BAO_0000218,,,1,,CHEMBL621810,,Intermediate,,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,10090.0
5682,Mus musculus,BAO_0000218,,,1,,CHEMBL875164,,Intermediate,,14239,,N,50594,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,10090.0
5683,Mus musculus,BAO_0000218,,,1,,CHEMBL621811,,Intermediate,,14239,,N,50594,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,10090.0
5684,Mus musculus,BAO_0000218,,,1,,CHEMBL621812,,Intermediate,,4890,,N,50594,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,10090.0
5685,Mus musculus,BAO_0000218,,,1,,CHEMBL621813,,Intermediate,,429,,N,50594,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,10090.0
5686,Mus musculus,BAO_0000218,,,1,,CHEMBL621814,,Intermediate,,429,,N,50594,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,10090.0
5687,Mus musculus,BAO_0000218,,,1,,CHEMBL621815,,Intermediate,,5969,,N,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,10090.0
5688,Mus musculus,BAO_0000218,,,1,,CHEMBL621816,,Intermediate,,5969,,N,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,10090.0
5689,Mus musculus,BAO_0000218,,,1,,CHEMBL621817,,Intermediate,,5969,,N,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0
5690,Mus musculus,BAO_0000218,,,1,,CHEMBL621818,,Intermediate,,6091,,N,50594,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,10090.0
5691,Mus musculus,BAO_0000218,,,1,,CHEMBL621819,,Intermediate,,6091,,N,50594,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,10090.0
5692,Mus musculus,BAO_0000218,,,1,,CHEMBL621820,,Intermediate,,6091,,N,50594,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,10090.0
5693,Mus musculus,BAO_0000218,,,1,,CHEMBL621821,,Intermediate,,6091,,N,50594,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,10090.0
5694,Mus musculus,BAO_0000218,,,1,,CHEMBL621822,,Intermediate,,6178,,N,50594,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,10090.0
5695,Mus musculus,BAO_0000218,,,1,,CHEMBL619474,,Intermediate,,6178,,N,50594,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,10090.0
5696,Mus musculus,BAO_0000218,,,1,,CHEMBL619475,,Intermediate,,6619,,N,50594,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,10090.0
5697,Mus musculus,BAO_0000218,,,1,,CHEMBL619476,,Intermediate,,6619,,N,50594,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,10090.0
5698,Mus musculus,BAO_0000218,,,1,,CHEMBL619477,,Intermediate,,3760,,N,50594,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,10090.0
5699,Mus musculus,BAO_0000218,,,1,,CHEMBL619478,,Intermediate,,3760,,N,50594,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,10090.0
5700,Mus musculus,BAO_0000218,,,1,,CHEMBL619479,,Intermediate,,3760,,N,50594,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,10090.0
5701,Mus musculus,BAO_0000218,,,1,,CHEMBL619480,,Intermediate,,3760,,N,50594,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,10090.0
5702,Mus musculus,BAO_0000218,,,1,,CHEMBL619481,,Intermediate,,3192,,N,50594,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,10090.0
5703,Mus musculus,BAO_0000218,,,1,,CHEMBL619482,,Intermediate,,3192,,N,50594,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,10090.0
5704,Mus musculus,BAO_0000218,,,1,,CHEMBL619483,,Intermediate,,2675,,N,50594,1,Area under the curve was evaluated in mice after intravenous administration,A,10090.0
5705,Mus musculus,BAO_0000218,,,1,,CHEMBL619484,,Intermediate,,2675,,N,50594,1,Area under the curve was evaluated in mice after oral administration,A,10090.0
5706,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL619485,,Intermediate,,16597,,N,50594,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
5707,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL619486,,Intermediate,,16597,,N,50594,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
5708,Mus musculus,BAO_0000218,,,1,,CHEMBL619487,,Intermediate,,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,10090.0
5709,Mus musculus,BAO_0000218,,,1,,CHEMBL619488,,Intermediate,,17734,,N,50594,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
5710,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL620106,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,10090.0
5711,,BAO_0000219,,,1,,CHEMBL620107,,Intermediate,,15345,,N,80653,1,The compound was tested in vitro for anticancer activity against 9L cells,F,
5712,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL620283,,Autocuration,,2181,,U,22226,1,Anti proliferation activity determined; Weak effect,F,10116.0
5713,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL875176,,Autocuration,,2181,,U,22226,1,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,10116.0
5714,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL620284,,Autocuration,,2181,,U,22226,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,10116.0
5715,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL623515,,Autocuration,,2181,,U,22226,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,10116.0
5716,Mus musculus,BAO_0000019,,,0,,CHEMBL623516,,Autocuration,,10486,,U,22226,1,The cytotoxic activity was in vitro tested by 9PS assay method,F,10090.0
5717,Mus musculus,BAO_0000019,,,0,,CHEMBL623517,,Autocuration,,10486,,U,22226,1,The cytotoxic activity was in vitro tested by 9PS assay method.,F,10090.0
5718,,BAO_0000019,,,0,,CHEMBL857878,,Autocuration,,15508,,U,22224,1,Partition coefficient (logD6.5),A,
5719,Homo sapiens,BAO_0000219,,,1,,CHEMBL623518,,Expert,,5242,,N,81034,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,9606.0
5720,Homo sapiens,BAO_0000219,,,1,,CHEMBL624195,,Intermediate,,16167,,N,80018,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,9606.0
5721,Homo sapiens,BAO_0000219,,,1,,CHEMBL624196,,Expert,,4782,,N,80852,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,9606.0
5722,Homo sapiens,BAO_0000219,,,9,,CHEMBL624197,,Expert,,16093,,D,9,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,9606.0
5723,Homo sapiens,BAO_0000219,,,1,,CHEMBL624198,,Intermediate,,2596,,N,80021,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,9606.0
5724,Homo sapiens,BAO_0000219,,,1,,CHEMBL621287,,Intermediate,,2596,,N,80021,1,in vitro cytotoxicity against A 498 cancer cell line,F,9606.0
5725,Homo sapiens,BAO_0000219,,,1,,CHEMBL621288,,Intermediate,,3239,,N,80021,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,9606.0
5726,Homo sapiens,BAO_0000219,,,1,,CHEMBL876496,,Intermediate,,1847,,N,80021,1,Cytotoxic activity against A 498 renal cancer cell lines.,F,9606.0
5727,Homo sapiens,BAO_0000219,,,1,,CHEMBL621289,,Intermediate,,10553,,N,80021,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,9606.0
5728,Staphylococcus aureus,BAO_0000019,,,0,,CHEMBL621290,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1280.0
5729,Staphylococcus aureus,BAO_0000019,,,0,,CHEMBL621291,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1280.0
5730,Staphylococcus aureus,BAO_0000019,,,0,,CHEMBL621292,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1280.0
5731,Staphylococcus aureus,BAO_0000019,,,0,,CHEMBL621293,,Autocuration,,16219,,U,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1280.0
5732,Homo sapiens,BAO_0000219,,,1,,CHEMBL621294,,Intermediate,,4782,,N,80682,1,Inhibitory concentration required against A 549 lung cancer cell line,F,9606.0
5733,Homo sapiens,BAO_0000219,,,1,,CHEMBL621295,,Intermediate,,11805,,N,80682,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,9606.0
5734,Homo sapiens,BAO_0000219,,,1,,CHEMBL884007,,Intermediate,,11805,,N,80682,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,9606.0
5735,Homo sapiens,BAO_0000219,,,1,,CHEMBL621296,,Intermediate,,2007,,N,80682,1,In vitro cytotoxicity against lung cancer A 549 cell lines,F,9606.0
5736,Homo sapiens,BAO_0000219,,,1,,CHEMBL621297,,Intermediate,,4594,,N,80682,1,Compound was tested for its cytotoxicity against A 549 cell line,F,9606.0
5737,Homo sapiens,BAO_0000219,,,1,,CHEMBL839828,,Expert,,6018,,N,80682,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,9606.0
5738,Homo sapiens,BAO_0000219,,,1,,CHEMBL620397,,Intermediate,,6018,,N,80682,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,9606.0
5739,Homo sapiens,BAO_0000219,,,1,,CHEMBL620398,,Expert,,3599,,N,80682,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,9606.0
5740,Homo sapiens,BAO_0000219,,,1,,CHEMBL620399,,Intermediate,,2551,,N,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,9606.0
5741,Homo sapiens,BAO_0000219,,,1,,CHEMBL620400,,Expert,,16132,,N,80682,1,In vitro inhibition of A549 (human lung cancer) cell growth.,F,9606.0
5742,Homo sapiens,BAO_0000219,,,1,,CHEMBL620401,,Intermediate,,16132,,N,80682,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,9606.0
5743,Homo sapiens,BAO_0000219,,,1,,CHEMBL620402,,Expert,,2551,,N,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,9606.0
5744,Homo sapiens,BAO_0000219,,,1,,CHEMBL620403,,Expert,,2551,,N,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,9606.0
5745,,BAO_0000218,,,0,,CHEMBL620404,,Autocuration,,11913,,U,22226,1,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,
5746,,BAO_0000218,,,4,,CHEMBL620405,,Autocuration,In vivo,12621,,H,104694,1,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,
5747,,BAO_0000218,,,4,,CHEMBL620406,,Autocuration,In vivo,12621,,H,104694,1,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,
5748,,BAO_0000218,,,4,,CHEMBL620407,,Autocuration,In vivo,12621,,H,104694,1,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,
5749,,BAO_0000218,,,4,,CHEMBL620408,,Autocuration,In vivo,12621,,H,104694,1,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,
5750,,BAO_0000218,,,4,,CHEMBL620409,,Autocuration,In vivo,12621,,H,104694,1,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,
5751,Homo sapiens,BAO_0000219,,,1,,CHEMBL620410,,Expert,,3600,,N,80021,1,Inhibition of A-498 human Renal cell proliferation,F,9606.0
5752,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL620411,,Autocuration,,1796,,U,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,10116.0
5753,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL620412,,Autocuration,,1796,,U,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,10116.0
5754,Rattus norvegicus,BAO_0000019,,,0,,CHEMBL876596,,Autocuration,,1796,,U,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,10116.0
5755,Homo sapiens,BAO_0000219,,,1,,CHEMBL620413,,Expert,,16464,,N,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,9606.0
5756,Homo sapiens,BAO_0000219,,,1,,CHEMBL620414,,Intermediate,,16464,,N,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5757,Homo sapiens,BAO_0000219,,,1,,CHEMBL620415,,Intermediate,,16464,,N,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5758,Homo sapiens,BAO_0000219,,,1,,CHEMBL620416,,Expert,,13617,,N,80682,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,9606.0
5759,Homo sapiens,BAO_0000219,,,1,,CHEMBL620417,,Intermediate,,4584,,N,80682,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,9606.0
5760,Homo sapiens,BAO_0000219,,,1,,CHEMBL620418,,Expert,,13799,,N,80682,1,Cytotoxic activity evaluated against A549 tumor cells,F,9606.0
5761,Homo sapiens,BAO_0000219,,,1,,CHEMBL620419,,Intermediate,,16726,,N,80682,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,9606.0
5762,Homo sapiens,BAO_0000219,,,1,,CHEMBL620420,,Intermediate,,16109,,N,80682,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,9606.0
5763,Homo sapiens,BAO_0000219,,,1,,CHEMBL620421,,Intermediate,,16109,,N,80682,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,9606.0
5764,Homo sapiens,BAO_0000219,,,1,,CHEMBL620422,,Intermediate,,15474,,N,80682,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,9606.0
5765,Homo sapiens,BAO_0000219,,,1,,CHEMBL620423,,Intermediate,,6851,,N,80682,1,Cytotoxicity of compound against A549 cell line,F,9606.0
5766,Homo sapiens,BAO_0000219,,,1,,CHEMBL620424,,Expert,,17534,,N,80682,1,Cytotoxicity against human lung cell carcinoma A549 cell line,F,9606.0
5767,Homo sapiens,BAO_0000219,,,1,,CHEMBL620425,,Intermediate,,2621,,N,80682,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,9606.0
5768,Homo sapiens,BAO_0000219,,,1,,CHEMBL620426,,Intermediate,,830,,N,80682,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,9606.0
5769,Homo sapiens,BAO_0000219,,,1,,CHEMBL620427,,Intermediate,,14255,,N,80682,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,9606.0
5770,Homo sapiens,BAO_0000219,,,1,,CHEMBL620428,,Intermediate,,14255,,N,80682,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,9606.0
5771,Homo sapiens,BAO_0000219,,,1,,CHEMBL620429,,Intermediate,,1590,,N,80682,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,9606.0
5772,Homo sapiens,BAO_0000219,,,1,,CHEMBL620430,,Expert,,6146,,N,80682,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,9606.0
5773,Homo sapiens,BAO_0000219,,,1,,CHEMBL839887,,Expert,,17427,,N,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0
5774,Homo sapiens,BAO_0000219,,,1,,CHEMBL620431,,Intermediate,,5280,,N,80682,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,9606.0
5775,Homo sapiens,BAO_0000219,,,1,,CHEMBL884010,,Intermediate,,16786,,N,80682,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,9606.0
5776,Homo sapiens,BAO_0000219,,,1,,CHEMBL620538,,Intermediate,,5895,,N,80682,1,In vitro cytotoxicity against A549 (human lung cancer),F,9606.0
5777,Homo sapiens,BAO_0000219,,,1,,CHEMBL620539,,Expert,,14297,,N,80682,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,9606.0
5778,Homo sapiens,BAO_0000218,,,1,,CHEMBL623373,,Intermediate,,17824,,N,80682,1,In vivo antiproliferative activity against A549 cell line,F,9606.0
5779,Homo sapiens,BAO_0000219,,,1,,CHEMBL623374,,Intermediate,,14368,,N,80682,1,Inhibition of non-small-cell lung adenocarcinoma (A549),F,9606.0
5780,Homo sapiens,BAO_0000219,,,1,,CHEMBL623375,,Intermediate,,14368,,N,80682,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,9606.0
5781,Homo sapiens,BAO_0000219,,,1,,CHEMBL623376,,Intermediate,,14254,,N,80682,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,9606.0
5782,Homo sapiens,BAO_0000219,,,1,,CHEMBL623377,,Intermediate,,15897,,N,80682,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,9606.0
5783,Homo sapiens,BAO_0000219,,,1,,CHEMBL623378,,Intermediate,,13866,,N,80682,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,9606.0
5784,Homo sapiens,BAO_0000219,,,1,,CHEMBL623379,,Intermediate,,13370,,N,80682,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,9606.0
5785,Homo sapiens,BAO_0000219,,,1,,CHEMBL623380,,Intermediate,,4862,,N,80682,1,Inhibitory activity against A549 lung cancer cell line,F,9606.0
5786,Homo sapiens,BAO_0000219,,,1,,CHEMBL623381,,Intermediate,,4862,,N,80682,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,9606.0
5787,Homo sapiens,BAO_0000219,,,1,,CHEMBL623382,,Intermediate,,4862,,N,80682,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,9606.0
5788,Homo sapiens,BAO_0000219,,,1,,CHEMBL623383,,Intermediate,,15970,,N,80682,1,Inhibitory concentration against A549 (lung cancer) cell line,F,9606.0
5789,Homo sapiens,BAO_0000219,,,1,,CHEMBL623384,,Expert,,17713,,N,80682,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,9606.0
5790,Homo sapiens,BAO_0000219,,,1,,CHEMBL623385,,Intermediate,,4833,,N,80682,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,9606.0
5791,Homo sapiens,BAO_0000219,,,1,,CHEMBL623386,,Expert,,13736,,N,80682,1,Activity against A549 cancer cell line.,F,9606.0
5792,Homo sapiens,BAO_0000219,,,1,,CHEMBL884105,,Intermediate,,4312,,N,80682,1,The compound was evaluated for cytotoxicity against A549 cell line,F,9606.0
5793,Homo sapiens,BAO_0000219,,,1,,CHEMBL623387,,Intermediate,,5421,,N,80682,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,9606.0
5794,Homo sapiens,BAO_0000219,,,1,,CHEMBL621568,,Intermediate,,5421,,N,80682,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,9606.0
5795,Homo sapiens,BAO_0000219,,,1,,CHEMBL621569,,Intermediate,,14717,,N,80682,1,Growth inhibitory activity was measured for human A549 tumor cell line.,F,9606.0
5796,Homo sapiens,BAO_0000219,,,1,,CHEMBL621570,,Intermediate,,4634,,N,80682,1,Inhibitory activity against A549 lung cancer cell line,F,9606.0
5797,Homo sapiens,BAO_0000219,,,1,,CHEMBL621571,,Intermediate,,1149,,N,80682,1,Inhibitory activity against A549 cell line; inactive,F,9606.0
5798,Homo sapiens,BAO_0000219,,,1,,CHEMBL621572,,Expert,,5421,,N,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,9606.0
5799,Homo sapiens,BAO_0000219,,,1,,CHEMBL621573,,Expert,,5421,,N,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,9606.0
5800,Homo sapiens,BAO_0000219,,,1,,CHEMBL621574,,Intermediate,,5421,,N,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,9606.0
5801,Homo sapiens,BAO_0000219,,,1,,CHEMBL621575,,Intermediate,,3320,,N,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,9606.0
5802,Homo sapiens,BAO_0000219,,,1,,CHEMBL621576,,Intermediate,,3320,,N,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,9606.0
5803,Homo sapiens,BAO_0000219,,,1,,CHEMBL621577,,Intermediate,,3320,,N,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,9606.0
5804,Homo sapiens,BAO_0000219,,,1,,CHEMBL621578,,Intermediate,,3320,,N,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,9606.0
5805,Homo sapiens,BAO_0000219,,,1,,CHEMBL621579,,Intermediate,,3320,,N,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,9606.0
5806,Homo sapiens,BAO_0000219,,,1,,CHEMBL621580,,Intermediate,,5726,,N,80682,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,9606.0
5807,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621581,,Intermediate,In vivo,17800,,N,50588,1,Plasma clearance (in vivo) in mongrel dogs was determined,A,9615.0
5808,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621582,,Intermediate,In vivo,5985,,N,50588,1,Plasma clearance was measured in dog,A,9615.0
5809,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621583,,Intermediate,In vivo,5530,,N,50588,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,9615.0
5810,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621584,,Intermediate,In vivo,5530,,N,50588,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,9615.0
5811,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621585,,Intermediate,In vivo,4839,,N,50588,1,Tested for plasma clearance in dog,A,9615.0
5812,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621586,,Intermediate,In vivo,3639,,N,50588,1,The compound was tested for clearance in dog plasma.,A,9615.0
5813,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875835,,Intermediate,In vivo,4838,,N,50588,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,9615.0
5814,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621587,,Intermediate,In vivo,4137,,N,50588,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,9615.0
5815,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621588,,Intermediate,In vivo,5017,,N,50588,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,9615.0
5816,Canis lupus familiaris,BAO_0000218,2107.0,,1,Liver,CHEMBL621589,,Intermediate,In vitro,17538,,N,50588,1,In vitro clearance in dog liver microsomes,A,9615.0
5817,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621590,,Intermediate,In vivo,6161,,N,50588,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,9615.0
5818,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621591,,Intermediate,In vivo,6161,,N,50588,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,9615.0
5819,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621592,,Intermediate,In vivo,1696,,N,50588,1,Plasma clearance in dog,A,9615.0
5820,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621593,,Intermediate,In vivo,6762,,N,50588,1,Clearance rate in dog,A,9615.0
5821,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621594,,Intermediate,In vivo,5932,,N,50588,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,9615.0
5822,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621595,,Intermediate,In vivo,6305,,N,50588,1,Clearance in dogs,A,9615.0
5823,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621596,,Intermediate,In vivo,4942,,N,50588,1,Plasma clearance in dogs,A,9615.0
5824,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621597,,Intermediate,In vivo,4219,,N,50588,1,Plasma clearance was determined,A,9615.0
5825,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621598,,Intermediate,In vivo,17853,,N,50588,1,Lower clearance in dog (i.v.) at 0.5 mpk,A,9615.0
5826,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621599,,Intermediate,In vivo,4514,,N,50588,1,Plasma clearance in Beagle dogs,A,9615.0
5827,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875836,,Intermediate,In vivo,6448,,N,50588,1,Plasma clearance (Clp) in dog,A,9615.0
5828,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621600,,Intermediate,In vivo,6227,,N,50588,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,9615.0
5829,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621601,,Intermediate,In vivo,6227,,N,50588,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,9615.0
5830,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618474,,Intermediate,In vivo,6062,,N,50588,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,9615.0
5831,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618475,,Intermediate,In vivo,6821,,N,50588,1,Plasma clearance of compound was determined in dog,A,9615.0
5832,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624524,,Intermediate,In vivo,4709,,N,50588,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,9615.0
5833,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624525,,Intermediate,In vivo,4521,,N,50588,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0
5834,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624526,,Intermediate,In vivo,5374,,N,50588,1,Plasma clearance in dog was determined,A,9615.0
5835,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624527,,Intermediate,In vivo,6057,,N,50588,1,Plasma clearance was calculated in dog,A,9615.0
5836,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624528,,Intermediate,In vivo,4727,,N,50588,1,Plasma clearance at the dose of 2 mg/kg in dog,A,9615.0
5837,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624529,,Intermediate,In vivo,5145,,N,50588,1,Plasma clearance in dog,A,9615.0
5838,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624530,,Intermediate,In vivo,17657,,N,50588,1,Plasma clearance in dog,A,9615.0
5839,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624531,,Intermediate,In vivo,17657,,N,50588,1,Plasma clearance in dog; Unable to calculate,A,9615.0
5840,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624532,,Intermediate,In vivo,5145,,N,50588,1,Plasma clearance in rhesus monkey,A,9615.0
5841,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624533,,Intermediate,In vivo,6642,,N,50588,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0
5842,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624534,,Intermediate,In vivo,6641,,N,50588,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
5843,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624535,,Intermediate,In vivo,6642,,N,50588,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
5844,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624536,,Intermediate,In vivo,5472,,N,50588,1,Plasma clearance was evaluated in dog,A,9615.0
5845,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624537,,Intermediate,In vivo,5472,,N,50588,1,Plasma clearance was evaluated in dog; Not tested,A,9615.0
5846,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624538,,Intermediate,In vivo,5472,,N,50588,1,Plasma clearance was evaluated in rhesus,A,9615.0
5847,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624539,,Intermediate,In vivo,5472,,N,50588,1,Plasma clearance was evaluated in rhesus; Not tested,A,9615.0
5848,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624540,,Intermediate,In vivo,4257,,N,50588,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,9615.0
5849,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624541,,Intermediate,In vivo,6679,,N,50588,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0
5850,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624542,,Intermediate,In vivo,5546,,N,50588,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0
5851,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624543,,Intermediate,In vivo,6348,,N,50588,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
5852,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624544,,Intermediate,In vivo,5474,,N,50588,1,Clearance value at a dose of 0.2 mg/kg i.v.,A,9615.0
5853,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624545,,Intermediate,In vivo,6316,,N,50588,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,9615.0
5854,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624546,,Intermediate,In vivo,17594,,N,50588,1,Cmax after oral dose of compound at 3 mg/kg in dogs,A,9615.0
5855,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875957,,Intermediate,In vivo,17594,,N,50588,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,9615.0
5856,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624547,,Intermediate,In vivo,5802,,N,50588,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0
5857,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624548,,Intermediate,In vivo,6535,,N,50588,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,9615.0
5858,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624549,,Intermediate,In vivo,6535,,N,50588,1,Cmax in dog after administration of 1 mg/kg iv,A,9615.0
5859,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624550,,Intermediate,In vivo,1466,,N,50588,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0
5860,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621613,,Intermediate,In vivo,6505,,N,50588,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,9615.0
5861,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621614,,Intermediate,In vivo,5668,,N,50588,1,Cmax was determine after peroral administration at 10 mpk in dog,A,9615.0
5862,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623431,,Intermediate,In vivo,5668,,N,50588,1,Cmax was determine after peroral administration at 5 mpk in dog,A,9615.0
5863,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623432,,Intermediate,In vivo,5668,,N,50588,1,Cmax was determine after peroral administration at 5 mg/kg in dog,A,9615.0
5864,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623433,,Intermediate,In vivo,5600,,N,50588,1,Cmax after 0.3 mg/kg po administration in dog,A,9615.0
5865,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623434,,Intermediate,In vivo,17764,,N,50588,1,Cmax after peroral administration in dogs at 2.4 uM/kg,A,9615.0
5866,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623435,,Intermediate,In vivo,6123,,N,50588,1,Cmax in dog after oral administration at 1 mg/kg,A,9615.0
5867,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623436,,Intermediate,In vivo,6123,,N,50588,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,9615.0
5868,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875958,,Intermediate,In vivo,6757,,N,50588,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,9615.0
5869,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623437,,Intermediate,In vivo,16907,,N,50588,1,Cmax value after 15 mg/kg iv dose in Dogs,A,9615.0
5870,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL623438,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5871,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL623439,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5872,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL623440,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5873,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL623441,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5874,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL623442,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5875,Mus musculus,BAO_0000218,,,1,,CHEMBL623469,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5876,Mus musculus,BAO_0000218,,,1,,CHEMBL623470,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5877,Mus musculus,BAO_0000218,,,1,,CHEMBL623471,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5878,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL623472,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5879,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL623473,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5880,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL623474,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5881,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623475,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5882,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623476,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5883,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623477,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5884,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL621896,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5885,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL621897,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5886,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL621898,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5887,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621899,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5888,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621900,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5889,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621901,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5890,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621902,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5891,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621903,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5892,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL622587,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5893,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL620285,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5894,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL875285,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5895,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL620286,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5896,Mus musculus,BAO_0000218,,,1,,CHEMBL620287,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5897,Mus musculus,BAO_0000218,,,1,,CHEMBL620288,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5898,Mus musculus,BAO_0000218,,,1,,CHEMBL620289,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5899,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL620290,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5900,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL620291,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5901,Mus musculus,BAO_0000218,160.0,,1,Intestine,CHEMBL620292,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5902,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL620293,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5903,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL620294,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5904,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618614,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
5905,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL618615,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
5906,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL618616,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0
5907,Homo sapiens,BAO_0000219,,,1,,CHEMBL618617,,Expert,,2036,,N,80012,1,Cytotoxicity against A-172 human tumor cell lines,F,9606.0
5908,Homo sapiens,BAO_0000219,,,1,,CHEMBL618618,,Intermediate,,2357,,N,80012,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,9606.0
5909,Homo sapiens,BAO_0000219,,,1,,CHEMBL618619,,Intermediate,,1457,,N,80014,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,9606.0
5910,Homo sapiens,BAO_0000219,,,1,,CHEMBL618620,,Intermediate,,4379,,N,81034,1,Tested for antiproliferative activity against A-2780 tumoral cell line,F,9606.0
5911,Homo sapiens,BAO_0000219,,,1,,CHEMBL618621,,Intermediate,,1093,,N,80018,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,9606.0
5912,Homo sapiens,BAO_0000219,,,1,,CHEMBL618622,,Intermediate,,12152,,N,80018,1,Tested in vitro against A-375 cell line human melanoma,F,9606.0
5913,Homo sapiens,BAO_0000219,,,1,,CHEMBL618623,,Expert,,16464,,N,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,9606.0
5914,Homo sapiens,BAO_0000219,,,1,,CHEMBL618624,,Intermediate,,16464,,N,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5915,Homo sapiens,BAO_0000219,,,1,,CHEMBL618625,,Expert,,16582,,N,80019,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,9606.0
5916,Homo sapiens,BAO_0000219,,,1,,CHEMBL618626,,Intermediate,,16464,,N,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0
5917,Homo sapiens,BAO_0000219,,,1,,CHEMBL618627,,Intermediate,,10413,,N,80019,1,Antitumor activity on A-427 lung carcinoma cell lines,F,9606.0
5918,Homo sapiens,BAO_0000219,,,1,,CHEMBL618628,,Intermediate,,6418,,N,80019,1,Cytotoxic activity against human A-427 lung tumor cell line,F,9606.0
5919,Homo sapiens,BAO_0000219,,,1,,CHEMBL618629,,Expert,,17134,,N,80019,1,In vitro antitumor effects against human A-427 cell lines.,F,9606.0
5920,Homo sapiens,BAO_0000219,,,1,,CHEMBL618630,,Expert,,16132,,N,80019,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,9606.0
5921,Homo sapiens,BAO_0000219,,,1,,CHEMBL618631,,Intermediate,,16132,,N,80019,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,9606.0
5922,Homo sapiens,BAO_0000219,,,1,,CHEMBL618632,,Intermediate,,16780,,N,80019,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,9606.0
5923,Homo sapiens,BAO_0000219,,,1,,CHEMBL618633,,Expert,,4085,,N,80852,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,9606.0
5924,Homo sapiens,BAO_0000219,,,1,,CHEMBL619315,,Intermediate,,1276,,N,80021,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,9606.0
5925,Homo sapiens,BAO_0000219,,,1,,CHEMBL619316,,Expert,,3498,,N,80021,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,9606.0
5926,Homo sapiens,BAO_0000219,,,1,,CHEMBL619317,,Intermediate,,1169,,N,80021,1,Cytotoxicity against human kidney carcinoma A-498cell lines,F,9606.0
5927,Homo sapiens,BAO_0000219,,,1,,CHEMBL619318,,Intermediate,,4450,,N,80021,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,9606.0
5928,Homo sapiens,BAO_0000219,,,1,,CHEMBL619319,,Intermediate,,3311,,N,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,9606.0
5929,Homo sapiens,BAO_0000219,,,1,,CHEMBL619739,,Intermediate,,4461,,N,80021,1,Antitumor cytotoxic activity against A-498 cell line was determined,F,9606.0
5930,Homo sapiens,BAO_0000219,,,1,,CHEMBL619740,,Intermediate,,3311,,N,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,9606.0
5931,Homo sapiens,BAO_0000219,,,1,,CHEMBL883158,,Intermediate,,3311,,N,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,9606.0
5932,Homo sapiens,BAO_0000219,,,1,,CHEMBL884012,,Intermediate,,1457,,N,80021,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,9606.0
5933,Homo sapiens,BAO_0000219,,,1,,CHEMBL619741,,Intermediate,,3664,,N,80021,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,9606.0
5934,Homo sapiens,BAO_0000219,,,1,,CHEMBL619742,,Intermediate,,15895,,N,80021,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,9606.0
5935,Homo sapiens,BAO_0000219,,,1,,CHEMBL876610,,Intermediate,,11843,,N,80682,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,9606.0
5936,Homo sapiens,BAO_0000219,,,1,,CHEMBL619743,,Intermediate,,11843,,N,80682,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,9606.0
5937,Homo sapiens,BAO_0000219,,,1,,CHEMBL619744,,Intermediate,,17705,,N,80682,1,In vitro antiproliferative activity against human A-549 NSCL cell line,F,9606.0
5938,Homo sapiens,BAO_0000219,,,1,,CHEMBL619745,,Intermediate,,17705,,N,80682,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,9606.0
5939,Homo sapiens,BAO_0000219,,,1,,CHEMBL619746,,Intermediate,,4369,,N,80682,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,9606.0
5940,Homo sapiens,BAO_0000219,,,1,,CHEMBL619747,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,9606.0
5941,Homo sapiens,BAO_0000219,,,1,,CHEMBL619748,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,9606.0
5942,Homo sapiens,BAO_0000219,,,1,,CHEMBL619749,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,9606.0
5943,Homo sapiens,BAO_0000219,,,1,,CHEMBL619750,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,9606.0
5944,Homo sapiens,BAO_0000219,,,1,,CHEMBL624014,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,9606.0
5945,Homo sapiens,BAO_0000219,,,1,,CHEMBL624015,,Intermediate,,4369,,N,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,9606.0
5946,Homo sapiens,BAO_0000219,,,1,,CHEMBL885344,,Expert,,4787,,N,80682,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,9606.0
5947,Homo sapiens,BAO_0000219,,,1,,CHEMBL623224,,Intermediate,,4787,,N,80682,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,9606.0
5948,Homo sapiens,BAO_0000219,,,1,,CHEMBL623225,,Intermediate,,6513,,N,80682,1,Cytotoxic activity against A-549 cell line,F,9606.0
5949,Homo sapiens,BAO_0000219,,,1,,CHEMBL622698,,Intermediate,,6690,,N,80682,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,9606.0
5950,Homo sapiens,BAO_0000219,,,1,,CHEMBL622699,,Intermediate,,6690,,N,80682,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,9606.0
5951,Homo sapiens,BAO_0000219,,,1,,CHEMBL622700,,Expert,,12263,,N,80682,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,9606.0
5952,Homo sapiens,BAO_0000219,,,1,,CHEMBL622701,,Intermediate,,1054,,N,80682,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,9606.0
5953,Homo sapiens,BAO_0000219,,,1,,CHEMBL622702,,Intermediate,,1359,,N,80682,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,9606.0
5954,Homo sapiens,BAO_0000219,,,1,,CHEMBL622703,,Intermediate,,3547,,N,80682,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,9606.0
5955,Homo sapiens,BAO_0000219,,,1,,CHEMBL622704,,Expert,,5771,,N,80682,1,Cytotoxic activity towards A-549 cells,F,9606.0
5956,Homo sapiens,BAO_0000219,,,1,,CHEMBL622705,,Intermediate,,14425,,N,80682,1,"In vitro percent inhibition of A549, lung carcinoma.",F,9606.0
5957,Homo sapiens,BAO_0000219,,,1,,CHEMBL622706,,Intermediate,,14425,,N,80682,1,"In vitro percent inhibition of A549, lung carcinoma",F,9606.0
5958,Homo sapiens,BAO_0000219,,,1,,CHEMBL622707,,Intermediate,,14425,,N,80682,1,"In vitro percent inhibition of A549, lung carcinoma.",F,9606.0
5959,Homo sapiens,BAO_0000219,,,1,,CHEMBL622708,,Intermediate,,14425,,N,80682,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,9606.0
5960,Homo sapiens,BAO_0000219,,,1,,CHEMBL622709,,Intermediate,,5280,,N,80682,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,9606.0
5961,Homo sapiens,BAO_0000219,,,1,,CHEMBL622710,,Intermediate,,15176,,N,80682,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,9606.0
5962,Homo sapiens,BAO_0000219,,,1,,CHEMBL622711,,Intermediate,,15300,,N,80682,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,9606.0
5963,Homo sapiens,BAO_0000218,,,1,,CHEMBL622712,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0
5964,Homo sapiens,BAO_0000218,,,1,,CHEMBL622713,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0
5965,Homo sapiens,BAO_0000218,,,1,,CHEMBL622714,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0
5966,Homo sapiens,BAO_0000218,,,1,,CHEMBL622715,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0
5967,Homo sapiens,BAO_0000218,,,1,,CHEMBL622716,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0
5968,Homo sapiens,BAO_0000219,,,1,,CHEMBL622717,,Intermediate,,17824,,N,80682,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,9606.0
5969,Homo sapiens,BAO_0000218,,,1,,CHEMBL622718,,Intermediate,,17528,,N,80682,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,9606.0
5970,Homo sapiens,BAO_0000219,,,1,,CHEMBL622719,,Expert,,6870,,N,80682,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,9606.0
5971,Homo sapiens,BAO_0000219,,,1,,CHEMBL622720,,Intermediate,,6870,,N,80682,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,9606.0
5972,Homo sapiens,BAO_0000219,,,1,,CHEMBL622721,,Intermediate,,6870,,N,80682,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,9606.0
5973,Homo sapiens,BAO_0000219,,,1,,CHEMBL622722,,Intermediate,,6870,,N,80682,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,9606.0
5974,Homo sapiens,BAO_0000219,,,1,,CHEMBL876030,,Intermediate,,16726,,N,80682,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,9606.0
5975,Homo sapiens,BAO_0000219,,,1,,CHEMBL620206,,Intermediate,,6170,,N,80682,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,9606.0
5976,Homo sapiens,BAO_0000219,,,1,,CHEMBL620207,,Expert,,6583,,N,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,9606.0
5977,Homo sapiens,BAO_0000219,,,1,,CHEMBL620208,,Expert,,6583,,N,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,9606.0
5978,Homo sapiens,BAO_0000219,,,1,,CHEMBL620209,,Expert,,6583,,N,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,9606.0
5979,Homo sapiens,BAO_0000219,,,1,,CHEMBL620210,,Expert,,6583,,N,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,9606.0
5980,Homo sapiens,BAO_0000219,,,1,,CHEMBL621639,,Expert,,6583,,N,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,9606.0
5981,Homo sapiens,BAO_0000219,,,1,,CHEMBL621640,,Intermediate,,17321,,N,80682,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,9606.0
5982,Homo sapiens,BAO_0000219,,,1,,CHEMBL621641,,Expert,,17528,,N,80682,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,9606.0
5983,Homo sapiens,BAO_0000219,,,1,,CHEMBL621642,,Expert,,12888,,N,80682,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,9606.0
5984,Homo sapiens,BAO_0000219,,,1,,CHEMBL621643,,Intermediate,,4312,,N,80682,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,9606.0
5985,Homo sapiens,BAO_0000219,,,1,,CHEMBL621644,,Intermediate,,4312,,N,80682,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,9606.0
5986,Homo sapiens,BAO_0000219,,,1,,CHEMBL621645,,Intermediate,,4312,,N,80682,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,9606.0
5987,Mus musculus,BAO_0000219,,,1,,CHEMBL621646,,Intermediate,,17737,,N,80682,1,In vitro antiproliferative activity against A549 cell line,F,10090.0
5988,,BAO_0000219,,,1,,CHEMBL621647,,Intermediate,,6630,,N,80682,1,Synergism with indomethacin in A549 cells,F,
5989,,BAO_0000219,,,1,,CHEMBL621648,,Intermediate,,6630,,N,80682,1,Synergism with tolmetin in A549 cells,F,
5990,,BAO_0000219,,,1,,CHEMBL621649,,Intermediate,,6630,,N,80682,1,Synergism with sulindac in A549 cells,F,
5991,,BAO_0000219,,,1,,CHEMBL621650,,Intermediate,,6630,,N,80682,1,Antagonism of indomethacin in A549 cells,F,
5992,,BAO_0000219,,,1,,CHEMBL621651,,Intermediate,,6630,,N,80682,1,Antagonism of sulindac in A549 cells,F,
5993,,BAO_0000219,,,1,,CHEMBL621652,,Intermediate,,6630,,N,80682,1,Antagonism of tolmetin in A549 cells,F,
5994,,BAO_0000219,,,1,,CHEMBL621653,,Intermediate,,6630,,N,80682,1,Synergism with indomethacin in A549 cells,F,
5995,,BAO_0000219,,,1,,CHEMBL621654,,Intermediate,,6630,,N,80682,1,Synergism with sulindac in A549 cells,F,
5996,,BAO_0000219,,,1,,CHEMBL621655,,Intermediate,,6630,,N,80682,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,
5997,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621656,,Intermediate,In vivo,16907,,N,50588,1,Cmax value after 30 mg/kg po dose in Dogs,A,9615.0
5998,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621657,,Intermediate,In vivo,5944,,N,50588,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0
5999,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621658,,Intermediate,In vivo,5944,,N,50588,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,9615.0
6000,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621659,,Intermediate,In vivo,5944,,N,50588,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0
6001,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621660,,Intermediate,In vivo,5944,,N,50588,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,9615.0
6002,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621661,,Intermediate,In vivo,2959,,N,50588,1,Cmax value after administration of 4 mg/Kg oral dose in dog,A,9615.0
6003,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621662,,Intermediate,In vivo,6241,,N,50588,1,Cmax value in dog,A,9615.0
6004,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621663,,Intermediate,In vivo,6241,,N,50588,1,Cmax value in dogs after oral administration at 1 mg/kg,A,9615.0
6005,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621664,,Intermediate,In vivo,2652,,N,50588,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,9615.0
6006,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621665,,Intermediate,In vivo,1806,,N,50588,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,9615.0
6007,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621666,,Intermediate,In vivo,1806,,N,50588,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,9615.0
6008,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621667,,Intermediate,In vivo,1021,,N,50588,1,Concentration maxima after oral dosing in dogs,A,9615.0
6009,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876738,,Intermediate,In vivo,1021,,N,50588,1,Concentration maxima after oral dosing in dogs; not available,A,9615.0
6010,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621668,,Intermediate,In vivo,1021,,N,50588,1,Concentration maxima after oral dosing in dogs; not available,A,9615.0
6011,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621669,,Intermediate,In vivo,5444,,N,50588,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,9615.0
6012,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621670,,Intermediate,In vivo,5444,,N,50588,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,9615.0
6013,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621671,,Intermediate,In vivo,5444,,N,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,9615.0
6014,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622360,,Intermediate,In vivo,5444,,N,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,9615.0
6015,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622361,,Intermediate,In vivo,5444,,N,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,9615.0
6016,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622362,,Intermediate,In vivo,5130,,N,50588,1,Cmax in dog plasma after oral dose (1 mg/kg),A,9615.0
6017,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622363,,Intermediate,In vivo,3249,,N,50588,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,9615.0
6018,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622364,,Intermediate,In vivo,5473,,N,50588,1,Maximal plasma concentration at a dose of 1 mg/kg,A,9615.0
6019,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622365,,Intermediate,In vivo,5474,,N,50588,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,9615.0
6020,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622533,,Intermediate,In vivo,4657,,N,50588,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,9615.0
6021,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622534,,Intermediate,In vivo,3031,,N,50588,1,Maximum concentration of compound in dog was evaluated.,A,9615.0
6022,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622535,,Intermediate,In vivo,4527,,N,50588,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0
6023,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876739,,Intermediate,In vivo,4186,,N,50588,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,9615.0
6024,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622536,,Intermediate,In vivo,5007,,N,50588,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0
6025,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL622537,,Intermediate,In vivo,3132,,N,50588,1,Maximum concentration obtained in dog plasma was determined,A,9615.0
6026,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622538,,Intermediate,In vivo,5006,,N,50588,1,Maximum concentration was determined,A,9615.0
6027,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL627867,,Intermediate,In vivo,4727,,N,50588,1,Maximum concentration at the dose of 2 mg/kg in dog,A,9615.0
6028,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL627868,,Intermediate,In vivo,1916,,N,50588,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0
6029,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627869,,Intermediate,In vivo,1918,,N,50588,1,Maximum concentration was evaluated in dog plasma,A,9615.0
6030,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL627870,,Intermediate,In vivo,3045,,N,50588,1,Maximum concentration was evaluated after 75 min after administration in dog,A,9615.0
6031,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627871,,Intermediate,In vivo,9579,,N,50588,1,Maximum plasma concentration determined in dog after oral administration of 17b,A,9615.0
6032,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627872,,Intermediate,In vivo,9579,,N,50588,1,Maximum plasma concentration determined in dog after oral administration of 2b,A,9615.0
6033,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627873,,Intermediate,In vivo,933,,N,50588,1,Maximum plasma concentration in dog,A,9615.0
6034,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627874,,Intermediate,In vivo,17839,,N,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,9615.0
6035,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627875,,Intermediate,In vivo,17839,,N,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,9615.0
6036,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627876,,Intermediate,In vivo,17839,,N,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,9615.0
6037,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627877,,Intermediate,In vivo,17839,,N,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,9615.0
6038,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627878,,Intermediate,In vivo,6348,,N,50588,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
6039,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627879,,Intermediate,In vivo,16367,,N,50588,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,9615.0
6040,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL875355,,Intermediate,In vivo,1337,,N,50588,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
6041,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627880,,Intermediate,In vivo,1337,,N,50588,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
6042,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627881,,Intermediate,In vivo,5199,,N,50588,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,9615.0
6043,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627882,,Intermediate,In vivo,17650,,N,50588,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,9615.0
6044,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL627883,,Intermediate,In vivo,6679,,N,50588,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,9615.0
6045,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL628526,,Intermediate,In vivo,5356,,N,50588,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,9615.0
6046,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL628527,,Intermediate,In vivo,5356,,N,50588,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,9615.0
6047,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL628528,,Intermediate,In vivo,6227,,N,50588,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,9615.0
6048,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL628529,,Intermediate,In vivo,6227,,N,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,9615.0
6049,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL628530,,Intermediate,In vivo,6227,,N,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,9615.0
6050,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL625243,,Intermediate,In vivo,6227,,N,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,9615.0
6051,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL625244,,Expert,In vivo,3598,,N,50588,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
6052,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625245,,Intermediate,In vivo,4368,,N,50588,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,9615.0
6053,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625246,,Intermediate,In vivo,6265,,N,50588,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,9615.0
6054,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL625247,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0
6055,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL625248,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0
6056,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL625249,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,10090.0
6057,Mus musculus,BAO_0000218,1088.0,,1,Urine,CHEMBL625250,,Intermediate,In vivo,7767,,N,50594,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,10090.0
6058,Mus musculus,BAO_0000218,,,1,,CHEMBL625251,,Intermediate,,17811,,N,50594,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,10090.0
6059,Mus musculus,BAO_0000218,,,1,,CHEMBL875356,,Intermediate,,17811,,N,50594,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,10090.0
6060,Mus musculus,BAO_0000218,,,1,,CHEMBL625252,,Intermediate,,17827,,N,50594,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,10090.0
6061,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL625253,,Intermediate,,17827,,N,50594,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,10090.0
6062,Mus musculus,BAO_0000218,,,1,,CHEMBL625254,,Intermediate,,17827,,N,50594,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,10090.0
6063,Mus musculus,BAO_0000218,,,1,,CHEMBL625255,,Intermediate,,17827,,N,50594,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,10090.0
6064,Mus musculus,BAO_0000218,,,1,,CHEMBL625256,,Intermediate,,17827,,N,50594,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,10090.0
6065,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL625257,,Intermediate,,17827,,N,50594,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,10090.0
6066,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL625258,,Intermediate,,17827,,N,50594,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,10090.0
6067,Mus musculus,BAO_0000218,,,1,,CHEMBL625259,,Intermediate,,17827,,N,50594,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,10090.0
6068,Mus musculus,BAO_0000218,,,1,,CHEMBL625260,,Intermediate,,17827,,N,50594,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,10090.0
6069,Mus musculus,BAO_0000218,,,1,,CHEMBL625261,,Intermediate,,17827,,N,50594,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0
6070,Mus musculus,BAO_0000218,,,1,,CHEMBL625262,,Intermediate,,17827,,N,50594,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0
6071,Mus musculus,BAO_0000218,,,1,,CHEMBL622639,,Intermediate,,17827,,N,50594,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0
6072,Mus musculus,BAO_0000218,,,1,,CHEMBL622640,,Intermediate,,17257,,N,50594,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,10090.0
6073,Mus musculus,BAO_0000218,,,1,,CHEMBL622812,,Intermediate,,17257,,N,50594,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,10090.0
6074,Mus musculus,BAO_0000218,,,1,,CHEMBL622813,,Intermediate,,17257,,N,50594,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,10090.0
6075,Mus musculus,BAO_0000218,,,1,,CHEMBL622814,,Intermediate,,17257,,N,50594,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,10090.0
6076,Mus musculus,BAO_0000218,,,1,,CHEMBL622815,,Intermediate,,17827,,N,50594,1,Time at maximum activity in mice (Radiolabeled compound),A,10090.0
6077,Mus musculus,BAO_0000218,,,1,,CHEMBL625342,,Intermediate,,3760,,N,50594,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,10090.0
6078,Mus musculus,BAO_0000218,,,1,,CHEMBL625343,,Intermediate,,3760,,N,50594,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,10090.0
6079,Mus musculus,BAO_0000218,,,1,,CHEMBL877591,,Intermediate,,17409,,N,50594,1,Binding towards mouse plasma protein at 10 uM,A,10090.0
6080,Mus musculus,BAO_0000218,,,1,,CHEMBL625344,,Intermediate,,17409,,N,50594,1,Binding towards mouse plasma protein at 100 uM,A,10090.0
6081,Mus musculus,BAO_0000218,,,1,,CHEMBL625345,,Intermediate,In vivo,2675,,N,50594,1,Bioavailability was evaluated in mice after intravenous administration,A,10090.0
6082,Mus musculus,BAO_0000218,,,1,,CHEMBL625346,,Intermediate,In vivo,2675,,N,50594,1,Bioavailability was evaluated in mice after oral administration,A,10090.0
6083,Mus musculus,BAO_0000218,,,1,,CHEMBL625347,,Intermediate,In vivo,3132,,N,50594,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,10090.0
6084,Mus musculus,BAO_0000218,,,1,,CHEMBL625348,,Intermediate,In vivo,3132,,N,50594,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,10090.0
6085,Mus musculus,BAO_0000218,,,1,,CHEMBL625349,,Intermediate,In vivo,16597,,N,50594,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
6086,Mus musculus,BAO_0000218,,,1,,CHEMBL625350,,Intermediate,In vivo,2862,,N,50594,1,Oral bioavailability in mouse,A,10090.0
6087,Mus musculus,BAO_0000218,,,1,,CHEMBL882952,,Intermediate,In vivo,17764,,N,50594,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,10090.0
6088,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL625351,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6089,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL625352,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6090,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL877592,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6091,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL625353,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6092,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL625354,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6093,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL626019,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6094,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL626020,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6095,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL626021,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6096,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL626022,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6097,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL626192,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6098,Homo sapiens,BAO_0000219,,,1,,CHEMBL626193,,Intermediate,,1276,,N,80682,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,9606.0
6099,Homo sapiens,BAO_0000219,,,1,,CHEMBL626194,,Expert,,3498,,N,80682,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,9606.0
6100,Homo sapiens,BAO_0000219,,,1,,CHEMBL626195,,Intermediate,,1169,,N,80682,1,Cytotoxicity against human lung carcinoma A-549 cell lines,F,9606.0
6101,Homo sapiens,BAO_0000219,,,1,,CHEMBL626196,,Intermediate,,4450,,N,80682,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,9606.0
6102,Homo sapiens,BAO_0000219,,,1,,CHEMBL626197,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,9606.0
6103,Homo sapiens,BAO_0000219,,,1,,CHEMBL626198,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,9606.0
6104,Homo sapiens,BAO_0000219,,,1,,CHEMBL626199,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,9606.0
6105,Homo sapiens,BAO_0000219,,,1,,CHEMBL626200,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,9606.0
6106,Homo sapiens,BAO_0000219,,,1,,CHEMBL626201,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,9606.0
6107,Homo sapiens,BAO_0000219,,,1,,CHEMBL626202,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,9606.0
6108,Homo sapiens,BAO_0000219,,,1,,CHEMBL626203,,Intermediate,,358,,N,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,9606.0
6109,Homo sapiens,BAO_0000219,,,1,,CHEMBL626204,,Intermediate,,15167,,N,80682,1,In vitro cytotoxicity against A-549 human lung cancer cells,F,9606.0
6110,Homo sapiens,BAO_0000219,,,1,,CHEMBL624701,,Intermediate,,4139,,N,80682,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,9606.0
6111,Homo sapiens,BAO_0000219,,,1,,CHEMBL624702,,Intermediate,,833,,N,80682,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,9606.0
6112,Homo sapiens,BAO_0000219,,,1,,CHEMBL624703,,Expert,,15718,,N,80682,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0
6113,Homo sapiens,BAO_0000219,,,1,,CHEMBL624704,,Intermediate,,12373,,N,80682,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,9606.0
6114,Homo sapiens,BAO_0000219,,,1,,CHEMBL624705,,Intermediate,,637,,N,80682,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,9606.0
6115,Homo sapiens,BAO_0000219,,,1,,CHEMBL624706,,Expert,,14867,,N,80682,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,9606.0
6116,Homo sapiens,BAO_0000219,,,1,,CHEMBL624707,,Intermediate,,4461,,N,80682,1,Antitumor cytotoxic activity against A-549 cell line was determined,F,9606.0
6117,Homo sapiens,BAO_0000219,,,1,,CHEMBL624708,,Intermediate,,5406,,N,80682,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,9606.0
6118,Homo sapiens,BAO_0000219,,,1,,CHEMBL624709,,Intermediate,,4457,,N,80682,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,9606.0
6119,Homo sapiens,BAO_0000219,,,1,,CHEMBL884107,,Expert,,1386,,N,80682,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,9606.0
6120,Homo sapiens,BAO_0000219,,,1,,CHEMBL624710,,Intermediate,,3265,,N,80682,1,Antitumoral activity was assayed against A-549 cell line,F,9606.0
6121,Homo sapiens,BAO_0000219,,,1,,CHEMBL624711,,Intermediate,,2359,,N,80682,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,9606.0
6122,Homo sapiens,BAO_0000219,,,1,,CHEMBL624712,,Intermediate,,4457,,N,80682,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,9606.0
6123,Homo sapiens,BAO_0000219,,,1,,CHEMBL624713,,Expert,,12454,,N,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0
6124,Homo sapiens,BAO_0000219,,,1,,CHEMBL624714,,Intermediate,,1481,,N,80682,1,Compound was tested for inhibition of cell growth of A-549 cells,F,9606.0
6125,Homo sapiens,BAO_0000219,,,1,,CHEMBL624715,,Intermediate,,1750,,N,80682,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,9606.0
6126,Homo sapiens,BAO_0000219,,,1,,CHEMBL624716,,Intermediate,,5065,,N,80682,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,9606.0
6127,Homo sapiens,BAO_0000219,,,1,,CHEMBL619505,,Expert,,808,,N,80682,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,9606.0
6128,Homo sapiens,BAO_0000219,,,1,,CHEMBL619506,,Expert,,16364,,N,80682,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,9606.0
6129,Homo sapiens,BAO_0000219,,,1,,CHEMBL619507,,Intermediate,,1847,,N,80682,1,Cytotoxic activity against A-549 cell lines.,F,9606.0
6130,Homo sapiens,BAO_0000219,,,1,,CHEMBL619508,,Expert,,1747,,N,80682,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,9606.0
6131,Homo sapiens,BAO_0000219,,,1,,CHEMBL619509,,Intermediate,,1003,,N,80682,1,Cytotoxicity against human A549 non small cell lung cell lines,F,9606.0
6132,Homo sapiens,BAO_0000219,,,1,,CHEMBL619510,,Expert,,15313,,N,80682,1,Inhibition of cell growth in (A-549) lung cell line,F,9606.0
6133,Homo sapiens,BAO_0000219,,,1,,CHEMBL619511,,Intermediate,,3122,,N,80682,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,9606.0
6134,Homo sapiens,BAO_0000219,,,1,,CHEMBL619512,,Intermediate,,16049,,N,80682,1,In vitro antitumor activity against A-549 tumor cells.,F,9606.0
6135,Homo sapiens,BAO_0000219,,,1,,CHEMBL619513,,Expert,,17134,,N,80682,1,In vitro antitumor effects against human A-549 cell lines.,F,9606.0
6136,Homo sapiens,BAO_0000219,,,1,,CHEMBL619514,,Intermediate,,6406,,N,80682,1,In vitro cytotoxic activity of compound against A-549 cell line,F,9606.0
6137,Homo sapiens,BAO_0000219,,,1,,CHEMBL619515,,Intermediate,,627,,N,80682,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,9606.0
6138,Homo sapiens,BAO_0000219,,,1,,CHEMBL619516,,Intermediate,,12307,,N,80682,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,9606.0
6139,Homo sapiens,BAO_0000219,,,1,,CHEMBL884005,,Intermediate,,17861,,N,80682,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,9606.0
6140,Homo sapiens,BAO_0000219,,,1,,CHEMBL619517,,Expert,,6682,,N,80682,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,9606.0
6141,Homo sapiens,BAO_0000219,,,1,,CHEMBL619518,,Intermediate,,6663,,N,80682,1,Inhibitory concentration of compound against A-549 cell line,F,9606.0
6142,Homo sapiens,BAO_0000219,,,1,,CHEMBL619519,,Intermediate,,2454,,N,80682,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,9606.0
6143,Homo sapiens,BAO_0000219,,,1,,CHEMBL876489,,Intermediate,,14709,,N,80682,1,cytotoxic activity against leukemia (A-549) cancer cell line,F,9606.0
6144,Homo sapiens,BAO_0000219,,,1,,CHEMBL619520,,Expert,,15718,,N,80682,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0
6145,Homo sapiens,BAO_0000219,,,1,,CHEMBL619521,,Intermediate,,15718,,N,80682,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0
6146,Homo sapiens,BAO_0000219,,,1,,CHEMBL619522,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,9606.0
6147,Homo sapiens,BAO_0000219,,,1,,CHEMBL619523,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,9606.0
6148,Homo sapiens,BAO_0000219,,,1,,CHEMBL619524,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,9606.0
6149,Homo sapiens,BAO_0000219,,,1,,CHEMBL619525,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,9606.0
6150,,BAO_0000219,,,1,,CHEMBL619526,,Intermediate,,6630,,N,80682,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,
6151,Homo sapiens,BAO_0000219,,,1,,CHEMBL619527,,Intermediate,,16726,,N,80682,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,9606.0
6152,Homo sapiens,BAO_0000219,,,1,,CHEMBL619528,,Intermediate,,17846,,N,80682,1,Cytotoxicity against A549 cells; No cytotoxicity,F,9606.0
6153,Homo sapiens,BAO_0000219,,,1,,CHEMBL619529,,Expert,,3415,,N,80682,1,Cytotoxicity against human lung carcinoma (A549) cell lines,F,9606.0
6154,Homo sapiens,BAO_0000219,,,1,,CHEMBL619530,,Expert,,3415,,N,80682,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,9606.0
6155,Homo sapiens,BAO_0000219,,,1,,CHEMBL876490,,Intermediate,,5609,,N,80682,1,In vitro anticancer activity against human lung (A549) cell line,F,9606.0
6156,Homo sapiens,BAO_0000219,,,1,,CHEMBL619531,,Intermediate,,17206,,N,80682,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,9606.0
6157,Homo sapiens,BAO_0000219,,,1,,CHEMBL619532,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,9606.0
6158,Homo sapiens,BAO_0000219,,,1,,CHEMBL619533,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,9606.0
6159,Homo sapiens,BAO_0000219,,,1,,CHEMBL619534,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,9606.0
6160,Homo sapiens,BAO_0000219,,,1,,CHEMBL620164,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,9606.0
6161,Homo sapiens,BAO_0000219,,,1,,CHEMBL620165,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,9606.0
6162,Homo sapiens,BAO_0000219,,,1,,CHEMBL620166,,Expert,,16295,,N,80682,1,Inhibition of A549 human lung tumor cell proliferation,F,9606.0
6163,Homo sapiens,BAO_0000219,,,1,,CHEMBL620167,,Intermediate,,16825,,N,80682,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,9606.0
6164,Homo sapiens,BAO_0000219,,,1,,CHEMBL620168,,Expert,,3439,,N,80682,1,In vitro cytotoxicity against human tumor cell line A549,F,9606.0
6165,Homo sapiens,BAO_0000219,,,1,,CHEMBL620338,,Intermediate,,10870,,N,80682,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,9606.0
6166,Homo sapiens,BAO_0000219,,,1,,CHEMBL620339,,Intermediate,,4845,,N,80682,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,9606.0
6167,Homo sapiens,BAO_0000219,,,1,,CHEMBL620340,,Intermediate,,5822,,N,80682,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,9606.0
6168,Homo sapiens,BAO_0000219,,,1,,CHEMBL620341,,Intermediate,,5822,,N,80682,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,9606.0
6169,Homo sapiens,BAO_0000219,,,1,,CHEMBL876491,,Intermediate,,5822,,N,80682,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,9606.0
6170,Homo sapiens,BAO_0000219,,,1,,CHEMBL620342,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,9606.0
6171,Homo sapiens,BAO_0000219,,,1,,CHEMBL620343,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,9606.0
6172,Homo sapiens,BAO_0000219,,,1,,CHEMBL620344,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,9606.0
6173,Homo sapiens,BAO_0000219,,,1,,CHEMBL620345,,Intermediate,,5609,,N,80682,1,In vitro anticancer activity against human lung (A549) cell line,F,9606.0
6174,Homo sapiens,BAO_0000219,,,1,,CHEMBL620346,,Intermediate,,4644,,N,80682,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,9606.0
6175,Homo sapiens,BAO_0000219,,,1,,CHEMBL620347,,Intermediate,,4644,,N,80682,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,9606.0
6176,Homo sapiens,BAO_0000219,,,1,,CHEMBL620348,,Intermediate,,4644,,N,80682,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,9606.0
6177,Homo sapiens,BAO_0000219,,,1,,CHEMBL620349,,Intermediate,,4644,,N,80682,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,9606.0
6178,Homo sapiens,BAO_0000219,,,1,,CHEMBL618667,,Intermediate,,5822,,N,80682,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,9606.0
6179,Homo sapiens,BAO_0000219,,,1,,CHEMBL618668,,Expert,,3415,,N,80682,1,Percentage inhibition of human lung carcinoma (A549) cell lines,F,9606.0
6180,Homo sapiens,BAO_0000219,,,1,,CHEMBL876031,,Intermediate,,16726,,N,80682,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,9606.0
6181,Homo sapiens,BAO_0000219,,,1,,CHEMBL618759,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,9606.0
6182,Homo sapiens,BAO_0000219,,,1,,CHEMBL618760,,Intermediate,,17206,,N,80682,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,9606.0
6183,Homo sapiens,BAO_0000219,,,1,,CHEMBL619000,,Intermediate,,17206,,N,80682,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,9606.0
6184,Homo sapiens,BAO_0000219,,,1,,CHEMBL619001,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,9606.0
6185,Homo sapiens,BAO_0000219,,,1,,CHEMBL619002,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,9606.0
6186,Homo sapiens,BAO_0000219,,,1,,CHEMBL619003,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,9606.0
6187,Homo sapiens,BAO_0000219,,,1,,CHEMBL619597,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,9606.0
6188,Homo sapiens,BAO_0000219,,,1,,CHEMBL619598,,Intermediate,,17206,,N,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,9606.0
6189,Homo sapiens,BAO_0000219,,,1,,CHEMBL619599,,Intermediate,,17206,,N,80682,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,9606.0
6190,Homo sapiens,BAO_0000219,,,1,,CHEMBL619600,,Intermediate,,17206,,N,80682,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,9606.0
6191,Homo sapiens,BAO_0000219,,,1,,CHEMBL619601,,Intermediate,,16726,,N,80682,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,9606.0
6192,Homo sapiens,BAO_0000219,,,1,,CHEMBL619602,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,9606.0
6193,Homo sapiens,BAO_0000219,,,1,,CHEMBL619603,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,9606.0
6194,Homo sapiens,BAO_0000219,,,1,,CHEMBL619604,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,9606.0
6195,Homo sapiens,BAO_0000219,,,1,,CHEMBL619605,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,9606.0
6196,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619606,,Intermediate,In vivo,6084,,N,50588,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,9615.0
6197,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876032,,Intermediate,In vivo,6084,,N,50588,1,Pharmacokinetic activity (Cmax) in dog,A,9615.0
6198,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619607,,Intermediate,In vivo,4809,,N,50588,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0
6199,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619608,,Intermediate,In vivo,5983,,N,50588,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,9615.0
6200,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619609,,Intermediate,In vivo,6251,,N,50588,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,9615.0
6201,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL619610,,Intermediate,In vivo,5932,,N,50588,1,Cmax in dog plasma after 30mg/kg oral dose,A,9615.0
6202,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL619611,,Intermediate,In vivo,4273,,N,50588,1,Tested for the peak blood level in dog,A,9615.0
6203,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619612,,Intermediate,In vivo,5313,,N,50588,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,9615.0
6204,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619613,,Intermediate,In vivo,5313,,N,50588,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,9615.0
6205,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL619614,,Intermediate,In vivo,6221,,N,50588,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,9615.0
6206,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619615,,Intermediate,,4709,,N,50588,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,9615.0
6207,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619616,,Intermediate,,167,,N,50588,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,9615.0
6208,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL619617,,Intermediate,,6241,,N,50588,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,9615.0
6209,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619618,,Intermediate,,344,,N,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,9615.0
6210,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876033,,Intermediate,,344,,N,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,9615.0
6211,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619619,,Intermediate,,344,,N,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,9615.0
6212,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619620,,Intermediate,,2189,,N,50588,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,9615.0
6213,Canis lupus familiaris,BAO_0000218,1088.0,,1,Urine,CHEMBL619621,,Intermediate,,2189,,N,50588,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,9615.0
6214,Canis lupus familiaris,BAO_0000218,1088.0,,1,Urine,CHEMBL619622,,Intermediate,,2189,,N,50588,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,9615.0
6215,Canis lupus familiaris,BAO_0000218,1088.0,,1,Urine,CHEMBL618874,,Intermediate,,2189,,N,50588,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,9615.0
6216,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618875,,Intermediate,In vivo,4257,,N,50588,1,Absolute bioavailability was evaluated in dog,A,9615.0
6217,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618876,,Intermediate,In vivo,6221,,N,50588,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,9615.0
6218,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618877,,Intermediate,In vivo,6215,,N,50588,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,9615.0
6219,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618878,,Intermediate,In vivo,17267,,N,50588,1,Bioavailability in dog,A,9615.0
6220,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618879,,Intermediate,In vivo,6621,,N,50588,1,Bioavailability in dog,A,9615.0
6221,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618880,,Intermediate,In vivo,3854,,N,50588,1,Bioavailability after intravenous administration in dogs,A,9615.0
6222,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618881,,Intermediate,In vivo,3854,,N,50588,1,Bioavailability after peroral administration in dogs,A,9615.0
6223,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618882,,Intermediate,In vivo,5007,,N,50588,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,9615.0
6224,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624226,,Intermediate,In vivo,4333,,N,50588,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,9615.0
6225,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624227,,Intermediate,In vivo,4333,,N,50588,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,9615.0
6226,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624228,,Intermediate,In vivo,5006,,N,50588,1,Bioavailability,A,9615.0
6227,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624229,,Intermediate,In vivo,5199,,N,50588,1,Bioavailability,A,9615.0
6228,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624230,,Intermediate,In vivo,4368,,N,50588,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,9615.0
6229,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624231,,Intermediate,In vivo,3771,,N,50588,1,Bioavailability in dog,A,9615.0
6230,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624232,,Intermediate,In vivo,4953,,N,50588,1,Bioavailability in dog,A,9615.0
6231,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625127,,Intermediate,In vivo,5064,,N,50588,1,Bioavailability in dog,A,9615.0
6232,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625128,,Intermediate,In vivo,17657,,N,50588,1,Bioavailability in dog,A,9615.0
6233,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621675,,Intermediate,In vivo,17796,,N,50588,1,Bioavailability in dog,A,9615.0
6234,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621676,,Intermediate,In vivo,17853,,N,50588,1,Bioavailability in dog (p.o.) at 2.0 mpk,A,9615.0
6235,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621677,,Intermediate,In vivo,4521,,N,50588,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,9615.0
6236,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621678,,Intermediate,In vivo,4521,,N,50588,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0
6237,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621679,,Intermediate,In vivo,5006,,N,50588,1,Bioavailability in dog,A,9615.0
6238,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621680,,Intermediate,In vivo,16365,,N,50588,1,Bioavailability was evaluated after oral administration in dog,A,9615.0
6239,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621681,,Intermediate,In vivo,1916,,N,50588,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0
6240,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876740,,Intermediate,In vivo,1918,,N,50588,1,Bioavailability was evaluated in dog,A,9615.0
6241,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621682,,Intermediate,In vivo,4239,,N,50588,1,Bioavailability in dog,A,9615.0
6242,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621683,,Intermediate,In vivo,6505,,N,50588,1,Bioavailability in dog,A,9615.0
6243,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621684,,Intermediate,In vivo,5334,,N,50588,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0
6244,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621685,,Intermediate,In vivo,5334,,N,50588,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,9615.0
6245,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621686,,Intermediate,In vivo,4809,,N,50588,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0
6246,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621687,,Intermediate,In vivo,6348,,N,50588,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
6247,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621688,,Intermediate,In vivo,6005,,N,50588,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,9615.0
6248,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621689,,Intermediate,In vivo,17804,,N,50588,1,Bioavailability of compound in dog was determined after peroral administration,A,9615.0
6249,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621690,,Intermediate,In vivo,3184,,N,50588,1,Oral bioavailability in dog,A,9615.0
6250,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621691,,Intermediate,In vivo,1806,,N,50588,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,9615.0
6251,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875941,,Intermediate,In vivo,1806,,N,50588,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,9615.0
6252,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621692,,Intermediate,In vivo,1806,,N,50588,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,9615.0
6253,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621693,,Intermediate,In vivo,4839,,N,50588,1,Bioavailability in dog,A,9615.0
6254,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621694,,Intermediate,In vivo,5017,,N,50588,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,9615.0
6255,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621695,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6256,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621696,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6257,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621697,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6258,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621698,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6259,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623420,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6260,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623421,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6261,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623422,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6262,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623423,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6263,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623424,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6264,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623425,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6265,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623426,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6266,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623427,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6267,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623428,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6268,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL875947,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6269,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623429,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6270,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623430,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6271,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL622588,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6272,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL622589,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6273,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL622751,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6274,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL622752,,Intermediate,In vivo,846,,N,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0
6275,Mus musculus,BAO_0000218,,,1,,CHEMBL622753,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,10090.0
6276,Mus musculus,BAO_0000218,,,1,,CHEMBL622647,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,10090.0
6277,Mus musculus,BAO_0000218,,,1,,CHEMBL875163,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,10090.0
6278,Mus musculus,BAO_0000218,,,1,,CHEMBL622648,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,10090.0
6279,Mus musculus,BAO_0000218,,,1,,CHEMBL622649,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,10090.0
6280,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622650,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,10090.0
6281,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622651,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,10090.0
6282,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622652,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,10090.0
6283,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622653,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,10090.0
6284,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL622654,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,10090.0
6285,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622655,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,10090.0
6286,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622656,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,10090.0
6287,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622657,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,10090.0
6288,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622658,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,10090.0
6289,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL622659,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,10090.0
6290,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL624630,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,10090.0
6291,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL624631,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,10090.0
6292,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL624632,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,10090.0
6293,Homo sapiens,BAO_0000219,,,1,,CHEMBL624633,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,9606.0
6294,Homo sapiens,BAO_0000219,,,1,,CHEMBL624634,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,9606.0
6295,Homo sapiens,BAO_0000219,,,1,,CHEMBL624635,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,9606.0
6296,Homo sapiens,BAO_0000219,,,1,,CHEMBL624636,,Intermediate,,17130,,N,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,9606.0
6297,Homo sapiens,BAO_0000219,,,1,,CHEMBL857055,,Expert,,3263,,N,80682,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,9606.0
6298,Homo sapiens,BAO_0000219,,,1,,CHEMBL624637,,Expert,,6663,,N,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,9606.0
6299,Homo sapiens,BAO_0000219,,,1,,CHEMBL624638,,Expert,,6663,,N,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,9606.0
6300,Homo sapiens,BAO_0000219,,,1,,CHEMBL874366,,Expert,,6663,,N,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,9606.0
6301,Homo sapiens,BAO_0000219,,,1,,CHEMBL624639,,Expert,,6663,,N,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,9606.0
6302,Homo sapiens,BAO_0000219,,,1,,CHEMBL624640,,Expert,,6663,,N,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,9606.0
6303,Homo sapiens,BAO_0000219,,,1,,CHEMBL624641,,Intermediate,,6663,,N,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,9606.0
6304,Homo sapiens,BAO_0000219,,,1,,CHEMBL624642,,Intermediate,,6663,,N,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,9606.0
6305,Homo sapiens,BAO_0000219,,,1,,CHEMBL624643,,Intermediate,,6663,,N,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,9606.0
6306,Homo sapiens,BAO_0000219,,,1,,CHEMBL624644,,Intermediate,,6663,,N,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,9606.0
6307,Homo sapiens,BAO_0000219,,,1,,CHEMBL624645,,Intermediate,,6663,,N,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,9606.0
6308,Homo sapiens,BAO_0000219,,,1,,CHEMBL619445,,Intermediate,,3983,,N,80682,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,9606.0
6309,Homo sapiens,BAO_0000219,,,1,,CHEMBL839886,,Expert,,11141,,N,80682,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,9606.0
6310,Homo sapiens,BAO_0000219,,,1,,CHEMBL619446,,Intermediate,,5076,,N,80682,1,Cytotoxic activity of compound against A-549 tumor cell line.,F,9606.0
6311,Homo sapiens,BAO_0000219,,,1,,CHEMBL619447,,Intermediate,,3311,,N,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,9606.0
6312,Homo sapiens,BAO_0000219,,,1,,CHEMBL619448,,Intermediate,,3311,,N,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,9606.0
6313,Homo sapiens,BAO_0000219,,,1,,CHEMBL619449,,Intermediate,,3311,,N,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,9606.0
6314,Homo sapiens,BAO_0000219,,,1,,CHEMBL619450,,Intermediate,,5076,,N,80682,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,9606.0
6315,Homo sapiens,BAO_0000219,,,1,,CHEMBL619451,,Intermediate,,4150,,N,80682,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,9606.0
6316,Homo sapiens,BAO_0000219,,,1,,CHEMBL619452,,Expert,,2150,,N,80682,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,9606.0
6317,Homo sapiens,BAO_0000219,,,1,,CHEMBL619453,,Intermediate,,4644,,N,80682,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,9606.0
6318,Homo sapiens,BAO_0000219,,,1,,CHEMBL874367,,Intermediate,,263,,N,80682,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,9606.0
6319,Homo sapiens,BAO_0000219,,,1,,CHEMBL619454,,Intermediate,,11333,,N,80682,1,Cytotoxic concentration against A-549 tumor cells.,F,9606.0
6320,Homo sapiens,BAO_0000219,,,1,,CHEMBL619455,,Intermediate,,11333,,N,80682,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,9606.0
6321,Homo sapiens,BAO_0000219,,,1,,CHEMBL619456,,Intermediate,,15895,,N,80682,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,9606.0
6322,Acinetobacter baumannii,BAO_0000218,,,1,,CHEMBL619457,,Expert,,16677,,N,50191,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,470.0
6323,Acinetobacter calcoaceticus,BAO_0000218,,,1,,CHEMBL619458,,Intermediate,,10624,,N,50192,1,Activity against Acinetobacter calcoaceticus (AC54),F,471.0
6324,Aspergillus flavus,BAO_0000218,,,1,,CHEMBL619459,,Expert,,16717,,N,50274,1,In vitro antifungal activity against Aspergillus flavus CM74,F,5059.0
6325,Aspergillus flavus,BAO_0000218,,,1,,CHEMBL619460,,Expert,,16717,,N,50274,1,In vitro antifungal activity against Aspergillus flavus CM74,F,5059.0
6326,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL619461,,Intermediate,,5513,,N,50416,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,746128.0
6327,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL619462,,Intermediate,,15962,,N,50416,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,746128.0
6328,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL620388,,Intermediate,,15962,,N,50416,1,Antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0
6329,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL620389,,Intermediate,,15962,,N,50416,1,Antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0
6330,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL620390,,Intermediate,,15962,,N,50416,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0
6331,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL620391,,Expert,,16717,,N,50416,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,746128.0
6332,Aspergillus fumigatus,BAO_0000218,,,1,,CHEMBL621073,,Expert,,16717,,N,50416,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,746128.0
6333,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL621074,,Intermediate,,8117,,N,50296,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,1655.0
6334,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL621075,,Intermediate,,8117,,N,50366,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,1656.0
6335,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL619554,,Intermediate,,15472,,N,50535,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,6277.0
6336,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL619555,,Intermediate,,15472,,N,50535,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,6277.0
6337,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,1,,CHEMBL619556,,Intermediate,,16443,,N,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,714.0
6338,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,1,,CHEMBL619557,,Intermediate,,16443,,N,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,714.0
6339,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,1,,CHEMBL619558,,Intermediate,,16443,,N,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,714.0
6340,Homo sapiens,BAO_0000219,,,1,,CHEMBL619559,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,9606.0
6341,Homo sapiens,BAO_0000219,,,1,,CHEMBL619560,,Intermediate,,17206,,N,80682,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,9606.0
6342,Homo sapiens,BAO_0000219,,,1,,CHEMBL619561,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,9606.0
6343,Homo sapiens,BAO_0000219,,,1,,CHEMBL619562,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,9606.0
6344,Homo sapiens,BAO_0000219,,,1,,CHEMBL619563,,Intermediate,,16381,,N,80682,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,9606.0
6345,Homo sapiens,BAO_0000219,,,1,,CHEMBL857457,,Intermediate,,16381,,N,80682,1,GI values against A549 cells (lung cancer),F,9606.0
6346,Homo sapiens,BAO_0000219,,,1,,CHEMBL619564,,Intermediate,,17206,,N,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,9606.0
6347,Homo sapiens,BAO_0000219,,,1,,CHEMBL619565,,Intermediate,,16325,,N,80682,1,Inhibitory activity against A549 human adenocarcinoma,F,9606.0
6348,Homo sapiens,BAO_0000218,,,1,,CHEMBL619566,,Intermediate,,10708,,N,80682,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,9606.0
6349,Homo sapiens,BAO_0000218,,,1,,CHEMBL619567,,Intermediate,,10708,,N,80682,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,9606.0
6350,Homo sapiens,BAO_0000219,,,1,,CHEMBL619568,,Intermediate,,17376,,N,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line,F,9606.0
6351,Homo sapiens,BAO_0000219,,,1,,CHEMBL619569,,Intermediate,,17376,,N,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,9606.0
6352,Homo sapiens,BAO_0000219,,,1,,CHEMBL619570,,Intermediate,,17488,,N,80682,1,Cytotoxicity against human A549 lung cells,F,9606.0
6353,Homo sapiens,BAO_0000218,,,1,,CHEMBL619571,,Intermediate,,17404,,N,80682,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,9606.0
6354,Homo sapiens,BAO_0000219,,,1,,CHEMBL619572,,Expert,,10958,,N,80682,1,Growth inhibition of A549 (human lung carcinoma) cell line.,F,9606.0
6355,Homo sapiens,BAO_0000219,,,1,,CHEMBL619573,,Expert,,17099,,N,80682,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,9606.0
6356,Homo sapiens,BAO_0000219,,,1,,CHEMBL619574,,Intermediate,,17099,,N,80682,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,9606.0
6357,Homo sapiens,BAO_0000219,,,1,,CHEMBL619575,,Intermediate,,4096,,N,80682,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,9606.0
6358,Homo sapiens,BAO_0000219,,,1,,CHEMBL619576,,Expert,,4096,,N,80682,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,9606.0
6359,Homo sapiens,BAO_0000219,,,1,,CHEMBL619577,,Intermediate,,4096,,N,80682,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,9606.0
6360,Homo sapiens,BAO_0000219,,,1,,CHEMBL619578,,Intermediate,,2525,,N,80682,1,In vitro inhibitory activity against A549 tumor cell culture,F,9606.0
6361,Homo sapiens,BAO_0000219,,,1,,CHEMBL884009,,Intermediate,,2525,,N,80682,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,9606.0
6362,Homo sapiens,BAO_0000219,,,1,,CHEMBL619579,,Intermediate,,5302,,N,80682,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,9606.0
6363,Homo sapiens,BAO_0000219,,,1,,CHEMBL619580,,Intermediate,,16325,,N,80682,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,9606.0
6364,Homo sapiens,BAO_0000219,,,1,,CHEMBL619581,,Intermediate,,16939,,N,80682,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,9606.0
6365,Homo sapiens,BAO_0000219,,,1,,CHEMBL619582,,Intermediate,,17229,,N,80682,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,9606.0
6366,Homo sapiens,BAO_0000219,,,1,,CHEMBL619583,,Intermediate,,17380,,N,80682,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,9606.0
6367,Homo sapiens,BAO_0000219,,,1,,CHEMBL876502,,Intermediate,,17380,,N,80682,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,9606.0
6368,Homo sapiens,BAO_0000219,,,1,,CHEMBL619584,,Intermediate,,1903,,N,80682,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,9606.0
6369,Homo sapiens,BAO_0000219,,,1,,CHEMBL619585,,Intermediate,,3838,,N,80682,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,9606.0
6370,Homo sapiens,BAO_0000219,,,1,,CHEMBL619586,,Intermediate,,14696,,N,80682,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,9606.0
6371,Homo sapiens,BAO_0000219,,,1,,CHEMBL619587,,Intermediate,,3838,,N,80682,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,9606.0
6372,Homo sapiens,BAO_0000219,,,1,,CHEMBL619588,,Intermediate,,1522,,N,80682,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,9606.0
6373,Homo sapiens,BAO_0000219,,,1,,CHEMBL619589,,Intermediate,,12400,,N,80682,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,9606.0
6374,Homo sapiens,BAO_0000219,,,1,,CHEMBL619590,,Intermediate,,14696,,N,80682,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,9606.0
6375,Homo sapiens,BAO_0000219,,,1,,CHEMBL619591,,Intermediate,,14769,,N,80682,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,9606.0
6376,Homo sapiens,BAO_0000219,,,1,,CHEMBL619592,,Intermediate,,14696,,N,80682,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,9606.0
6377,Homo sapiens,BAO_0000219,,,1,,CHEMBL619593,,Intermediate,,1888,,N,80682,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,9606.0
6378,Homo sapiens,BAO_0000219,,,1,,CHEMBL620217,,Intermediate,,12016,,N,80682,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,9606.0
6379,Homo sapiens,BAO_0000219,,,1,,CHEMBL620218,,Intermediate,,6058,,N,80682,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,9606.0
6380,Homo sapiens,BAO_0000219,,,1,,CHEMBL620219,,Intermediate,,17708,,N,80682,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,9606.0
6381,Homo sapiens,BAO_0000219,,,1,,CHEMBL620220,,Intermediate,,12301,,N,80682,1,Antitumor activity against A549/ATCC cell line,F,9606.0
6382,Homo sapiens,BAO_0000219,,,1,,CHEMBL625141,,Intermediate,,11970,,N,80682,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,9606.0
6383,Homo sapiens,BAO_0000219,,,1,,CHEMBL625142,,Expert,,11818,,N,80682,1,In vitro cytotoxicity against A549/ATCC cell line.,F,9606.0
6384,Homo sapiens,BAO_0000219,,,1,,CHEMBL625143,,Intermediate,,12400,,N,80682,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,9606.0
6385,Homo sapiens,BAO_0000219,,,1,,CHEMBL625144,,Intermediate,,3381,,N,80682,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,9606.0
6386,Homo sapiens,BAO_0000219,,,1,,CHEMBL622474,,Intermediate,,17376,,N,80682,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,9606.0
6387,Homo sapiens,BAO_0000219,,,1,,CHEMBL884104,,Intermediate,,10708,,N,80682,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,9606.0
6388,Homo sapiens,BAO_0000219,,,0,,CHEMBL622475,,Autocuration,,2964,,U,22226,1,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,9606.0
6389,Canis lupus familiaris,BAO_0000218,,,0,,CHEMBL622476,,Intermediate,In vivo,5005,,U,22224,1,Compound was tested for oral bioavailability in dogs,A,9615.0
6390,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875831,,Intermediate,In vivo,6229,,N,50588,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,9615.0
6391,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622477,,Intermediate,In vivo,6229,,N,50588,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,9615.0
6392,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622478,,Intermediate,In vivo,5374,,N,50588,1,Oral bioavailability in dog,A,9615.0
6393,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623172,,Intermediate,In vivo,5374,,N,50588,1,Compound was tested for the oral bioavailability in dog; No availability,A,9615.0
6394,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623173,,Intermediate,In vivo,6265,,N,50588,1,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0
6395,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623174,,Intermediate,In vivo,5654,,N,50588,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,9615.0
6396,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623175,,Intermediate,In vivo,5654,,N,50588,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,9615.0
6397,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623340,,Intermediate,In vivo,16456,,N,50588,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,9615.0
6398,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623341,,Intermediate,In vivo,5302,,N,50588,1,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0
6399,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623342,,Intermediate,In vivo,3624,,N,50588,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,9615.0
6400,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623343,,Intermediate,In vivo,16452,,N,50588,1,Oral bioavailability of active FTIs in dogs,A,9615.0
6401,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623344,,Intermediate,In vivo,5802,,N,50588,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,9615.0
6402,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623345,,Expert,In vivo,3598,,N,50588,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
6403,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875832,,Intermediate,In vivo,17839,,N,50588,1,Oral bioavailability in dog,A,9615.0
6404,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623346,,Intermediate,In vivo,6762,,N,50588,1,Oral bioavailability in dog,A,9615.0
6405,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623347,,Intermediate,In vivo,6821,,N,50588,1,Oral bioavailability in dog,A,9615.0
6406,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623348,,Intermediate,In vivo,6821,,N,50588,1,Oral bioavailability of compound was determined in dog; Not tested,A,9615.0
6407,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623349,,Intermediate,In vivo,5210,,N,50588,1,Oral bioavailability in dog,A,9615.0
6408,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623350,,Intermediate,In vivo,6227,,N,50588,1,Oral bioavailability (10 mg/kg) was determined in dog,A,9615.0
6409,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623351,,Intermediate,In vivo,761,,N,50588,1,Oral bioavailability,A,9615.0
6410,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623352,,Intermediate,In vivo,761,,N,50588,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,9615.0
6411,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623353,,Intermediate,In vivo,761,,N,50588,1,Oral bioavailability administered in solution in rats,A,9615.0
6412,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875833,,Intermediate,In vivo,16907,,N,50588,1,Oral bioavailability after 30 mg/kg po dose in Dogs,A,9615.0
6413,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623354,,Intermediate,In vivo,5474,,N,50588,1,Oral bioavailability at a dose of 1 mg/kg in dogs,A,9615.0
6414,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623355,,Intermediate,In vivo,6535,,N,50588,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,9615.0
6415,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623356,,Intermediate,In vivo,6535,,N,50588,1,Oral bioavailability in Dog; ND = not determined,A,9615.0
6416,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623357,,Intermediate,In vivo,3352,,N,50588,1,Oral bioavailability in dog,A,9615.0
6417,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623358,,Intermediate,In vivo,6168,,N,50588,1,Oral bioavailability in dog,A,9615.0
6418,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623359,,Intermediate,In vivo,5988,,N,50588,1,Oral bioavailability in dog,A,9615.0
6419,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623360,,Intermediate,In vivo,4942,,N,50588,1,Oral bioavailability in dog,A,9615.0
6420,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623361,,Intermediate,In vivo,4942,,N,50588,1,Oral bioavailability in dogs; No data,A,9615.0
6421,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623362,,Intermediate,In vivo,14541,,N,50588,1,Oral bioavailability measured in dogs,A,9615.0
6422,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623363,,Intermediate,In vivo,4449,,N,50588,1,Oral bioavailability in dog,A,9615.0
6423,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623364,,Intermediate,In vivo,6057,,N,50588,1,Oral bioavailability was calculated in dog,A,9615.0
6424,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875834,,Intermediate,In vivo,5600,,N,50588,1,Oral bioavailability after 0.3 mg/kg po administration in dog,A,9615.0
6425,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623365,,Intermediate,In vivo,5542,,N,50588,1,Oral bioavailability in dog (i.v. dosing),A,9615.0
6426,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623366,,Intermediate,In vivo,5542,,N,50588,1,Oral bioavailability in dog,A,9615.0
6427,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623367,,Intermediate,In vivo,5546,,N,50588,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,9615.0
6428,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623368,,Intermediate,In vivo,4514,,N,50588,1,Oral bioavailability in Beagle dogs,A,9615.0
6429,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623369,,Intermediate,In vivo,3624,,N,50588,1,Oral bioavailability in dog,A,9615.0
6430,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623370,,Intermediate,In vivo,3854,,N,50588,1,Oral bioavailability in dog,A,9615.0
6431,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623371,,Intermediate,In vivo,5836,,N,50588,1,Oral bioavailability in dog,A,9615.0
6432,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623372,,Intermediate,In vivo,5940,,N,50588,1,Oral bioavailability in dog,A,9615.0
6433,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621351,,Intermediate,In vivo,6168,,N,50588,1,Oral bioavailability in dog,A,9615.0
6434,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621352,,Intermediate,In vivo,6227,,N,50588,1,Oral bioavailability in dog,A,9615.0
6435,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621353,,Intermediate,In vivo,6251,,N,50588,1,Oral bioavailability in dog,A,9615.0
6436,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621354,,Intermediate,In vivo,6448,,N,50588,1,Oral bioavailability in dog,A,9615.0
6437,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621355,,Intermediate,In vivo,6647,,N,50588,1,Oral bioavailability in dog,A,9615.0
6438,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621356,,Intermediate,In vivo,5940,,N,50588,1,Oral bioavailability in dog,A,9615.0
6439,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621357,,Intermediate,In vivo,933,,N,50588,1,Oral bioavailability in dog,A,9615.0
6440,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621358,,Intermediate,In vivo,5210,,N,50588,1,Oral bioavailability in dog,A,9615.0
6441,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621359,,Intermediate,In vivo,6642,,N,50588,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,9615.0
6442,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621360,,Intermediate,In vivo,6641,,N,50588,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,9615.0
6443,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621361,,Intermediate,In vivo,6642,,N,50588,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,9615.0
6444,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621362,,Intermediate,In vivo,5472,,N,50588,1,Oral bioavailability in dog,A,9615.0
6445,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621363,,Intermediate,In vivo,5985,,N,50588,1,Oral bioavailability in dog,A,9615.0
6446,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621364,,Intermediate,In vivo,15660,,N,50588,1,Oral bioavailability in dog,A,9615.0
6447,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621166,,Intermediate,In vivo,5530,,N,50588,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,9615.0
6448,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621167,,Intermediate,In vivo,5530,,N,50588,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0
6449,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621168,,Intermediate,In vivo,6305,,N,50588,1,Oral bioavailability (F) in dogs,A,9615.0
6450,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621169,,Intermediate,In vivo,5210,,N,50588,1,Oral bioavailability in dog,A,9615.0
6451,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875950,,Intermediate,In vivo,5238,,N,50588,1,Bioavailability in dog,A,9615.0
6452,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621170,,Intermediate,In vivo,5668,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0
6453,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621171,,Intermediate,In vivo,5668,,N,50588,1,Oral bioavailability after peroral administration at 5 mpk in Dog,A,9615.0
6454,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621172,,Intermediate,In vivo,5668,,N,50588,1,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0
6455,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621173,,Intermediate,In vivo,6084,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0
6456,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621174,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,10090.0
6457,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621175,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,10090.0
6458,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621176,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,10090.0
6459,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621177,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,10090.0
6460,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621178,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,10090.0
6461,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621179,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,10090.0
6462,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621180,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,10090.0
6463,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL875951,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,10090.0
6464,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621181,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,10090.0
6465,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621182,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,10090.0
6466,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621183,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,10090.0
6467,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL621184,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,10090.0
6468,Mus musculus,BAO_0000218,,,1,,CHEMBL621185,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,10090.0
6469,Mus musculus,BAO_0000218,,,1,,CHEMBL621186,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,10090.0
6470,Mus musculus,BAO_0000218,,,1,,CHEMBL621187,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,10090.0
6471,Mus musculus,BAO_0000218,,,1,,CHEMBL621188,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,10090.0
6472,Mus musculus,BAO_0000218,,,1,,CHEMBL621189,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,10090.0
6473,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL621190,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,10090.0
6474,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618520,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,10090.0
6475,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL621739,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,10090.0
6476,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL621740,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,10090.0
6477,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL621741,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,10090.0
6478,Mus musculus,BAO_0000218,,,1,,CHEMBL621742,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,10090.0
6479,Mus musculus,BAO_0000218,,,1,,CHEMBL621743,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,10090.0
6480,Mus musculus,BAO_0000218,,,1,,CHEMBL621744,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,10090.0
6481,Mus musculus,BAO_0000218,,,1,,CHEMBL621745,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,10090.0
6482,Mus musculus,BAO_0000218,,,1,,CHEMBL621746,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,10090.0
6483,Mus musculus,BAO_0000218,,,1,,CHEMBL621747,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,10090.0
6484,Mus musculus,BAO_0000218,,,1,,CHEMBL621748,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,10090.0
6485,Mus musculus,BAO_0000218,,,1,,CHEMBL621749,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,10090.0
6486,Mus musculus,BAO_0000218,,,1,,CHEMBL621750,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,10090.0
6487,Mus musculus,BAO_0000218,,,1,,CHEMBL621751,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,10090.0
6488,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621752,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,10090.0
6489,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621753,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,10090.0
6490,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL875955,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,10090.0
6491,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621754,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,10090.0
6492,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621755,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,10090.0
6493,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621756,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,10090.0
6494,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624199,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,10090.0
6495,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624200,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,10090.0
6496,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624375,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,10090.0
6497,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624376,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,10090.0
6498,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624377,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,10090.0
6499,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624378,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,10090.0
6500,aeinetobacter anitrotap,BAO_0000218,,,1,,CHEMBL857901,,Intermediate,,12269,,N,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0
6501,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,,1,,CHEMBL875274,,Intermediate,,12269,,N,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0
6502,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,,1,,CHEMBL624379,,Intermediate,,12269,,N,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0
6503,aeinetobacter anitrotap,BAO_0000218,,,1,,CHEMBL624380,,Intermediate,,12269,,N,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0
6504,Acinetobacter calcoaceticus,BAO_0000218,,,1,,CHEMBL624381,,Intermediate,,10624,,N,50192,1,Activity against Acinetobacter calcoaceticus (AC54),F,471.0
6505,Anolis carolinensis,BAO_0000218,,,1,,CHEMBL624382,,Intermediate,,17216,,N,50714,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,28377.0
6506,Anolis carolinensis,BAO_0000218,,,1,,CHEMBL624383,,Intermediate,,17216,,N,50714,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,28377.0
6507,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624384,,Intermediate,,9560,,N,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,1655.0
6508,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624385,,Intermediate,,9560,,N,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,1655.0
6509,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624386,,Intermediate,,9560,,N,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,1655.0
6510,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624387,,Intermediate,,9560,,N,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,1655.0
6511,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624388,,Intermediate,,9560,,N,50296,1,Plaque bactericidal index against Actinomyces naeslundii 631,F,1655.0
6512,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624389,,Intermediate,,9560,,N,50296,1,Plaque bactericidal index against Actinomyces naeslundii N/9,F,1655.0
6513,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL624390,,Intermediate,,9560,,N,50296,1,Plaque bactericidal index against Actinomyces naeslundii B74,F,1655.0
6514,Actinomyces naeslundii,BAO_0000218,,,1,,CHEMBL875275,,Intermediate,,9560,,N,50296,1,Plaque bactericidal index against Actinomyces naeslundii N/3,F,1655.0
6515,Artemia salina,BAO_0000218,,,1,,CHEMBL624391,,Intermediate,,114,,N,50056,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,85549.0
6516,Artemia salina,BAO_0000218,,,1,,CHEMBL623636,,Intermediate,,114,,N,50056,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,85549.0
6517,Ascaris suum,BAO_0000218,,,1,,CHEMBL623637,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,6253.0
6518,Ascaris suum,BAO_0000218,,,1,,CHEMBL623638,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,6253.0
6519,Ascaris suum,BAO_0000218,,,1,,CHEMBL623639,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,6253.0
6520,Ascaris suum,BAO_0000218,,,1,,CHEMBL623640,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,6253.0
6521,Ascaris suum,BAO_0000218,,,1,,CHEMBL623641,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,6253.0
6522,Ascaris suum,BAO_0000218,,,1,,CHEMBL623642,,Intermediate,,10841,,N,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,6253.0
6523,Ascaris suum,BAO_0000218,,,1,,CHEMBL623643,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,6253.0
6524,Ascaris suum,BAO_0000218,,,1,,CHEMBL623644,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,6253.0
6525,Ascaris suum,BAO_0000218,,,1,,CHEMBL623645,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,6253.0
6526,Ascaris suum,BAO_0000218,,,1,,CHEMBL623646,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,6253.0
6527,Ascaris suum,BAO_0000218,,,1,,CHEMBL623647,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,6253.0
6528,Ascaris suum,BAO_0000218,,,1,,CHEMBL623648,,Intermediate,,10841,,N,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,6253.0
6529,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623649,,Intermediate,,8117,,N,50366,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1656.0
6530,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623650,,Intermediate,,8117,,N,50366,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1656.0
6531,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623651,,Intermediate,,9560,,N,50366,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,1656.0
6532,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623652,,Expert,,9560,,N,50366,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,1656.0
6533,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623653,,Intermediate,,9560,,N,50366,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,1656.0
6534,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623654,,Intermediate,,9560,,N,50366,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,1656.0
6535,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623655,,Intermediate,,9560,,N,50366,1,Plaque bactericidal index against Actinomyces viscosus 8A06,F,1656.0
6536,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623656,,Intermediate,,9560,,N,50366,1,Plaque bactericidal index against Actinomyces viscosus M-100,F,1656.0
6537,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623657,,Expert,,9560,,N,50366,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,1656.0
6538,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623658,,Intermediate,,9560,,N,50366,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1656.0
6539,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623659,,Intermediate,,9560,,N,50366,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1656.0
6540,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623660,,Intermediate,,9560,,N,50366,1,Plaque bactericidal index against Actinomyces viscosus 626,F,1656.0
6541,Actinomyces viscosus,BAO_0000218,,,1,,CHEMBL623661,,Intermediate,,9560,,N,50366,1,Plaque bactericidal index against Actinomyces viscosus T14V,F,1656.0
6542,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL875281,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,6277.0
6543,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL623662,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,6277.0
6544,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL623663,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,6277.0
6545,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL623664,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,6277.0
6546,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL623665,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,6277.0
6547,Homo sapiens,BAO_0000219,,,1,,CHEMBL621856,,Intermediate,,10708,,N,80023,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,9606.0
6548,Homo sapiens,BAO_0000219,,,1,,CHEMBL620432,,Intermediate,,10708,,N,80661,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,9606.0
6549,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL620433,,Autocuration,,416,,U,22226,1,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,10116.0
6550,Mus musculus,BAO_0000219,,,1,,CHEMBL620434,,Intermediate,,14354,,N,80024,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,10090.0
6551,Mus musculus,BAO_0000219,,,1,,CHEMBL620435,,Intermediate,,14354,,N,80024,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,10090.0
6552,Homo sapiens,BAO_0000219,,,1,,CHEMBL620436,,Intermediate,,5116,,N,80024,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,9606.0
6553,Homo sapiens,BAO_0000219,,,1,,CHEMBL876597,,Intermediate,,5116,,N,80024,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,9606.0
6554,Homo sapiens,BAO_0000219,,,1,,CHEMBL620437,,Expert,,15694,,N,81037,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,9606.0
6555,Mus musculus,BAO_0000219,,,1,,CHEMBL620438,,Expert,,13038,,N,80024,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,10090.0
6556,Mus musculus,BAO_0000219,,,1,,CHEMBL620439,,Expert,,13038,,N,80024,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,10090.0
6557,Mus musculus,BAO_0000219,,,1,,CHEMBL619657,,Expert,,10923,,N,80024,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,10090.0
6558,Mus musculus,BAO_0000219,,,1,,CHEMBL619658,,Intermediate,,10923,,N,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,10090.0
6559,Mus musculus,BAO_0000219,,,1,,CHEMBL619659,,Intermediate,,10923,,N,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,10090.0
6560,,BAO_0000019,,,8,,CHEMBL619660,,Expert,,10923,,H,10649,1,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,
6561,Mus musculus,BAO_0000219,,,1,,CHEMBL619661,,Intermediate,,10923,,N,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,10090.0
6562,Mus musculus,BAO_0000219,,,1,,CHEMBL619662,,Intermediate,,10923,,N,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,10090.0
6563,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619663,,Intermediate,,8158,,N,80663,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,10029.0
6564,Homo sapiens,BAO_0000219,,,0,,CHEMBL619664,,Autocuration,,15494,,U,22226,1,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,9606.0
6565,Homo sapiens,BAO_0000219,,,0,,CHEMBL619665,,Autocuration,,15494,,U,22226,1,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,9606.0
6566,Homo sapiens,BAO_0000219,,,1,,CHEMBL883244,,Intermediate,,12348,,N,80662,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,9606.0
6567,Homo sapiens,BAO_0000219,,,1,,CHEMBL884011,,Intermediate,,12348,,N,80662,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,9606.0
6568,Homo sapiens,BAO_0000219,,,1,,CHEMBL619666,,Intermediate,,2726,,N,80662,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,9606.0
6569,Homo sapiens,BAO_0000219,,,1,,CHEMBL619667,,Intermediate,,2726,,N,80566,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,9606.0
6570,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619668,,Intermediate,,10747,,N,80578,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,10029.0
6571,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619669,,Expert,,11005,,N,80089,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,10029.0
6572,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL876608,,Intermediate,,12687,,N,80089,1,Average intracellular compound concentration when the hypoxic SER=1.6,F,10029.0
6573,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619670,,Intermediate,,12687,,N,80089,1,Average intracellular compound concentration when the hypoxic SER=1.6.,F,10029.0
6574,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619671,,Intermediate,,12687,,N,80089,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,10029.0
6575,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619672,,Intermediate,,12687,,N,80089,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,10029.0
6576,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619673,,Intermediate,,12687,,N,80089,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,10029.0
6577,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619674,,Intermediate,,13436,,N,80089,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,10029.0
6578,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619675,,Intermediate,,13435,,N,80089,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,10029.0
6579,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619676,,Intermediate,,13302,,N,80089,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,10029.0
6580,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619677,,Intermediate,,12687,,N,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,10029.0
6581,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619678,,Intermediate,,12687,,N,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,10029.0
6582,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619679,,Intermediate,,12687,,N,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,10029.0
6583,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL619680,,Expert,,12878,,N,80089,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,10029.0
6584,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL621457,,Intermediate,,12878,,N,80089,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,10029.0
6585,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL876609,,Expert,,14367,,N,80089,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,10029.0
6586,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL621458,,Intermediate,,14367,,N,80089,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,10029.0
6587,hampster,BAO_0000219,,,1,,CHEMBL621459,,Expert,,12398,,N,80089,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,36483.0
6588,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL621460,,Expert,,12878,,N,80089,1,Aerobic growth inhibition in Chinese hamster cell line AA8,F,10029.0
6589,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL621461,,Expert,,13820,,N,80089,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,10029.0
6590,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL621462,,Expert,,13436,,N,80089,1,Inhibition of growth under aerobic conditions in AA8 cells,F,10029.0
6591,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621463,,Intermediate,In vivo,6084,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0
6592,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621464,,Intermediate,In vivo,5711,,N,50588,1,Oral bioavailability in dog at 10 mg/kg of the compound,A,9615.0
6593,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621465,,Intermediate,In vivo,4353,,N,50588,1,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0
6594,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621466,,Intermediate,In vivo,4353,,N,50588,1,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0
6595,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621467,,Intermediate,In vivo,17800,,N,50588,1,Oral bioavailability in dog (mongrel),A,9615.0
6596,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621468,,Intermediate,In vivo,3994,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0
6597,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876734,,Intermediate,In vivo,3994,,N,50588,1,Oral bioavailability in dog (dose 10 mg/kg),F,9615.0
6598,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618476,,Intermediate,In vivo,5145,,N,50588,1,Bioavailability in dog,A,9615.0
6599,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618477,,Intermediate,In vivo,16452,,N,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0
6600,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618478,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,9615.0
6601,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618479,,Intermediate,In vivo,5983,,N,50588,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,9615.0
6602,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618480,,Intermediate,In vivo,4273,,N,50588,1,Bioavailability in dog,A,9615.0
6603,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618481,,Intermediate,In vivo,12500,,N,50588,1,Bioavailability in dog (dose 3-10 mg/kg),A,9615.0
6604,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618482,,Intermediate,In vivo,12500,,N,50588,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,9615.0
6605,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618483,,Intermediate,In vivo,3639,,N,50588,1,Oral bioavailability in dog,A,9615.0
6606,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618484,,Intermediate,In vivo,3880,,N,50588,1,Oral bioavailability in dog,A,9615.0
6607,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618485,,Intermediate,In vivo,4838,,N,50588,1,Bioavailability in dog,A,9615.0
6608,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618486,,Intermediate,In vivo,15600,,N,50588,1,oral bioavailability was measured in dogs,A,9615.0
6609,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618487,,Intermediate,,17248,,N,50588,1,Compound was tested for plasma protein binding in dog; Not determined,A,9615.0
6610,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618488,,Intermediate,,17248,,N,50588,1,Compound was tested for plasma protein binding of dog,A,9615.0
6611,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876735,,Intermediate,,17248,,N,50588,1,Compound was tested for plasma protein binding of dog; Not determined,A,9615.0
6612,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618489,,Intermediate,,17443,,N,50588,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,9615.0
6613,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618490,,Intermediate,In vivo,4186,,N,50588,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,9615.0
6614,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618491,,Intermediate,,3749,,N,50588,1,Half life was determined,A,9615.0
6615,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618492,,Intermediate,In vivo,3249,,N,50588,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,9615.0
6616,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873354,,Intermediate,,3022,,N,50588,1,Half life was evaluated in dog,A,9615.0
6617,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618493,,Intermediate,,3749,,N,50588,1,Half life was determined,A,9615.0
6618,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618494,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6619,Canis lupus familiaris,BAO_0000218,948.0,,1,Heart,CHEMBL618495,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6620,Canis lupus familiaris,BAO_0000218,2113.0,,1,Kidney,CHEMBL618496,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6621,Canis lupus familiaris,BAO_0000218,2107.0,,1,Liver,CHEMBL618497,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6622,Canis lupus familiaris,BAO_0000218,2048.0,,1,Lung,CHEMBL618498,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6623,Canis lupus familiaris,BAO_0000218,2106.0,,1,Spleen,CHEMBL618499,,Intermediate,In vivo,2517,,N,50588,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0
6624,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876736,,Intermediate,,3639,,N,50588,1,LogP in dog,A,9615.0
6625,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618500,,Intermediate,,6227,,N,50588,1,Partition coefficient (logP),A,9615.0
6626,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL857831,,Intermediate,,6227,,N,50588,1,Partition coefficient in dog,A,9615.0
6627,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618501,,Intermediate,In vivo,17764,,N,50588,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
6628,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618502,,Intermediate,In vivo,4809,,N,50588,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,9615.0
6629,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618503,,Intermediate,,5600,,N,50588,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,9615.0
6630,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618504,,Intermediate,,14294,,N,50588,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,9615.0
6631,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618505,,Intermediate,,14294,,N,50588,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,9615.0
6632,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618506,,Intermediate,,14294,,N,50588,1,Metabolism of compound in dog S9 microsomes; Trace,A,9615.0
6633,Canis lupus familiaris,BAO_0000218,2107.0,,1,Liver,CHEMBL618507,,Intermediate,,6251,,N,50588,1,In vitro metabolic potential in dog liver microsomes,A,9615.0
6634,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876737,,Intermediate,In vivo,3748,,N,50588,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,9615.0
6635,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618508,,Intermediate,In vivo,2713,,N,50588,1,Oral bioavailability in dog,A,9615.0
6636,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618509,,Intermediate,In vivo,6512,,N,50588,1,Oral bioavailability in dog,A,9615.0
6637,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618510,,Intermediate,In vivo,6679,,N,50588,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0
6638,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618511,,Intermediate,In vivo,3749,,N,50588,1,The compound was tested for bioavailability in dogs,A,9615.0
6639,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618512,,Intermediate,In vivo,3749,,N,50588,1,The compound was tested for oral bioavailability in dogs,A,9615.0
6640,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618513,,Intermediate,In vivo,6742,,N,50588,1,Oral bioavailability in dog,A,9615.0
6641,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618514,,Intermediate,,6227,,N,50588,1,Compound was tested for percent protein binding (PB) in dog,A,9615.0
6642,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620052,,Intermediate,,6874,,N,50588,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,9615.0
6643,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620053,,Intermediate,In vivo,2877,,N,50588,1,Compound was evaluated for plasma clearance.,A,9615.0
6644,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620054,,Intermediate,In vivo,12500,,N,50588,1,The compound was tested for plasma clearance in dog,A,9615.0
6645,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620055,,Intermediate,In vivo,12500,,N,50588,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,9615.0
6646,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620056,,Intermediate,,4709,,N,50588,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,9615.0
6647,Canis lupus familiaris,BAO_0000218,2107.0,,1,Liver,CHEMBL620057,,Intermediate,,5542,,N,50588,1,In vitro relative rate of metabolism was determined in dog liver microsomes,A,9615.0
6648,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618939,,Intermediate,In vivo,17594,,N,50588,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,9615.0
6649,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618940,,Intermediate,In vivo,2652,,N,50588,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,9615.0
6650,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618941,,Intermediate,In vivo,17764,,N,50588,1,Half life after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
6651,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624473,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,10090.0
6652,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624474,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,10090.0
6653,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624475,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,10090.0
6654,Mus musculus,BAO_0000218,,,1,,CHEMBL624476,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,10090.0
6655,Mus musculus,BAO_0000218,,,1,,CHEMBL623478,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,10090.0
6656,Mus musculus,BAO_0000218,,,1,,CHEMBL623479,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,10090.0
6657,Mus musculus,BAO_0000218,,,1,,CHEMBL623480,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,10090.0
6658,Mus musculus,BAO_0000218,,,1,,CHEMBL623481,,Intermediate,,6599,,N,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,10090.0
6659,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL623482,,Intermediate,,17641,,N,50594,1,C2 in brain of mice at the oral dose of 50 mg/kg,A,10090.0
6660,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623483,,Intermediate,,17641,,N,50594,1,C2 in kidney of mice at the oral dose of 50 mg/kg,A,10090.0
6661,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623484,,Intermediate,,17641,,N,50594,1,C2 in liver of mice at the oral dose of 50 mg/kg,A,10090.0
6662,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623485,,Intermediate,,17641,,N,50594,1,C2 in lungs of mice at the oral dose of 50 mg/kg,A,10090.0
6663,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL623486,,Intermediate,,17641,,N,50594,1,C2 in spleen of mice at the oral dose of 50 mg/kg,A,10090.0
6664,Mus musculus,BAO_0000218,,,1,,CHEMBL623487,,Intermediate,In vivo,17852,,N,50594,1,Plasma clearance in mouse,A,10090.0
6665,Mus musculus,BAO_0000218,,,1,,CHEMBL623488,,Intermediate,In vivo,17764,,N,50594,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,10090.0
6666,Mus musculus,BAO_0000218,,,1,,CHEMBL623489,,Intermediate,In vivo,17837,,N,50594,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,10090.0
6667,Mus musculus,BAO_0000218,,,1,,CHEMBL875157,,Intermediate,In vivo,2675,,N,50594,1,Clearance was evaluated in mice after intravenous administration,A,10090.0
6668,Mus musculus,BAO_0000218,,,1,,CHEMBL623490,,Intermediate,In vivo,2675,,N,50594,1,Clearance was evaluated in mice after oral administration,A,10090.0
6669,Mus musculus,BAO_0000218,,,1,,CHEMBL623491,,Intermediate,In vivo,4239,,N,50594,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,10090.0
6670,Mus musculus,BAO_0000218,,,1,,CHEMBL623492,,Intermediate,In vivo,17753,,N,50594,1,Plasma clearance of compound was determined at 40 mg/Kg,A,10090.0
6671,Mus musculus,BAO_0000218,,,1,,CHEMBL623493,,Intermediate,In vivo,17753,,N,50594,1,Plasma clearance of at 24 mg/Kg,A,10090.0
6672,Mus musculus,BAO_0000218,,,1,,CHEMBL623494,,Intermediate,In vivo,17753,,N,50594,1,Plasma clearance at 24 mg/Kg,A,10090.0
6673,Mus musculus,BAO_0000218,,,1,,CHEMBL623495,,Intermediate,In vivo,17753,,N,50594,1,Plasma clearance at 5 mg/Kg,A,10090.0
6674,Mus musculus,BAO_0000218,,,1,,CHEMBL623496,,Intermediate,In vivo,5727,,N,50594,1,Plasma clearance in mice,A,10090.0
6675,Mus musculus,BAO_0000218,,,1,,CHEMBL623497,,Intermediate,In vivo,2862,,N,50594,1,Plasma clearance value upon iv administration in mouse,A,10090.0
6676,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623498,,Intermediate,In vivo,5980,,N,50594,1,Total plasma clearance in mice,A,10090.0
6677,Mus musculus,BAO_0000218,,,1,,CHEMBL623499,,Intermediate,In vivo,17592,,N,50594,1,Clearance in mouse,A,10090.0
6678,Mus musculus,BAO_0000218,,,1,,CHEMBL623500,,Intermediate,In vivo,17718,,N,50594,1,Clearance value was determined,A,10090.0
6679,Mus musculus,BAO_0000218,,,1,,CHEMBL623501,,Intermediate,In vivo,16597,,N,50594,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
6680,,BAO_0000100,,,0,,CHEMBL875158,,Intermediate,,17384,,U,22229,1,Calculated partition coefficient (clogP),P,
6681,Mus musculus,BAO_0000218,,,1,,CHEMBL623502,,Intermediate,In vivo,6062,,N,50594,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,10090.0
6682,Mus musculus,BAO_0000218,,,1,,CHEMBL623503,,Intermediate,In vivo,17734,,N,50594,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
6683,Mus musculus,BAO_0000218,,,1,,CHEMBL623504,,Intermediate,In vivo,6348,,N,50594,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0
6684,Mus musculus,BAO_0000218,,,1,,CHEMBL623505,,Intermediate,In vivo,5969,,N,50594,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,10090.0
6685,Mus musculus,BAO_0000218,,,1,,CHEMBL623506,,Intermediate,In vivo,5969,,N,50594,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,10090.0
6686,Mus musculus,BAO_0000218,,,1,,CHEMBL623507,,Intermediate,In vivo,5969,,N,50594,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0
6687,Mus musculus,BAO_0000218,,,1,,CHEMBL623508,,Intermediate,In vivo,16597,,N,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,10090.0
6688,Mus musculus,BAO_0000218,,,1,,CHEMBL623509,,Intermediate,In vivo,5781,,N,50594,1,Cmax after oral administration at 30 mg/kg in ICR mouse,A,10090.0
6689,Mus musculus,BAO_0000218,,,1,,CHEMBL875159,,Intermediate,In vivo,17764,,N,50594,1,Cmax after peroral administration in mice at 2.4 uM/kg,A,10090.0
6690,Mus musculus,BAO_0000218,955.0,,1,Brain,CHEMBL623510,,Intermediate,In vivo,17641,,N,50594,1,Cmax in brain of mice at the oral dose of 50 mg/kg,A,10090.0
6691,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL623511,,Intermediate,In vivo,17641,,N,50594,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,10090.0
6692,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL623512,,Intermediate,In vivo,17641,,N,50594,1,Cmax in liver of mice at the oral dose of 50 mg/kg,A,10090.0
6693,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623513,,Intermediate,In vivo,17641,,N,50594,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,10090.0
6694,Mus musculus,BAO_0000218,,,1,,CHEMBL623514,,Intermediate,In vivo,17764,,N,50594,1,Cmax in mice at 18 uM/kg i.p. administration,F,10090.0
6695,Mus musculus,BAO_0000218,,,1,,CHEMBL622609,,Intermediate,In vivo,17764,,N,50594,1,Cmax in mice at 23 uM/kg i.v. administration,F,10090.0
6696,Mus musculus,BAO_0000218,,,1,,CHEMBL622610,,Intermediate,In vivo,17764,,N,50594,1,Cmax in mice at 24 uM/kg i.p. administration,F,10090.0
6697,Mus musculus,BAO_0000218,,,1,,CHEMBL621823,,Intermediate,In vivo,17764,,N,50594,1,Cmax in mice at 25 uM/kg i.p. administration,F,10090.0
6698,Mus musculus,BAO_0000218,,,1,,CHEMBL621824,,Intermediate,In vivo,17764,,N,50594,1,Cmax in mice at 26 uM/kg i.p. administration,F,10090.0
6699,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL621825,,Intermediate,In vivo,17641,,N,50594,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,10090.0
6700,Mus musculus,BAO_0000218,,,1,,CHEMBL621826,,Intermediate,In vivo,16597,,N,50594,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0
6701,Mus musculus,BAO_0000218,,,1,,CHEMBL621827,,Intermediate,In vivo,16597,,N,50594,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0
6702,Mus musculus,BAO_0000218,,,1,,CHEMBL621828,,Intermediate,In vivo,5727,,N,50594,1,Cmax value was determined,A,10090.0
6703,Mus musculus,BAO_0000218,,,1,,CHEMBL621829,,Intermediate,In vivo,5951,,N,50594,1,Cmax value in IRC mice,A,10090.0
6704,Mus musculus,BAO_0000218,,,1,,CHEMBL621830,,Intermediate,In vivo,5506,,N,50594,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0
6705,Mus musculus,BAO_0000218,,,1,,CHEMBL621831,,Intermediate,In vivo,5506,,N,50594,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0
6706,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL621832,,Intermediate,In vivo,14239,,N,50594,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,10090.0
6707,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL624579,,Intermediate,In vivo,4890,,N,50594,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,10090.0
6708,Mus musculus,BAO_0000218,,,1,,CHEMBL624580,,Intermediate,In vivo,429,,N,50594,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,10090.0
6709,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL624581,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,6277.0
6710,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL624582,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,6277.0
6711,Acanthocheilonema viteae,BAO_0000218,,,1,,CHEMBL624583,,Intermediate,,10986,,N,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,6277.0
6712,Homo sapiens,BAO_0000219,,,1,,CHEMBL624584,,Intermediate,,13227,,N,80018,1,Inhibitory activity against human tumor cell line A0375 melanoma.,F,9606.0
6713,Rattus norvegicus,BAO_0000249,,,9,,CHEMBL624585,,Expert,,4481,,D,12512,1,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,10116.0
6714,Homo sapiens,BAO_0000019,,,9,,CHEMBL875165,,Expert,,16931,,D,114,1,Forskolin-induced cAMP production at human A1 adenosine receptor,F,9606.0
6715,,BAO_0000219,,,8,,CHEMBL619490,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,
6716,,BAO_0000219,,,8,,CHEMBL619491,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,
6717,,BAO_0000219,,,8,,CHEMBL619492,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,
6718,,BAO_0000219,,,8,,CHEMBL619493,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,
6719,,BAO_0000219,,,8,,CHEMBL619494,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,
6720,,BAO_0000219,,,8,,CHEMBL619495,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,
6721,,BAO_0000219,,,8,,CHEMBL619496,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,
6722,Homo sapiens,BAO_0000219,,,9,,CHEMBL619497,,Expert,,3850,,D,114,1,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,9606.0
6723,,BAO_0000219,,,8,,CHEMBL619498,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,
6724,,BAO_0000219,,,8,,CHEMBL619499,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,
6725,,BAO_0000219,,,8,,CHEMBL619500,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,
6726,,BAO_0000219,,,8,,CHEMBL619501,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,
6727,,BAO_0000219,,,8,,CHEMBL619502,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,
6728,,BAO_0000219,,,8,,CHEMBL619503,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,
6729,,BAO_0000219,,,8,,CHEMBL619504,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,
6730,,BAO_0000219,,,8,,CHEMBL621298,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,
6731,,BAO_0000219,,,8,,CHEMBL621299,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,
6732,,BAO_0000219,,,8,,CHEMBL621300,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,
6733,,BAO_0000219,,,8,,CHEMBL621301,,Autocuration,,3850,,H,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,
6734,,BAO_0000219,,,8,,CHEMBL621302,,Expert,,3850,,H,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,
6735,Oryctolagus cuniculus,BAO_0000219,,,1,,CHEMBL621303,,Intermediate,,12680,,N,80013,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,9986.0
6736,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL621304,,Autocuration,,1313,,U,22226,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,10116.0
6737,Rattus norvegicus,BAO_0000219,,,0,,CHEMBL621305,,Autocuration,,1313,,U,22226,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,10116.0
6738,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL621306,,Intermediate,,17567,,N,80013,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,10116.0
6739,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618444,,Intermediate,,17567,,N,80013,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,10116.0
6740,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL618445,,Intermediate,,11819,,N,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,10116.0
6741,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618446,,Intermediate,,13436,,N,80089,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,10029.0
6742,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618447,,Intermediate,,12687,,N,80089,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,10029.0
6743,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618448,,Intermediate,,12651,,N,80089,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,10029.0
6744,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618449,,Intermediate,,13300,,N,80089,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,10029.0
6745,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618637,,Intermediate,,15296,,N,80089,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,10029.0
6746,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618638,,Intermediate,,15328,,N,80089,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,10029.0
6747,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618639,,Intermediate,,13302,,N,80089,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,10029.0
6748,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618640,,Expert,,14367,,N,80089,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,10029.0
6749,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618641,,Expert,,17002,,N,80089,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,10029.0
6750,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618642,,Intermediate,,13436,,N,80089,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,10029.0
6751,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618643,,Intermediate,,13435,,N,80089,1,Inhibitory activity against aerobic growth of AA8 cells.,F,10029.0
6752,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL884013,,Intermediate,,10503,,N,80089,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,10029.0
6753,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622723,,Expert,,10503,,N,80089,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,10029.0
6754,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622724,,Intermediate,,10503,,N,80089,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,10029.0
6755,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622725,,Expert,,15090,,N,80089,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,10029.0
6756,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622726,,Expert,,10368,,N,80089,1,Cytotoxicity against AA8 cell line,F,10029.0
6757,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622727,,Intermediate,,12651,,N,80089,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,10029.0
6758,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622728,,Intermediate,,12687,,N,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,10029.0
6759,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622729,,Intermediate,,12687,,N,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,10029.0
6760,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622730,,Intermediate,,12687,,N,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,10029.0
6761,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622731,,Intermediate,,1890,,N,80089,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,10029.0
6762,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622732,,Intermediate,,10747,,N,80089,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,10029.0
6763,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622733,,Intermediate,,10747,,N,80089,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,10029.0
6764,Cricetulus griseus,BAO_0000218,,,0,,CHEMBL622734,,Autocuration,,11616,,U,22224,1,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,10029.0
6765,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL622735,,Expert,,11616,,N,80089,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,10029.0
6766,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618746,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,10029.0
6767,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618747,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,10029.0
6768,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL620540,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,10029.0
6769,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL620541,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,10029.0
6770,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL620542,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,10029.0
6771,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL620543,,Autocuration,,3471,,U,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,10029.0
6772,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618832,,Autocuration,,3471,,U,22224,1,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,10029.0
6773,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL618833,,Expert,,11616,,N,80089,1,Concentration required to reduce AA8 cell survival by 10%,F,10029.0
6774,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618834,,Autocuration,,2656,,U,22224,1,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,10029.0
6775,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618835,,Autocuration,,10518,,U,22224,1,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,10029.0
6776,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618836,,Autocuration,,10518,,U,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,10029.0
6777,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618837,,Autocuration,,10518,,U,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,10029.0
6778,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618838,,Autocuration,,10518,,U,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,10029.0
6779,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618839,,Autocuration,,16156,,U,22224,1,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,10029.0
6780,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618840,,Autocuration,,2656,,U,22224,1,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,10029.0
6781,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL618841,,Autocuration,,11005,,U,22224,1,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,10029.0
6782,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618842,,Autocuration,,11942,,U,22224,1,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,10029.0
6783,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL618843,,Autocuration,,2128,,U,22224,1,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,10029.0
6784,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618844,,Intermediate,In vivo,16907,,N,50588,1,Half life period after 15 mg/kg iv dose in Dogs,A,9615.0
6785,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618845,,Intermediate,In vivo,16907,,N,50588,1,Half life period after 30 mg/kg po dose in Dogs,A,9615.0
6786,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618846,,Intermediate,In vivo,9579,,N,50588,1,Half life was measured after oral 2b administration (tested in 6 dogs),A,9615.0
6787,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618847,,Intermediate,In vivo,9579,,N,50588,1,Half life was measured in dog after oral 17b administration,A,9615.0
6788,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618848,,Intermediate,In vivo,9579,,N,50588,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,9615.0
6789,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618849,,Intermediate,In vivo,9579,,N,50588,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,9615.0
6790,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618850,,Intermediate,In vivo,16907,,N,50588,1,Tmax value after 15 mg/kg iv dose in Dogs,A,9615.0
6791,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618851,,Intermediate,In vivo,16907,,N,50588,1,Tmax value after 30 mg/kg po dose in Dogs,A,9615.0
6792,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873815,,Intermediate,In vivo,3184,,N,50588,1,Compound was evaluated for its half life when administered intravenously in dog,A,9615.0
6793,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL618852,,Intermediate,In vivo,5017,,N,50588,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,9615.0
6794,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618853,,Intermediate,,6821,,N,50588,1,Elimination Half-life of compound was determined in dog,A,9615.0
6795,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618854,,Intermediate,In vivo,17839,,N,50588,1,Half life of compound in dog following oral administration,A,9615.0
6796,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618855,,Intermediate,,17267,,N,50588,1,Half life of compound was determined in dog,A,9615.0
6797,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL618856,,Intermediate,,4727,,N,50588,1,Half life of compound was determined in dog blood,A,9615.0
6798,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875827,,Intermediate,In vivo,5238,,N,50588,1,Half life after oral and iv dosing in dogs,A,9615.0
6799,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618857,,Intermediate,,4942,,N,50588,1,Half life in dogs in hours,A,9615.0
6800,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618858,,Intermediate,In vivo,6505,,N,50588,1,Half life on i.v. administration of 2 mg/kg was measured in dog,A,9615.0
6801,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618859,,Intermediate,In vivo,5130,,N,50588,1,t1/2 in dog after oral dose (1 mg/kg),A,9615.0
6802,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618860,,Intermediate,,1475,,N,50588,1,Half life was evaluated in dog,A,9615.0
6803,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618861,,Intermediate,In vivo,17804,,N,50588,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,9615.0
6804,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622539,,Intermediate,In vivo,17804,,N,50588,1,Half life period of compound was determined after peroral administration at 2 mg/kg,A,9615.0
6805,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622540,,Intermediate,In vivo,6084,,N,50588,1,Half life period (10 mg/kg) was determined in dog,A,9615.0
6806,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873803,,Intermediate,In vivo,6084,,N,50588,1,Half life period (10 mg/kg) was determined in dog,A,9615.0
6807,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873804,,Intermediate,In vivo,5542,,N,50588,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,9615.0
6808,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624311,,Intermediate,In vivo,5542,,N,50588,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,9615.0
6809,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624312,,Intermediate,,6084,,N,50588,1,Half life period in dog,A,9615.0
6810,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624313,,Intermediate,In vivo,6241,,N,50588,1,Half life period in dogs after oral administration at 1 mg/kg,A,9615.0
6811,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624314,,Intermediate,In vivo,1916,,N,50588,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0
6812,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624315,,Intermediate,,6621,,N,50588,1,Half-life of compound was determined in dogs,A,9615.0
6813,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624316,,Intermediate,,1696,,N,50588,1,Half-life in dog plasma,A,9615.0
6814,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624317,,Intermediate,,17800,,N,50588,1,Half-life in mongrel dogs was determined,A,9615.0
6815,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624318,,Intermediate,In vivo,17657,,N,50588,1,Half-life in dog upon oral administration,A,9615.0
6816,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624319,,Intermediate,In vivo,17657,,N,50588,1,Half-life in dog upon oral administration; Unable to calculate,A,9615.0
6817,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624496,,Intermediate,,4239,,N,50588,1,Half-life was measured in dog,A,9615.0
6818,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624497,,Intermediate,,5985,,N,50588,1,Half-life was measured in dog,A,9615.0
6819,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624498,,Intermediate,,9932,,N,50588,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,9615.0
6820,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624499,,Intermediate,In vivo,5199,,N,50588,1,Oral half life was determined,A,9615.0
6821,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624500,,Intermediate,In vivo,5199,,N,50588,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,9615.0
6822,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL624501,,Intermediate,,1475,,N,50588,1,Plasma half life was evaluated,A,9615.0
6823,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623666,,Intermediate,,1475,,N,50588,1,Plasma half life was evaluated in Dog,A,9615.0
6824,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623667,,Intermediate,,1475,,N,50588,1,Plasma half life was evaluated in dog,A,9615.0
6825,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623668,,Intermediate,In vivo,6316,,N,50588,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,9615.0
6826,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623669,,Intermediate,,4883,,N,50588,1,Tested for the half life value in dog,A,9615.0
6827,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623670,,Intermediate,In vivo,4727,,N,50588,1,Maximum time at the dose of 2 mg/kg in dog,A,9615.0
6828,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623671,,Intermediate,In vivo,1916,,N,50588,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0
6829,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL875945,,Intermediate,In vivo,1337,,N,50588,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
6830,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL623672,,Intermediate,In vivo,1337,,N,50588,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
6831,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623673,,Intermediate,In vivo,6265,,N,50588,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,9615.0
6832,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623674,,Intermediate,In vivo,4809,,N,50588,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0
6833,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623675,,Intermediate,In vivo,5983,,N,50588,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,9615.0
6834,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL872526,,Intermediate,,5313,,N,50588,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,9615.0
6835,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623676,,Intermediate,In vivo,5313,,N,50588,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,9615.0
6836,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623677,,Intermediate,In vivo,17650,,N,50588,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,9615.0
6837,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623678,,Intermediate,In vivo,5199,,N,50588,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,9615.0
6838,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623679,,Intermediate,,933,,N,50588,1,Time taken for maximum plasma concentration in dog,A,9615.0
6839,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623680,,Intermediate,In vivo,16367,,N,50588,1,Time to reach Cmax after oral administration to dogs,A,9615.0
6840,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623681,,Intermediate,In vivo,6348,,N,50588,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
6841,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623682,,Intermediate,In vivo,6316,,N,50588,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,9615.0
6842,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623683,,Intermediate,In vivo,6215,,N,50588,1,Tmax after peroral administration (1 mg/kg) was determined in dog,A,9615.0
6843,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623684,,Expert,In vivo,3598,,N,50588,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
6844,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622745,,Intermediate,In vivo,4527,,N,50588,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0
6845,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622746,,Intermediate,In vivo,17764,,N,50588,1,Tmax after peroral administration in dogs at 2.4 uM/kg,A,9615.0
6846,Mus musculus,BAO_0000218,,,1,,CHEMBL622747,,Intermediate,In vivo,5969,,N,50594,1,In vivo Cmax in mice at dose of 100 mg/kg,A,10090.0
6847,Mus musculus,BAO_0000218,,,1,,CHEMBL622748,,Intermediate,In vivo,5969,,N,50594,1,In vivo Cmax in mice at dose of 50 mg/kg,A,10090.0
6848,Mus musculus,BAO_0000218,,,1,,CHEMBL622749,,Intermediate,In vivo,4573,,N,50594,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,10090.0
6849,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622750,,Intermediate,In vivo,3277,,N,50594,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0
6850,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623411,,Intermediate,In vivo,17734,,N,50594,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,10090.0
6851,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL875946,,Intermediate,In vivo,3132,,N,50594,1,Maximum concentration obtained in mouse plasma was determined,A,10090.0
6852,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623412,,Intermediate,In vivo,3132,,N,50594,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,10090.0
6853,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623413,,Intermediate,In vivo,6348,,N,50594,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0
6854,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623414,,Intermediate,In vivo,17729,,N,50594,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,10090.0
6855,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623415,,Intermediate,In vivo,17729,,N,50594,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,10090.0
6856,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623416,,Intermediate,In vivo,17729,,N,50594,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,10090.0
6857,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623417,,Intermediate,In vivo,17728,,N,50594,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,10090.0
6858,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623418,,Intermediate,In vivo,17728,,N,50594,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,10090.0
6859,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623419,,Intermediate,In vivo,17728,,N,50594,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,10090.0
6860,Mus musculus,BAO_0000218,,,1,,CHEMBL622816,,Intermediate,In vivo,4066,,N,50594,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0
6861,Mus musculus,BAO_0000218,,,1,,CHEMBL623313,,Intermediate,In vivo,6178,,N,50594,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,10090.0
6862,Mus musculus,BAO_0000218,,,1,,CHEMBL623314,,Intermediate,In vivo,6178,,N,50594,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,10090.0
6863,Mus musculus,BAO_0000218,,,1,,CHEMBL876788,,Intermediate,In vivo,3760,,N,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,10090.0
6864,Mus musculus,BAO_0000218,,,1,,CHEMBL623315,,Intermediate,In vivo,3760,,N,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,10090.0
6865,Mus musculus,BAO_0000218,,,1,,CHEMBL623316,,Intermediate,In vivo,3760,,N,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,10090.0
6866,Mus musculus,BAO_0000218,,,1,,CHEMBL623317,,Intermediate,In vivo,3760,,N,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,10090.0
6868,Mus musculus,BAO_0000218,,,1,,CHEMBL623319,,Intermediate,In vivo,5961,,N,50594,1,Cmax in male mice after 2 mg/kg oral dose,A,10090.0
6869,Mus musculus,BAO_0000218,,,1,,CHEMBL623320,,Intermediate,In vivo,6137,,N,50594,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,10090.0
6870,Mus musculus,BAO_0000218,,,1,,CHEMBL623321,,Intermediate,In vivo,3802,,N,50594,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,10090.0
6871,Mus musculus,BAO_0000218,,,1,,CHEMBL623322,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,10090.0
6872,Mus musculus,BAO_0000218,,,1,,CHEMBL623323,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,10090.0
6873,Mus musculus,BAO_0000218,,,1,,CHEMBL623324,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,10090.0
6874,Mus musculus,BAO_0000218,,,1,,CHEMBL623325,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,10090.0
6875,Mus musculus,BAO_0000218,,,1,,CHEMBL623326,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,10090.0
6876,Mus musculus,BAO_0000218,,,1,,CHEMBL623327,,Intermediate,,3535,,N,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,10090.0
6877,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623328,,Intermediate,,2862,,N,50594,1,Maximum concentration in plasma upon oral administration in mouse,A,10090.0
6878,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623329,,Intermediate,,2675,,N,50594,1,Maximum plasma concentration was evaluated in mice after oral administration,A,10090.0
6879,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL623330,,Intermediate,In vivo,2675,,N,50594,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,10090.0
6880,Mus musculus,BAO_0000218,,,1,,CHEMBL876789,,Intermediate,,5399,,N,50594,1,Dose at which the compound induced fecal excretion in mice,A,10090.0
6893,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL623333,,Expert,,11819,,N,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,10116.0
6894,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL623334,,Expert,,11819,,N,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,10116.0
6895,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL627536,,Expert,,11819,,N,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,10116.0
6896,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL627537,,Expert,,11819,,N,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,10116.0
6897,Rattus norvegicus,BAO_0000219,,,1,,CHEMBL627538,,Intermediate,,16361,,N,80013,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,10116.0
6898,Homo sapiens,BAO_0000219,,,1,,CHEMBL884106,,Intermediate,,2288,,N,80655,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,9606.0
6899,Homo sapiens,BAO_0000219,,,1,,CHEMBL625294,,Intermediate,,10404,,N,80655,1,Anticancer activity against human ovarian carcinoma A121 cells,F,9606.0
6900,Homo sapiens,BAO_0000219,,,1,,CHEMBL625295,,Intermediate,,14790,,N,80655,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,9606.0
6901,Homo sapiens,BAO_0000219,,,1,,CHEMBL625296,,Intermediate,,14790,,N,80655,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,9606.0
6902,Homo sapiens,BAO_0000219,,,1,,CHEMBL625297,,Expert,,14253,,N,80655,1,Growth inhibition of human ovarian carcinoma (A121) cell line,F,9606.0
6903,Homo sapiens,BAO_0000219,,,1,,CHEMBL625298,,Expert,,13617,,N,80655,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,9606.0
6904,Homo sapiens,BAO_0000219,,,1,,CHEMBL625960,,Intermediate,,1003,,N,80655,1,Cytotoxicity against human A121 ovarian cells,F,9606.0
6905,Homo sapiens,BAO_0000219,,,1,,CHEMBL625961,,Intermediate,,830,,N,80655,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,9606.0
6906,Homo sapiens,BAO_0000219,,,1,,CHEMBL625962,,Intermediate,,12307,,N,80655,1,In vitro cytotoxicity against human ovarian carcinoma A21,F,9606.0
6907,Homo sapiens,BAO_0000219,,,1,,CHEMBL624717,,Intermediate,,14254,,N,80655,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,9606.0
6908,Homo sapiens,BAO_0000219,,,1,,CHEMBL624718,,Intermediate,,13370,,N,80655,1,Inhibitory activity of compound against human A121 ovarian cell line.,F,9606.0
6909,Homo sapiens,BAO_0000219,,,1,,CHEMBL624719,,Intermediate,,14790,,N,80655,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,9606.0
6910,Homo sapiens,BAO_0000219,,,1,,CHEMBL624720,,Intermediate,,3614,,N,80655,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,9606.0
6911,Homo sapiens,BAO_0000219,,,1,,CHEMBL624721,,Intermediate,,2664,,N,80012,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,9606.0
6912,Homo sapiens,BAO_0000219,,,1,,CHEMBL624722,,Expert,,2037,,N,80012,1,In vitro cytotoxicity against A172 human tumor cell lines.,F,9606.0
6913,Homo sapiens,BAO_0000219,,,1,,CHEMBL877597,,Intermediate,,14539,,N,80012,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,9606.0
6914,Homo sapiens,BAO_0000219,,,1,,CHEMBL624723,,Intermediate,,2836,,N,80012,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,9606.0
6915,Homo sapiens,BAO_0000219,,,1,,CHEMBL624724,,Intermediate,,10708,,N,80012,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,9606.0
6916,Canis lupus familiaris,BAO_0000224,,,4,,CHEMBL624725,,Autocuration,,8975,,H,104729,1,Association constant against A2 adenosine receptor,B,9615.0
6917,fish,BAO_0000219,,,1,,CHEMBL624726,,Intermediate,,7645,,N,80656,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,
6918,Rattus norvegicus,BAO_0000224,,,5,,CHEMBL857535,,Autocuration,,11377,,D,104713,1,Ratio of Ki for adenosine A2 and A1 receptor binding,B,10116.0
6919,Homo sapiens,BAO_0000219,,,1,,CHEMBL624727,,Expert,,13528,,N,80014,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,9606.0
6920,Homo sapiens,BAO_0000219,,,1,,CHEMBL624728,,Expert,,10160,,N,80014,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,9606.0
6921,Homo sapiens,BAO_0000219,,,1,,CHEMBL624729,,Intermediate,,15144,,N,80015,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,9606.0
6922,Homo sapiens,BAO_0000219,,,1,,CHEMBL624730,,Intermediate,,13160,,N,80657,1,Growth inhibition against Human squamous cell line(A 253),F,9606.0
6923,Homo sapiens,BAO_0000219,,,1,,CHEMBL624731,,Intermediate,,12898,,N,80657,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,9606.0
6924,Homo sapiens,BAO_0000219,,,1,,CHEMBL624732,,Intermediate,,13069,,N,80657,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,9606.0
6925,Homo sapiens,BAO_0000219,,,1,,CHEMBL883245,,Intermediate,,15984,,N,80657,1,Growth inhibition of A253 cell lines.,F,9606.0
6926,Homo sapiens,BAO_0000219,,,1,,CHEMBL624733,,Intermediate,,15564,,N,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,9606.0
6927,Homo sapiens,BAO_0000219,,,1,,CHEMBL624734,,Intermediate,,15564,,N,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,9606.0
6928,Homo sapiens,BAO_0000219,,,1,,CHEMBL624735,,Intermediate,,15564,,N,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,9606.0
6929,Homo sapiens,BAO_0000219,,,1,,CHEMBL621780,,Intermediate,,4720,,N,81034,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,9606.0
6930,Homo sapiens,BAO_0000219,,,1,,CHEMBL877598,,Intermediate,,16112,,N,81034,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,9606.0
6931,Homo sapiens,BAO_0000219,,,1,,CHEMBL621781,,Expert,,16597,,N,81034,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,9606.0
6932,Homo sapiens,BAO_0000219,,,1,,CHEMBL621782,,Intermediate,,16378,,N,81034,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,9606.0
6933,Homo sapiens,BAO_0000219,,,1,,CHEMBL621783,,Expert,,16085,,N,81034,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,9606.0
6934,Homo sapiens,BAO_0000219,,,1,,CHEMBL621784,,Intermediate,,16317,,N,81034,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,9606.0
6935,Homo sapiens,BAO_0000219,,,1,,CHEMBL621785,,Intermediate,,15748,,N,81034,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,9606.0
6936,Homo sapiens,BAO_0000219,,,1,,CHEMBL621968,,Expert,,16597,,N,81034,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,9606.0
6937,Homo sapiens,BAO_0000219,,,1,,CHEMBL621969,,Expert,,16597,,N,81034,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,9606.0
6938,Homo sapiens,BAO_0000219,,,1,,CHEMBL621970,,Expert,,16597,,N,81034,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,9606.0
6939,Homo sapiens,BAO_0000219,,,1,,CHEMBL621971,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,9606.0
6940,Homo sapiens,BAO_0000219,,,1,,CHEMBL621972,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,9606.0
6941,Homo sapiens,BAO_0000219,,,1,,CHEMBL884108,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,9606.0
6942,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL623826,,Autocuration,,15296,,U,22224,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,10029.0
6943,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623827,,Autocuration,,10251,,U,22224,1,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,10029.0
6944,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623828,,Autocuration,,10251,,U,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,10029.0
6945,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623829,,Autocuration,,10251,,U,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,10029.0
6946,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623830,,Autocuration,,10251,,U,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,10029.0
6947,Cricetulus griseus,BAO_0000019,,,0,,CHEMBL623831,,Autocuration,,11858,,U,22224,1,Growth inhibition against CHO-derived cell line AA8,F,10029.0
6948,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623832,,Autocuration,,11858,,U,22224,1,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,10029.0
6949,hampster,BAO_0000219,,,1,,CHEMBL623833,,Expert,,11616,,N,80089,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,36483.0
6950,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL623834,,Expert,,11616,,N,80089,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,10029.0
6951,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623835,,Autocuration,,10518,,U,22224,1,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,10029.0
6952,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623836,,Autocuration,,11396,,U,22224,1,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,10029.0
6953,Cricetulus griseus,BAO_0000219,,,0,,CHEMBL623837,,Autocuration,,10518,,U,22224,1,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,10029.0
6954,Cricetulus griseus,BAO_0000219,,,1,,CHEMBL623838,,Expert,,11616,,N,80089,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,10029.0
6955,,BAO_0000019,,,8,,CHEMBL623839,,Autocuration,,14837,,H,12675,1,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,
6956,,BAO_0000019,,,8,,CHEMBL623840,,Autocuration,,14837,,H,12675,1,Number of binding sites (n) of isolated serum protein AAG,F,
6957,,BAO_0000225,,,3,,CHEMBL623841,,Intermediate,,16037,,M,22222,1,Association constant for binding to AATT duplex,B,
6958,Homo sapiens,BAO_0000219,,,1,,CHEMBL623842,,Expert,,16597,,N,100090,1,Inhibition of ABAE human fibroblast cell proliferation,F,9606.0
6959,Mus musculus,BAO_0000218,,,1,,CHEMBL623843,,Intermediate,,8831,,N,80668,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,10090.0
6960,Oryctolagus cuniculus,BAO_0000218,,,9,,CHEMBL618669,,Expert,,13419,,D,102444,1,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,9986.0
6961,Oryctolagus cuniculus,BAO_0000218,,,9,,CHEMBL618670,,Expert,In vivo,13419,,D,102444,1,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,9986.0
6962,,BAO_0000357,,,8,,CHEMBL618671,,Autocuration,,15778,,H,69,1,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,
6963,,BAO_0000357,,,8,,CHEMBL618672,,Autocuration,,15778,,H,69,1,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,
6964,Homo sapiens,BAO_0000219,,,1,,CHEMBL618673,,Intermediate,,12988,,N,80669,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,9606.0
6965,Homo sapiens,BAO_0000219,,,1,,CHEMBL618674,,Intermediate,,12988,,N,80669,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,9606.0
6966,Human immunodeficiency virus 1,BAO_0000219,,,0,,CHEMBL618675,,Autocuration,,12988,,U,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,11676.0
6967,Human immunodeficiency virus 1,BAO_0000219,,,0,,CHEMBL618676,,Autocuration,,12988,,U,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,11676.0
6968,Human immunodeficiency virus 1,BAO_0000219,,,0,,CHEMBL618677,,Autocuration,,12988,,U,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,11676.0
6969,Homo sapiens,BAO_0000219,,,1,,CHEMBL618678,,Intermediate,,11843,,N,80025,1,Inhibition of growth of renal cancer ACHN cell line,F,9606.0
6970,Homo sapiens,BAO_0000219,,,1,,CHEMBL618679,,Intermediate,,16939,,N,80025,1,Inhibition of growth of ACHN renal cancer cell line,F,9606.0
6971,Homo sapiens,BAO_0000219,,,1,,CHEMBL618680,,Intermediate,,4782,,N,80025,1,Inhibitory concentration required against ACHN renal cancer cell line,F,9606.0
6972,Homo sapiens,BAO_0000219,,,1,,CHEMBL618681,,Expert,,6310,,N,80025,1,Concentration required to inhibit growth of human renal (ACHN) cell line,F,9606.0
6973,Homo sapiens,BAO_0000219,,,1,,CHEMBL618682,,Intermediate,,6310,,N,80025,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,9606.0
6974,Homo sapiens,BAO_0000219,,,1,,CHEMBL618683,,Intermediate,,12858,,N,80025,1,Cytotoxic activity against ACHN Renal cancer cell line,F,9606.0
6975,Homo sapiens,BAO_0000219,,,1,,CHEMBL618684,,Intermediate,,17380,,N,80025,1,Cytotoxicity evaluation against ACHN renal cancer cells,F,9606.0
6976,Homo sapiens,BAO_0000219,,,1,,CHEMBL618685,,Intermediate,,5858,,N,80025,1,In vitro antitumor activity against human renal ACHN cell line,F,9606.0
6977,Homo sapiens,BAO_0000219,,,1,,CHEMBL876499,,Intermediate,,3838,,N,80025,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,9606.0
6978,Homo sapiens,BAO_0000219,,,1,,CHEMBL618686,,Intermediate,,3838,,N,80025,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,9606.0
6979,Homo sapiens,BAO_0000219,,,1,,CHEMBL618687,,Intermediate,,5406,,N,80025,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,9606.0
6980,Homo sapiens,BAO_0000219,,,1,,CHEMBL618688,,Intermediate,,4071,,N,80025,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,9606.0
6981,Homo sapiens,BAO_0000219,,,1,,CHEMBL618689,,Expert,,4071,,N,80025,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,9606.0
6982,Homo sapiens,BAO_0000219,,,1,,CHEMBL618690,,Intermediate,,4071,,N,80025,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,9606.0
6983,Homo sapiens,BAO_0000219,,,1,,CHEMBL618691,,Intermediate,,15002,,N,80025,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,9606.0
6984,Homo sapiens,BAO_0000219,,,1,,CHEMBL619373,,Intermediate,,14769,,N,80025,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,9606.0
6985,Homo sapiens,BAO_0000219,,,1,,CHEMBL884008,,Intermediate,,13958,,N,80025,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,9606.0
6986,Homo sapiens,BAO_0000219,,,1,,CHEMBL619374,,Intermediate,,1665,,N,80025,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,9606.0
6987,Homo sapiens,BAO_0000219,,,1,,CHEMBL619375,,Intermediate,,15354,,N,80025,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,9606.0
6988,Homo sapiens,BAO_0000219,,,1,,CHEMBL619376,,Intermediate,,15354,,N,80025,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,9606.0
6989,Homo sapiens,BAO_0000219,,,1,,CHEMBL619377,,Intermediate,,13978,,N,80025,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,9606.0
6990,Homo sapiens,BAO_0000219,,,1,,CHEMBL619378,,Intermediate,,6798,,N,80025,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,9606.0
6991,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL872527,,Intermediate,In vivo,2959,,N,50588,1,Tmax value after administration of 4 mg/Kg oral dose in dog,A,9615.0
6992,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876500,,Intermediate,,9932,,N,50588,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,9615.0
6993,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619379,,Intermediate,,5546,,N,50588,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0
6994,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619538,,Intermediate,In vivo,16907,,N,50588,1,Volume distribution after 15 mg/kg iv dose in Dogs,A,9615.0
6995,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619539,,Intermediate,In vivo,16907,,N,50588,1,Volume distribution after 30 mg/kg po dose in Dogs,A,9615.0
6996,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619540,,Intermediate,In vivo,4257,,N,50588,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,9615.0
6997,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619541,,Intermediate,In vivo,4305,,N,50588,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,9615.0
6998,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619542,,Intermediate,In vivo,5472,,N,50588,1,Volume of distribution was evaluated in dog,A,9615.0
6999,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619543,,Intermediate,In vivo,6062,,N,50588,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,9615.0
7000,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619544,,Expert,,3598,,N,50588,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0
7001,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619545,,Intermediate,In vivo,12500,,N,50588,1,The compound was tested for volume of distribution in dog,A,9615.0
7002,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619546,,Intermediate,In vivo,12500,,N,50588,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,9615.0
7003,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619547,,Intermediate,In vivo,6227,,N,50588,1,Vd (1 mg/kg) was determined in dog (in vivo),A,9615.0
7004,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619548,,Intermediate,In vivo,6227,,N,50588,1,Vd in dog,A,9615.0
7005,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619549,,Intermediate,In vivo,4219,,N,50588,1,Volume distribution was determined,A,9615.0
7006,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619550,,Intermediate,In vivo,1696,,N,50588,1,Volume of distribution in dog,A,9615.0
7007,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876501,,Intermediate,In vivo,5542,,N,50588,1,Volume of distribution by as 4 fold increase by iv administration in dogs,A,9615.0
7008,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619551,,Intermediate,In vivo,5199,,N,50588,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,9615.0
7009,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619552,,Intermediate,In vivo,6348,,N,50588,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
7010,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619553,,Intermediate,In vivo,4727,,N,50588,1,Volume distribution at the dose of 2 mg/kg in dog,A,9615.0
7011,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618722,,Intermediate,In vivo,16367,,N,50588,1,Steady state volume of distribution was determined,A,9615.0
7012,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618723,,Intermediate,In vivo,2652,,N,50588,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,9615.0
7013,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618724,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0
7014,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618725,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0
7015,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618726,,Intermediate,In vivo,16452,,N,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0
7016,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618727,,Intermediate,In vivo,5334,,N,50588,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0
7017,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624233,,Intermediate,In vivo,4239,,N,50588,1,Pharmacokinetic property (vdss) was measured in dog,A,9615.0
7018,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624234,,Intermediate,In vivo,4709,,N,50588,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,9615.0
7019,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624235,,Intermediate,In vivo,5600,,N,50588,1,Vdss was determined after iv 0.1 mg/kg administration in dog,A,9615.0
7020,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624236,,Intermediate,In vivo,6057,,N,50588,1,Volume displacement was calculated in dog,A,9615.0
7021,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624237,,Intermediate,In vivo,5654,,N,50588,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0
7022,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624238,,Intermediate,In vivo,5505,,N,50588,1,Volume distribution constant was determined,A,9615.0
7023,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624239,,Intermediate,In vivo,4527,,N,50588,1,Volume distribution at a dose of 1 uM/kg in dog was determined,A,9615.0
7024,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875829,,Intermediate,In vivo,4521,,N,50588,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0
7025,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624240,,Intermediate,In vivo,4521,,N,50588,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0
7026,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624241,,Intermediate,In vivo,15660,,N,50588,1,Volume distribution (Vdss) was measured in dog,A,9615.0
7027,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624242,,Intermediate,In vivo,15660,,N,50588,1,Volume distribution (Vdss) was measured in dog,A,9615.0
7028,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624243,,Intermediate,In vivo,6679,,N,50588,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0
7029,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624244,,Intermediate,In vivo,5145,,N,50588,1,Volume of distribution in steady state was determined in dog,A,9615.0
7030,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624245,,Intermediate,In vivo,6821,,N,50588,1,Volume of distribution of compound was determined in dog,A,9615.0
7031,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624246,,Intermediate,In vivo,4137,,N,50588,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,9615.0
7032,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624247,,Intermediate,In vivo,5334,,N,50588,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,9615.0
7033,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624248,,Intermediate,In vivo,15660,,N,50588,1,Volume of distribution (Vdss) was measured in dog,A,9615.0
7034,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624249,,Intermediate,In vivo,6642,,N,50588,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0
7035,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624250,,Intermediate,In vivo,6641,,N,50588,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
7036,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624251,,Intermediate,In vivo,6642,,N,50588,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
7037,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624252,,Intermediate,,11659,,N,50588,1,Maximum rate of depolarization of the upstroke of the action potential,A,9615.0
7038,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624253,,Intermediate,In vivo,6448,,N,50588,1,Steady state volume distribution in dog,A,9615.0
7039,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624950,,Intermediate,In vivo,5474,,N,50588,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,9615.0
7040,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624951,,Intermediate,In vivo,1466,,N,50588,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0
7041,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875830,,Intermediate,In vivo,6535,,N,50588,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,9615.0
7042,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624952,,Intermediate,In vivo,6535,,N,50588,1,Volume distribution in dog after administration of 1 mg/kg iv,A,9615.0
7043,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624953,,Intermediate,In vivo,17764,,N,50588,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,9615.0
7044,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624954,,Intermediate,In vivo,6215,,N,50588,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0
7045,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624955,,Intermediate,In vivo,6505,,N,50588,1,Vss on i.v. administration of 2 mg/kg was measured in dog,A,9615.0
7046,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624956,,Intermediate,,3639,,N,50588,1,Vss was determined,A,9615.0
7047,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625129,,Intermediate,,3639,,N,50588,1,Vss in dog,A,9615.0
7048,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625130,,Intermediate,In vivo,6062,,N,50588,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,9615.0
7049,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625131,,Intermediate,In vivo,4942,,N,50588,1,Volume distribution in dogs,A,9615.0
7050,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625132,,Intermediate,In vivo,17796,,N,50588,1,Volume of distribution in dog,A,9615.0
7051,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL872263,,Intermediate,In vivo,4883,,N,50588,1,Tested for the oral bioavailability in dog,A,9615.0
7060,Mus musculus,BAO_0000218,,,1,,CHEMBL624336,,Intermediate,In vivo,17837,,N,50594,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,10090.0
7061,Mus musculus,BAO_0000218,,,1,,CHEMBL624337,,Intermediate,In vivo,17729,,N,50594,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,10090.0
7062,Mus musculus,BAO_0000218,,,1,,CHEMBL624338,,Intermediate,In vivo,17729,,N,50594,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,10090.0
7063,Mus musculus,BAO_0000218,,,1,,CHEMBL624339,,Intermediate,In vivo,4239,,N,50594,1,Bioavailability was measured in mouse,A,10090.0
7064,Mus musculus,BAO_0000218,,,1,,CHEMBL624340,,Intermediate,In vivo,17592,,N,50594,1,Bioavailability in mouse,A,10090.0
7065,Mus musculus,BAO_0000218,,,1,,CHEMBL624341,,Intermediate,In vivo,6348,,N,50594,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0
7066,Mus musculus,BAO_0000218,,,1,,CHEMBL624342,,Intermediate,In vivo,2801,,N,50594,1,Bioavailability in mouse,A,10090.0
7067,Mus musculus,BAO_0000218,,,1,,CHEMBL624343,,Intermediate,In vivo,2801,,N,50594,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,10090.0
7068,Mus musculus,BAO_0000218,,,1,,CHEMBL624344,,Intermediate,In vivo,17718,,N,50594,1,Oral bioavailability in mouse,A,10090.0
7069,Mus musculus,BAO_0000218,,,1,,CHEMBL624345,,Intermediate,In vivo,5727,,N,50594,1,Oral availability at 50 mg/kg po in male mice,A,10090.0
7070,Mus musculus,BAO_0000218,,,1,,CHEMBL624346,,Intermediate,In vivo,5302,,N,50594,1,Oral bioavailability in mouse (dose 10 mg/kg),A,10090.0
7071,Mus musculus,BAO_0000218,,,1,,CHEMBL624347,,Expert,In vivo,3598,,N,50594,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,10090.0
7072,Mus musculus,BAO_0000218,,,1,,CHEMBL624348,,Intermediate,In vivo,5961,,N,50594,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,10090.0
7074,Mus musculus,BAO_0000218,,,1,,CHEMBL622754,,Intermediate,In vivo,6091,,N,50594,1,Oral bioavailability in mouse,A,10090.0
7075,Mus musculus,BAO_0000218,,,1,,CHEMBL622755,,Intermediate,In vivo,6091,,N,50594,1,Oral bioavailability in vivo in mice;ND=Not determined,A,10090.0
7076,Mus musculus,BAO_0000218,,,1,,CHEMBL622756,,Intermediate,In vivo,5711,,N,50594,1,Oral bioavailability in mouse at 10 mg/kg of the compound,A,10090.0
7077,Mus musculus,BAO_0000218,,,1,,CHEMBL622757,,Intermediate,In vivo,17728,,N,50594,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,10090.0
7078,Mus musculus,BAO_0000218,,,1,,CHEMBL622758,,Intermediate,In vivo,17728,,N,50594,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,10090.0
7079,Mus musculus,BAO_0000218,,,1,,CHEMBL622759,,Intermediate,In vivo,3802,,N,50594,1,Tested for bioavailability of the compound,A,10090.0
7080,Mus musculus,BAO_0000218,,,1,,CHEMBL622760,,Intermediate,In vivo,3802,,N,50594,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,10090.0
7081,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622761,,Intermediate,,14029,,N,50594,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,10090.0
7082,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622762,,Intermediate,,14029,,N,50594,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,10090.0
7083,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622763,,Intermediate,,14029,,N,50594,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,10090.0
7084,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622764,,Intermediate,,14029,,N,50594,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,10090.0
7085,Mus musculus,BAO_0000218,1969.0,,1,Plasma,CHEMBL622765,,Intermediate,,14029,,N,50594,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,10090.0
7086,Mus musculus,BAO_0000218,,,1,,CHEMBL622766,,Intermediate,,17753,,N,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,10090.0
7087,Mus musculus,BAO_0000218,,,1,,CHEMBL622767,,Intermediate,,17753,,N,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,10090.0
7088,Mus musculus,BAO_0000218,,,1,,CHEMBL622768,,Intermediate,,17753,,N,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,10090.0
7089,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL875948,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7090,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622769,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7091,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622770,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7092,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622771,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7093,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622772,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7094,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622773,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7095,Mus musculus,BAO_0000218,178.0,,1,Blood,CHEMBL622774,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7096,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL621725,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7097,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL621726,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0
7098,Homo sapiens,BAO_0000219,,,1,,CHEMBL621727,,Intermediate,,15608,,N,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,9606.0
7099,Homo sapiens,BAO_0000219,,,1,,CHEMBL622413,,Expert,,3290,,N,81034,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0
7100,Homo sapiens,BAO_0000219,,,1,,CHEMBL622414,,Intermediate,,2859,,N,81034,1,Compound was evaluated for cytotoxicity against A2780 cell line,F,9606.0
7101,Homo sapiens,BAO_0000219,,,1,,CHEMBL622415,,Expert,,15688,,N,81034,1,Inhibition of A2780 cell clonogenic assay,F,9606.0
7102,Homo sapiens,BAO_0000219,,,1,,CHEMBL884001,,Expert,,5642,,N,81034,1,Cytotoxic effect on ovarian cancer cell line (A2780),F,9606.0
7103,Homo sapiens,BAO_0000219,,,1,,CHEMBL622416,,Intermediate,,6633,,N,81034,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,9606.0
7104,Homo sapiens,BAO_0000219,,,1,,CHEMBL622417,,Intermediate,,3906,,N,81034,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,9606.0
7105,Homo sapiens,BAO_0000219,,,1,,CHEMBL622590,,Expert,,6788,,N,81034,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,9606.0
7106,Homo sapiens,BAO_0000219,,,1,,CHEMBL622591,,Expert,,17582,,N,81034,1,Antiproliferative activity against human A2780 cells,F,9606.0
7107,Homo sapiens,BAO_0000219,,,1,,CHEMBL622592,,Expert,,17764,,N,81034,1,Inhibition of human A2780 cell proliferation,F,9606.0
7108,Homo sapiens,BAO_0000219,,,1,,CHEMBL622593,,Expert,,17764,,N,81034,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,9606.0
7109,Homo sapiens,BAO_0000219,,,1,,CHEMBL622594,,Expert,,17764,,N,81034,1,Inhibition of human A2780 cell proliferation (No data),F,9606.0
7110,Homo sapiens,BAO_0000219,,,1,,CHEMBL622595,,Intermediate,,2815,,N,81034,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,9606.0
7111,Homo sapiens,BAO_0000219,,,1,,CHEMBL622596,,Intermediate,,16930,,N,81034,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,9606.0
7112,Homo sapiens,BAO_0000219,,,1,,CHEMBL622597,,Expert,,17777,,N,81034,1,Growth inhibition against A2780 wild-type ovarian cell lines,F,9606.0
7113,Homo sapiens,BAO_0000219,,,1,,CHEMBL622598,,Intermediate,,17777,,N,81034,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,9606.0
7114,Homo sapiens,BAO_0000019,,,5,,CHEMBL622599,,Autocuration,,16936,,D,104766,1,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,9606.0
7115,Homo sapiens,BAO_0000219,,,1,,CHEMBL622600,,Intermediate,,13759,,N,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,9606.0
7116,Homo sapiens,BAO_0000219,,,1,,CHEMBL622601,,Intermediate,,13759,,N,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,9606.0
7117,Homo sapiens,BAO_0000219,,,1,,CHEMBL622602,,Intermediate,,13759,,N,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,9606.0
7118,Homo sapiens,BAO_0000219,,,1,,CHEMBL622603,,Intermediate,,13759,,N,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,9606.0
7119,Homo sapiens,BAO_0000219,,,1,,CHEMBL622604,,Intermediate,,15292,,N,81034,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,9606.0
7120,Homo sapiens,BAO_0000219,,,1,,CHEMBL622605,,Intermediate,,15292,,N,81034,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,9606.0
7121,Homo sapiens,BAO_0000219,,,1,,CHEMBL622606,,Expert,,15069,,N,81034,1,In vitro inhibition of human ovarian cell line A2780,F,9606.0
7122,Homo sapiens,BAO_0000219,,,1,,CHEMBL619463,,Expert,,15069,,N,81034,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,9606.0
7123,Homo sapiens,BAO_0000219,,,1,,CHEMBL619464,,Intermediate,,14073,,N,81034,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,9606.0
7124,Homo sapiens,BAO_0000219,,,1,,CHEMBL619465,,Expert,,14553,,N,81034,1,Concentration required to inhibit A2780-cell growth by 50%,F,9606.0
7125,Homo sapiens,BAO_0000219,,,1,,CHEMBL619466,,Expert,,13040,,N,81034,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,9606.0
7126,Homo sapiens,BAO_0000219,,,1,,CHEMBL619467,,Expert,,6891,,N,81034,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,9606.0
7127,Homo sapiens,BAO_0000219,,,1,,CHEMBL619468,,Intermediate,,15569,,N,81034,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,9606.0
7128,Homo sapiens,BAO_0000219,,,1,,CHEMBL619469,,Expert,,14190,,N,81034,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,9606.0
7129,Homo sapiens,BAO_0000219,,,1,,CHEMBL619470,,Expert,,15014,,N,81034,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0
7130,Homo sapiens,BAO_0000219,,,1,,CHEMBL619471,,Intermediate,,15014,,N,81034,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0
7131,Homo sapiens,BAO_0000219,,,1,,CHEMBL619472,,Intermediate,,17496,,N,81034,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,9606.0
7132,Homo sapiens,BAO_0000219,,,1,,CHEMBL619473,,Intermediate,,13617,,N,81034,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,9606.0
7133,Homo sapiens,BAO_0000219,,,1,,CHEMBL874368,,Intermediate,,13617,,N,81034,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,9606.0
7134,Homo sapiens,BAO_0000219,,,1,,CHEMBL884003,,Intermediate,,13617,,N,81034,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,9606.0
7135,Homo sapiens,BAO_0000219,,,1,,CHEMBL622690,,Intermediate,,13617,,N,81034,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,9606.0
7136,Homo sapiens,BAO_0000219,,,1,,CHEMBL622691,,Intermediate,,17672,,N,81034,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,9606.0
7137,Homo sapiens,BAO_0000219,,,1,,CHEMBL622692,,Intermediate,,4544,,N,81034,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,9606.0
7138,Homo sapiens,BAO_0000219,,,1,,CHEMBL623406,,Intermediate,,4544,,N,81034,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,9606.0
7139,Homo sapiens,BAO_0000219,,,1,,CHEMBL884004,,Intermediate,,16317,,N,81034,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,9606.0
7140,Homo sapiens,BAO_0000219,,,1,,CHEMBL623407,,Intermediate,,15099,,N,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,9606.0
7141,Homo sapiens,BAO_0000219,,,1,,CHEMBL623408,,Intermediate,,13978,,N,81034,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,9606.0
7142,Homo sapiens,BAO_0000219,,,1,,CHEMBL623409,,Expert,,12989,,N,81034,1,In vitro antitumor activity against A2780 cell line.,F,9606.0
7143,Homo sapiens,BAO_0000219,,,1,,CHEMBL623410,,Intermediate,,5574,,N,81034,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,9606.0
7144,Homo sapiens,BAO_0000219,,,1,,CHEMBL623576,,Expert,,13528,,N,81034,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,9606.0
7145,Homo sapiens,BAO_0000219,,,1,,CHEMBL623577,,Intermediate,,12782,,N,80025,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,9606.0
7146,Homo sapiens,BAO_0000219,,,1,,CHEMBL623578,,Intermediate,,14255,,N,80025,1,The IC50 value was measured on ACHN cell line in renal tumor type.,F,9606.0
7147,Homo sapiens,BAO_0000219,,,1,,CHEMBL623579,,Intermediate,,16364,,N,80025,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,9606.0
7148,Homo sapiens,BAO_0000219,,,1,,CHEMBL623580,,Expert,,17376,,N,80025,1,In vitro lethal concentration against most sensitive ACHN cell line,F,9606.0
7149,Homo sapiens,BAO_0000219,,,1,,CHEMBL623581,,Intermediate,,12016,,N,80025,1,Tested for cytotoxic activity against renal cancer ACHN cell line,F,9606.0
7150,Homo sapiens,BAO_0000219,,,1,,CHEMBL857456,,Intermediate,,6058,,N,80025,1,Compound tested for growth inhibition of renal cancer cell line ACHN,F,9606.0
7151,Homo sapiens,BAO_0000219,,,1,,CHEMBL623582,,Intermediate,,17708,,N,80025,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,9606.0
7152,Homo sapiens,BAO_0000219,,,1,,CHEMBL623583,,Intermediate,,15176,,N,80025,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,9606.0
7153,Homo sapiens,BAO_0000219,,,1,,CHEMBL623584,,Intermediate,,2806,,N,80025,1,In vitro anticancer activity against ACHN renal cancer cell line,F,9606.0
7154,Homo sapiens,BAO_0000219,,,1,,CHEMBL623585,,Intermediate,,15300,,N,80025,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,9606.0
7155,Homo sapiens,BAO_0000219,,,1,,CHEMBL623586,,Intermediate,,16364,,N,80025,1,Percent selectivity was evaluated in renal ACHN cell lines,F,9606.0
7156,Homo sapiens,BAO_0000219,,,1,,CHEMBL623587,,Intermediate,,13859,,N,80025,1,In vitro inhibitory activity against renal ACHN cancer cell line,F,9606.0
7157,Homo sapiens,BAO_0000219,,,1,,CHEMBL875279,,Intermediate,,11970,,N,80025,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,9606.0
7158,Homo sapiens,BAO_0000219,,,1,,CHEMBL623588,,Intermediate,,2450,,N,80025,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,9606.0
7159,Homo sapiens,BAO_0000219,,,1,,CHEMBL623589,,Intermediate,,12696,,N,80025,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,9606.0
7160,Homo sapiens,BAO_0000219,,,1,,CHEMBL623590,,Intermediate,,12400,,N,80025,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,9606.0
7161,Homo sapiens,BAO_0000219,,,1,,CHEMBL623591,,Expert,,12888,,N,80025,1,Cytotoxic effect on renal cancer line ACHN,F,9606.0
7162,Homo sapiens,BAO_0000219,,,1,,CHEMBL623592,,Intermediate,,3156,,N,80025,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,9606.0
7163,Homo sapiens,BAO_0000219,,,1,,CHEMBL623593,,Intermediate,,3381,,N,80025,1,In vitro inhibition of Renal Cancer ACHN cell lines,F,9606.0
7164,Homo sapiens,BAO_0000219,,,1,,CHEMBL623594,,Intermediate,,16747,,N,80025,1,Antitumor activity against human renal adenocarcinoma ACHN cells,F,9606.0
7165,Homo sapiens,BAO_0000219,,,1,,CHEMBL621833,,Expert,,16748,,N,80025,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,9606.0
7166,Homo sapiens,BAO_0000219,,,1,,CHEMBL621834,,Intermediate,,12062,,N,80025,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,9606.0
7167,Homo sapiens,BAO_0000219,,,1,,CHEMBL621835,,Intermediate,,14769,,N,80025,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,9606.0
7168,Homo sapiens,BAO_0000219,,,1,,CHEMBL621836,,Intermediate,,15895,,N,80025,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,9606.0
7169,Homo sapiens,BAO_0000219,,,1,,CHEMBL621837,,Intermediate,,17376,,N,80025,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,9606.0
7170,Homo sapiens,BAO_0000219,,,1,,CHEMBL875280,,Intermediate,,14882,,N,80025,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,9606.0
7171,Homo sapiens,BAO_0000219,,,1,,CHEMBL621838,,Intermediate,,14882,,N,80025,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,9606.0
7172,Homo sapiens,BAO_0000219,,,1,,CHEMBL621839,,Intermediate,,15661,,N,80025,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,9606.0
7173,,BAO_0000019,,,0,,CHEMBL621840,,Autocuration,,9680,,U,22224,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,
7174,,BAO_0000019,,,8,,CHEMBL621841,,Autocuration,,14579,,H,10647,1,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,
7175,Cytomegalovirus,BAO_0000218,,,1,,CHEMBL622979,,Expert,,17290,,N,50529,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,10358.0
7176,Cytomegalovirus,BAO_0000218,,,1,,CHEMBL876595,,Intermediate,,17290,,N,50529,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,10358.0
7177,,BAO_0000357,,,8,,CHEMBL620221,,Autocuration,,15891,,H,12159,1,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,
7178,,BAO_0000357,,,8,,CHEMBL620222,,Autocuration,,15890,,H,12159,1,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,
7179,Bos taurus,BAO_0000219,,,1,,CHEMBL620506,,Intermediate,,3801,,N,80670,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,9913.0
7180,Mus musculus,BAO_0000219,,,1,,CHEMBL620507,,Intermediate,,9222,,N,80671,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,10090.0
7181,Mus musculus,BAO_0000219,,,1,,CHEMBL620508,,Intermediate,,9222,,N,80671,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,10090.0
7182,Mus musculus,BAO_0000219,,,1,,CHEMBL620509,,Intermediate,,7257,,N,80671,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,10090.0
7183,Mus musculus,BAO_0000219,,,1,,CHEMBL620510,,Intermediate,,7257,,N,80671,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,10090.0
7184,Mus musculus,BAO_0000219,,,1,,CHEMBL620511,,Intermediate,,7257,,N,80671,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,10090.0
7185,Mus musculus,BAO_0000219,,,1,,CHEMBL620512,,Intermediate,,8084,,N,80671,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,10090.0
7186,Mus musculus,BAO_0000019,,,0,,CHEMBL620513,,Autocuration,,14943,,U,22224,1,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,10090.0
7187,Mus musculus,BAO_0000019,,,0,,CHEMBL620514,,Autocuration,,14943,,U,22224,1,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,10090.0
7188,Mus musculus,BAO_0000019,,,0,,CHEMBL620515,,Autocuration,,14943,,U,22224,1,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,10090.0
7189,Bacillus subtilis,BAO_0000218,,,0,,CHEMBL620516,,Autocuration,In vivo,10524,,U,22224,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1423.0
7190,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620517,,Intermediate,,3546,,N,50588,1,AUC value in dog after IV administration at a dose of 5 mg/kg,A,9615.0
7191,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL620518,,Intermediate,,3546,,N,50588,1,AUC value in dog after oral administration at a dose of 5 mg/kg,A,9615.0
7192,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL620519,,Intermediate,In vivo,3546,,N,50588,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,9615.0
7193,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621386,,Intermediate,In vivo,3546,,N,50588,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,9615.0
7194,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621387,,Intermediate,In vivo,3546,,N,50588,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,9615.0
7195,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621388,,Intermediate,In vivo,3184,,N,50588,1,Compound was evaluated for its clearance when administered intravenously in dog,A,9615.0
7196,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621389,,Intermediate,In vivo,16456,,N,50588,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0
7197,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621390,,Intermediate,In vivo,4809,,N,50588,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,9615.0
7198,,BAO_0000100,,,0,,CHEMBL621391,,Intermediate,,4219,,U,22229,1,Calculated partition coefficient (clogP),P,
7199,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621392,,Intermediate,,3748,,N,50588,1,Half life in dog,A,9615.0
7200,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621393,,Intermediate,,3132,,N,50588,1,Time taken for EC90 was determined when tested in dog,A,9615.0
7201,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621394,,Intermediate,,4219,,N,50588,1,Half life (iv) was determined,A,9615.0
7202,Canis lupus familiaris,BAO_0000218,2107.0,,1,Liver,CHEMBL621395,,Intermediate,,16907,,N,50588,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,9615.0
7203,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621396,,Intermediate,,6057,,N,50588,1,Area under the curve was calculated in dog after iv administration,A,9615.0
7204,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621397,,Intermediate,,6057,,N,50588,1,Area under the curve was calculated in dog after peroral administration,A,9615.0
7205,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621398,,Intermediate,,17853,,N,50588,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,9615.0
7206,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618818,,Intermediate,,3639,,N,50588,1,pKa was evaluated in dog,A,9615.0
7207,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618819,,Intermediate,,14541,,N,50588,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,9615.0
7208,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618820,,Intermediate,In vivo,16456,,N,50588,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0
7209,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873810,,Intermediate,In vivo,16456,,N,50588,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0
7210,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876606,,Intermediate,In vivo,2652,,N,50588,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,9615.0
7211,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618821,,Intermediate,,3624,,N,50588,1,Compound was evaluated for the half-life (t 1/2) in hours,A,9615.0
7212,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL618822,,Intermediate,In vivo,1337,,N,50588,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
7213,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL618823,,Intermediate,In vivo,1337,,N,50588,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0
7214,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618824,,Intermediate,In vivo,4709,,N,50588,1,Half life after intravenous administration of 1 mg/kg in dog,A,9615.0
7215,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618825,,Intermediate,,15660,,N,50588,1,Half life was measured in dog,A,9615.0
7216,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618826,,Intermediate,In vivo,5302,,N,50588,1,Half life period in dog after 5 mg/kg dose,A,9615.0
7217,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618827,,Intermediate,,17791,,N,50588,1,Half life period was evaluated in dog; 4-4.8,A,9615.0
7218,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618828,,Intermediate,In vivo,6348,,N,50588,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0
7219,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618829,,Intermediate,In vivo,4257,,N,50588,1,Half-life was determined in dog after a3 mg/kg of iv dose,A,9615.0
7220,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618830,,Intermediate,,3771,,N,50588,1,Half-life was determined,A,9615.0
7221,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL618831,,Intermediate,,6305,,N,50588,1,Half life in dogs,A,9615.0
7222,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL619489,,Intermediate,In vivo,13501,,N,50588,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,9615.0
7223,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619649,,Intermediate,In vivo,17594,,N,50588,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,9615.0
7224,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876607,,Intermediate,In vivo,3045,,N,50588,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,9615.0
7225,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619650,,Intermediate,In vivo,3043,,N,50588,1,Compound was evaluated for the half life period after oral administration in conscious dog.,A,9615.0
7226,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619651,,Intermediate,,4839,,N,50588,1,Compound was tested for half life in dog,A,9615.0
7227,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619652,,Intermediate,,4839,,N,50588,1,Compound was tested for its half life in dog,A,9615.0
7228,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619653,,Intermediate,In vivo,5802,,N,50588,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0
7229,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619654,,Intermediate,,17839,,N,50588,1,Half life of compound in dog was determined,A,9615.0
7230,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619655,,Intermediate,In vivo,4219,,N,50588,1,Half life (iv) was determined,A,9615.0
7231,Canis lupus familiaris,BAO_0000218,178.0,,1,Blood,CHEMBL619656,,Intermediate,,13966,,N,50588,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,9615.0
7232,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL873812,,Intermediate,In vivo,3994,,N,50588,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,9615.0
7233,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621365,,Intermediate,In vivo,3994,,N,50588,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,9615.0
7234,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621366,,Intermediate,,4453,,N,50588,1,Half life in dog,A,9615.0
7235,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621367,,Intermediate,,6535,,N,50588,1,Half life in dog plasma,A,9615.0
7236,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621368,,Intermediate,In vivo,6535,,N,50588,1,Half life in dog plasma after administration of 0.25 mg/kg iv,A,9615.0
7237,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621369,,Intermediate,In vivo,6535,,N,50588,1,Half life in dog plasma after administration of 1 mg/kg iv,A,9615.0
7238,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621370,,Intermediate,In vivo,3132,,N,50588,1,Half life in dog plasma was determined at dose 10 mg/kg,A,9615.0
7239,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621371,,Intermediate,,5374,,N,50588,1,Half life in dog was determined,A,9615.0
7240,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621372,,Intermediate,In vivo,5007,,N,50588,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0
7241,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621373,,Intermediate,,16907,,N,50588,1,Half life upon exposure to human plasma,A,9615.0
7242,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621374,,Intermediate,,6057,,N,50588,1,Half life was calculated in dog,A,9615.0
7243,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621375,,Intermediate,,5006,,N,50588,1,Half life was determined,A,9615.0
7244,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621376,,Intermediate,,5473,,N,50588,1,Half life was determined,A,9615.0
7245,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619624,,Intermediate,In vivo,4368,,N,50588,1,Half life by intravenous administration of 1.2 mg/kg in dog,A,9615.0
7246,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL875840,,Intermediate,,6448,,N,50588,1,Half life in dog,A,9615.0
7247,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619625,,Intermediate,,4353,,N,50588,1,Half life in dog after intra venous administration of the compound,A,9615.0
7248,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619626,,Intermediate,,4353,,N,50588,1,Half life in dog after intra venous administration of the compound; ND means Not determined,A,9615.0
7249,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619627,,Intermediate,In vivo,4353,,N,50588,1,Half life in dog after po administration of the compound,A,9615.0
7250,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873817,,Intermediate,In vivo,4353,,N,50588,1,Half life in dog after po administration of the compound; ND means Not determined,A,9615.0
7251,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619628,,Intermediate,In vivo,6265,,N,50588,1,Half life in dog at the single oral dose of 1 mg/kg,A,9615.0
7252,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619629,,Intermediate,,5006,,N,50588,1,Half life in dogs,A,9615.0
7253,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619630,,Intermediate,In vivo,5356,,N,50588,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,9615.0
7254,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619631,,Intermediate,,405,,N,50588,1,Half life in rat,A,9615.0
7255,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL619632,,Intermediate,In vivo,6642,,N,50588,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0
7256,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL619633,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7257,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL875841,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7258,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL619634,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7259,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL619635,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7260,Mus musculus,BAO_0000218,10000001.0,,1,Bone,CHEMBL619636,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7261,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619637,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7262,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619638,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7263,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619639,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7264,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619640,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7265,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619641,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7266,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619642,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7267,Mus musculus,BAO_0000218,10000004.0,,1,Gut,CHEMBL619643,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7268,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL619644,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7269,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621112,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7270,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621113,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7271,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621114,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7272,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621115,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7273,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621116,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7274,Mus musculus,BAO_0000218,948.0,,1,Heart,CHEMBL621117,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7275,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621118,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7276,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621119,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0
7277,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621120,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7278,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621757,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7279,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621758,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7280,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621759,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7281,Mus musculus,BAO_0000218,2113.0,,1,Kidney,CHEMBL621760,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7282,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621761,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7283,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621762,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7284,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL621763,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7285,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624502,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7286,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624503,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7287,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624504,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7288,Mus musculus,BAO_0000218,2107.0,,1,Liver,CHEMBL624505,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7289,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL624506,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7290,Homo sapiens,BAO_0000219,,,1,,CHEMBL624507,,Intermediate,,5895,,N,81034,1,In vitro cytotoxicity against A2780 (human ovarian cancer),F,9606.0
7291,Homo sapiens,BAO_0000219,,,1,,CHEMBL624508,,Intermediate,,6338,,N,81034,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,9606.0
7292,Homo sapiens,BAO_0000219,,,1,,CHEMBL624509,,Intermediate,,15163,,N,81034,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,9606.0
7293,Homo sapiens,BAO_0000219,,,1,,CHEMBL624510,,Intermediate,,15163,,N,81034,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,9606.0
7294,Homo sapiens,BAO_0000219,,,1,,CHEMBL875956,,Expert,,15000,,N,81034,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,9606.0
7295,Homo sapiens,BAO_0000219,,,1,,CHEMBL839885,,Expert,,15000,,N,81034,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,9606.0
7296,Homo sapiens,BAO_0000219,,,1,,CHEMBL624511,,Expert,,14729,,N,81034,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,9606.0
7297,Homo sapiens,BAO_0000219,,,1,,CHEMBL624512,,Intermediate,,17270,,N,81034,1,In vitro cytotoxicity against A2780 cell line,F,9606.0
7298,Homo sapiens,BAO_0000219,,,1,,CHEMBL624513,,Intermediate,,5685,,N,81034,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,9606.0
7299,Homo sapiens,BAO_0000219,,,1,,CHEMBL624514,,Intermediate,,3563,,N,81034,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,9606.0
7300,Homo sapiens,BAO_0000218,,,1,,CHEMBL618547,,Intermediate,,17753,,N,81034,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,9606.0
7301,Homo sapiens,BAO_0000219,,,1,,CHEMBL618548,,Intermediate,,16317,,N,81034,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,9606.0
7302,Homo sapiens,BAO_0000219,,,1,,CHEMBL618549,,Intermediate,,16936,,N,81034,1,Inhibition of tubulin polymerization in analogy of ca.,F,9606.0
7303,Homo sapiens,BAO_0000219,,,1,,CHEMBL618550,,Intermediate,,3801,,N,81034,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,9606.0
7304,Homo sapiens,BAO_0000219,,,1,,CHEMBL618551,,Expert,,6181,,N,81034,1,Cytotoxic effect in ovarian cancer cell line (A2780),F,9606.0
7305,Homo sapiens,BAO_0000219,,,1,,CHEMBL618552,,Intermediate,,5318,,N,81034,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,9606.0
7306,Homo sapiens,BAO_0000219,,,1,,CHEMBL618553,,Intermediate,,4840,,N,81034,1,Tested for the cytotoxicity in A2780 ovarian cell line,F,9606.0
7307,Homo sapiens,BAO_0000219,,,1,,CHEMBL618554,,Intermediate,,15748,,N,81034,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,9606.0
7308,Homo sapiens,BAO_0000219,,,1,,CHEMBL618555,,Intermediate,,15748,,N,81034,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,9606.0
7309,,BAO_0000219,,,1,,CHEMBL618556,,Intermediate,,15748,,N,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,
7310,,BAO_0000219,,,1,,CHEMBL618557,,Intermediate,,15748,,N,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,
7311,,BAO_0000219,,,1,,CHEMBL618558,,Intermediate,,15748,,N,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,
7312,,BAO_0000219,,,1,,CHEMBL618559,,Intermediate,,15748,,N,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,
7313,Homo sapiens,BAO_0000218,,,1,,CHEMBL618560,,Intermediate,,17753,,N,81034,1,In vivo log of cells killed after administration of compound in A2780 cell line,F,9606.0
7314,Homo sapiens,BAO_0000218,,,1,,CHEMBL618561,,Intermediate,In vivo,17753,,N,81034,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,9606.0
7315,Homo sapiens,BAO_0000219,,,1,,CHEMBL618562,,Intermediate,,16936,,N,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,9606.0
7316,Homo sapiens,BAO_0000219,,,1,,CHEMBL618563,,Intermediate,,16936,,N,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,9606.0
7317,Homo sapiens,BAO_0000219,,,1,,CHEMBL618564,,Intermediate,,16936,,N,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,9606.0
7318,Homo sapiens,BAO_0000219,,,1,,CHEMBL618565,,Intermediate,,16936,,N,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,9606.0
7319,Homo sapiens,BAO_0000218,,,1,,CHEMBL618566,,Intermediate,,17528,,N,81034,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,9606.0
7320,Homo sapiens,BAO_0000219,,,1,,CHEMBL618567,,Intermediate,,6633,,N,81034,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,9606.0
7321,Homo sapiens,BAO_0000219,,,1,,CHEMBL618568,,Expert,,15000,,N,81034,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,9606.0
7322,Homo sapiens,BAO_0000219,,,1,,CHEMBL618569,,Expert,,17528,,N,81034,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,9606.0
7323,Homo sapiens,BAO_0000219,,,1,,CHEMBL621857,,Intermediate,,16936,,N,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,9606.0
7324,Homo sapiens,BAO_0000219,,,1,,CHEMBL621858,,Intermediate,,16936,,N,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,9606.0
7325,Homo sapiens,BAO_0000219,,,1,,CHEMBL621859,,Intermediate,,16936,,N,81034,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,9606.0
7326,Homo sapiens,BAO_0000219,,,1,,CHEMBL621860,,Intermediate,,16936,,N,81034,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,9606.0
7327,Homo sapiens,BAO_0000219,,,1,,CHEMBL621861,,Intermediate,,16936,,N,81034,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,9606.0
7328,Homo sapiens,BAO_0000219,,,1,,CHEMBL621862,,Expert,,16936,,N,81034,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,9606.0
7329,Homo sapiens,BAO_0000219,,,1,,CHEMBL621863,,Intermediate,,16936,,N,81034,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0
7330,Homo sapiens,BAO_0000219,,,1,,CHEMBL621864,,Intermediate,,16936,,N,81034,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0
7331,Homo sapiens,BAO_0000219,,,1,,CHEMBL621865,,Intermediate,,16936,,N,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0
7332,Mus musculus,BAO_0000219,,,1,,CHEMBL621866,,Intermediate,,17737,,N,81034,1,In vitro antiproliferative activity against A2780 cell line,F,10090.0
7333,Mus musculus,BAO_0000219,,,1,,CHEMBL621867,,Expert,,17764,,N,81034,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,10090.0
7334,Homo sapiens,BAO_0000219,,,1,,CHEMBL621868,,Intermediate,,3830,,N,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,9606.0
7335,Homo sapiens,BAO_0000219,,,1,,CHEMBL875282,,Intermediate,,3829,,N,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,9606.0
7336,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621869,,Intermediate,,3546,,N,50588,1,Vc value in dog after IV administration at a dose of 5 mg/kg,A,9615.0
7337,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621870,,Intermediate,In vivo,3546,,N,50588,1,Half life period in dog after IV administration at a dose of 5 mg/kg,A,9615.0
7338,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621871,,Autocuration,,5668,,U,22224,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,9527.0
7339,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL621243,,Autocuration,,3443,,U,22224,1,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
7340,Cercopithecidae,BAO_0000218,1969.0,,0,Plasma,CHEMBL621244,,Autocuration,,3443,,U,22224,1,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
7341,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL621245,,Autocuration,In vivo,4256,,U,22224,1,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,9541.0
7342,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL621246,,Autocuration,In vivo,4256,,U,22224,1,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,9541.0
7343,Macaca fascicularis,BAO_0000218,,,0,,CHEMBL621247,,Autocuration,In vivo,4256,,U,22224,1,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,9541.0
7344,Rattus norvegicus,BAO_0000218,,,0,,CHEMBL618386,,Autocuration,In vivo,4256,,U,22224,1,Oral Bioavailability in rat,A,10116.0
7345,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618387,,Autocuration,,1916,,U,22224,1,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0
7346,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618388,,Autocuration,,5302,,U,22224,1,Area under curve value in monkey at a dose of 5 mg/kg,A,9527.0
7347,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618389,,Autocuration,,4257,,U,22224,1,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,9527.0
7348,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618574,,Autocuration,,5355,,U,22224,1,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,9527.0
7349,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618575,,Autocuration,,5355,,U,22224,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,9527.0
7350,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618576,,Autocuration,,5355,,U,22224,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,9527.0
7351,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618577,,Autocuration,,6078,,U,22224,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,9527.0
7352,Cercopithecidae,BAO_0000218,,,0,,CHEMBL876487,,Autocuration,,6078,,U,22224,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,9527.0
7353,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618578,,Autocuration,,6062,,U,22224,1,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,9527.0
7354,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618579,,Autocuration,,2661,,U,22224,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0
7355,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618580,,Autocuration,,2661,,U,22224,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0
7356,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618581,,Autocuration,,5394,,U,22224,1,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,9527.0
7357,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618582,,Autocuration,,4397,,U,22224,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,9527.0
7358,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618583,,Autocuration,,17509,,U,22224,1,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,9527.0
7359,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618584,,Autocuration,,17509,,U,22224,1,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,9527.0
7360,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618585,,Autocuration,In vivo,6641,,U,22224,1,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,9527.0
7361,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618586,,Autocuration,,5355,,U,22224,1,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,9527.0
7362,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618587,,Autocuration,In vivo,3443,,U,22224,1,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
7363,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618588,,Autocuration,In vivo,3443,,U,22224,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0
7364,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618589,,Autocuration,,17409,,U,22224,1,Binding towards monkey plasma protein at 10 uM,A,9527.0
7365,Cercopithecidae,BAO_0000019,,,0,,CHEMBL618590,,Autocuration,,17409,,U,22224,1,Binding towards monkey plasma protein at 100 uM,A,9527.0
7366,Cercopithecidae,BAO_0000218,,,0,,CHEMBL872262,,Autocuration,In vivo,1052,,U,22224,1,Apparent bioavailability in squirrel monkey was determined,A,9527.0
7367,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618591,,Autocuration,In vivo,13501,,U,22224,1,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,9527.0
7368,monkey,BAO_0000218,,,0,,CHEMBL618592,,Autocuration,In vivo,17509,,U,22224,1,Bioavailability in monkey (dose 2 mg/kg),A,9443.0
7369,Cercopithecidae,BAO_0000218,,,0,,CHEMBL876488,,Autocuration,In vivo,5394,,U,22224,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,9527.0
7370,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618593,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0
7371,monkey,BAO_0000218,,,0,,CHEMBL618594,,Autocuration,In vivo,11219,,U,22224,1,Bioavailability in monkey (i.d. dosing),A,9443.0
7372,Cercopithecidae,BAO_0000218,,,0,,CHEMBL618595,,Autocuration,In vivo,3045,,U,22224,1,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,9527.0
7373,Cercopithecidae,BAO_0000019,,,0,,CHEMBL621469,,Autocuration,,17796,,U,22224,1,Clearance of the drug was measured in cynomolgus,A,9527.0
7374,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621470,,Autocuration,In vivo,1399,,U,22224,1,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,9527.0
7375,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621471,,Autocuration,In vivo,2661,,U,22224,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0
7376,Macaca mulatta,BAO_0000218,1969.0,,0,Plasma,CHEMBL621472,,Autocuration,In vivo,5005,,U,22224,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0
7377,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621473,,Autocuration,In vivo,17267,,U,22224,1,Plasma clearance in rhesus monkey was determined,A,9527.0
7378,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621474,,Autocuration,In vivo,6535,,U,22224,1,Plasma clearance in monkey after administration of 1 mg/kg iv,A,9527.0
7379,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621475,,Autocuration,In vivo,5922,,U,22224,1,Plasma clearance in cynomolgus monkey,A,9527.0
7380,Cercopithecidae,BAO_0000218,,,0,,CHEMBL621476,,Autocuration,In vivo,6221,,U,22224,1,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0
7381,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624290,,Autocuration,In vivo,5668,,U,22224,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,9527.0
7382,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624291,,Autocuration,In vivo,5355,,U,22224,1,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,9527.0
7383,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624292,,Autocuration,In vivo,5355,,U,22224,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0
7384,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624293,,Autocuration,In vivo,5355,,U,22224,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0
7385,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624294,,Autocuration,In vivo,4578,,U,22224,1,Tested for Clearance upon iv administration to african green monkey,A,9527.0
7386,Cercopithecidae,BAO_0000218,,,0,,CHEMBL624295,,Autocuration,In vivo,17592,,U,22224,1,Clearance in monkey,A,9527.0
7387,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624296,,Intermediate,In vivo,6641,,N,50588,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
7388,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624297,,Intermediate,In vivo,6642,,N,50588,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0
7389,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624298,,Intermediate,In vivo,16367,,N,50588,1,Half life was evaluated after intravenous administration to dogs,A,9615.0
7390,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624299,,Intermediate,,5472,,N,50588,1,Half life was evaluated in dog,A,9615.0
7391,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624300,,Intermediate,,5474,,N,50588,1,Half life was evaluated in dog,A,9615.0
7392,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624301,,Intermediate,In vivo,5654,,N,50588,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0
7393,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624302,,Intermediate,In vivo,6227,,N,50588,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,9615.0
7394,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876026,,Intermediate,In vivo,6227,,N,50588,1,Half life period after intravenous administration in dog,A,9615.0
7395,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624303,,Intermediate,In vivo,6221,,N,50588,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,9615.0
7396,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624304,,Intermediate,,4527,,N,50588,1,Half life period at a dose of 1 uM/kg in dog was determined,A,9615.0
7397,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624305,,Intermediate,In vivo,5668,,N,50588,1,Half life period was determine after peroral administration at 10 mpk in dog,A,9615.0
7398,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624306,,Intermediate,In vivo,5668,,N,50588,1,Half life period was determine after peroral administration at 5 mpk in dog,A,9615.0
7399,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624307,,Intermediate,,3854,,N,50588,1,Half life period was determined,A,9615.0
7400,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624308,,Intermediate,,5505,,N,50588,1,Half life period was determined,A,9615.0
7401,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624309,,Intermediate,In vivo,6251,,N,50588,1,Half life period by iv administration in dog at a dose of 6 mg/kg,A,9615.0
7402,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624310,,Intermediate,,1918,,N,50588,1,Half life period was evaluated in dog,A,9615.0
7403,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625003,,Intermediate,In vivo,5546,,N,50588,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0
7404,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625004,,Intermediate,In vivo,4809,,N,50588,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,9615.0
7405,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625005,,Intermediate,In vivo,6215,,N,50588,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0
7406,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873813,,Intermediate,In vivo,4527,,N,50588,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0
7407,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625006,,Intermediate,In vivo,17594,,N,50588,1,Half-life after oral dose of compound at 3 mg/kg in dogs,A,9615.0
7408,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625007,,Intermediate,In vivo,17839,,N,50588,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,9615.0
7409,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876027,,Intermediate,In vivo,17839,,N,50588,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,9615.0
7410,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625008,,Intermediate,In vivo,17839,,N,50588,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,9615.0
7411,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625009,,Intermediate,In vivo,17839,,N,50588,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,9615.0
7412,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL625010,,Intermediate,,5210,,N,50588,1,Half-life of compound in plasma of dog was determined,A,9615.0
7413,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL625011,,Intermediate,,5210,,N,50588,1,Half-life of compound was determined in dogs,A,9615.0
7414,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621553,,Intermediate,In vivo,2959,,N,50588,1,Half-life after administration of 4 mg/Kg oral dose in dog,A,9615.0
7415,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621554,,Intermediate,In vivo,4137,,N,50588,1,Half-life after intravenous administration of 1 mg/kg/h in dog,A,9615.0
7416,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621555,,Intermediate,,5064,,N,50588,1,Half-life in Dog,A,9615.0
7417,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621556,,Intermediate,,5147,,N,50588,1,Half-life in Dog,A,9615.0
7418,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621557,,Intermediate,,5145,,N,50588,1,Half-life in dog,A,9615.0
7419,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621558,,Intermediate,In vivo,6123,,N,50588,1,Half-life in dog after oral administration at 1 mg/kg,A,9615.0
7420,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621559,,Intermediate,In vivo,6123,,N,50588,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,9615.0
7421,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621560,,Intermediate,,4333,,N,50588,1,Half-life in dogs,A,9615.0
7422,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL876028,,Intermediate,,4333,,N,50588,1,Half-life in dogs; ND indicates not determined,A,9615.0
7423,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621561,,Intermediate,,12500,,N,50588,1,Half-life in plasma of dog,A,9615.0
7424,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL621562,,Intermediate,,12500,,N,50588,1,Half-life in plasma of dog at dose of 3-10 mgkg,A,9615.0
7425,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621563,,Intermediate,In vivo,6005,,N,50588,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,9615.0
7426,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621564,,Intermediate,In vivo,6062,,N,50588,1,Half-life was measured in dog after an iv dose of 1 mg/kg,A,9615.0
7427,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621565,,Intermediate,In vivo,17650,,N,50588,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,9615.0
7428,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621566,,Intermediate,In vivo,5530,,N,50588,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,9615.0
7429,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL621567,,Intermediate,In vivo,5530,,N,50588,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,9615.0
7430,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL622978,,Intermediate,In vivo,5600,,N,50588,1,Half-life of the compound after 0.3 mg/kg po administration in dog,A,9615.0
7431,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL873814,,Intermediate,In vivo,6039,,N,50588,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,9615.0
7432,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623219,,Intermediate,In vivo,6039,,N,50588,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,9615.0
7433,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624477,,Intermediate,In vivo,6039,,N,50588,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,9615.0
7434,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624478,,Intermediate,,6227,,N,50588,1,t1/2 in dog,A,9615.0
7435,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624479,,Intermediate,,14541,,N,50588,1,Half-life period measured in dogs,A,9615.0
7436,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL624480,,Intermediate,In vivo,4521,,N,50588,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0
7437,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623595,,Intermediate,In vivo,4521,,N,50588,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0
7438,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623596,,Intermediate,In vivo,6679,,N,50588,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0
7439,Canis lupus familiaris,BAO_0000218,1969.0,,1,Plasma,CHEMBL623597,,Intermediate,In vitro,1116,,N,50588,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,9615.0
7440,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623598,,Intermediate,In vivo,5444,,N,50588,1,In vivo half life period was calculated at 1 mg/kg in dog,A,9615.0
7441,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623599,,Intermediate,In vivo,5444,,N,50588,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,9615.0
7442,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623600,,Intermediate,In vivo,17853,,N,50588,1,Longer half-life in dog (i.v.) at 0.5 mpk,A,9615.0
7443,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623601,,Intermediate,In vivo,4353,,N,50588,1,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0
7444,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623602,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0
7445,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623603,,Intermediate,In vivo,16452,,N,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0
7446,Canis lupus familiaris,BAO_0000218,,,1,,CHEMBL623604,,Intermediate,In vivo,16452,,N,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0
7447,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623605,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0
7448,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623606,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7449,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623607,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7450,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623608,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7451,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623609,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7452,Mus musculus,BAO_0000218,2048.0,,1,Lung,CHEMBL623610,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7453,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623611,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7454,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623612,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0
7455,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623613,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7456,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623614,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7457,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623615,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7458,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623616,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7459,Mus musculus,BAO_0000218,2385.0,,1,Muscle tissue,CHEMBL623617,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7460,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL875944,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7461,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623618,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7462,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623619,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7463,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623620,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7464,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623621,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7465,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623622,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7466,Mus musculus,BAO_0000218,14.0,,1,Zone of skin,CHEMBL623623,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7467,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL623624,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7468,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618521,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7469,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618522,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7470,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618523,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7471,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618524,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7472,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL618525,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7473,Mus musculus,BAO_0000218,2106.0,,1,Spleen,CHEMBL624586,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7474,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624587,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0
7475,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624588,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0
7476,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624589,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0
7477,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624590,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0
7478,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624591,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0
7479,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624592,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0
7480,Mus musculus,BAO_0000218,945.0,,1,Stomach,CHEMBL624593,,Intermediate,In vivo,10107,,N,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0
7481,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624594,,Intermediate,In vivo,4689,,N,50597,1,Oral bioavailability in rat,A,10116.0
7482,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624595,,Intermediate,In vivo,4950,,N,50597,1,Tested for the bioavailability in rat,A,10116.0
7483,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624596,,Intermediate,In vivo,5328,,N,50597,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0
7484,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624597,,Intermediate,In vivo,406,,N,50597,1,Bioavailability in rat,A,10116.0
7485,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624598,,Intermediate,In vivo,12500,,N,50597,1,Bioavailability in rat,A,10116.0
7486,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624599,,Intermediate,In vivo,12500,,N,50597,1,Bioavailability in rat (dose 3-10 mg/kg),A,10116.0
7487,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL875166,,Intermediate,In vivo,5247,,N,50597,1,Bioavailability in rat,A,10116.0
7488,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL624600,,Intermediate,In vivo,4186,,N,50597,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0
7489,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL624601,,Intermediate,In vivo,4186,,N,50597,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,10116.0
7490,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624602,,Intermediate,In vivo,6647,,N,50597,1,Half life after oral administration was determined in rats at 6 mg/kg,A,10116.0
7491,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624603,,Intermediate,,6484,,N,50597,1,Half life was determined,A,10116.0
7492,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624604,,Intermediate,In vivo,3249,,N,50597,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,10116.0
7493,Rattus norvegicus,BAO_0000218,1969.0,,1,Plasma,CHEMBL624605,,Intermediate,In vivo,6281,,N,50597,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,10116.0
7494,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624606,,Intermediate,,3307,,N,50597,1,Half life in rats,A,10116.0
7495,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624607,,Intermediate,In vivo,12058,,N,50597,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,10116.0
7496,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624608,,Intermediate,,8833,,N,50597,1,Hill coefficient of the compound,A,10116.0
7497,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624609,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,10116.0
7498,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624610,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,10116.0
7499,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624611,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,10116.0
7500,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624612,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,10116.0
7501,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL875167,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,10116.0
7502,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624613,,Intermediate,,3193,,N,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,10116.0
7503,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624614,,Intermediate,,3193,,N,50597,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,10116.0
7504,Rattus norvegicus,BAO_0000218,,,1,,CHEMBL624392,,Intermediate,,5960,,N,50597,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,10116.0
7505,Rattus norvegicus,BAO_0000218,955.0,,1,Brain,CHEMBL624393,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,10116.0
7506,Rattus norvegicus,BAO_0000218,955.0,,1,Brain,CHEMBL624394,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,10116.0
7507,Rattus norvegicus,BAO_0000218,955.0,,1,Brain,CHEMBL624395,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,10116.0
7508,Rattus norvegicus,BAO_0000218,955.0,,1,Brain,CHEMBL624396,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,10116.0
7509,Rattus norvegicus,BAO_0000218,955.0,,1,Brain,CHEMBL624397,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,10116.0
7510,Rattus norvegicus,BAO_0000218,2046.0,,1,Thyroid gland,CHEMBL624398,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,10116.0
7511,Rattus norvegicus,BAO_0000218,2046.0,,1,Thyroid gland,CHEMBL624399,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,10116.0
7512,Rattus norvegicus,BAO_0000218,2046.0,,1,Thyroid gland,CHEMBL624400,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,10116.0
7513,Rattus norvegicus,BAO_0000218,2046.0,,1,Thyroid gland,CHEMBL624401,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,10116.0
7514,Rattus norvegicus,BAO_0000218,2046.0,,1,Thyroid gland,CHEMBL624402,,Intermediate,In vivo,13950,,N,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,10116.0
7515,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624403,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0
7516,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624404,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,10116.0
7517,Rattus norvegicus,BAO_0000218,178.0,,1,Blood,CHEMBL624405,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0
7518,Rattus norvegicus,BAO_0000218,10000001.0,,1,Bone,CHEMBL624406,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0
7519,Rattus norvegicus,BAO_0000218,10000001.0,,1,Bone,CHEMBL624407,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,10116.0
7520,Rattus norvegicus,BAO_0000218,10000001.0,,1,Bone,CHEMBL624408,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0
7521,Rattus norvegicus,BAO_0000218,948.0,,1,Heart,CHEMBL618644,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0
7522,Rattus norvegicus,BAO_0000218,948.0,,1,Heart,CHEMBL618645,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,10116.0
7523,Rattus norvegicus,BAO_0000218,948.0,,1,Heart,CHEMBL618646,,Intermediate,In vivo,9866,,N,50597,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0
